0001822359
false
--12-31
0001822359
2021-11-05
2021-11-05
0001822359
dei:FormerAddressMember
2021-11-05
2021-11-05
0001822359
DCGO:CommonStockParValue0.0001PerShareMember
2021-11-05
2021-11-05
0001822359
DCGO:WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember
2021-11-05
2021-11-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 5, 2021
DOCGO INC.
(Exact name of registrant as specified in its
charter)
|
Delaware
|
|
001-39618
|
|
85-2515483
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
35 West 35th Street, Floor 5,
New York, New York
|
|
10001
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(844) 443-6246
(Registrant’s telephone number, including
area code)
Motion Acquisition Corp.
c/o Graubard Miller
405 Lexington Avenue, 11th Floor
New York, New York 10174
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on
which registered
|
|
Common stock, par value $0.0001 per share
|
|
DCGO
|
|
The Nasdaq Stock Market LLC
|
|
Warrants, each exercisable for one share of common stock at an exercise price of $11.50 per share
|
|
DCGOW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
INTRODUCTORY NOTE
On November 5, 2021 (the “Closing Date”),
DocGo Inc., a Delaware corporation (formerly known as Motion Acquisition Corp.) (prior to the Closing Date, “Motion” and after
the Closing Date, “DocGo”, “we,” “us,” and “our”) consummated the previously announced
business combination (the “Closing”) pursuant to that certain Agreement and Plan of Merger dated March 8, 2021 (the “Merger
Agreement”), by and among Motion Acquisition Corp., a Delaware corporation (“Motion”), Motion Merger Sub Corp., a Delaware
corporation and a direct wholly owned subsidiary of Motion (“Merger Sub”), and Ambulnz, Inc., a Delaware corporation (“Ambulnz”).
In connection with the Closing, the registrant changed its name from Motion Acquisition Corp. to DocGo Inc.
As contemplated by the Merger Agreement and as
described in Motion’s definitive proxy statement/consent solicitation/prospectus filed with the U.S. Securities and Exchange Commission
(the “SEC”) on October 14, 2021 (the “Prospectus”), Merger Sub was merged with and into Ambulnz, with Ambulnz
continuing as the surviving corporation (the “Merger” and, together with the other transactions contemplated by the Merger
Agreement, the “Business Combination”). As a result of the Merger, Ambulnz is a wholly-owned subsidiary of DocGo and each
share of Series A preferred stock of Ambulnz, no par value (“Ambulnz Preferred Stock”), Class A common stock of Ambulnz, no
par value (“Ambulnz Class A Common Stock”), and Class B common stock of Ambulnz, no par value (“Ambulnz Class B Common
Stock”, together with Ambulnz Class A Common Stock, “Ambulnz Common Stock”) was cancelled and converted into the right
to receive a portion of merger consideration issuable as common stock of DocGo, par value $0.0001 (“Common Stock”), pursuant
to the terms and conditions set forth in the Merger Agreement. The material provisions of the Merger Agreement are described in the Prospectus
in the section entitled “Proposal No.1—The Business Combination Proposal—The Merger Agreement” beginning
on page 97, which is incorporated by reference herein. The foregoing description of the Merger Agreement and the transactions contemplated
thereby is not complete and is qualified in its entirety by reference to the complete text of Merger Agreement, a copy of which is filed
as Exhibits 2.1 hereto and is incorporated herein by reference.
Item 1.01 Entry into a Material Definitive
Agreement.
A&R Registration Rights Agreement
On November 5, 2021, immediately prior to the Closing, Motion Acquisition
LLC (“Sponsor”), Motion and certain holders of Ambulnz Common Stock and Ambulnz Preferred Stock amended
and restated the existing Registration Rights Agreement, by and between Sponsor and Motion, dated October 14, 2020 (“A&R Registration
Rights Agreement”). Pursuant to the A&R Registration Rights Agreement, DocGo will register for resale under the Securities Act
of 1933, as amended (the “Securities Act”), after the lapse or expiration of any transfer restrictions, lock-up, or escrow
provisions which may apply, the shares of Common Stock held by Sponsor prior to the Closing (“Founder Shares”) and certain
holders of Ambulnz Common Stock and Ambulnz Preferred Stock (including those shares of Common Stock issuable upon exercise of those certain
options to acquire shares of Ambulnz outstanding immediately prior to the Closing). Any other stockholders of DocGo with piggyback registration
rights may also participate in any such registrations, subject to customary cutbacks in an underwritten offering.
The foregoing description of the A&R Registration
Rights Agreement is not complete and is qualified in its entirety by reference to the complete text of the A&R Registration Rights
Agreement, a copy of which is attached hereto as Exhibit 10.4 and is incorporated herein by reference.
Incentive Plan
On March 4, 2021, Motion’s board of directors
approved the DocGo Inc. 2021 Stock Incentive Plan (the “Incentive Plan”). On November 2, 2021, Motion’s shareholders
approved the Incentive Plan at an annual meeting of stockholders of Motion (the “Meeting”) and on November 5, 2021, the newly
constituted board of directors of DocGo ratified the Incentive Plan. The purpose of the Incentive Plan is to advance the interests of
DocGo and its stockholders by providing an incentive program that will enable DocGo to attract, retain and award employees, consultants
and directors and to provide them with an equity interest in the growth and profitability of DocGo. These incentives are provided through
the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units,
other stock-based awards and cash-based awards. No awards were granted under the Incentive Plan prior to its approval by the shareholders
of Motion. Restricted stock units, and their terms and conditions, will be approved and issued pursuant to the Incentive Plan upon registration
of a Form S-8, which is expected to be filed in 60 days following the Closing Date. All awards under the Incentive Plan will be granted
at the discretion of the board of directors of DocGo.
The foregoing description of the Incentive Plan
is not complete and is qualified in its entirety by reference to the complete text of the Incentive Plan, a copy of which is attached
hereto as Exhibit 10.5 and is incorporated herein by reference.
Executive Employment Agreements
On November 5, 2021, immediately prior to
the Closing, each of Messrs. Stan Vashovsky, Andre Oberholzer, Anthony Capone, and Norman Rosenberg entered into employment
agreements with Motion, to be effective upon consummation of the Business Combination (the “New Employment Agreements”).
The New Employment Agreements provide for each executive’s annual base salary, eligibility to receive an annual performance
bonus, participation in DocGo’s benefit plans, eligibility to receive annual equity incentive grants beginning in fiscal year
2022 pursuant to the Incentive Plan and a one-time grant of restricted stock units pursuant to the Incentive Plan (the
“Closing Grant”).
The New Employment Agreements provide for the
following severance benefits in connection with an Involuntary Termination Without Cause or a voluntary termination for Good Reason (each
a “Covered Termination” and as defined in the New Employment Agreements) which does not occur during the period beginning
three (3) months prior to a Change in Control (as defined in the Incentive Plan) and ending twelve (12) months after a Change in Control:
(i) a cash payment equal to twelve (12) months of the executive’s base salary payable in equal instalments over twelve (12) months,
(ii) a pro-rata portion of the executive’s annual bonus for the fiscal year of termination based on actual achievement of the bonus
objectives and the number of days the executive was employed during the fiscal year, (iii) payment or reimbursement for the premium for
executive and executive’s covered dependents to maintain continued health coverage pursuant to the provisions of COBRA through the
earlier of (A) the twelve (12) month anniversary of the date of executive’s termination of employment and (B) the date executive
and executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s plan(s) and (iv)
accelerated vesting of the unvested portion of the Closing Grant that would have vested assuming that executive remained employed by DocGo
through the date that is twelve (12) months following the date of executive’s termination of employment. In connection with a Covered
Termination during the period beginning three (3) months prior to a Change in Control and ending twelve (12) months after a Change in
Control, each executive would be entitled to: (i) a lump sum cash payment equal to the sum of (A) executive’s base salary and (B)
executive’s target bonus, (ii) a pro-rata portion of the executive’s annual bonus for the fiscal year of termination based
on actual achievement of the bonus objectives and the number of days the executive was employed during the fiscal year, (iii) the amount
of any annual bonus earned, but not yet paid, for the fiscal year prior to executive’s termination, (iv) payment or reimbursement
for the premium for executive and executive’s covered dependents to maintain continued health coverage pursuant to the provisions
of COBRA through the earlier of (A) the twelve (12) month anniversary of the date of executive’s termination of employment and (B)
the date executive and executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s) and (v) full accelerated vesting of the unvested portion of the Closing Grant. The New Employment Agreements provide for a “best
net” after-tax 280G provision (and not any “gross-ups”) to the extent any payments made pursuant to the New Employment
Agreements or otherwise would constitute a “parachute payment” under Code Section 280G.
The foregoing description of the New Employment
Agreements is not complete and is qualified in its entirety by reference to the complete text of each of the New Employment Agreements,
copies of which are attached hereto and filed as Exhibits 10.6 through 10.9 to this Current Report on Form 8-K and are incorporated herein
by reference.
Indemnification Agreements
On November 5, 2021, concurrent with the
Closing, DocGo entered into indemnification agreements with each of its directors and executive officers, which obligates DocGo to
indemnify such directors and officers to the maximum extent permitted by Delaware law (the “Indemnification
Agreements”). The Indemnification Agreements provide that, if a director or executive officer is a party to, or witness in, or
is threatened to be made a party to, or witness in, any proceeding by reason of his or her service as a director, officer, employee,
agent, or trustee of DocGo or as a director, officer, employee, agent, or trustee of another corporation or of a partnership, joint
venture, trust, employee benefit plan or other enterprise that he or she is or was serving in such capacity at our request, DocGo
must indemnify the director or executive officer for all expenses and liabilities actually and reasonably incurred by him or her, or
on his or her behalf, to the maximum extent permitted under Delaware law, including in any proceeding brought by the director or
executive officer to enforce his or her rights under the indemnification agreement, to the extent provided by the agreement. The
Indemnification Agreements also require DocGo to advance reasonable expenses incurred by the indemnitee within twenty days of the
receipt by DocGo of a statement from the indemnitee requesting the advance, provided the statement evidences the expenses and
includes or is accompanied by a written undertaking, which may be unsecured, by the indemnitee or on his or her behalf to repay the
amount paid if it shall ultimately be established by final judicial decision of a court from which there is no further right to
appeal, that the indemnitee is not entitled to be indemnified for such expenses by DocGo as provided by the indemnification
agreements or otherwise.
The Indemnification Agreements also provide for
procedures for the determination of entitlement to indemnification, including requiring such determination be made by independent counsel
after a change of control of DocGo.
The foregoing description of the Indemnification
Agreements is not complete and is qualified in its entirety by reference to the complete text of each of the Indemnification Agreements,
the form of which is attached hereto and filed as Exhibit 10.10 to this Current Report on Form 8-K and is incorporated herein by reference.
Sponsor Escrow Agreement
On November 5, 2021, immediately prior to the Closing, Sponsor entered
into an escrow agreement (the “Sponsor Escrow Agreement”) with Motion and Continental Stock Transfer & Trust Company,
as escrow agent, whereby, immediately following the Closing, the Sponsor deposited (i) 575,000 Founder Shares (the “Sponsor Earnout
Shares”) into escrow and (ii) 162,965 Founder Shares (the “Additional Escrow Shares”) into escrow pursuant to the Amended
and Restated Sponsor Agreement, dated November 4, 2021, by and among Motion, Sponsor and Ambulnz (the “A&R Sponsor Agreement”).
The Sponsor Escrow Agreement provides that such
Sponsor Earnout Shares will either be released to the Sponsor or terminated and canceled by DocGo if certain stock price conditions are
met or not, as follows: (i) with respect to 287,500 Sponsor Earnout Shares, the closing stock price equals or exceeds $12.50 per share
on any 20 trading days in a 30-trading-day period at any time until the third anniversary of the Closing Date, and (ii) with respect to
287,500 Sponsor Earnout Shares, the closing stock price equals or exceeds $15.00 per share on any 20 trading days in a 30-trading-day
period at any time at any time until the fifth anniversary of the Closing Date.
Additional Earnout Shares will be released to
the Sponsor or terminated and cancelled by DocGo if certain price conditions are met or not, as follows: (i) 25% of the Additional Earnout
Shares if the closing price of Common Stock equals or exceeds $12.50 per share (as adjusted for share splits, share dividends, reorganizations,
and recapitalizations) on any twenty (20) trading days in a thirty (30)-trading-day period at any time after the closing date and by the
first anniversary of the closing date; (ii) an additional 25% of the Additional Earnout Shares if the closing price of the Common Stock
equals or exceeds $15.00 per share (as adjusted for share splits, share dividends, reorganizations, and recapitalizations) on any twenty
(20) trading days in a thirty (30)-trading-day period at any time after the closing date and by the third anniversary of the closing date;
(iii) an additional 25% of the Additional Earnout Shares if the closing price of the Common Stock equals or exceeds $18.00 per share (as
adjusted for share splits, share dividends, reorganizations, and recapitalizations) on any twenty (20) trading days in a thirty (30)-trading-day
period at any time after the closing date and by the third anniversary of the closing date; and (iv) the remaining 25% of the Additional
Earnout Shares if the closing price of the Common Stock equals or exceeds $21.00 per share (as adjusted for share splits, share dividends,
reorganizations, and recapitalizations) on any twenty (20) trading days in a thirty (30)-trading-day period at any time after the closing
date and by the fifth anniversary of the closing date.
The foregoing description of the Sponsor Escrow
Agreement is not complete and is qualified in its entirety by reference to the complete text of the Sponsor Escrow Agreement, a copy of
which is attached hereto and filed as Exhibit 10.11 to this Current Report on Form 8-K and are incorporated herein by reference.
Item 2.01 Completion of Acquisition or Disposition
of Assets.
The disclosure set forth in the “Introductory
Note” above is incorporated into this Item 2.01 by reference.
Each of stockholder proposals included in
the Prospectus was approved by Motion’s stockholders at the Meeting.
Pursuant to the Merger Agreement, immediately
prior to the Closing, each share Ambulnz Preferred Stock was converted into Ambulnz Class A Common Stock on a one-for-one basis (“Preferred
Conversion”). Following the Preferred Conversion, but prior to the effective time of the Merger, each share of Ambulnz Class A Common
Stock and Ambulnz Class B Common Stock was cancelled and converted into the right to receive a pro rata portion of shares of Common Stock
issuable by DocGo as consideration for the Merger.
Concurrent with the Closing, each option to
acquire securities of Ambulnz outstanding immediately prior to the Closing (an “Ambulnz Option”), by virtue of the
occurrence of the Effective Time and without any action on the part of Ambulnz, Motion or the holders thereof, were assumed and
converted into an equivalent option to acquire Common Stock of DocGo (“DocGo Substitute Option”) with respect to a
number of shares of Common Stock equal to the number of whole shares of Ambulnz Common Stock subject to such Ambulnz Option that
were issuable immediately prior to the effective time of the Merger multiplied by 645.1452 (the “Exchange Ratio”),
rounded down to the nearest number of whole shares of Common Stock. The per share exercise price for the shares of Common Stock
issuable upon exercise of such DocGo Substitute Option will be equal to the quotient determined by dividing the exercise price per
share of Ambulnz Common Stock at which such Ambulnz Option was exercisable immediately prior to the effective time of the Merger by
the Exchange Ratio, rounded up to the nearest whole cent.
As of the Closing Date, and immediately following
the consummation of the Business Combination, DocGo had the following issued and outstanding securities:
|
|
●
|
100,069,438
shares of Common Stock (inclusive of the issuances pursuant to the Merger Agreement and those subscription agreements entered by and
between Motion and certain investors on March 8, 2021 (“Subscription Agreements”) and the forfeiture of 301,787 shares of
Common Stock by the Sponsor pursuant to the A&R Sponsor Agreement);
|
|
|
●
|
3,783,724
public warrants, each exercisable for one share of Common Stock at a price of $11.50 per share (the “Public Warrants”); and
|
|
|
●
|
2,533,333
private placement warrants, each exercisable for one share of Common Stock at a price of $11.50 per share (“Private Warrants”,
together with Public Warrants, the “Warrants”).
|
FORM 10 INFORMATION
Prior to the Closing,
Motion was a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”))
with no operations, formed as a vehicle to effect a business combination with one or more businesses or entities. After the Closing, DocGo
became a holding company whose only assets consist of equity interests in Ambulnz.
Cautionary Note Regarding Forward-Looking
Statements
This Current Report on
Form 8-K includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial
of DocGo. These statements are based on the reasonable beliefs and assumptions of the management of DocGo. Although DocGo believes that
its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, DocGo cannot assure
you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks,
uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed
future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded
by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,”
“may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,”
“intends” or similar expressions. Forward-looking statements contained in Current Report on Form 8-K include, but are not
limited to, statements about the ability of DocGo to:
|
|
●
|
access, collect and use personal data about consumers;
|
|
|
●
|
execute its business strategy, including monetization of services provided
and expansions in and into existing and new lines of business;
|
|
|
●
|
anticipate the impact of the coronavirus disease 2019 (“COVID-19”)
pandemic and its effect on business and financial conditions;
|
|
|
●
|
manage risks associated with operational changes in response to the COVID-19
pandemic;
|
|
|
●
|
realize the benefits expected from the Merger;
|
|
|
●
|
anticipate the uncertainties inherent in the development of new business
lines and business strategies;
|
|
|
●
|
retain and hire necessary employees;
|
|
|
●
|
increase brand awareness;
|
|
|
●
|
attract, train and retain effective officers, key employees or directors;
|
|
|
●
|
upgrade and maintain information technology systems;
|
|
|
●
|
acquire and protect intellectual property;
|
|
|
●
|
meet future liquidity requirements and comply with restrictive covenants
related to long-term indebtedness;
|
|
|
●
|
effectively respond to general economic and business conditions;
|
|
|
●
|
maintain the listing on Nasdaq
|
|
|
●
|
obtain additional capital, including use of the debt market;
|
|
|
●
|
enhance future operating and financial results;
|
|
|
●
|
anticipate rapid technological changes;
|
|
|
●
|
comply with laws and regulations applicable to its business, including laws
and regulations related to data privacy and insurance operations;
|
|
|
●
|
stay abreast of modified or new laws and regulations applying to its business;
|
|
|
●
|
anticipate the impact of, and response to, new accounting standards;
|
|
|
●
|
respond to fluctuations in foreign currency exchange rates and political
unrest and regulatory changes in international markets from various events;
|
|
|
●
|
anticipate the rise in interest rates which would increase the cost of capital;
|
|
|
●
|
anticipate the significance and timing of contractual obligations;
|
|
|
●
|
maintain key strategic relationships with partners and distributors;
|
|
|
●
|
respond to uncertainties associated with product and service development
and market acceptance;
|
|
|
●
|
anticipate the ability of the renewable sector to develop to the size or
at the rate it expects;
|
|
|
●
|
manage to finance operations on an economically viable basis;
|
|
|
●
|
anticipate the impact of new U.S. federal income tax law, including the impact
on deferred tax assets;
|
|
|
●
|
successfully defend litigation; and
|
|
|
●
|
successfully deploy the proceeds from the Merger.
|
These and other factors
that could cause actual results to differ from those implied by the forward-looking statements in this Current Report on Form 8-K are
more fully described below under the heading “Risk Factors” and elsewhere in this Current Report on Form 8-K. The risks
described under the heading “Risk Factors” are not exhaustive. Other sections of this Current Report on Form 8-K describe
additional factors that could adversely affect the business, financial condition or results of operations of DocGo. New risk factors emerge
from time to time and it is not possible to predict all such risk factors, nor can DocGo assess the impact of all such risk factors on
the business of DocGo or the extent to which any factor or combination of factors may cause actual results to differ materially from those
contained in any forward-looking statements. All forward-looking statements attributable to DocGo or persons acting on its behalf are
expressly qualified in their entirety by the foregoing cautionary statements. DocGo undertakes no obligations to update or revise publicly
any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
In addition, statements of belief and similar
statements reflect the reasonable beliefs and opinions of DocGo on the relevant subject. These statements are based upon information available
to DocGo as of the date of this Current Report on Form 8-K, and while such party believes such information forms a reasonable basis for
such statements, such information may be limited or incomplete, and statements should not be read to indicate that DocGo has conducted
an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, involve
risks and are subject to change based on various factors, and you are cautioned not to unduly rely upon these statements.
Business and Properties
The information set forth in the section of the
Prospectus entitled “Information About DocGo” beginning on page 168, including the information regarding the properties
used in DocGo’s business included in the subsection thereof entitled “Information About DocGo—Properties”
on page 182, and in the section of the Prospectus entitled “Information About Motion” beginning on page 153 is incorporated
herein by reference.
Risk Factors
The risks associated with DocGo’s business
and operations are described in the Prospectus in the section entitled “Risk Factors” beginning on page 34, which is
incorporated herein by reference.
Financial Information
Unaudited Condensed
Consolidated Financial Statements
The unaudited condensed consolidated financial
statements of Motion as of June 30, 2021 and for the three and six month periods then ended beginning on page F-2 of the Prospectus are
incorporated herein by reference. These unaudited condensed consolidated financial statements should be read in conjunction with the historical
audited financial statements of Motion from August 11, 2020 (inception) through December 31, 2020 and the related notes thereto, which
are included in the Prospectus beginning on page F-19 and are incorporated herein by reference.
The unaudited condensed consolidated
financial statements of Ambulnz as of June 30, 2021 and 2020 and for the three and six month periods then ended beginning on page
F-40 of the Prospectus are incorporated herein by reference. These unaudited condensed consolidated financial statements should be
read in conjunction with the historical audited financial statements of Docgo for the years ended December 31, 2020 and 2019 and the
related notes thereto, which are included in the Prospectus beginning on page F-67 and are incorporated herein by reference.
Selected Historical
Financial and Other Information
The selected historical financial information
set forth in the section of the Prospectus entitled “Selected Historical Financial Information of Motion” beginning
on page 26 and “Selected Historical Financial Information of DocGo” beginning on page 27 are incorporated herein by
reference.
Unaudited Pro Forma
Condensed Combined Financial Information
The information set forth in Exhibit 99.1 to this
Current Report on Form 8-K is incorporated by reference herein.
Management’s Discussion
and Analysis of Financial Condition and Results of Operations
Managements’ discussion and analysis of
the financial condition and results of operation prior to the Merger is included in the Prospectus in the sections entitled “Motion’s
Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on page 163 and “DocGo’s
Management’s Discussion and Analysis of Financial Condition and Results of Operations” beginning on page 188, which are
incorporated herein by reference.
Security Ownership of Certain Beneficial Owners
and Management
The following table sets forth information known
to DocGo regarding beneficial ownership of shares of Common Stock as of November 5, 2021 by:
|
|
●
|
each person who is known by us to be the beneficial owner of more than five percent (5%) of the outstanding shares of Common Stock;
|
|
|
●
|
each of our current executive officers and directors; and
|
|
|
●
|
all current executive officers and directors as a group.
|
Beneficial ownership is determined under the rules
of the SEC and generally includes voting or investment power over securities. Except in cases where community property laws apply or as
indicated in the footnotes to this table, we believe that each securityholder identified in the table possesses sole voting and investment
power over all securities shown as beneficially owned thereby. Shares of Common Stock subject to options and Warrants that are exercisable
or will be exercisable within 60 days of the date of this Current Report on Form 8-K are considered outstanding and beneficially owned
by the person holding the option or Warrant for the purpose of computing the percentage ownership of that person but are not treated as
outstanding for the purpose of computing the percentage ownership of any other person. The beneficial ownership percentages set forth
in the table below are based on 100,069,438 shares of Common Stock issued and outstanding as of November 5, 2021.
|
Name and Address of Beneficial Owners(1)
|
|
Number of
Shares of
Common Stock
Beneficially Owned
|
|
|
Percentage of
Outstanding
Common Stock
|
|
|
Named Executive Officers and Directors:
|
|
|
|
|
|
|
|
|
|
Stan Vashovsky
|
|
|
13,160,962
|
|
|
|
13.2
|
%
|
|
Chris Fillo(2)
|
|
|
4,552,925
|
|
|
|
4.6
|
%
|
|
Ely D. Tendler(3)
|
|
|
21,935
|
|
|
|
*
|
%
|
|
Ira Smedra
|
|
|
—
|
|
|
|
—
|
%
|
|
Steven Katz
|
|
|
—
|
|
|
|
—
|
%
|
|
James Travers(4)
|
|
|
2,573,213
|
|
|
|
2.6
|
%
|
|
Michael Burdiek(4)
|
|
|
2,573,213
|
|
|
|
2.6
|
%
|
|
Anthony Capone(5)
|
|
|
516,116
|
|
|
|
*
|
%
|
|
Andre Oberholzer
|
|
|
1,290,290
|
|
|
|
1.3
|
%
|
|
Norm Rosenberg(6)
|
|
|
120,965
|
|
|
|
*
|
%
|
|
Mike Witkowski(7)
|
|
|
48,386
|
|
|
|
*
|
%
|
|
Dr. Mark Merlin
|
|
|
—
|
|
|
|
—
|
%
|
|
All directors and executive officers as a group (12 individuals)
|
|
|
17,731,867
|
|
|
|
22.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
5% Stockholders:
|
|
|
|
|
|
|
|
|
|
Entities Affiliated with Louis M. Bacon(8)
|
|
|
5,907,927
|
|
|
|
6.4
|
%
|
|
(1)
|
|
Unless otherwise
noted, the business address of each of the executive officers and directors of DocGo is c/o DocGo Inc., 35 West 35th Street, Floor 5,
New York, New York.
|
|
(2)
|
|
Represents (a)
4,530,990 shares held by 1868 Univeritas Fund LP (“Univeritas Fund”) and (b) 21,935 shares over which Univeritas Fund has
the right to acquire upon the exercise of DocGo Substitute Options exercisable as of or within 60 days after November 5, 2021. The
general partner of Univeritas Fund is 1868 Univeritas GP, LLC (“Univeritas GP”). Mr. Fillo is an officer of and
controls Univeritas GP and may be deemed the beneficial owner of the shares held by Univeritas Fund. The business address
of Univeritas Fund, Univeritas GP and Mr. Fillo is 3110 Main Street, Suite 310 Santa Monica, CA 90405
|
|
(3)
|
|
Represents shares
over which Ely D. Tendler has the right to acquire upon the exercise of DocGo Substitute Options exercisable as of or within 60 days
after November 5, 2021.
|
|
(4)
|
|
Represents shares
held by Motion Acquisition LLC. James Travers, Michael Burdiek, Richard Vitelle and Garo Sarkissian are each managing members of Motion
Acquisition LLC and, accordingly, each may be deemed to be the beneficial owner of the securities held by Motion Acquisition LLC. Each
such individual disclaims beneficial ownership over any securities held by Motion Acquisition LLC except to the extent of his pecuniary
interest therein. The business address of Motion Acquisition LLC is c/o Graubard Miller, 405 Lexington Avenue, 11th Floor,
New York, New York 10174.
|
|
(5)
|
|
Represents shares
over which Anthony Capone has the right to acquire upon the exercise of DocGo Substitute Options exercisable as of or within 60 days
after November 5, 2021.
|
|
(6)
|
|
Represents shares
over which Norm Rosenberg has the right to acquire upon the exercise of DocGo Substitute Options exercisable as of or within 60 days
after November 5, 2021.
|
|
(7)
|
|
Represents shares
over which Mike Witkowski has the right to acquire upon the exercise of DocGo Substitute Options exercisable as of or within 60 days
after November 5, 2021.
|
|
(8)
|
|
Represents (a)
5,407,927 shares held by Kendall AF, LLC (“KAF”) and (b) 1,000,000 shares held by MMF LT, LLC (“MMF”). Mr. Louis
M. Bacon controls KAF and may be deemed the beneficial owner of the shares held by KAF. Moore Capital Management, LP (“MCM”)
is the investment manager of MMF and has voting and investment control over the shares held by MCM. Louis M. Bacon also controls the
general partner of MCM. Mr. Bacon may be deemed the beneficial owner of the shares held by MMF. The address of KAF, MMF, MCM and Mr.
Bacon is 11 Times Square, 38th Floor, New York, New York 10036.
|
Information about Directors and Executive Officers
Our directors and officers
are as follows:
|
Name
|
|
Age
|
|
Position
|
|
Stan Vashovsky
|
|
49
|
|
Chairman; Chief Executive Officer
|
|
Chris Fillo
|
|
57
|
|
Director
|
|
Ely D. Tendler
|
|
53
|
|
Director; General Counsel and Secretary
|
|
Ira Smedra
|
|
72
|
|
Director
|
|
James M. Travers
|
|
70
|
|
Director
|
|
Michael Burdiek
|
|
62
|
|
Director
|
|
Steven Katz
|
|
73
|
|
Director
|
|
Anthony Capone
|
|
34
|
|
President
|
|
Andre Oberholzer
|
|
63
|
|
Chief Financial Officer
|
|
Norman Rosenberg
|
|
52
|
|
Chief Financial Officer (Ambulnz Holdings, LLC)
|
|
Mike Witkowski
|
|
53
|
|
Chief Compliance Officer
|
|
Dr. Mark Merlin
|
|
54
|
|
Chief Medical Officer (Ambulnz Holdings, LLC)
|
Information with respect to DocGo’s directors
appointed immediately after the Closing, including biographical information regarding these individuals, is set forth in the Prospectus
in the section entitled “Proposal No. 3 — The Director Election Proposal” beginning on page 132, which information
is incorporated herein by reference. Information with respect to DocGo’s officers appointed immediately after the Closing, including
biographical information regarding these individuals, is set forth in the Prospectus in the section entitled “Management of DocGo
After the Merger” beginning on page 214, which information is incorporated herein by reference.
Resignations and Appointments
In connection with the Closing, other than Mr.
Travers and Mr. Burdiek, each of Motion’s directors prior to the Closing resigned from their respective position as a director of
Motion, in each case effective as of the effective time on the Closing Date.
In connection with the Closing, the structure
of the board of directors increased to seven (7) directors. Effective as of immediately following the Closing, the board of directors
appointed Messrs. Vashovsky, Fillo, Tendler, Smedra and Katz to serve on the board of directors, until the expiration of such director’s
initial term (as set forth below) or until their successors have been duly elected and qualified, or until their earlier death, resignation,
retirement or removal. Biographies of each of Messrs. Vashovsky, Fillo, Tendler, Smedra and Katz are set forth in the Prospectus entitled
“Proposal No. 3 — The Director Election Proposal” beginning on page 132, and are incorporated by reference herein.
Additionally, the board of directors is divided into three classes with only one class of directors being elected in each year and each
class (except for those directors appointed prior to our first annual meeting of stockholders) serving a three-year term. Messrs. Vashovsky,
Tendler and Smedra will be Class I directors serving until DocGo’s 2022 annual meeting of stockholders; Messrs. Fillo and Travers
will be Class II directors serving until DocGo’s 2023 annual meeting of stockholders; and Messrs. Katz and Burdiek, will be Class
III directors serving until DocGo’s 2024 annual meeting of stockholders, and in each case, until their successors are elected and
qualified.
In connection with the Closing, each of Motion’s
and its subsidiaries’ executive officers prior to the Closing resigned from his respective position as an executive officer of Motion,
in each case effective as of the effective time on the Closing Date.
Effective as of immediately following the Closing,
on the Closing Date, Mr. Vashovsky was appointed to serve as DocGo’s Chief Executive Officer, Mr. Capone was appointed to serve
as DocGo’s President, Mr. Oberholzer was appointed to serve as DocGo’s Chief Financial Officer, Mr. Rosenberg was appointed
to serve as the Chief Financial Officer of Ambulnz Holdings, LLC, Mr. Witkowski was appointed to serve as DocGo’s Chief Compliance
Officer, and Dr. Merlin was appointed to serve as Chief Medical Officer of Ambulnz Holdings, LLC.
Role of Board in Risk Oversight
The board of directors has extensive involvement
in the oversight of risk management related to us and our business and accomplishes this oversight through the regular reporting to the
board of directors by the audit committee. The audit committee represents the board of directors by periodically reviewing our accounting,
reporting and financial practices, including the integrity of our financial statements, the surveillance of administrative and financial
controls and our compliance with legal and regulatory requirements. Through its regular meetings with management, including the finance,
legal, internal audit and information technology functions, the audit committee reviews and discusses all significant areas of our business
and summarizes for the board of directors all areas of risk and the appropriate mitigating factors. In addition, our board of directors
receives periodic detailed operating performance reviews from management.
Director Independence
The board of directors has determined that each
of Messrs. Smedra, Fillo, Travers, Burdiek and Katz are independent as defined under the Nasdaq listing standards.
Committees of the Board
of Directors
Messrs. Katz, Fillo and Burdiek serving as
members of the audit committee of the board of directors, with Mr. Katz serving as its chair. Messrs. Smedra and Katz serving as members
of the compensation committee of the board of directors, with Mr. Smedra serving as its chair. Messrs. Fillo, Smedra and Katz serving
as members of the nominating and governance committee of the board of directors, with Mr. Fillo servings as its chair. Each committee
operates under a charter that has been approved by our board of directors and is available on our website at https://ir.docgo.com/corporate-governance/governance-overview.
The committees have the composition and responsibilities described below.
Audit Committee
Our board of directors has established
an Audit Committee. The primary role of the Audit Committee is to exercise primary financial oversight on behalf of the board of directors.
DocGo’s management team is responsible for preparing financial statements, and DocGo’s independent registered public accounting
firm is responsible for auditing those financial statements. The Audit Committee is directly responsible for the selection, engagement,
compensation, retention and oversight of DocGo’s independent registered public accounting firm. The Audit Committee is also responsible
for the review of any proposed related persons transactions.
The Audit Committee
consists of Mr. Katz, who serves as the chair and member of the Audit Committee, along with Messrs. Fillo and Burdiek serving as
members. Each member of the Audit Committee qualifies as an independent director under and meets the financial literacy requirements
of the Nasdaq listing standards and SEC rules applicable to audit committee members. Our board of directors has determined that Mr.
Katz is as an “audit committee financial expert” as defined in applicable SEC rules.
Compensation
Committee
Our board of directors has established
a Compensation Committee. The Compensation Committee acts on behalf of and in conjunction with the board of directors to establish or
recommend the compensation of executive officers of DocGo and to provide oversight of DocGo’s overall compensation programs and
philosophy. The Compensation Committee is responsible for approving the compensation, including performance bonuses, payable to the executive
officers of DocGo, and administering DocGo’s equity compensation plans.
Messrs. Smedra and Katz will
serve as members of the Compensation Committee, with Mr. Smedra serving as its chair. Our board of directors
has determined that each member of the Compensation Committee qualifies as an independent director under and meets the requirements of
the Nasdaq listing standards and applicable SEC rules.
Nominating and
Governance Committee
Our board of directors has established
a Nominating and Governance Committee. The Nominating and Governance Committee assists the board of directors by identifying and recommending
individuals qualified to become members of the board. The Nominating and Governance Committee is responsible for evaluating the composition,
size and governance of the board and its committees and making recommendations regarding future planning and the appointment of directors
to the committees, establishing a policy for considering stockholder nominees to the board, reviewing the corporate governance principles
and making recommendations to the board regarding possible changes; and reviewing and monitoring compliance with DocGo’s Amended
and Restated Code of Business Conduct and Ethics.
Mr. Fillo is the chair and member
of the Nominating and Governance Committee, along with Messrs. Smedra and Katz serving as members. Our board of directors has determined
that each member of the Nominating and Governance Committee qualifies as an independent director under the Nasdaq listing standards and
applicable SEC rules.
Code of Ethics
On November 5, 2021, our board
of directors adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our
principal executive officer, principal financial officer and principal accounting officer. Copies of the Code of Business Conduct and
Ethics and charters for each of our committees is available on our website at https://ir.docgo.com/corporate-governance/governance-overview.
In the event DocGo makes any amendments to, or grants any waiver from, a provision of the code that applies to our principal executive
officer, principal financial officer or principal accounting officer that requires disclosure under applicable SEC or Nasdaq rules, DocGo
will disclose such amendment or waiver and reasons therefore on its website at www.docgo.com within the time period required by such rules.
Our website is not part of this Current Report on Form 8-K.
Corporate Governance
Guidelines
Our board of directors has adopted
a corporate governance guidelines in accordance with the corporate governance rules of Nasdaq that serve as a flexible framework within
which our board of directors and its committees operate. These guidelines cover a number of areas including board membership criteria
and director qualifications, director responsibilities, board agenda, meetings of independent directors, committee responsibilities and
assignments, board member access to management and independent advisors, director communications with third parties, director compensation,
director orientation and continuing education, evaluation of senior management and management succession planning. A copy of our corporate
governance guidelines is available on our website at https://ir.docgo.com/corporate-governance/governance-overview.
Director Compensation
The Compensation Committee will determine the
annual compensation to be paid to the members of the board of directors. Directors’ fees have yet to be determined, but are expected
to consist of two components: a cash payment and the issuance of restricted stock units. DocGo anticipates that directors who also serve
as an employee of DocGo will not receive additional compensation for their service as a director.
Executive Compensation
The compensation for Ambulnz’s executive
officers before the Closing is described in the Prospectus in the section entitled “Executive and Director Compensation—Executive
and Director Compensation of DocGo” beginning on page 210, which information is incorporated herein by reference. The compensation
of the named executive officers of Motion prior to the Closing is set forth in the Prospectus in the section entitled “Executive
and Director Compensation—Executive and Director Compensation of Motion” beginning on page 210, which information is incorporated
herein by reference.
The general compensation programs of DocGo’s
executive officers after the Closing are described in the section of the Prospectus entitled “Management of DocGo After the Merger—DocGo
Director and Executive Compensation” beginning on page 216, which information is incorporated herein by reference. The disclosure
set forth above in Item 1.01 of this Current Report on Form 8-K under the section entitled “Executive Employment Agreements”
is incorporated herein by reference.
The Incentive Plan was approved by DocGo’s
stockholders at the Meeting. A description of the Incentive Plan is set forth in the section of the Prospectus entitled “Proposal
No. 5—The Incentive Plan Proposal” beginning on page 137 and is incorporated herein by reference. A copy of the complete
text of the Incentive Plan is filed as Exhibit 10.5 to this Current Report on Form 8-K and is incorporated herein by reference.
Certain Relationships and Related Transactions
Our board of directors adopted a written policy
regarding the review and approval or disapproval by our Audit Committee of transactions between us or any of our subsidiaries and any
related person (defined to include our executive officers, directors or director nominees, any stockholder beneficially owning in excess
of 5% of our stock or securities exchangeable for our stock, and any immediate family member of any of the foregoing persons) in which
one or more of such related persons has a direct or indirect interest. In approving or rejecting any such transaction, our Audit Committee
will consider the relevant facts and circumstances available and deemed relevant to the Audit Committee. Any member of the Audit Committee
who is a related person with respect to a transaction under review will not be permitted to participate in the deliberations or vote on
approval or disapproval of the transaction.
Certain relationships and related party transactions
of DocGo are described in the Prospectus in the section entitled “Certain Relationships and Related Party Transactions”
beginning on page 222 of the Prospectus, which is incorporated herein by reference. On November 10, 2021, the Audit Committee approved such related party transactions pursuant to DocGo's Related Person Transaction Policy
and Procedures.
Legal Proceedings
From time to time, DocGo and its subsidiaries
may become involved in additional legal proceedings arising in the ordinary course of our business. DocGo and its subsidiaries have been
and continue to be involved in legal proceedings that arise in the ordinary course of business, the outcome of which, if determined adversely
to DocGo or any of its subsidiaries, would not individually or in the aggregate have a material adverse effect on DocGo’s business,
financial condition and results of operations.
Market Price of and Dividends on the Registrant’s
Common Equity and Related Stockholder Matters
Market Information
and Holders
Motion’s common
stock and warrants were historically quoted on Nasdaq under the symbols “MOTN” and “MOTNW,” respectively. On November
8, 2021, the Common Stock and Public Warrants were listed on Nasdaq under the new trading symbols of “DCGO” and “DCGOW,”
respectively.
As of the Closing Date
and following the completion of the Merger, DocGo had 100,069,438 shares of Common Stock issued and outstanding held of record by 193
holders and 6,317,057 warrants outstanding held of record by 2 holders. Such numbers do not include Depository Trust Company participants
or beneficial owners holding shares through nominee names.
Dividends
DocGo has not paid any
cash dividends on Common Stock to date. DocGo may retain future earnings, if any, for future operations, expansion and debt repayment
and has no current plans to pay cash dividends for the foreseeable future. Any decision to declare and pay dividends in the future will
be made at the discretion of the board of directors and will depend on, among other things, DocGo’s results of operations, financial
condition, cash requirements, contractual restrictions and other factors that the board of directors may deem relevant. In addition, DocGo’s
ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness DocGo or its subsidiaries incur.
DocGo does not anticipate declaring any cash dividends to holders of Common Stock in the foreseeable future.
Recent Sales of Unregistered
Securities
The description of the
issuances pursuant to the Merger Agreement and the transactions contemplated thereby, as set forth in Item 2.01 of this Current Report
on Form 8-K, is incorporated herein by reference.
Information regarding unregistered sales of
securities is set forth in Part II, Item 2 of Motion’s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021.
DocGo intends to file with the SEC a registration
statement on Form S-1 covering the following share issuances: (A) 2,573,213 Founder Shares, (B) 2,533,333 Private Warrants that were issued
prior to Motion’s initial public offering that, pursuant to the terms of the Warrant Agreement, dated October 14, 2020, by and between
Motion and Continental Stock Transfer & Trust Company (the “Warrant Agreement”), representing a right to acquire
2,533,333 shares of Common Stock, (C) 2,533,333 shares of Common Stock that, pursuant to the Warrant Agreement, underly the Private Warrants,
(D) 3,783,724 shares of Common Stock that, pursuant to the Warrant Agreement, underly the 3,783,724 Public Warrants, (E) 12,500,000 shares
of Common Stock that were issued to the those certain investors in connection with the consummation of the Business Combination pursuant
to the Subscription Agreements, and (F) 13,160,962 shares of Common Stock issued to certain holders of Ambulnz securities as consideration
for the Merger.
Description of Registrant’s Securities
Authorized Capital Stock
Our Second Amended and
Restated Charter (the “Second A&R Charter”) authorizes the issuance of 550,000,000 shares of capital stock, consisting
of (i) 500,000,000 shares of Common Stock, and (ii) 50,000,000 shares of preferred stock, par value $0.0001 per share.
Common Stock
The Second A&R Charter provides that DocGo
will have one class of common stock.
Preferred Stock
The Second A&R Charter
provides that shares of preferred stock may be issued from time to time in one or more series. The board of directors of DocGo will be
authorized to fix the voting rights, if any, designations, powers, preferences and relative, participating, optional, special and other
rights, if any, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The DocGo board
is able, without stockholder approval, to issue preferred stock with voting and other rights that could adversely affect the voting power
and other rights of the holders of the Common Stock and could have anti-takeover effects. The ability of board of directors of DocGo to
issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of us
or the removal of existing management. We have no preferred stock outstanding at the date hereof. Although we do not currently intend
to issue any shares of preferred stock, we cannot assure you that we will not do so in the future.
DocGo
Substitute Option
Concurrent with the Closing,
each Ambulnz Option by virtue of the occurrence of the Effective Time and without any action on the part of Ambulnz, Motion or the holders
thereof, were assumed and converted into a an equivalent DocGo Substitute Option with respect to a number of shares of Common Stock equal
to the number of whole shares of Ambulnz Common Stock subject to such Ambulnz Option that were issuable immediately prior to the effective
time of the Merger multiplied by the Exchange Ratio, rounded down to the nearest number of whole shares of Common Stock. The per share
exercise price for the shares of Common Stock issuable upon exercise of such DocGo Substitute Option will be equal to the quotient determined
by dividing the exercise price per share of Ambulnz Common Stock at which such Ambulnz Option was exercisable immediately prior to the
effective time of the Merger by the Exchange Ratio, rounded up to the nearest whole cent..
3,900,868 shares have
been reserved for issuance by DocGo upon the exercise of the DocGo Substitute Options. DocGo does not intend to register the DocGo Substitute
Options.
Warrants
As of the Closing Date,
there were 6,317,057 Warrants outstanding, consisting of 3,783,724 Public Warrants and 2,533,333 Private Warrants.
Public Warrants
Each whole Warrant entitles
the registered holder to purchase one share of our Common Stock at a price of $11.50 per share, subject to adjustment as discussed below,
at any time commencing 30 days after the completion of the Merger, except as described below. Pursuant to the Warrant Agreement, a warrant
holder may exercise its warrants only for a whole number of shares of Common Stock. This means that only a whole warrant may be exercised
at any given time by a warrant holder. The warrants will expire five years after the completion of the Merger, at 5:00 p.m., New York
City time, or earlier upon redemption or liquidation.
We will not be obligated
to deliver any shares of Common Stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise
unless a registration statement under the Securities Act covering the issuance of the shares of Common Stock underlying the warrants is
then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to
registration. No warrant will be exercisable and we will not be obligated to issue shares of Common Stock upon exercise of a warrant unless
the Common Stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of
the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences
are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant
may have no value and expire worthless. In no event will we be required to net cash settle any warrant.
As soon as practicable,
but in no event later than 15 business days after the Closing, we will use our reasonable best efforts to file, and within 60 business
days following the Closing to have declared effective, a registration statement under the Securities Act covering the issuance of the
shares of Common Stock issuable upon exercise of the warrants. Accordingly, DocGo will use its reasonable best efforts to maintain
the effectiveness of such registration statement and a current prospectus relating to those shares of Common Stock until the warrants
expire or are redeemed. Notwithstanding the above, if the Common Stock is not listed on a national securities exchange at the time of
any exercise of a warrant, such that the Common Stock does not satisfy the definition of a “covered security” under Section
18(b)(1) of the Securities Act at that time, we may, at our option, require holders of public warrants who exercise their warrants to
do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event we so elect, we will
not be required to file or maintain in effect a registration statement, but we will be required to use our best efforts to register or
qualify the shares under applicable blue sky laws to the extent an exemption is not available.
Redemption of warrants
when the price per share of Common Stock equals or exceeds $18.00. Once the warrants become exercisable, we may redeem the outstanding
warrants (except as described herein with respect to the Private Warrants):
|
|
●
|
in whole and not in part;
|
|
|
●
|
at a price of $0.01 per warrant;
|
|
|
●
|
upon not less than 30 days’ prior written
notice of redemption (the “30-day redemption period”) to each warrant holder; and
|
|
|
●
|
if, and only if, the last reported sale price
of the Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations
and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending on the
third trading day prior to the date on which we send the notice of redemption to the warrant holders.
|
If and when the warrants
become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for
sale under all applicable state securities laws. As a result, we may redeem the warrants as set forth above even if the holders are otherwise
unable to exercise the warrants.
We have established the
$18.00 per share (subject to adjustment) redemption criteria discussed above to prevent a redemption call unless there is at the time
of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption
of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled redemption date. However, the price
of the Common Stock may fall below the $18.00 redemption trigger price (as adjusted for stock splits, stock dividends, reorganizations,
recapitalizations and the like) as well as the $11.50 (for whole shares) warrant exercise price after the redemption notice is issued.
If we call the warrants
for redemption for cash as described above, our management will have the option to require any holder that wishes to exercise its warrant
to do so on a “cashless basis.” In determining whether to require all holders to exercise their warrants on a “cashless
basis,” our management will consider, among other factors, our cash position, the number of warrants that are outstanding and the
dilutive effect on our stockholders of issuing the maximum number of shares of Common Stock issuable upon the exercise of our warrants.
If our management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants
for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common
Stock underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price
of the warrants by (y) the fair market value. The “fair market value” for this purpose shall mean the average last reported
sale price of the Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of warrants. If our management takes advantage of this option, the notice of redemption will contain the information
necessary to calculate the number of shares of Common Stock to be received upon exercise of the warrants, including the “fair market
value” in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen
the dilutive effect of a warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the
exercise of the warrants after our initial business combination. If we call our warrants for redemption and our management does not take
advantage of this option, the initial purchasers and their permitted transferees would still be entitled to exercise their Private Warrants
for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had
all warrant holders been required to exercise their warrants on a cashless basis, as described in more detail below.
Redemption of warrants
when the price per share of Common Stock equals or exceeds $10.00. Commencing ninety days after the warrants become exercisable,
we may redeem the outstanding warrants:
|
|
●
|
in whole and not in part;
|
|
|
●
|
at $0.10 per warrant upon a minimum of 30 days’
prior written notice of redemption provided that holders will be able to exercise their warrants prior to redemption and receive that
number of shares of Common Stock to be determined by reference to the table below, based on the redemption date and the “fair market
value” of our Common Stock (as defined below) except as otherwise described below;
|
|
|
●
|
if, and only if, the last reported sale price
of Common Stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations
and the like) on the trading day prior to the date on which we send the notice of redemption to the warrant holders;
|
|
|
●
|
if, and only if, the Private Warrants are also
concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above; and
|
|
|
●
|
if, and only if, there is an effective registration
statement covering the issuance of the shares of Common Stock issuable upon exercise of the warrants and a current prospectus relating
thereto available throughout the 30-day period after written notice of redemption is given.
|
The numbers in the table
below represent the number of shares of Common Stock that a warrant holder will receive upon exercise in connection with a redemption
by us pursuant to this redemption feature, based on the “fair market value” of our Common Stock on the corresponding redemption
date (assuming holders elect to exercise their warrants and such warrants are not redeemed for $0.10 per warrant), determined based on
the average of the last reported sales price for the 10 trading days ending on the third trading day prior to the date on which the notice
of redemption is sent to the holders of warrants, and the number of months that the corresponding redemption date precedes the expiration
date of the warrants, each as set forth in the table below.
The stock prices set
forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of
a warrant is adjusted as set forth in the first three paragraphs under the heading “— Anti-dilution Adjustments” below.
The adjusted stock prices in the column headings will equal the stock prices immediately prior to such adjustment, multiplied by a fraction,
the numerator of which is the number of shares deliverable upon exercise of a warrant immediately prior to such adjustment and the denominator
of which is the number of shares deliverable upon exercise of a warrant as so adjusted. The number of shares in the table below shall
be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a warrant.
Redemption
Date (period to
|
|
Fair Market Value of Common
Stock
|
|
|
expiration of warrants)
|
|
$10.00
|
|
|
$11.00
|
|
|
$12.00
|
|
|
$13.00
|
|
|
$14.00
|
|
|
$15.00
|
|
|
$16.00
|
|
|
$17.00
|
|
|
$18.00
|
|
|
57 months
|
|
|
0.233
|
|
|
|
0.255
|
|
|
|
0.275
|
|
|
|
0.293
|
|
|
|
0.309
|
|
|
|
0.324
|
|
|
|
0.338
|
|
|
|
0.350
|
|
|
|
0.361
|
|
|
54 months
|
|
|
0.229
|
|
|
|
0.251
|
|
|
|
0.272
|
|
|
|
0.291
|
|
|
|
0.307
|
|
|
|
0.323
|
|
|
|
0.337
|
|
|
|
0.350
|
|
|
|
0.361
|
|
|
51 months
|
|
|
0.225
|
|
|
|
0.248
|
|
|
|
0.269
|
|
|
|
0.288
|
|
|
|
0.305
|
|
|
|
0.321
|
|
|
|
0.336
|
|
|
|
0.349
|
|
|
|
0.361
|
|
|
48 months
|
|
|
0.220
|
|
|
|
0.243
|
|
|
|
0.265
|
|
|
|
0.285
|
|
|
|
0.303
|
|
|
|
0.320
|
|
|
|
0.335
|
|
|
|
0.349
|
|
|
|
0.361
|
|
|
45 months
|
|
|
0.214
|
|
|
|
0.239
|
|
|
|
0.261
|
|
|
|
0.282
|
|
|
|
0.301
|
|
|
|
0.318
|
|
|
|
0.334
|
|
|
|
0.348
|
|
|
|
0.361
|
|
|
42 months
|
|
|
0.208
|
|
|
|
0.234
|
|
|
|
0.257
|
|
|
|
0.278
|
|
|
|
0.298
|
|
|
|
0.316
|
|
|
|
0.333
|
|
|
|
0.348
|
|
|
|
0.361
|
|
|
39 months
|
|
|
0.202
|
|
|
|
0.228
|
|
|
|
0.252
|
|
|
|
0.275
|
|
|
|
0.295
|
|
|
|
0.314
|
|
|
|
0.331
|
|
|
|
0.347
|
|
|
|
0.361
|
|
|
36 months
|
|
|
0.195
|
|
|
|
0.222
|
|
|
|
0.247
|
|
|
|
0.271
|
|
|
|
0.292
|
|
|
|
0.312
|
|
|
|
0.330
|
|
|
|
0.346
|
|
|
|
0.361
|
|
|
33 months
|
|
|
0.187
|
|
|
|
0.215
|
|
|
|
0.241
|
|
|
|
0.266
|
|
|
|
0.288
|
|
|
|
0.309
|
|
|
|
0.328
|
|
|
|
0.345
|
|
|
|
0.361
|
|
|
30 months
|
|
|
0.179
|
|
|
|
0.208
|
|
|
|
0.235
|
|
|
|
0.261
|
|
|
|
0.284
|
|
|
|
0.306
|
|
|
|
0.326
|
|
|
|
0.345
|
|
|
|
0.361
|
|
|
27 months
|
|
|
0.170
|
|
|
|
0.199
|
|
|
|
0.228
|
|
|
|
0.255
|
|
|
|
0.280
|
|
|
|
0.303
|
|
|
|
0.324
|
|
|
|
0.343
|
|
|
|
0.361
|
|
|
24 months
|
|
|
0.159
|
|
|
|
0.190
|
|
|
|
0.220
|
|
|
|
0.248
|
|
|
|
0.274
|
|
|
|
0.299
|
|
|
|
0.322
|
|
|
|
0.342
|
|
|
|
0.361
|
|
|
21 months
|
|
|
0.148
|
|
|
|
0.179
|
|
|
|
0.210
|
|
|
|
0.240
|
|
|
|
0.268
|
|
|
|
0.295
|
|
|
|
0.319
|
|
|
|
0.341
|
|
|
|
0.361
|
|
|
18 months
|
|
|
0.135
|
|
|
|
0.167
|
|
|
|
0.200
|
|
|
|
0.231
|
|
|
|
0.261
|
|
|
|
0.289
|
|
|
|
0.315
|
|
|
|
0.339
|
|
|
|
0.361
|
|
|
15 months
|
|
|
0.120
|
|
|
|
0.153
|
|
|
|
0.187
|
|
|
|
0.220
|
|
|
|
0.253
|
|
|
|
0.283
|
|
|
|
0.311
|
|
|
|
0.337
|
|
|
|
0.361
|
|
|
12 months
|
|
|
0.103
|
|
|
|
0.137
|
|
|
|
0.172
|
|
|
|
0.207
|
|
|
|
0.242
|
|
|
|
0.275
|
|
|
|
0.306
|
|
|
|
0.335
|
|
|
|
0.361
|
|
|
9 months
|
|
|
0.083
|
|
|
|
0.117
|
|
|
|
0.153
|
|
|
|
0.191
|
|
|
|
0.229
|
|
|
|
0.266
|
|
|
|
0.300
|
|
|
|
0.332
|
|
|
|
0.361
|
|
|
6 months
|
|
|
0.059
|
|
|
|
0.092
|
|
|
|
0.130
|
|
|
|
0.171
|
|
|
|
0.213
|
|
|
|
0.254
|
|
|
|
0.292
|
|
|
|
0.328
|
|
|
|
0.361
|
|
|
3 months
|
|
|
0.030
|
|
|
|
0.060
|
|
|
|
0.100
|
|
|
|
0.145
|
|
|
|
0.193
|
|
|
|
0.240
|
|
|
|
0.284
|
|
|
|
0.324
|
|
|
|
0.361
|
|
|
0 months
|
|
|
0.000
|
|
|
|
0.000
|
|
|
|
0.042
|
|
|
|
0.115
|
|
|
|
0.179
|
|
|
|
0.233
|
|
|
|
0.281
|
|
|
|
0.324
|
|
|
|
0.361
|
|
For example, if the average
last reported sale price of Common Stock for the 10 trading days ending on the third trading date prior to the date on which the notice
of redemption is sent to the holders of the warrants is $11 per share, and at such time there are 57 months until the expiration of the
warrants, holders may choose to, in connection with this redemption feature, exercise their warrants for 0.255 shares of Common Stock
for each whole warrant. However, the exact fair market value and redemption date may not be set forth in the table above, in which case,
if the fair market value is between two values in the table or the redemption date is between two redemption dates in the table, the number
of shares of Common Stock to be issued for each warrant exercised will be determined by a straight-line interpolation between the number
of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a
365 or 366-day year, as applicable. For an example where the exact fair market value and redemption date are not as set forth in the table
above, if the average last reported sale price of Common Stock for the 10 trading days ending on the third trading date prior to the date
on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such time there are 38 months until
the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants for 0.284 shares
of Common Stock for each whole warrant. In no event will the warrants be exercisable in connection with this redemption feature for more
than 0.361 shares of Common Stock per warrant. Once the average last reported sale price of Common Stock exceeds $18.00, we will have
the option to redeem the warrants using this method or as described above under the heading “Redemption of warrants when the price
per share of Common Stock equals or exceeds $18.00.”
This redemption feature
differs from the typical warrant redemption features used in other blank check companies, which typically only provide for a redemption
of warrants only when the trading price for the common stock exceeds $18.00 per share for a specified period of time. This redemption
feature is structured to allow for all of the outstanding warrants to be redeemed when the Common Stock is trading at or above $10.00
per share, which may be at a time when the trading price of Common Stock is below the exercise price of the warrants. We have established
this redemption feature to provide us with the flexibility to redeem the warrants without the warrants having to reach the $18.00 per
share threshold set forth above under “— Redemption of warrants when the price per share of Common Stock equals or exceeds
$18.00.” Holders choosing to exercise their warrants in connection with a redemption pursuant to this feature will, in effect, receive
a number of shares representing the applicable redemption price for their warrants based on an option pricing model with a fixed volatility
input as of the date of this prospectus. This redemption right provides us with an additional mechanism by which to redeem all of the
outstanding warrants, and therefore have certainty as to our capital structure. As such, we would redeem the warrants in this manner when
we believe it is in our best interest to update our capital structure to remove the warrants.
As stated above, we can
redeem the warrants when the Common Stock is trading at a price starting at $10.00, which is below the exercise price of $11.50, because
it will provide certainty with respect to our capital structure and cash position while providing warrant holders with the opportunity
to exercise their warrants on a cashless basis for the applicable number of shares. If we choose to redeem the warrants when the Common Stock is trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer
shares of Common Stock than they would have received if they had exercised their warrants for shares of Common Stock if and when the Common
Stock trades at a price higher than the exercise price of $11.50.
No fractional shares
of Common Stock will be issued upon exercise of the warrants. If, upon exercise, a holder would be entitled to receive a fractional interest
in a share, we will round up to the nearest whole number of the number of shares of Common Stock to be issued to the holder. If, at the
time of redemption, the warrants are exercisable for a security other than the shares of Common Stock pursuant to the Warrant Agreement
(for instance, if we are not the surviving company in our initial business combination), the warrants may be exercised for such security.
Exercise Limitations.
A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the
right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person’s
affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 4.8% or 9.8% (or such other amount as
a holder may specify) of the shares of Common Stock outstanding immediately after giving effect to such exercise.
Anti-Dilution Adjustments.
If the number of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up
of shares of Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event, the number
of shares of Common Stock issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding shares
of Common Stock. A rights offering to holders of Common Stock entitling holders to purchase shares of Common Stock at a price less than
the fair market value will be deemed a stock dividend of a number of shares of Common Stock equal to the product of (i) the number of
shares of Common Stock sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are
convertible into or exercisable for Common Stock) multiplied by (ii) one (1) minus the quotient of (x) the price per share of Common Stock
paid in such rights offering divided by (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible
into or exercisable for Common Stock, in determining the price payable for Common Stock, there will be taken into account any consideration
received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume
weighted average price of Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the first
date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without the right
to receive such rights.
In addition, if we, at
any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to
the holders of Common Stock on account of such shares of Common Stock (or other shares of our capital stock into which the warrants are
convertible), other than (a) as described above and (b) certain ordinary cash dividends, then the warrant exercise price will be decreased,
effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or
other assets paid on each share of Common Stock in respect of such event.
If the number of outstanding
shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock
or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar
event, the number of shares of Common Stock issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding
shares of Common Stock.
Whenever the number of
shares of Common Stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will
be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will
be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the
denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter.
In case of any reclassification
or reorganization of the outstanding shares of Common Stock (other than those described above or that solely affects the par value of
such shares of Common Stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation
or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding
shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of
us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the warrants will thereafter
have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the
shares of our Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the
kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization,
merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received
if such holder had exercised their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders
of Common Stock in such a transaction is payable in the form of common stock in the successor entity that is listed for trading on a national
securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following
such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure
of such transaction, the warrant exercise price will be reduced as specified in the Warrant Agreement based on the Black-Scholes value
(as defined in the Warrant Agreement) of the warrant.
The warrant holders do
not have the rights or privileges of holders of Common Stock or any voting rights until they exercise their warrants and receive shares
of Common Stock. After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one (1) vote
for each share held of record on all matters to be voted on by stockholders.
No fractional shares
will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest
in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrant holder.
Private Warrants
The Private Warrants
(including the warrants that may be issued upon conversion of working capital loans and the Common Stock issuable upon exercise of such
warrants) will not be transferable, assignable or salable until 30 days after the Closing (except to certain permitted transferees, each
of which will be subject to the same transfer restrictions) and they will not be redeemable by us so long as they are held by the initial
purchasers or their permitted transferees (except as described under “Redemption of warrants when the price per share of common
Stock equals or exceeds $10.00”). The initial purchasers, or their permitted transferees, have the option to exercise the Private
Warrants on a cashless basis and the initial purchasers and their permitted transferees will also have certain registration rights related
to the Private Warrants (including the shares of Common Stock issuable upon exercise of the Private Warrants), as described below. Otherwise,
the Private Warrants have terms and provisions that are identical to those of the public warrants, including as to exercise price, exercisability
and exercise period. If the Private Warrants are held by holders other than the initial purchasers or their permitted transferees, the
Private Warrants will be redeemable by us in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants.
If holders of the Private
Warrants elect to exercise them on a cashless basis other than in connection with the above $10.00 redemption, they would pay the exercise
price by surrendering their warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product
of the number of shares of Common Stock underlying the warrants, multiplied by the excess of the “private warrant fair market value”
(defined below) over the exercise price of the warrants by (y) the private warrant fair market value. The “private warrant fair
market value” shall mean the average last reported sale price of the Common Stock for the 10 trading days ending on the third trading
day prior to the date on which the notice of warrant exercise is sent to the warrant agent. The reason that we have agreed that these
warrants will be exercisable on a cashless basis so long as they are held by the initial purchasers or their permitted transferees is
because it is not known at this time whether they will be affiliated with us following an initial business combination. If they remain
affiliated with us, their ability to sell our securities in the open market will be significantly limited. We expect to have policies
in place that prohibit insiders from selling our securities except during specific periods of time. Even during such periods of time when
insiders will be permitted to sell our securities, an insider cannot trade in our securities if he or she is in possession of material
non-public information. Accordingly, unlike public stockholders who could sell the shares of Common Stock issuable upon exercise of the
warrants freely in the open market, the insiders could be significantly restricted from doing so. As a result, we believe that allowing
the holders to exercise such warrants on a cashless basis is appropriate.
Indemnification of
Directors and Officers
A description of DocGo’s
indemnification obligations in respect of its directors and officers is included in the Prospectus in the section entitled “Description
of New DocGo Capital Stock—Limitations on Liability and Indemnification of Officers and Directors” beginning on pages
239 of the Prospectus, which is incorporated herein by reference. The disclosure set forth above in Item 1.01 of this Current Report on
Form 8-K under the section entitled “Indemnification Agreements” is incorporated herein by reference.
Financial Statements and Supplementary
Data
The information set forth
under Item 9.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 3.02 Unregistered
Sales of Equity Securities.
The description of the
issuances pursuant to the Merger Agreement and the transactions contemplated thereby, as set forth in Item 2.01 of this Current Report
on Form 8-K, is incorporated herein by reference.
Information regarding unregistered sales of
securities is set forth in Part II, Item 2 of Motion’s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021.
DocGo intends to file with the SEC a registration
statement on Form S-1 covering the following share issuances: (A) 2,573,213 Founder Shares, (B) 2,533,333 Private Warrants that were issued
prior to Motion’s initial public offering that, pursuant to the terms of the Warrant Agreement, dated October 14, 2020, by and between
Motion and Continental Stock Transfer & Trust Company (the “Warrant Agreement”), representing a right to acquire
2,533,333 shares of Common Stock, (C) 2,533,333 shares of Common Stock that, pursuant to the Warrant Agreement, underly the Private Warrants,
(D) 3,783,724 shares of Common Stock that, pursuant to the Warrant Agreement, underly the 3,783,724 Public Warrants, (E) 12,500,000 shares
of Common Stock that were issued to the those certain investors in connection with the consummation of the Business Combination pursuant
to the Subscription Agreements, and (F) 13,160,962 shares of Common Stock issued to certain holders of Ambulnz securities as consideration
for the Merger.
Item 3.03 Material Modification to Rights
of Security Holders.
On the Closing Date,
DocGo filed the Second A&R Charter with the Secretary of State of the State of Delaware. The material terms of the Second A&R
Charter and the general effect upon the rights of holders of DocGo’s capital stock are described in the sections of the Prospectus
entitled “Proposal Nos. 2—The Charter Proposals” beginning on page 128 of the Prospectus, which information
is incorporated herein by reference. A copy of the Second A&R Charter is filed as Exhibit 3.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
In addition, upon the
Closing, pursuant to the terms of the Merger Agreement, DocGo adopted the Amended and Restated Bylaws (the “Bylaws”). A copy
of the Bylaws is filed as Exhibit 3.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 4.01. Change in the Registrant’s
Certifying Accountant.
On November 10,
2021, the members of the audit committee of the Board unanimously approved a resolution appointing Urish Popeck & Co. LLC
(“Urish”) as DocGo’s independent registered public accounting firm to audit DocGo’s consolidated financial
statements for the fiscal year ending December 31, 2021. Urish served as the independent registered public accounting firm of
Ambulnz prior to the Business Combination. Accordingly, WithumSmith+Brown, PC (“Withum”), Motion’s independent
registered public accounting firm prior to the Business Combination, was informed on November 10, 2021 that it was dismissed as
DocGo’s independent registered public accounting firm.
The audit report of Withum
on Motion’s financial statements for the fiscal year ending December 31, 2020, its year of formation and sole reporting fiscal year,
did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainties, audit scope or accounting
principles, except that such audit report emphasized the restatement of Motion’s financial statements due to its change in accounting
for warrants.
During the period from
August 11, 2020 (inception) through December 31, 2020 and the subsequent interim period through November 5, 2021, there were no disagreements
between Motion and Withum on any matter of accounting principles or practices, financial disclosure or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of Withum, would have caused it to make reference to the subject matter of the disagreements
in its reports on Motion’s financial statements for such year.
During the period from
August 21, 2020 (inception) through December 31, 2020 and the subsequent interim period through November 5, 2021, there were no “reportable
events” (as defined in Item 304(a)(1)(v) of Regulation S-K under the Exchange Act), except for a material weakness in Motion’s
pre-Business Combination internal control over financial reporting related to the accounting for warrants issued by Motion.
DocGo provided Withum
with a copy of the foregoing disclosures prior to the filing of this Current Report on Form 8-K with the SEC and has requested that Withum
furnish DocGo with a letter addressed to the SEC stating whether it agrees with the statements made by DocGo set forth above. A copy of
Withum’s letter, dated November 10, 2021, is filed as Exhibit 16.1 to this Current Report on Form 8-K.
During the fiscal year
ending December 31, 2020 and the subsequent interim period through November 10, 2021, neither DocGo, nor any party on behalf of DocGo,
consulted with Urish with respect to either (i) the application of accounting principles to a specified transaction, either completed
or proposed, or the type of the audit opinion that might be rendered with respect to DocGo’s consolidated financial statements,
and no written report or oral advice was provided to DocGo by Urish that was an important factor considered by Urish in reaching a decision
as to any accounting, auditing or financial reporting issue, or (ii) any matter that was subject to any disagreement (as that term is
defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as that term is defined in Item 304(a)(1)(v)
of Regulation S-K).
Item 5.01 Changes in Control of the Registrant
The information set forth
above under “Introductory Note” and in the section entitled “Security Ownership of Certain Beneficial Owners
and Management” in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Incentive
Plan
The information set forth
under the heading “Incentive Plan” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Directors
and Executive Officers
The information regarding
DocGo’s directors and executive officers set forth under the headings “Directors and Executive Officers” and
“Executive Compensation” in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 5.03 Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year.
The information set forth
in Item 3.03 of this Current Report on Form 8-K is incorporated herein by reference.
Item 5.06 Change in Shell Company Status
As a result of the Merger,
which fulfilled the definition of a business combination as required by the amended and restated certificate of incorporation of Motion,
DocGo ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing Date. The material terms of the
Merger are described in the Prospectus in the section entitled “Proposal No.1—The Business Combination Proposal—The
Merger Agreement” beginning on page 97 of the Prospectus, which is incorporated herein by reference.
Item 8.01 Other Events
Any stockholder proposal submitted pursuant to Rule 14a-8 under the Securities
Exchange Act of 1934 for inclusion in the Company's proxy materials for the 2022 Annual Meeting must be received by our corporate secretary
at our principal executive offices no later than the close of business on January 4, 2022.
Item 9.01 Financial Statements and Exhibits
(a) Financial Statements of Business
Acquired
The following historical
financial statements of Motion and the related notes beginning on page F-2 of the Prospectus are incorporated herein by reference:
(i) unaudited financial statements as of June 30, 2021 and for the three and six month periods then ended and (ii) audited financial statements
as of December 31, 2020 and for the period from August 11, 2020 (inception) through December 31, 2020.
The following historical
financial statements of Ambulnz and the related notes beginning on page F-40 of the Prospectus are incorporated herein by reference:
(i) audited consolidated statements of operations and comprehensive loss for the years ended December 31, 2020 and 2019, (ii) audited
consolidated balance sheets data as of December 31, 2020 and 2019, (iii) unaudited consolidated statements of operations and comprehensive
loss for the three and six months ended June 30, 2021 and June 30, 2020, (iv) unaudited consolidated balance sheet data as of June 30,
2021.
(b) Pro Forma Financial Information
The unaudited pro forma
condensed combined balance sheet as of June 30, 2021 and the unaudited pro forma condensed combined statement of operations for the six
months ended June 30, 2021 and the year ended December 31, 2020 is set forth in Exhibit 99.1 hereto and is incorporated by reference
herein.
(c) Exhibits
Exhibit Index
|
Exhibit
No.
|
|
Description
|
|
2.1+
|
|
Agreement
and Plan of Merger, dated as of March 8, 2021, by and among Motion Acquisition Corp., Motion Merger Sub Corp., and Ambulnz, Inc.
(incorporated by reference to Exhibit 2.1 to Motion’s Current Report on Form 8-K, filed with the SEC on March
9, 2021).
|
|
3.1*
|
|
Second Amended and Restated Certificate of Incorporation of DocGo Inc, dated November 5, 2021.
|
|
3.2*
|
|
Amended and Restated Bylaws of DocGo Inc.
|
|
4.1
|
|
Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to Motion’s Registration Statement on Form S-1/A (File No. 333-249061), filed with the SEC on October 5, 2020).
|
|
4.2
|
|
Warrant Agreement, dated October 14, 2020, by and between Motion Acquisition Corp. and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to Motion’s Current Report on Form 8-K, filed with the SEC on October 16, 2020).
|
|
4.3*
|
|
Specimen Common Stock Certificate of DocGo Inc.
|
|
10.1
|
|
Form of Letter Agreement between Motion Acquisition Corp., Motion Acquisition LLC, and each of Motion Acquisition Corp.’s officers and directors (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to Motion’s Registration Statement on Form S-1 (File No. 333-249061) filed on October 5, 2020).
|
|
10.2#
|
|
Form of Indemnification Agreement, between Motion Acquisition Corp. and its officers and directors (incorporated by reference to Exhibit 10.4 of Motion’s Form 8-K, filed with the SEC on October 16, 2020).
|
|
10.3
|
|
Form of Lock-up Agreement, dated as of March 8, 2021, by and between Motion Acquisition Corp., Ambulnz, Inc., and certain equity holders of Ambulnz, Inc. (incorporated by reference to Exhibit 10.3 to Motion’s Current Report on Form 8-K, filed with the SEC on March 9, 2021).
|
|
10.4*
|
|
Amended and Restated Registration Rights Agreement, dated as of November 5, 2021, by and among Motion Acquisition Corp., Motion Acquisition LLC, and Stan Vashovsky.
|
|
10.5#
|
|
DocGo Inc. 2021 Stock Incentive Plan (incorporated by reference to Annex D to Motion’s Proxy Statement/Consent Solicitation/Prospectus (File No. 333-257681), filed with the SEC on October 14, 2021).
|
|
10.6*#
|
|
New Executive Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Stan Vashovsky.
|
|
10.7*#
|
|
New Executive Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Andre Oberholzer.
|
|
10.8*#
|
|
New Executive Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Anthony Capone.
|
|
10.9*#
|
|
New Executive Agreement, effective November 5, 2021, by and between Motion Acquisition Corp. and Norm Rosenberg.
|
|
10.10*#
|
|
Form of Indemnification Agreement of DocGo Inc.
|
|
10.11*
|
|
Stock
Escrow Agreement, dated as of November 5, 2021, by and among Motion Acquisition Corp., Motion Acquisition LLC, and Continental Stock
& Transfer Company
|
|
10.12
|
|
Amended and Restated Sponsor Agreement, dated as of November 4, 2021, by and among Motion Acquisition Corp., Motion Acquisition LLC and Ambulnz, Inc. (incorporated by reference to Exhibit 10.1 of Motion’s Form 8-K, filed with the SEC on November 5, 2021).
|
|
10.13
|
|
Form of Subscription Agreement (incorporated by reference to Exhibit 10.1 of Motion’s Form 8-K, filed with the SEC on March 9, 2021).
|
|
14.1*
|
|
DocGo Inc. Code of Business Conduct and Ethics.
|
|
16.1*
|
|
Letter from WithumSmith+Brown, PC addressed to the Securities and Exchange Commission, dated as of November 10, 2021.
|
|
21.1
|
|
Subsidiaries of DocGo Inc. (incorporated by reference to Exhibit 21.1 to Motion’s Proxy Statement/Consent Solicitation/Prospectus (File No. 333-257681), filed with the SEC on October 7, 2021, as amended).
|
|
99.1*
|
|
DocGo Inc. unaudited pro forma condensed combined balance sheet as of June 30, 2021 and the unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2021 and the year ended December 31, 2020.
|
|
104
|
|
Cover
Page Interactive Data File (formatted as Inline XBRL).
|
|
|
+
|
The
schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule
and/or exhibit will be furnished to the SEC upon request.
|
|
|
#
|
Indicates
a management contract or compensatory plan, contract or arrangement.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
DOCGO INC.
|
|
|
|
|
|
|
By:
|
/s/ Andre Oberholzer
|
|
|
|
Name:
|
Andre Oberholzer
|
|
|
|
Title:
|
Chief Financial Officer
|
Date: November 12, 2021
-
18 -
Exhibit 3.1
SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
MOTION ACQUISITION CORP.
(a Delaware corporation)
Motion Acquisition Corp., a
corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as
follows:
|
|
1.
|
The name of the Corporation is “Motion Acquisition Corp.,” and is changing its name to “DocGo
Inc.” pursuant to this Second Amended and Restated Certificate (as defined below). The original certificate of incorporation of
the Corporation was filed with the office of the Secretary of State of the State of Delaware on August 11, 2020.
|
|
|
2.
|
This Second Amended and Restated Certificate of Incorporation (this “Second Amended and Restated
Certificate”) amends, restates and integrates provisions of the Amended and Restated Certificate of Incorporation that was filed
with the Secretary of State of the State of Delaware on October 14, 2020 (the “Amended and Restated Certificate”)
and was duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of
Delaware (the “DGCL”).
|
|
|
3.
|
The text of the Amended and Restated Certificate is hereby amended and restated in its entirety to provide
as herein set forth in full.
|
Article
I
NAME
The name of the Corporation
is DocGo Inc.
Article
II
AGENT
The address of the Corporation’s
registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington 19808, County of New Castle, and the name
of the Corporation’s registered agent at such address is Corporation Service Company.
Article
III
PURPOSE
The purpose of the Corporation
is to engage in any lawful act or activity for which corporations may be organized under the DGCL.
Article
IV
STOCK
Section
4.1 Authorized Stock. Effective as of the effectiveness of this Second Amended and Restated Certificate (the “Effective
Time”), each share of Class A Common Stock of the Corporation, par value $0.0001 per share (the “Old Common Stock”),
issued prior to the Effective Time (including shares held by the Corporation as treasury stock) shall be reclassified and changed into
one validly issued, fully paid and nonassessable share of Common Stock and each stock certificate the represented Old Common Stock prior
to the Effective Time shall, from and after the Effective Time, represent an equal number of shares of Common Stock. The total number
of shares that the Corporation shall have authority to issue is 550,000,000 shares, of which 500,000,000 shares shall be designated
as common stock, par value $0.0001 per share (the “Common Stock”), and 50,000,000 shares shall be designated as
preferred stock, par value $0.0001 per share (the “Preferred Stock”).
Section
4.2 Common Stock.
(a) Voting
Rights. Each holder of Common Stock, as such, shall be entitled to one vote for each share of Common Stock held of record by such
holder on all matters on which stockholders generally are entitled to vote; provided, however, that, except as
otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate of Incorporation,
including any certificate of designations relating to any series of Preferred Stock (each hereinafter referred to as a “Preferred
Stock Designation”), that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of
such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant
to this Certificate of Incorporation (including any Preferred Stock Designation).
(b) Dividends.
Subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled
to receive any dividends to the extent permitted by law when, as and if declared by the board of directors of the Corporation (the “Board”).
(c) Liquidation.
Upon the dissolution, liquidation or winding up of the Corporation, subject to the rights of the holders of any outstanding series of
Preferred Stock, the holders of shares of Common Stock shall be entitled to receive the assets of the Corporation available for distribution
to its stockholders ratably in proportion to the number of shares held by them.
Section
4.3 Preferred Stock. The Preferred Stock may be issued from time to time in one or more series. Subject to limitations
prescribed by law and the provisions of this Article (including any Preferred Stock Designation), the Board is hereby authorized to provide
by resolution and by causing the filing of a Preferred Stock Designation for the issuance of the shares of Preferred Stock in one or more
series, and to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers,
preferences, and relative, participating, optional or other rights, if any, and the qualifications, limitations or restrictions, if any,
of the shares of each such series.
Section 4.4 No Class
Vote on Changes in Authorized Number of Shares of Stock. Subject to the rights of the holders of any outstanding series of Preferred
Stock, the number of authorized shares of Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares
thereof then outstanding) by the affirmative vote of at least a majority of the voting power of the stock outstanding and entitled to
vote thereon irrespective of the provisions of Section 242(b)(2) of the DGCL.
Article
V
BOARD OF DIRECTORS
Section
5.1 Number. The number of directors of the Corporation shall be fixed solely by resolution adopted from time to time
by the Board by a majority of the directors then in office.
Section
5.2 Classification.
(a) Except
as may be otherwise provided with respect to directors elected by the holders of any series of Preferred Stock provided for or fixed pursuant
to the provisions of Article IV hereof (including any Preferred Stock Designation) (the “Preferred Stock Directors”),
the Board shall be divided into three classes designated Class I, Class II and Class III. Class I directors shall initially serve until
the first annual meeting of stockholders following the initial effectiveness of this Second Amended and Restated Certificate; Class II
directors shall initially serve until the second annual meeting of stockholders following the initial effectiveness of this this Second
Amended and Restated Certificate; and Class III directors shall initially serve until the third annual meeting of stockholders following
the initial effectiveness of this this Second Amended and Restated Certificate. Commencing with the first annual meeting of stockholders
following the initial effectiveness of this Second Amended and Restated Certificate, each of the successors elected to replace the class
of directors whose term expires at such annual meeting shall be elected to hold office for a three-year term and until the election
and qualification of their respective successors in office. The Board is authorized to assign members of the Board already in office to
Class I, Class II or Class III, with such assignment becoming effective as of the initial effectiveness of this Second Amended and Restated
Certificate.
(b) Subject
to the rights of the holders of any outstanding series of Preferred Stock, and unless otherwise required by law, newly created directorships
resulting from any increase in the authorized number of directors and any vacancies in the Board resulting from death, resignation, retirement,
disqualification, removal from office or other cause shall be filled solely by the affirmative vote of a majority of the remaining directors
then in office, even though less than a quorum of the Board, or by the sole remaining director. Any director so chosen shall hold office
until the next election of the class for which such director shall have been chosen and until his or her successor shall have been
duly elected and qualified. No decrease in the authorized number of directors shall shorten the term of any incumbent director.
(c) Any
director, or the entire Board, may be removed from office at any time, but only for cause and only by the affirmative vote of at least
66⅔% of the voting power of the stock outstanding and entitled to vote thereon.
(d) During
any period when the holders of any series of Preferred Stock have the right to elect additional directors as provided for or fixed pursuant
to the provisions of Article IV hereof (including any Preferred Stock Designation), and upon commencement and for the duration of
the period during which such right continues: (i) the then otherwise total authorized number of directors of the Corporation shall
automatically be increased by such number of directors that the holders of any series of Preferred Stock have a right to elect, and the
holders of such Preferred Stock shall be entitled to elect the additional directors so provided for or fixed pursuant to said provisions;
and (ii) each Preferred Stock Director shall serve until such Preferred Stock Director’s successor shall have been duly elected
and qualified, or until such director’s right to hold such office terminates pursuant to said provisions, whichever occurs earlier,
subject to his or her earlier death, disqualification, resignation or removal. Except as otherwise provided for or fixed pursuant to the
provisions of Article IV hereof (including any Preferred Stock Designation), whenever the holders of any series of Preferred Stock
having such right to elect additional directors are divested of such right pursuant to said provisions, the terms of office of all Preferred
Stock Directors elected by the holders of such Preferred Stock, or elected to fill any vacancies resulting from the death, resignation,
disqualification or removal of such additional directors, shall forthwith terminate (in which case each such Preferred Stock Director
shall cease to be qualified as a director and shall cease to be a director) and the total authorized number of directors of the Corporation
shall be automatically reduced accordingly.
Section
5.3 Powers. Except as otherwise required by the DGCL or as provided in this Certificate of Incorporation (including any
Preferred Stock Designation), the business and affairs of the Corporation shall be managed by or under the direction of the Board.
Section
5.4 Election; Notice of Nominations and Business.
(a) Ballot
Not Required. The directors of the Corporation need not be elected by written ballot unless the Bylaws of the Corporation (the “Bylaws”)
so provide.
(b) Notice.
Advance notice of nominations for the election of directors, and of business other than nominations, to be proposed by stockholders for
consideration at a meeting of stockholders of the Corporation shall be given in the manner and to the extent provided in or contemplated
by the Bylaws.
(c) Annual
Meeting. The annual meeting of stockholders, for the election of directors to succeed those whose terms expire and for the transaction
of such other business as may properly come before the meeting, shall be held at such place, if any, either within or without the State
of Delaware, on such date, and at such time as the Board shall fix.
Article
VI
Stockholder action
Section
6.1 No Action Without Meeting. Except as otherwise provided for or fixed with respect to actions required or permitted
to be taken solely by holders of Preferred Stock pursuant to the provisions of Article IV hereof (including any Preferred Stock Designation),
no action that is required or permitted to be taken by the stockholders of the Corporation may be effected by consent of stockholders
in lieu of a meeting of stockholders.
Section
6.2 Special Meetings. Except as otherwise required by law, and except as otherwise provided for or fixed pursuant to
the provisions of Article IV hereof (including any Preferred Stock Designation), a special meeting of the stockholders of the Corporation
may be called at any time only by the Board. Only such business shall be conducted at a special meeting of stockholders as shall have
been brought before the meeting by or at the direction of the Board.
Article
VII
EXISTENCE
The Corporation shall have perpetual existence.
Article
VIII
AMENDMENT
Section
8.1 Amendment of Certificate of Incorporation. The Corporation reserves the right, at any time and from time to time,
to amend, alter, change or repeal any provision contained in this Certificate of Incorporation (including any Preferred Stock Designation),
and to add or insert other provisions authorized by the laws of the State of Delaware at the time in force, in the manner now or hereafter
prescribed by the laws of the State of Delaware. All powers, preferences and rights of any nature conferred upon stockholders, directors
or any other persons by and pursuant to this Certificate of Incorporation (including any Preferred Stock Designation) in its present form
or as hereafter amended are granted subject to this reservation; provided, however, that, except as otherwise
provided in this Certificate of Incorporation (including any provision of a Preferred Stock Designation that provides for a greater or
lesser vote) and in addition to any other vote required by law, the affirmative vote of at least 66⅔% of the voting power of the
stock outstanding and entitled to vote thereon, voting together as a single class, shall be required to amend or repeal, or adopt any
provision inconsistent with, Section 5.2 of Article V, Article VI, Article VIII, Article IX, Article X or
Article XI.
Section
8.2 Amendment of Bylaws. In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware,
but subject to the terms of any series of Preferred Stock then outstanding, the Board is expressly authorized to adopt, amend or repeal
the Bylaws. Except as otherwise provided in this Certificate of Incorporation (including the terms of any Preferred Stock Designation
that require an additional vote) or the Bylaws, and in addition to any requirements of law, the affirmative vote of at least 66⅔%
of the voting power of the stock outstanding and entitled to vote thereon, voting together as a single class, shall be required for the
stockholders to adopt, amend or repeal any provision of the Bylaws.
Article
IX
LIABILITY OF DIRECTORS
Section
9.1 No Personal Liability. To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended,
no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary
duty as a director.
Section
9.2 Indemnification and Advancement of Expenses.
(a) To
the fullest extent permitted by the applicable laws of the State of Delaware, as the same exists or may hereafter be amended, the Corporation
shall indemnify and hold harmless each person who is or was made a party or is threatened to be made a party to or is otherwise involved
in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, including
an action by or in the right of the Corporation to procure a judgment in its favor (a “proceeding”), by reason of the
fact that he or she is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving
at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture,
trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan (an “indemnitee”),
whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other
capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without
limitation, attorneys’ fees and disbursements, judgments, fines, ERISA excise taxes, damages, claims and penalties and amounts paid
in settlement) reasonably incurred by such indemnitee in connection with such proceeding. The Corporation shall to the fullest extent
not prohibited by applicable law pay the expenses (including attorneys’ fees) incurred by an indemnitee in defending or otherwise
participating in any proceeding in advance of its final disposition; provided, however, that, to the extent required by applicable
law, such payment of expenses in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking,
by or on behalf of the indemnitee, to repay all amounts so advanced if it shall ultimately be determined that the indemnitee is not entitled
to be indemnified under this Section 9.2 or otherwise. The rights to indemnification and advancement of expenses conferred by this
Section 9.2 shall be contractual rights and such rights shall continue as to an indemnitee who has ceased to be a director, officer,
employee or agent and shall inure to the benefit of his or her heirs, executors and administrators. Notwithstanding the foregoing provisions
of this Section 9.2(a), except for proceedings to enforce rights to indemnification and advancement of expenses, the Corporation
shall indemnify and advance expenses to an indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only
if such proceeding (or part thereof) was authorized by the Board.
(b) The
rights to indemnification and advancement of expenses conferred on any indemnitee by this Section 9.2 shall not be exclusive of any
other rights that any indemnitee may have or hereafter acquire under law, this Second Amended and Restated Certificate as it may be further
amended from time to time, the Bylaws, an agreement, vote of stockholders or disinterested directors, or otherwise.
(c) Any
repeal or amendment of this Section 9.2 by the stockholders of the Corporation or by changes in law, or the adoption of any other
provision of this Second Amended and Restated Certificate inconsistent with this Section 9.2, shall, unless otherwise required by
law, be prospective only (except to the extent such amendment or change in law permits the Corporation to provide broader indemnification
rights on a retroactive basis than permitted prior thereto), and shall not in any way diminish or adversely affect any right or protection
existing at the time of such repeal or amendment or adoption of such inconsistent provision in respect of any proceeding (regardless of
when such proceeding is first threatened, commenced or completed) arising out of, or related to, any act or omission occurring prior to
such repeal or amendment or adoption of such inconsistent provision.
(d) This
Section 9.2 shall not limit the right of the Corporation, to the extent and in the manner authorized or permitted by law, to indemnify
and to advance expenses to persons other than indemnitees.
(e) The
Corporation shall maintain directors’ and officers’ liability insurance coverage, on terms reasonably satisfactory to the
Board, of at least $5,000,000 per occurrence, to the fullest extent permitted by law covering, among other things, violations of federal
or state securities laws. The Corporation will pay all premiums due thereon and will not make any material alteration to the terms thereof,
or the coverage provided by, such insurance policy without the prior written consent of the Board.
Section
9.3 Amendment or Repeal. Any amendment, repeal or elimination of this Article IX, or the adoption of any provision of
the Corporation’s certificate of incorporation inconsistent with this Article IX, shall not affect its application with respect
to an act or omission by a director occurring before such amendment, adoption, repeal or elimination.
Article
X
Corporate opportunity
Section
10.1 Corporate Opportunities. To the maximum extent allowed by law, the doctrine of corporate opportunity, or any other
analogous doctrine, shall not apply with respect to the Corporation or any of its officers or directors, or any of their respective affiliates,
in circumstances where the application of any such doctrine would conflict with any fiduciary duties or contractual obligations they may
have as of the date of this Second Amended and Restated Certificate or in the future, and the Corporation renounces any expectancy that
any of the directors or officers of the Corporation will offer any such corporate opportunity of which he or she may become aware to the
Corporation, except, the doctrine of corporate opportunity shall apply with respect to any of the directors or officers of the Corporation.
Section
10.2 Amendments. Neither the alteration, amendment, addition to or repeal of this Article X, nor the adoption of any
provision of this Second Amended and Restated Certificate (including any Preferred Stock Designation) inconsistent with this Article X,
shall eliminate or reduce the effect of this Article X in respect of any business opportunity first identified or any other matter occurring,
or any cause of action, suit or claim that, but for this Article X, would accrue or arise, prior to such alteration, amendment, addition,
repeal or adoption. This Article X shall not limit any protections or defenses available to, or indemnification or advancement rights
of, any director or officer of the Corporation under this Second Amended and Restated Certificate, the Bylaws or applicable law.
Article
XI
Forum For ADJUDICATION OF DISPUTES
Section
11.1 Forum. Unless the Corporation, in writing, selects or consents to the selection of an alternative forum: (a) the
sole and exclusive forum for any complaint asserting any internal corporate claims (as defined below), to the fullest extent permitted
by law, and subject to applicable jurisdictional requirements, shall be the Court of Chancery of the State of Delaware (or, if the Court
of Chancery does not have, or declines to accept, jurisdiction, another state court or a federal court located within the State of Delaware);
and (b) the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, to the fullest
extent permitted by law, shall be the federal district courts of the United States of America. Notwithstanding anything herein to the
contrary, and for the avoidance of doubt: this Article shall not apply to suits brought to enforce a duty or liability created by the
Securities Exchange Act of 1934. For purposes of this Article, internal corporate claims means claims, including claims in the right of
the Corporation that are based upon a violation of a duty by a current or former director, officer, employee or stockholder in such capacity,
or as to which the DGCL confers jurisdiction upon the Court of Chancery. Any person or entity purchasing or otherwise acquiring or holding
any interest in shares of stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article.
Section
11.2 Enforceability. If any provision of this Article shall be held to be invalid, illegal or unenforceable as applied
to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality
and enforceability of such provision in any other circumstance and of the remaining provisions of this Article (including, without limitation,
each portion of any sentence of this Article containing any such provision held to be invalid, illegal or unenforceable that is not itself
held to be invalid, illegal or unenforceable), and the application of such provision to other persons or entities or circumstances shall
not in any way be affected or impaired thereby.
IN
WITNESS WHEREOF, this Second Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer
of this corporation on this November 5, 2021.
|
|
By:
|
/s/ Stan Vashovsky
|
|
|
Name:
|
Stan Vashovsky
|
|
|
Title:
|
CEO
|
[Signature Page – Second Amended and Restated
Certificate of Incorporation]
7
Exhibit
3.2
AMENDED AND RESTATED BYLAWS
OF
DOCGO INC.
(a Delaware corporation)
ARTICLE I
CORPORATE OFFICES
Section 1.1 Registered
Office. The registered office of DocGo Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation
of the Corporation.
Section 1.2 Other
Offices. The Corporation may also have an office or offices, and keep the books and records of the Corporation, except as otherwise
required by law, at such other place or places, either within or without the State of Delaware, as the Corporation may from time to time
determine or the business of the Corporation may require.
ARTICLE II
MEETINGS OF STOCKHOLDERS
Section 2.1 Annual
Meeting. The annual meeting of stockholders, for the election of directors to succeed those whose terms expire and for the transaction
of such other business as may properly come before the meeting, shall be held at such place, if any, either within or without the State
of Delaware, on such date, and at such time as the Board of Directors shall fix. The Board of Directors may postpone, reschedule or cancel
any annual meeting of stockholders previously scheduled by the Board of Directors.
Section 2.2 Special
Meeting. Except as otherwise required by law, and except as otherwise provided for or fixed pursuant to the Certificate of Incorporation,
including any certificate of designations relating to any series of Preferred Stock (each hereinafter referred to as a “Preferred
Stock Designation”), a special meeting of the stockholders of the Corporation may be called at any time only by the Board of
Directors. The Board of Directors may postpone, reschedule or cancel any special meeting of stockholders previously scheduled by the Board
of Directors. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting
by or at the direction of the Board of Directors.
Section 2.3 Notice
of Stockholders’ Meetings.
(a) Whenever stockholders
are required or permitted to take any action at a meeting, notice of the place, if any, date, and time of the meeting of stockholders,
the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for determining
the stockholders entitled to notice of the meeting), the means of remote communications, if any, by which stockholders and proxyholders
may be deemed to be present in person and vote at such meeting and, if the meeting is to be held solely by means of remote communications,
the means for accessing the list of stockholders contemplated by Section 2.5 of these Bylaws, shall be given. The notice shall be
given not less than 10 nor more than 60 days before the date on which the meeting is to be held, to each stockholder entitled to
vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting, except as otherwise provided
by law, the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws. In the case of a special meeting,
the purpose or purposes for which the meeting is called also shall be set forth in the notice.
(b) Except as otherwise
required by law, notice may be given in writing directed to a stockholder’s mailing address as it appears on the records of the
Corporation and shall be given: (i) if mailed, when notice is deposited in the U.S. mail, postage prepaid; and (ii) if delivered
by courier service, the earlier of when the notice is received or left at such stockholder’s address.
(c) So long as the
Corporation is subject to the Securities and Exchange Commission’s proxy rules set forth in Regulation 14A under the Securities
Exchange Act of 1934 (the “Exchange Act”), notice shall be given in the manner required by such rules. To the extent
permitted by such rules, notice may be given by electronic transmission directed to the stockholder’s electronic mail address, and
if so given, shall be given when directed to such stockholder’s electronic mail address unless the stockholder has notified the
Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited
by Section 232(e) of the General Corporation Law of the State of Delaware (the “DGCL”). If notice is given by
electronic mail, such notice shall comply with the applicable provisions of Sections 232(a) and 232(d) of the DGCL.
(d) Notice may be given
by other forms of electronic transmission with the consent of a stockholder in the manner permitted by Section 232(b) of the DGCL,
and shall be deemed given as provided therein.
(e) An affidavit that
notice has been given, executed by the Secretary of the Corporation, Assistant Secretary or any transfer agent or other agent of the Corporation,
shall be prima facie evidence of the facts stated in the notice in the absence of fraud. Notice shall be deemed to have
been given to all stockholders who share an address if notice is given in accordance with the “householding” rules set forth
in Rule 14a-3(e) under the Exchange Act and Section 233 of the DGCL.
(f) When a meeting
is adjourned to another time or place, notice need not be given of the adjourned meeting if the place, if any, date and time thereof,
and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote
at such adjourned meeting are announced at the meeting at which the adjournment is taken; provided, however, that
if the adjournment is for more than 30 days, a notice of the adjourned meeting shall be given to each stockholder of record entitled
to vote at the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting,
the Board of Directors shall fix a new record date for notice of such adjourned meeting in accordance with Section 7.6(a), and shall
give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed
for notice of such adjourned meeting.
Section 2.4 Organization.
(a) Unless otherwise
determined by the Board of Directors, meetings of stockholders shall be presided over by the Chairman of the Board of Directors, or in
his or her absence, by the Chief Executive Officer or, in his or her absence, by another person designated by the Board of Directors.
The Secretary of the Corporation, or in his or her absence, an Assistant Secretary, or in the absence of the Secretary and all Assistant
Secretaries, a person whom the chairman of the meeting shall appoint, shall act as secretary of the meeting and keep a record of the proceedings
thereof.
(b) The date and time
of the opening and the closing of the polls for each matter upon which the stockholders shall vote at a meeting of stockholders shall
be announced at the meeting. The Board of Directors may adopt such rules and regulations for the conduct of any meeting of stockholders
as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors,
the chairman of the meeting shall have the authority to adopt and enforce such rules and regulations for the conduct of any meeting of
stockholders and the safety of those in attendance as, in the judgment of the chairman, are necessary, appropriate or convenient for the
conduct of the meeting. Rules and regulations for the conduct of meetings of stockholders, whether adopted by the Board of Directors or
by the chairman of the meeting, may include, without limitation, establishing: (i) an agenda or order of business for the meeting;
(ii) rules and procedures for maintaining order at the meeting and the safety of those present; (iii) limitations on attendance
at or participation in the meeting to stockholders entitled to vote at the meeting, their duly authorized and constituted proxies and
such other persons as the chairman of the meeting shall permit; (iv) restrictions on entry to the meeting after the time fixed for
the commencement thereof; (v) limitations on the time allotted for consideration of each agenda item and for questions and comments
by participants; (vi) regulations for the opening and closing of the polls for balloting and matters which are to be voted on by
ballot (if any); and (vii) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to attend
the meeting. Subject to any rules and regulations adopted by the Board of Directors, the chairman of the meeting may convene and, for
any or no reason, from time to time, adjourn and/or recess any meeting of stockholders pursuant to Section 2.7. The chairman of the
meeting, in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall have the power to
declare that a nomination or other business was not properly brought before the meeting if the facts warrant (including if a determination
is made, pursuant to Section 2.10(c)(i) of these Bylaws, that a nomination or other business was not made or proposed, as the case
may be, in accordance with Section 2.10 of these Bylaws), and if such chairman should so declare, such nomination shall be disregarded
or such other business shall not be transacted.
Section 2.5 List
of Stockholders. The Corporation shall prepare, at least 10 days before every meeting of stockholders, a complete list of the
stockholders entitled to vote at the meeting; provided, however, that if the record date for determining the stockholders
entitled to vote is less than 10 days before the date of the meeting, the list shall reflect the stockholders entitled to vote as
of the 10th day before the meeting date. Such list shall be arranged in alphabetical order and shall show the address
of each stockholder and the number of shares registered in the name of each stockholder. Nothing in this Section 2.5 shall require
the Corporation to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to
the examination of any stockholder, for any purpose germane to the meeting at least 10 days prior to the meeting: (a) on a reasonably
accessible electronic network, provided that the information required to gain access to such list is provided with the
notice of meeting; or (b) during ordinary business hours at the principal place of business of the Corporation. In the event that
the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that
such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then a list of stockholders
entitled to vote at the meeting shall be produced and kept at the time and place of the meeting during the whole time thereof and may
be examined by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall
also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network,
and the information required to access such list shall be provided with the notice of the meeting. Except as otherwise required by law,
the stock ledger shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required by this
Section 2.5 or to vote in person or by proxy at any meeting of stockholders.
Section 2.6 Quorum.
Except as otherwise required by law, the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws, at
any meeting of stockholders, a majority of the voting power of the stock outstanding and entitled to vote at the meeting, present in person
or represented by proxy, shall constitute a quorum for the transaction of business; provided, however, that where
a separate vote by a class or series or classes or series is required, a majority of the voting power of the stock of such class or series
or classes or series outstanding and entitled to vote on that matter, present in person or represented by proxy, shall constitute a quorum
entitled to take action with respect to such matter. If a quorum is not present or represented at any meeting of stockholders, then the
chairman of the meeting, or a majority of the voting power of the stock present in person or represented by proxy at the meeting and entitled
to vote thereon, shall have power to adjourn or recess the meeting from time to time in accordance with Section 2.7, until a quorum
is present or represented. Subject to applicable law, if a quorum initially is present at any meeting of stockholders, the stockholders
may continue to transact business until adjournment or recess, notwithstanding the withdrawal of enough stockholders to leave less than
a quorum, but if a quorum is not present at least initially, no business other than adjournment or recess may be transacted.
Section 2.7 Adjourned
or Recessed Meeting. Any annual or special meeting of stockholders, whether or not a quorum is present, may be adjourned or recessed
for any or no reason from time to time by the chairman of the meeting, subject to any rules and regulations adopted by the Board of Directors
pursuant to Section 2.4(b). Any such meeting may be adjourned for any or no reason (and may be recessed if a quorum is not present
or represented) from time to time by a majority of the voting power of the stock present in person or represented by proxy at the meeting
and entitled to vote thereon. At any such adjourned or recessed meeting at which a quorum is present, any business may be transacted that
might have been transacted at the meeting as originally called.
Section 2.8 Voting.
(a) Except as otherwise
required by law or the Certificate of Incorporation (including any Preferred Stock Designation), each holder of stock of the Corporation
entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of such stock held of record by such holder
that has voting power upon the subject matter in question.
(b) Except as otherwise
required by law, the Certificate of Incorporation (including any Preferred Stock Designation), these Bylaws or any law, rule or regulation
applicable to the Corporation or its securities, at each meeting of stockholders at which a quorum is present, all corporate actions to
be taken by vote of the stockholders shall be authorized by the affirmative vote of at least a majority of the voting power of the stock
present in person or represented by proxy and entitled to vote on the subject matter, and where a separate vote by a class or series or
classes or series is required, if a quorum of such class or series or classes or series is present, such act shall be authorized by the
affirmative vote of at least a majority of the voting power of the stock of such class or series or classes or series present in person
or represented by proxy and entitled to vote on the subject matter. Voting at meetings of stockholders need not be by written ballot.
Section 2.9 Proxies.
Every stockholder entitled to vote for directors, or on any other matter, shall have the right to do so either in person or by one or
more persons authorized to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its
date, unless the proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable and if, and only
as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A proxy may be made irrevocable regardless
of whether the interest with which it is coupled is an interest in the stock itself or an interest in the Corporation generally. A stockholder
may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary of the Corporation
a revocation of the proxy or an executed new proxy bearing a later date.
Section 2.10 Notice of Stockholder
Business and Nominations.
(a) Annual Meeting.
(i) Nominations of
persons for election to the Board of Directors and the proposal of business other than nominations to be considered by the stockholders
may be made at an annual meeting of stockholders only: (A) pursuant to the Corporation’s notice of meeting (or any supplement
thereto); (B) by or at the direction of the Board of Directors (or any authorized committee thereof); or (C) by any stockholder
of the Corporation who is a stockholder of record at the time the notice provided for in this Section 2.10(a) is delivered to the
Secretary of the Corporation, who is entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 2.10(a).
For the avoidance of doubt, the foregoing clause (C) shall be the exclusive means for a stockholder to make nominations or propose
other business at an annual meeting of stockholders (other than a proposal included in the Corporation’s proxy statement pursuant
to and in compliance with Rule 14a-8 under the Exchange Act).
(ii) For nominations or
other business to be properly brought before an annual meeting by a stockholder pursuant to clause (C) of the foregoing
paragraph, the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation and, in the case of
business other than nominations, such business must be a proper subject for stockholder action. To be timely, a stockholder’s
notice must be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business
(as defined in Section 2.10(c)(ii) below) on the 90th day nor earlier than the close of business on the
120th day prior to the first anniversary of the preceding year’s annual
meeting; provided, however, that in the event that the date of the annual meeting is more than 30 days
before or more than 60 days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the
stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to such
annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or
the 10th day following the date on which public announcement (as defined in Section 2.10(c)(ii) below) of
the date of such meeting is first made by the Corporation. In no event shall an adjournment or recess of an annual meeting, or a
postponement of an annual meeting for which notice of the meeting has already been given to stockholders or a public announcement of
the meeting date has already been made, commence a new time period (or extend any time period) for the giving of a
stockholder’s notice as described above. The number of nominees a stockholder may nominate for election at the annual meeting
(or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may
nominate for election at the annual meeting on behalf of the beneficial owner) shall not exceed the number of directors to be
elected at such annual meeting. For purposes of this Section 2.10, the 2021 annual meeting of stockholders shall be deemed to
have been held on November 2, 2021. Such stockholder’s notice shall set forth:
(A) as to each person
whom the stockholder proposes to nominate for election or re-election as a director: (1) all information relating to such person
that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required,
in each case pursuant to and in accordance with Regulation 14A under the Exchange Act; and (2) such person’s written consent
to serving as a director, if elected, for the full term for which such person is standing for election; provided, however,
that, in addition to the information required in the stockholder’s notice pursuant to this Section 2.10(a)(ii)(A), such person
shall also provide the Corporation such other information that the Corporation may reasonably request and that is necessary to permit
the Corporation to determine the eligibility of such person to serve as a director of the Corporation, including information relevant
to a determination whether such person can be considered an independent director;
(B) as to any other
business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the
meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event that
such business includes a proposal to amend the Bylaws of the Corporation, the language of the proposed amendment), the reasons for conducting
such business at the meeting and any substantial interest (within the meaning of Item 5 of Schedule 14A under the Exchange Act)
in such business of such stockholder and the beneficial owner (within the meaning of Section 13(d) of the Exchange Act), if any,
on whose behalf the proposal is made;
(C) as to the stockholder
giving the notice and the beneficial owner, if any, on whose behalf the nomination is made or the other business is proposed:
(1) the name
and address of such stockholder, as they appear on the Corporation’s books, and the name and address of such beneficial owner;
(2) the class
or series and number of shares of stock of the Corporation which are owned of record by such stockholder and such beneficial owner as
of the date of the notice, and a representation that the stockholder will notify the Corporation in writing within five business days
after the record date for such meeting of the class or series and number of shares of stock of the Corporation owned of record by the
stockholder and such beneficial owner as of the record date for the meeting; and
(3) a representation
that the stockholder (or a qualified representative of the stockholder) intends to appear at the meeting to make such nomination or propose
such business;
(D) as to the stockholder
giving the notice or, if the notice is given on behalf of a beneficial owner on whose behalf the nomination is made or the other business
is proposed, as to such beneficial owner, and if such stockholder or beneficial owner is an entity, as to each director, executive, managing
member or control person of such entity (any such individual or control person, a “control person”):
(1) the class
or series and number of shares of stock of the Corporation which are beneficially owned (as defined in Section 2.10(c)(ii) below)
by such stockholder or beneficial owner and by any control person as of the date of the notice, and a representation that the stockholder
will notify the Corporation in writing within five business days after the record date for such meeting of the class or series and number
of shares of stock of the Corporation beneficially owned by such stockholder or beneficial owner and by any control person as of the record
date for the meeting;
(2) a description
of any agreement, arrangement or understanding with respect to the nomination or other business between or among such stockholder, beneficial
owner or control person and any other person, including, without limitation any agreements that would be required to be disclosed pursuant
to Item 5 or Item 6 of Exchange Act Schedule 13D (regardless of whether the requirement to file a Schedule 13D is
applicable) and a representation that the stockholder will notify the Corporation in writing within five business days after the record
date for such meeting of any such agreement, arrangement or understanding in effect as of the record date for the meeting;
(3) a description
of any agreement, arrangement or understanding (including, without limitation, any derivative or short positions, profit interests, options,
hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder’s notice by, or
on behalf of, such stockholder, beneficial owner or control person, the effect or intent of which is to mitigate loss, manage risk or
benefit from changes in the share price of any class or series of the Corporation’s stock, or maintain, increase or decrease the
voting power of the stockholder, beneficial owner or control person with respect to securities of the Corporation, and a representation
that the stockholder will notify the Corporation in writing within five business days after the record date for such meeting of any such
agreement, arrangement or understanding in effect as of the record date for the meeting; and
(4) a representation
whether the stockholder or the beneficial owner, if any, will engage in a solicitation with respect to the nomination or other business
and, if so, the name of each participant in such solicitation (as defined in Item 4 of Schedule 14A under the Exchange Act)
and whether such person intends or is part of a group which intends to deliver a proxy statement and/or form of proxy to holders of shares
representing at least 50% of the voting power of the stock entitled to vote generally in the election of directors in the case of a nomination,
or holders of at least the percentage of the Corporation’s stock required to approve or adopt the business to be proposed in the
case of other business.
(iii) Notwithstanding anything
in Section 2.10(a)(ii) above or Section 2.10(b) below to the contrary, if the record date for determining the stockholders
entitled to vote at any meeting of stockholders is different from the record date for determining the stockholders entitled to notice
of the meeting, a stockholder’s notice required by this Section 2.10 shall set forth a representation that the stockholder
will notify the Corporation in writing within five business days after the record date for determining the stockholders entitled to vote
at the meeting, or by the opening of business on the date of the meeting (whichever is earlier), of the information required under clauses
(ii)(C)(2) and (ii)(D)(1)(3) of this Section 2.10(a), and such information when provided to the Corporation shall be current as of
the record date for determining the stockholders entitled to vote at the meeting.
(iv) This
Section 2.10(a) shall not apply to a proposal proposed to be made by a stockholder if the stockholder has notified the
Corporation of his or her intention to present the proposal at an annual or special meeting only pursuant to and in compliance with
Rule 14a-8 under the Exchange Act and such proposal has been included in a proxy statement that has been prepared by the
Corporation to solicit proxies for such meeting.
(v) Notwithstanding
anything in this Section 2.10(a) to the contrary, in the event that the number of directors to be elected to the Board of
Directors at an annual meeting is increased and there is no public announcement by the Corporation naming all of the nominees for
director or specifying the size of the increased Board of Directors made by the Corporation at least 10 days prior to the last
day a stockholder may deliver a notice in accordance with Section 2.10(a)(ii) above, a stockholder’s notice required
by this Section 2.10(a) shall also be considered timely, but only with respect to nominees for any new positions created by
such increase, if it shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation
not later than the close of business on the 10th day following the day on which such public announcement is first
made by the Corporation.
(b) Special Meeting.
Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are
to be elected pursuant to the Corporation’s notice of meeting: (i) by or at the direction of the Board of Directors (or any
authorized committee thereof); or (ii) provided that one or more directors are to be elected at such meeting, by any
stockholder of the Corporation who is a stockholder of record at the time the notice provided for in this Section 2.10(b) is delivered
to the Secretary of the Corporation, who is entitled to vote at the meeting and upon such election and who delivers notice thereof in
writing setting forth the information required by Section 2.10(a) above. In the event the Corporation calls a special meeting of
stockholders for the purpose of electing one or more directors to the Board of Directors, any stockholder entitled to vote in such election
of directors may nominate a person or persons (as the case may be) for election to such position(s) as specified in the Corporation’s
notice of meeting, if the notice required by this Section 2.10(b) shall be delivered to the Secretary at the principal executive
offices of the Corporation not earlier than the close of business on the 120th day prior to such special meeting and not
later than the close of business on the later of the 90th day prior to such special meeting or the 10th day
following the date on which public announcement of the date of the special meeting and of the nominees proposed by the Board of Directors
to be elected at such meeting is first made by the Corporation. The number of nominees a stockholder may nominate for election at the
special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder
may nominate for election at the annual meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected
at such special meeting. In no event shall an adjournment, recess or postponement of a special meeting commence a new time period (or
extend any time period) for the giving of a stockholder’s notice as described above.
(c) General.
(i) Except as otherwise
required by law, only such persons who are nominated in accordance with the procedures set forth in this Section 2.10 shall be eligible
to be elected at any meeting of stockholders of the Corporation to serve as directors and only such other business shall be conducted
at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 2.10.
Except as otherwise required by law, each of the Chairman of the Board of Directors or the chairman of the meeting shall have the power
to determine whether a nomination or any other business proposed to be brought before the meeting was made or proposed, as the case may
be, in accordance with the procedures set forth in this Section 2.10 (including whether a stockholder or beneficial owner solicited
(or is part of a group which solicited) or did not so solicit, as the case may be, proxies in compliance with such stockholder’s
representation as required by clause (a)(ii)(D)(4) of this Section 2.10). If any proposed nomination or other business is not in
compliance with this Section 2.10, then except as otherwise required by law, the chairman of the meeting shall have the power to
declare that such nomination shall be disregarded or that such other business shall not be transacted. Notwithstanding the foregoing provisions
of this Section 2.10, unless otherwise required by law, or otherwise determined by the Chairman of the Board of Directors or the
chairman of the meeting, if the stockholder does not provide the information required under clauses (a)(ii)(C)(2) and (a)(ii)(D)(1)(3)
of this Section 2.10 to the Corporation within the time frames specified herein, any such nomination shall be disregarded and any
such other business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation.
Notwithstanding the foregoing provisions of this Section 2.10, unless otherwise required by law, or otherwise determined by the Chairman
of the Board of Directors or the chairman of the meeting, if the stockholder (or a qualified representative of the stockholder) does not
appear at the annual or special meeting of stockholders of the Corporation to present a nomination or other business (whether pursuant
to the requirements of these Bylaws or in accordance with Rule 14a-8 under the Exchange Act), such nomination shall be disregarded
and such other business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation.
To be considered a qualified representative of a stockholder pursuant to the preceding sentence, a person must be a duly authorized officer,
manager or partner of such stockholder or authorized by a writing executed by such stockholder (or a reliable reproduction of the writing)
delivered to the Corporation prior to the making of such nomination or proposal at such meeting (and in any event not fewer than five
days before the meeting) stating that such person is authorized to act for such stockholder as proxy at the meeting of stockholders.
(ii) For purposes of this
Section 2.10, the “close of business” shall mean 6:00 p.m. local time at the principal executive offices of the
Corporation on any calendar day, whether or not the day is a business day, and a “public announcement” shall mean disclosure
in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly
filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act. For
purposes of clause (a)(ii)(D)(1) of this Section 2.10, shares shall be treated as “beneficially owned” by a person
if the person beneficially owns such shares, directly or indirectly, for purposes of Section 13(d) of the Exchange Act and Regulations
13D and 13G thereunder or has or shares pursuant to any agreement, arrangement or understanding (whether or not in writing): (A) the
right to acquire such shares (whether such right is exercisable immediately or only after the passage of time or the fulfillment of a
condition or both); (B) the right to vote such shares, alone or in concert with others; and/or (C) investment power with respect
to such shares, including the power to dispose of, or to direct the disposition of, such shares.
(iii) Nothing in this Section 2.10
shall be deemed to affect any rights of the holders of any series of Preferred Stock to elect directors pursuant to any applicable provisions
of the Certificate of Incorporation (including any Preferred Stock Designation).
Section 2.11 No Action by Written
Consent.
Except as otherwise provided for or fixed pursuant
to the Certificate of Incorporation (including any Preferred Stock Designation), no action that is required or permitted to be taken by
the stockholders of the Corporation may be effected by consent of stockholders in lieu of a meeting of stockholders.
Section 2.12 Inspectors of
Election. Before any meeting of stockholders, the Corporation may, and shall if required by law, appoint one or more inspectors
of election to act at the meeting and make a written report thereof. Inspectors may be employees of the Corporation. The Corporation
may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is
able to act at a meeting of stockholders, the chairman of the meeting may, and shall if required by law, appoint one or more
inspectors to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an
oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability.
Inspectors need not be stockholders. No director or nominee for the office of director at an election shall be appointed as an
inspector at such election.
Such inspectors shall:
(a) determine the number
of shares outstanding and the voting power of each, the number of shares represented at the meeting, the existence of a quorum, and the
validity of proxies and ballots;
(b) determine and retain
for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors;
(c) count and tabulate
all votes and ballots; and
(d) certify their determination
of the number of shares represented at the meeting, and their count of all votes and ballots.
Section 2.13 Meetings by
Remote Communications. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held
at any place, but may instead be held solely by means of remote communication in accordance with Section 211(a)(2) of the DGCL. If
authorized by the Board of Directors in its sole discretion, and subject to such guidelines and procedures as the Board of Directors may
adopt, stockholders and proxyholders not physically present at a meeting of stockholders may, by means of remote communication: (a) participate
in a meeting of stockholders; and (b) be deemed present in person and vote at a meeting of stockholders whether such meeting is to
be held at a designated place or solely by means of remote communication, provided that: (i) the Corporation shall
implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication
is a stockholder or proxyholder; (ii) the Corporation shall implement reasonable measures to provide such stockholders and proxyholders
a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity
to read or hear the proceedings of the meeting substantially concurrently with such proceedings; and (iii) if any stockholder or
proxyholder votes or takes other action at the meeting by means of remote communication, a record of such vote or other action shall be
maintained by the Corporation.
Section 2.14 Delivery to
the Corporation. Whenever this Article II requires one or more persons (including a record or beneficial owner of stock) to deliver
a document or information to the Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire,
revocation, representation or other document or agreement), the Corporation shall not be required to accept delivery of such document
or information unless the document or information is in writing exclusively (and not in an electronic transmission) and delivered exclusively
by hand (including, without limitation, overnight courier service) or by certified or registered mail, return receipt requested.
ARTICLE III
DIRECTORS
Section 3.1 Powers.
Except as otherwise required by the DGCL or as provided in the Certificate of Incorporation (including any Preferred Stock Designation),
the business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. In addition to the powers
and authorities these Bylaws expressly confer upon it, the Board of Directors may exercise all such powers of the Corporation and do all
such lawful acts and things as are not by law, the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws
required to be exercised or done by the stockholders.
Section 3.2 Number
and Election. The number of directors of the Corporation shall be fixed solely by resolution adopted from time to time by a majority
of the directors then in office. The directors shall hold office in the manner provided in the Certificate of Incorporation. At any meeting
of stockholders at which directors are to be elected, directors shall be elected by a plurality of the votes cast. Directors need not
be stockholders unless so required by the Certificate of Incorporation (including any Preferred Stock Designation) or these Bylaws, wherein
other qualifications for directors may be prescribed.
Section 3.3 Vacancies
and Newly Created Directorships. Subject to the rights of the holders of any outstanding series of Preferred Stock, and unless otherwise
required by law newly created directorships resulting from any increase in the authorized number of directors and any vacancies in the
Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause shall be filled
solely by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum, or by the sole
remaining director, and any director so chosen shall hold office until the next election of the class for which such director shall
have been chosen and until his or her successor shall have been duly elected and qualified. No decrease in the authorized number of directors
shall shorten the term of any incumbent director.
Section 3.4 Resignations
and Removal.
(a) Any director may
resign at any time upon notice given in writing or by electronic transmission to the Board of Directors, the Chairman of the Board of
Directors or the Secretary of the Corporation. Such resignation shall take effect upon delivery, unless the resignation specifies a later
effective date or time or an effective date or time determined upon the happening of an event or events. Unless otherwise specified therein,
the acceptance of such resignation shall not be necessary to make it effective.
(b) Except for such
additional directors, if any, as are elected by the holders of any series of Preferred Stock as provided for or fixed pursuant to the
Certificate of Incorporation (including any Preferred Stock Designation), any director, or the entire Board of Directors, may be removed
from office at any time, but only for cause and only by the affirmative vote of at least 66⅔% of the voting power of the stock
outstanding and entitled to vote thereon.
Section 3.5 Regular
Meetings. Regular meetings of the Board of Directors shall be held at such place or places, within or without the State of Delaware,
on such date or dates and at such time or times, as shall have been established by the Board of Directors and publicized among all directors.
A notice of each regular meeting shall not be required.
Section 3.6 Special
Meetings. Special meetings of the Board of Directors for any purpose or purposes may be called at any time by the Chairman of the
Board of Directors, the Chief Executive Officer or a majority of the directors then in office. The person or persons authorized to call
special meetings of the Board of Directors may fix the place, within or without the State of Delaware, date and time of such meetings.
Notice of each such meeting shall be given to each director, if by mail, addressed to such director at his or her residence or usual place
of business, at least five days before the day on which such meeting is to be held, or shall be sent to such director by electronic transmission,
or be delivered personally or by telephone, in each case at least 24 hours prior to the time set for such meeting. A notice of special
meeting need not state the purpose of such meeting, and, unless indicated in the notice thereof, any and all business may be transacted
at a special meeting.
Section 3.7 Participation
in Meetings by Conference Telephone. Members of the Board of Directors, or of any committee thereof, may participate in a meeting
of such Board of Directors or committee by means of conference telephone or other communications equipment by means of which all persons
participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting.
Section 3.8 Quorum
and Voting. Except as otherwise required by law, the Certificate of Incorporation or these Bylaws, a majority of the total number
of directors then authorized shall constitute a quorum for the transaction of business at any meeting of the Board of Directors, and the
vote of a majority of the directors present at a duly held meeting at which a quorum is present shall be the act of the Board of Directors.
The chairman of the meeting or a majority of the directors present may adjourn the meeting to another time and place whether or not a
quorum is present. At any adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted
at the meeting as originally called.
Section 3.9 Board
of Directors Action by Written Consent Without a Meeting. Unless otherwise restricted by the Certificate of Incorporation or these
Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or any committee thereof, may be taken
without a meeting, provided that all members of the Board of Directors or committee, as the case may be, consent in writing
or by electronic transmission to such action. After an action is taken, the consent or consents relating thereto shall be filed with the
minutes or proceedings of the Board of Directors or committee in the same paper or electronic form as the minutes are maintained. Any
person (whether or not then a director) may provide, whether through instruction to an agent or otherwise, that a consent to action shall
be effective at a future time (including a time determined upon the happening of an event), no later than 60 days after such instruction
is given or such provision is made and such consent shall be deemed to have been given at such effective time so long as such person is
then a director and did not revoke the consent prior to such time. Any such consent shall be revocable prior to its becoming effective.
Section 3.10 Chairman of
the Board. The Chairman of the Board shall preside at meetings of stockholders (unless otherwise determined by the Board of Directors)
and at meetings of directors and shall perform such other duties as the Board of Directors may from time to time determine. If the Chairman
of the Board is not present at a meeting of the Board of Directors, another director chosen by the Board of Directors shall preside.
Section 3.11 Rules and
Regulations. The Board of Directors may adopt such rules and regulations not inconsistent with the provisions of law, the Certificate
of Incorporation or these Bylaws for the conduct of its meetings and management of the affairs of the Corporation as the Board of Directors
shall deem proper.
Section 3.12 Fees and Compensation
of Directors. Unless otherwise restricted by the Certificate of Incorporation, directors may receive such compensation, if any, for
their services on the Board of Directors and its committees, and such reimbursement of expenses, as may be fixed or determined by resolution
of the Board of Directors.
Section 3.13 Emergency
Bylaws. This Section 3.13 shall be operative during any emergency condition as contemplated by Section 110 of the DGCL (an
“Emergency”), notwithstanding any different or conflicting provisions in these Bylaws, the Certificate of Incorporation or
the DGCL. In the event of any Emergency, or other similar emergency condition, the director or directors in attendance at a meeting of
the Board of Directors or a standing committee thereof shall constitute a quorum. Such director or directors in attendance may further
take action to appoint one or more of themselves or other directors to membership on any standing or temporary committees of the Board
of Directors as they shall deem necessary and appropriate. Except as the Board may otherwise determine, during any Emergency, the Corporation
and its directors and officers, may exercise any authority and take any action or measure contemplated by Section 110 of the DGCL.
ARTICLE IV
COMMITTEES
Section 4.1 Committees
of the Board of Directors. (a) The Board of Directors may designate one or more committees, each such committee to consist of
one or more of the directors of the Corporation; (b) the Board of Directors may designate one or more directors as alternate members
of any committee to replace any absent or disqualified member at any meeting of the committee; (c) in the absence or disqualification
of a member of a committee, the member or members present at any meeting and not disqualified from voting, whether or not he, she or they
constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent
or disqualified member; and (d) any such committee, to the extent permitted by law and provided in the resolution of the Board of
Directors establishing such committee, shall have and may exercise all the powers and authority of the Board of Directors in the management
of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require
it; but no such committee shall have the power or authority in reference to the following matters: (i) approving or adopting, or
recommending to the stockholders, any action or matter (other than the election or removal of directors) expressly required by the DGCL
to be submitted to stockholders for approval; or (ii) adopting, amending or repealing any bylaw of the Corporation. All committees
of the Board of Directors shall keep minutes of their meetings and shall report their proceedings to the Board of Directors when requested
or required by the Board of Directors.
Section 4.2 Meetings
and Action of Committees. Unless the Board of Directors provides otherwise by resolution, any committee of the Board of Directors
may adopt, alter and repeal such rules and regulations not inconsistent with the provisions of law, the Certificate of Incorporation or
these Bylaws for the conduct of its meetings as such committee may deem proper. A majority of the directors then serving on a committee
shall constitute a quorum for the transaction of business by the committee except as otherwise required by law, the Certificate of Incorporation
and these Bylaws, and except as otherwise provided in a resolution of the Board of Directors; provided, however,
that in no case shall a quorum be less than one-third of the directors then serving on the committee. Unless the Certificate of Incorporation,
these Bylaws, or a resolution of the Board of Directors requires a greater number, the vote of a majority of the members of a committee
present at a meeting at which a quorum is present shall be the act of the committee.
ARTICLE V
OFFICERS
Section 5.1 Officers.
The officers of the Corporation shall consist of a Chief Executive Officer, a Chief Financial Officer, a Secretary, a Treasurer, a Controller
and such other officers as the Board of Directors may from time to time determine, each of whom shall be elected by the Board of Directors,
each to have such authority, functions or duties as set forth in these Bylaws or as determined by the Board of Directors. Each officer
shall be elected by the Board of Directors and shall hold office for such term as may be prescribed by the Board of Directors and until
such person’s successor shall have been duly elected and qualified, or until such person’s earlier death, disqualification,
resignation or removal. Any number of offices may be held by the same person; provided, however, that no officer
shall execute, acknowledge or verify any instrument in more than one capacity if such instrument is required by law, the Certificate of
Incorporation or these Bylaws to be executed, acknowledged or verified by two or more officers. The Board of Directors may require any
officer, agent or employee to give security for the faithful performance of his or her duties.
Section 5.2 Compensation.
The salaries of the officers of the Corporation and the manner and time of the payment of such salaries shall be fixed and determined
by the Board of Directors or by a duly authorized officer and may be altered by the Board of Directors from time to time as it deems appropriate,
subject to the rights, if any, of such officers under any contract of employment.
Section 5.3 Removal,
Resignation and Vacancies. Any officer of the Corporation may be removed, with or without cause, by the Board of Directors or by a
duly authorized officer, without prejudice to the rights, if any, of such officer under any contract to which it is a party. Any officer
may resign at any time upon notice given in writing or by electronic transmission to the Corporation, without prejudice to the rights,
if any, of the Corporation under any contract to which such officer is a party. If any vacancy occurs in any office of the Corporation,
the Board of Directors may elect a successor to fill such vacancy for the remainder of the unexpired term and until a successor shall
have been duly elected and qualified.
Section 5.4 Chief
Executive Officer. The Chief Executive Officer shall have general supervision and direction of the business and affairs of the Corporation,
shall be responsible for corporate policy and strategy, and shall report directly to the Board of Directors. Unless otherwise provided
in these Bylaws or determined by the Board of Directors, all other officers of the Corporation shall report directly to the Chief Executive
Officer or as otherwise determined by the Chief Executive Officer. The Chief Executive Officer shall, if present and in the absence of
the Chairman of the Board of Directors, preside at meetings of the stockholders.
Section 5.5 Chief
Financial Officer. The Chief Financial Officer shall exercise all the powers and perform the duties of the office of the chief financial
officer and in general have overall supervision of the financial operations of the Corporation. The Chief Financial Officer shall, when
requested, counsel with and advise the other officers of the Corporation and shall perform such other duties as the Board of Directors
or the Chief Executive Officer may from time to time determine.
Section 5.6 Treasurer.
The Treasurer shall supervise and be responsible for all the funds and securities of the Corporation, the deposit of all moneys and other
valuables to the credit of the Corporation in depositories of the Corporation, borrowings and compliance with the provisions of all indentures,
agreements and instruments governing such borrowings to which the Corporation is a party, the disbursement of funds of the Corporation
and the investment of its funds, and in general shall perform all of the duties incident to the office of the Treasurer. The Treasurer
shall, when requested, counsel with and advise the other officers of the Corporation and shall perform such other duties as the Board
of Directors, the Chief Executive Officer or the Chief Financial Officer may from time to time determine.
Section 5.7 Controller.
The Controller shall have responsibility for the Corporation’s accounting policies and practices. The Controller shall, when requested,
counsel with and advise the other officers of the Corporation and shall perform such other duties as the Board of Directors, the Chief
Executive Officer or the Chief Financial Officer may from time to time determine.
Section 5.8 Secretary.
The powers and duties of the Secretary are: (i) to act as Secretary at all meetings of the Board of Directors, of the committees
of the Board of Directors and of the stockholders and to record the proceedings of such meetings in a book or books to be kept for that
purpose; (ii) to see that all notices required to be given by the Corporation are duly given and served; (iii) to act as custodian
of the seal of the Corporation and affix the seal or cause it to be affixed to all certificates of stock of the Corporation and to all
documents, the execution of which on behalf of the Corporation under its seal is duly authorized in accordance with the provisions of
these Bylaws; (iv) to have charge of the books, records and papers of the Corporation and see that the reports, statements and other
documents required by law to be kept and filed are properly kept and filed; and (v) to perform all of the duties incident to the
office of Secretary. The Secretary shall, when requested, counsel with and advise the other officers of the Corporation and shall perform
such other duties as the Board of Directors or the Chief Executive Officer may from time to time determine.
Section 5.9 Additional
Matters. The Chief Executive Officer and the Chief Financial Officer of the Corporation shall have the authority to designate employees
of the Corporation to have the title of Vice President, Assistant Vice President, Assistant Treasurer or Assistant Secretary. Any employee
so designated shall have the powers and duties determined by the officer making such designation. The persons upon whom such titles are
conferred shall not be deemed officers of the Corporation unless elected by the Board of Directors.
Section 5.10 Checks; Drafts;
Evidences of Indebtedness. From time to time, the Board of Directors shall determine the method, and designate (or authorize officers
of the Corporation to designate) the person or persons who shall have authority, to sign or endorse all checks, drafts, other orders for
payment of money and notes, bonds, debentures or other evidences of indebtedness that are issued in the name of or payable by the Corporation,
and only the persons so authorized shall sign or endorse such instruments.
Section 5.11 Corporate
Contracts and Instruments; How Executed. Except as otherwise provided in these Bylaws, the Board of Directors may determine the method,
and designate (or authorize officers of the Corporation to designate) the person or persons who shall have authority to enter into any
contract or execute any instrument in the name of and on behalf of the Corporation. Such authority may be general or confined to specific
instances. Unless so authorized, or within the power incident to a person’s office or other position with the Corporation, no person
shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable
for any purpose or for any amount.
Section 5.12 Signature
Authority. Unless otherwise determined by the Board of Directors or otherwise provided by law or these Bylaws, contracts, evidences
of indebtedness and other instruments or documents of the Corporation may be executed, signed or endorsed: (i) by the Chief Executive;
or (ii) by the Chief Financial Officer, Treasurer, Secretary or Controller, in each case only with regard to such instruments or
documents that pertain to or relate to such person’s duties or business functions.
Section 5.13 Action with
Respect to Securities of Other Corporations or Entities. The Chief Executive Officer or any other officer of the Corporation authorized
by the Board of Directors or the Chief Executive Officer is authorized to vote, represent, and exercise on behalf of the Corporation all
rights incident to any and all shares or other equity interests of any other corporation or entity or corporations or entities, standing
in the name of the Corporation. The authority herein granted may be exercised either by such person directly or by any other person authorized
to do so by proxy or power of attorney duly executed by the person having such authority.
Section 5.14 Delegation.
The Board of Directors may from time to time delegate the powers or duties of any officer to any other officers or agents, notwithstanding
the foregoing provisions of this Article V.
ARTICLE VI
INDEMNIFICATION AND ADVANCEMENT OF EXPENSES
Section 6.1 Right
to Indemnification.
(a) Each person who
was or is a party or is threatened to be made a party to, or was or is otherwise involved in, any action, suit, arbitration, alternative
dispute resolution mechanism, investigation, inquiry, judicial, administrative or legislative hearing, or any other threatened, pending
or completed proceeding, whether brought by or in the right of the Corporation or otherwise, including any and all appeals, whether of
a civil, criminal, administrative, legislative, investigative or other nature (hereinafter a “proceeding”), by reason
of the fact that he or she is or was a director or an officer (which means, for purposes of this Article VI, any individual designated
by the Board of Directors as an officer for purposes of Section 16 of the Exchange Act) of the Corporation or while a director or
officer of the Corporation is or was serving at the request of the Corporation as a director, officer, employee, agent, trustee or agent
of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit
plan (hereinafter an “indemnitee”), or by reason of anything done or not done by him or her in any such capacity, shall
be indemnified and held harmless by the Corporation to the fullest extent permitted by the DGCL, as the same exists or may hereafter be
amended, against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes, penalties and
amounts paid in settlement by or on behalf of the indemnitee) actually and reasonably incurred by such indemnitee in connection therewith,
all on the terms and conditions set forth in these Bylaws; provided, however, that, except as otherwise required
by law or provided in Section 6.3 with respect to suits to enforce rights under this Article VI, the Corporation shall indemnify
any such indemnitee in connection with a proceeding, or part thereof, voluntarily initiated by such indemnitee (including claims and counterclaims,
whether such counterclaims are asserted by: (i) such indemnitee; or (ii) the Corporation in a proceeding initiated by such indemnitee)
only if such proceeding, or part thereof, was authorized or ratified by the Board of Directors or the Board of Directors otherwise determines
that indemnification or advancement of expenses is appropriate.
Section 6.2 Right
to Advancement of Expenses.
(a) In addition to
the right to indemnification conferred in Section 6.1, an indemnitee shall, to the fullest extent permitted by law, also have the
right to be paid by the Corporation the expenses (including attorneys’ fees) incurred in defending any proceeding in advance of
its final disposition (hereinafter an “advancement of expenses”); provided, however, that an
advancement of expenses shall be made only upon delivery to the Corporation of an undertaking (hereinafter an “undertaking”),
by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision of
a court of competent jurisdiction from which there is no further right to appeal (hereinafter a “final adjudication”)
that such indemnitee is not entitled to be indemnified for such expenses under this Article VI or otherwise.
(b) Notwithstanding
the foregoing Section 6.2(a), the Corporation shall not make or continue to make advancements of expenses to an indemnitee if a determination
is reasonably made that the facts known at the time such determination is made demonstrate clearly and convincingly that the indemnitee
acted in bad faith or in a manner that the indemnitee did not reasonably believe to be in or not opposed to the best interests of the
Corporation, or, with respect to any criminal proceeding, that the indemnitee had reasonable cause to believe his or her conduct was unlawful.
Such determination shall be made: (i) by the Board of Directors by a majority vote of directors who are not parties to such proceeding,
whether or not such majority constitutes a quorum; (ii) by a committee of such directors designated by a majority vote of such directors,
whether or not such majority constitutes a quorum; or (iii) if there are no such directors, or if such directors so direct, by independent
legal counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the indemnitee.
(c) The indemnification
and advancement of expenses provided by, or granted pursuant to, this Section 6 shall, unless otherwise provided when authorized
or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the
heirs, executors and administrators of such a person.
Section 6.3 Right
of Indemnitee to Bring Suit. If a request for indemnification under Section 6.1 is not paid in full by the Corporation within
60 days, or if a request for an advancement of expenses under Section 6.2 is not paid in full by the Corporation within 20 days,
after a written request has been received by the Secretary of the Corporation, the indemnitee may at any time thereafter bring suit against
the Corporation in a court of competent jurisdiction in the State of Delaware seeking an adjudication of entitlement to such indemnification
or advancement of expenses. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an
advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall be entitled to be paid also the expense of prosecuting
or defending such suit to the fullest extent permitted by law. In any suit brought by the indemnitee to enforce a right to indemnification
hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses) it shall be a defense that indemnification
is prohibited by law, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including
its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have
made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances, nor
an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors,
independent legal counsel or its stockholders) that the indemnification is prohibited, shall create a presumption that indemnification
is prohibited. In any suit brought by the indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder,
or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that
the indemnitee is not entitled to be indemnified, or to such advancement of expenses, under applicable law, this Article VI or otherwise
shall be on the Corporation.
Section 6.4 Non-Exclusivity of
Rights. The rights to indemnification and to the advancement of expenses conferred in this Article VI shall not be exclusive
of any other right which any person may have or hereafter acquire under any law, agreement, vote of stockholders or disinterested directors,
provisions of a certificate of incorporation or bylaws, or otherwise.
Section 6.5 Insurance.
The Corporation may secure and maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the
Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether
or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.
Section 6.6 Indemnification
of Employees and Agents of the Corporation. This Article VI shall not limit the right of the Corporation to the extent and in
the manner authorized or permitted by law to indemnify and to advance expenses to persons other than indemnitees. Without limiting the
foregoing, the Corporation may, to the extent and in the manner permitted by law, and to the extent authorized from time to time, grant
rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation and to any other person who is
or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership,
joint venture, trust or other enterprise, including service with respect to an employee benefit plan, to the fullest extent of the provisions
of this Article VI with respect to the indemnification and advancement of expenses of indemnitees under this Article VI.
Section 6.7 Nature
of Rights. The rights conferred upon indemnitees in this Article VI shall be contract rights and such rights shall continue as
to an indemnitee who has ceased to be a director or officer and shall inure to the benefit of the indemnitee’s heirs, executors
and administrators. Any amendment, alteration or repeal of this Article VI that adversely affects any right of an indemnitee or its
successors shall be prospective only and shall not limit or eliminate any such right with respect to any proceeding involving any occurrence
or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.
Section 6.8 Settlement
of Claims. Notwithstanding anything in this Article VI to the contrary, the Corporation shall not be liable to indemnify any
indemnitee under this Article VI for any amounts paid in settlement of any proceeding effected without the Corporation’s written
consent, which consent shall not be unreasonably withheld.
Section 6.9 Subrogation.
In the event of payment under this Article VI, the Corporation shall be subrogated to the extent of such payment to all of the rights
of recovery of the indemnitee (excluding insurance obtained on the indemnitee’s own behalf), and the indemnitee shall execute all
papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary
to enable the Corporation effectively to bring suit to enforce such rights.
Section 6.10 Severability.
If any provision or provisions of this Article VI shall be held to be invalid, illegal or unenforceable as applied to any person
or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law: (a) the validity, legality and
enforceability of such provision in any other circumstance and of the remaining provisions of this Article VI (including, without
limitation, all portions of any paragraph of this Article VI containing any such provision held to be invalid, illegal or unenforceable,
that are not by themselves invalid, illegal or unenforceable) and the application of such provision to other persons or entities or circumstances
shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Article VI
(including, without limitation, all portions of any paragraph of this Article VI containing any such provision held to be invalid,
illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent
of the parties that the Corporation provide protection to the indemnitee to the fullest extent set forth in this Article VI.
Section 6.11 Personal Liability.
No director or officer of the Corporation shall be personally liable to the Corporation or to any stockholder of the Corporation for monetary
damages for breach of fiduciary duty as a director or officer, provided that this provision shall not limit the liability of a director
or officer (i) for any breach of the director’s or the officer’s duty of loyalty to the Corporation or its stockholders,
(ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under
Section 174 of the General Corporation Law of Delaware, or (iv) for any transaction from which the director or officer derived
an improper personal benefit
ARTICLE VII
CAPITAL STOCK
Section 7.1 Certificates
of Stock. The shares of the Corporation shall be represented by certificates; provided, however, that the
Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of stock shall be uncertificated
shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation.
Every holder of stock represented by certificates shall be entitled to have a certificate signed by or in the name of the Corporation
by any two authorized officers of the Corporation, including, without limitation, the Chief Executive Officer, the Chief Financial Officer,
the Treasurer, the Controller, the Secretary, or an Assistant Treasurer or Assistant Secretary, of the Corporation certifying the number
of shares owned by such holder in the Corporation. Any or all such signatures may be facsimiles. In case any officer, transfer agent or
registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent
or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer,
transfer agent or registrar at the date of issue.
Section 7.2 Special
Designation on Certificates. If the Corporation is authorized to issue more than one class of stock or more than one series of any
class, then the powers, the designations, the preferences, and the relative, participating, optional or other special rights of each class
of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in
full or summarized on the face or back of the certificate that the Corporation shall issue to represent such class or series of stock; provided, however,
that, except as otherwise provided in Section 202 of the DGCL, in lieu of the foregoing requirements there may be set forth on the
face or back of the certificate that the Corporation shall issue to represent such class or series of stock a statement that the Corporation
will furnish without charge to each stockholder who so requests the powers, the designations, the preferences, and the relative, participating,
optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such
preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the registered owner thereof
shall be given a notice, in writing or by electronic transmission, containing the information required to be set forth or stated on certificates
pursuant to this Section 7.2 or Sections 151, 156, 202(a) or 218(a) of the DGCL or with respect to this Section 7.2 and
Section 151 of the DGCL a statement that the Corporation will furnish without charge to each stockholder who so requests the powers,
the designations, the preferences, and the relative, participating, optional or other special rights of each class of stock or series
thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided
by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders of certificates
representing stock of the same class and series shall be identical.
Section 7.3 Transfers
of Stock. Transfers of shares of stock of the Corporation shall be made only on the books of the Corporation upon authorization by
the registered holder thereof or by such holder’s attorney thereunto authorized by a power of attorney duly executed and filed with
the Secretary of the Corporation or a transfer agent for such stock, and if such shares are represented by a certificate, upon surrender
of the certificate or certificates for such shares properly endorsed or accompanied by a duly executed stock transfer power and the payment
of any taxes thereon; provided, however, that the Corporation shall be entitled to recognize and enforce any lawful
restriction on transfer. Transfers may also be made in any manner authorized by the Corporation (or its authorized transfer agent) and
permitted by Section 224 of the DGCL.
Section 7.4 Lost
Certificates. The Corporation may issue a new share certificate or uncertificated shares in the place of any certificate theretofore
issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed
certificate or the owner’s legal representative to give the Corporation a bond (or other adequate security) sufficient to indemnify
it against any claim that may be made against it (including any expense or liability) on account of the alleged loss, theft or destruction
of any such certificate or the issuance of such new certificate or uncertificated shares. The Board of Directors may adopt such other
provisions and restrictions with reference to lost certificates, not inconsistent with applicable law, as it shall in its discretion deem
appropriate.
Section 7.5 Registered
Stockholders. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner
of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest
in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise
required by law.
Section 7.6 Record
Date for Determining Stockholders.
(a) In order that the
Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjourned meeting, the Board of Directors
may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the
Board of Directors, and which record date shall, unless otherwise required by law, not be more than 60 nor less than 10 days before
the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders
entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on
or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors,
the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business
on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding
the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders
shall apply to any adjourned meeting; provided, however, that the Board of Directors may fix a new record date
for the determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for
stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders
entitled to vote in accordance herewith at the adjourned meeting.
(b) In order that the
Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights,
or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action,
the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record
date is adopted by the Board of Directors, and which record date shall not be more than 60 days prior to such action. If no such
record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on
which the Board of Directors adopts the resolution relating thereto.
Section 7.7 Regulations.
To the extent permitted by applicable law, the Board of Directors may make such additional rules and regulations as it may deem expedient
concerning the issue, transfer and registration of shares of stock of the Corporation.
Section 7.8 Waiver
of Notice. Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these Bylaws,
a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether
before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a
waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the
meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted
at, nor the purpose of, any regular or special meeting of the stockholders, the Board of Directors or a committee of the Board of Directors
need be specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate of Incorporation
or these Bylaws.
ARTICLE VIII
GENERAL MATTERS
Section 8.1 Fiscal
Year. The fiscal year of the Corporation shall begin on the first day of January of each year and end on the last day of December
of the same year, or shall extend for such other 12 consecutive months as the Board of Directors may designate.
Section 8.2 Corporate
Seal. The Board of Directors may provide a suitable seal, containing the name of the Corporation, which seal shall be in the charge
of the Secretary of the Corporation. If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal
may be kept and used by the Treasurer or by an Assistant Secretary or Assistant Treasurer.
Section 8.3 Reliance
Upon Books, Reports and Records. Each director and each member of any committee designated by the Board of Directors shall, in the
performance of his or her duties, be fully protected in relying in good faith upon the books of account or other records of the Corporation
and upon such information, opinions, reports or statements presented to the Corporation by any of its officers or employees, or committees
of the Board of Directors so designated, or by any other person as to matters which such director or committee member reasonably believes
are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf
of the Corporation.
Section 8.4 Subject
to Law; Certificate of Incorporation. All powers, duties and responsibilities provided for in these Bylaws, whether or not explicitly
so qualified, are qualified by the Certificate of Incorporation (including any Preferred Stock Designation) and applicable law.
Section 8.5 Electronic
Signatures, etc. Except as otherwise required by the Certificate of Incorporation (including as otherwise required by any Preferred
Stock Designation) or these Bylaws (including, without limitation, as otherwise required by Section 2.14), any document, including,
without limitation, any consent, agreement, certificate or instrument, required by the DGCL, the Certificate of Incorporation (including
any Preferred Stock Designation) or these Bylaws to be executed by any officer, director, stockholder, employee or agent of the Corporation
may be executed using a facsimile or other form of electronic signature to the fullest extent permitted by applicable law. All other contracts,
agreements, certificates or instruments to be executed on behalf of the Corporation may be executed using a facsimile or other form of
electronic signature to the fullest extent permitted by applicable law. The terms “electronic mail,” “electronic mail
address,” “electronic signature” and “electronic transmission” as used herein shall have the meanings ascribed
thereto in the DGCL.
ARTICLE IX
AMENDMENTS
Section 9.1 Amendments.
In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, the Board of Directors is expressly
authorized to adopt, amend or repeal these Bylaws. Except as otherwise provided in the Certificate of Incorporation (including the terms
of any Preferred Stock Designation that provides for a greater or lesser vote) or these Bylaws and in addition to any other vote required
by law, the affirmative vote of at least 66⅔% of the voting power of the stock outstanding and entitled to vote thereon, voting
together as a single class, shall be required for the stockholders to adopt, amend or repeal, or adopt any provision inconsistent with,
any provision of these Bylaws.
The foregoing Amended and Restated Bylaws were
adopted by the Board of Directors on November 5, 2021.
17
Exhibit 4.3
SPECIMEN COMMON STOCK CERTIFICATE
|
NUMBER
|
NUMBER OF SHARES OF COMMON STOCK
|
|
|
SEE REVERSE FOR CERTAIN DEFINITIONS
|
|
|
CUSIP 256086 109
|
DOCGO INC.
INCORPORATED UNDER THE LAWS OF THE STATE OF
DELAWARE
COMMON STOCK
This Certifies that
is the owner of
FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE OF $0.0001 PER SHARE, OF DOCGO
INC. (THE “COMPANY”) transferable on the books of the Company in person or by duly authorized attorney upon surrender
of this certificate properly endorsed.
This certificate is not valid unless countersigned by the Transfer
Agent and registered by the Registrar.
Witness the seal of the Company and the facsimile signatures of its
duly authorized officers.
Dated: ___________________
|
|
[Corporate Seal]
|
|
|
Chief Executive Officer
|
Delaware
|
Chief Financial officer
|
|
|
|
|
|
|
|
|
DOCGO INC.
The Company will furnish without charge to each
stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each
class of stock or series thereof of the Company and the qualifications, limitations, or restrictions of such preferences and/or rights.
This certificate and the shares of common stock represented hereby are issued and shall be held subject to all the provisions of the Company’s
certificate of incorporation and all amendments thereto and resolutions of the Board of Directors providing for the issue of securities
(copies of which may be obtained from the secretary of the Company), to all of which the holder of this certificate by acceptance hereof
assents.
The following abbreviations, when used in the
inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or
regulations:
|
TEN COM
|
|
--
|
|
as tenants in common
|
|
TEN ENT
|
|
--
|
|
as tenants by the entireties
|
|
JT TEN
|
|
--
|
|
as joint tenants with right of survivorship and not as tenants in common
|
|
UNIF GIFT MIN ACT --
|
|
|
Custodian
|
|
|
|
(Cust)
|
|
|
(Minor)
|
|
|
|
|
|
|
|
|
under Uniform Gifts to Minors Act
|
|
|
|
|
|
|
|
|
|
|
|
(State)
|
|
|
|
Additional abbreviations may also be used though not in the above list.
For value received,
hereby sells, assigns and transfers unto
|
(PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING
NUMBER(S) OF ASSIGNEE(S))
|
|
(PLEASE PRINT OR TYPEWRITE NAME(S) AND ADDRESS(ES),
INCLUDING ZIP CODE, OF ASSIGNEE(S))
|
|
|
|
Shares of the capital
stock represented by the within Certificate, and does hereby irrevocably constitute and appoint
|
|
Attorney to transfer the said shares on the books of the within named Company with full power of substitution in the premises.
|
|
Dated: _______________________________
|
|
|
|
Shareholder: _______________________________
|
|
|
|
|
|
NOTICE: THE SIGNATURE(S) TO THIS ASSIGNMENT MUST CORRESPOND WITH
THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER.
|
|
Signature(s) Guaranteed:
By
|
THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE
GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE
MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED).
Exhibit 10.4
AMENDED AND RESTATED
REGISTRATION RIGHTS AGREEMENT
THIS
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of November 5, 2021,
by and among Motion Acquisition Corp., a Delaware corporation (the “Company”) and the undersigned parties listed
under Investors on the signature page hereto (each, an “Investor” and collectively, the “Investors”).
WHEREAS,
certain Investors and the Company are party to that certain Registration Rights Agreement, dated as of October 14, 2020 (the “Original
Registration Rights Agreement”)
WHEREAS,
the Company entered into that certain Merger Agreement, dated as of March 8, 2021, by and among the Company, Motion Merger Sub Corp.,
a Delaware corporation and wholly-owned subsidiary of the Company, and Ambulnz, Inc., a Delaware corporation (the “Merger
Agreement”); and
WHEREAS,
the Investors and the Company desire to amend and restate the Original Registration Rights Agreement in its entirety and enter into this
Agreement, pursuant to which the Company shall grant the Investors registration rights with respect to certain securities of the Company,
as set forth in the Agreement.
NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. DEFINITIONS.
The following capitalized terms used herein have the following meanings:
“Agreement”
means this Agreement, as amended, restated, supplemented, or otherwise modified from time to time.
“Ambulnz
Holder” is defined in Section 6.2.3.
“Ambulnz
Permitted Transferee” is defined in Section 6.2.3.
“Block
Trade” is defined in Section 2.4.
“Block
Trade Notice” is defined in Section 2.4.
“Block
Trade Offer Notice” is defined in Section 2.4.
“Business
Day” means any calendar day other than a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized
or required to close.
“Closing”
has the meaning given in the Merger Agreement.
“Commission”
means the Securities and Exchange Commission, or any other Federal agency then administering the Securities Act or the Exchange Act.
“Common
Stock” means the common stock, par value $0.0001 per share, of the Company.
“Company”
is defined in the preamble to this Agreement.
“Demand
Registration” is defined in Section 2.1.1.
“Demanding
Holder” is defined in Section 2.1.1.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time.
“Form S-3”
is defined in Section 2.3.
“Indemnified
Party” is defined in Section 4.3.
“Indemnifying
Party” is defined in Section 4.3.
“Insider
Letter Agreement” means that Letter Agreement, by and among the Company, the Motion Holder and the officers and directors
of the Company, dated October 14, 2020.
“Investor”
is defined in the preamble to this Agreement.
“Investor
Indemnified Party” is defined in Section 4.1.
“Maximum
Number of Shares” is defined in Section 2.1.4.
“Merger
Agreement” is defined in the Recitals.
“Motion
Holder” is defined in Section 6.2.2.
“Motion
Permitted Transferee” is defined in Section 6.2.2.
“Notices”
is defined in Section 6.3.
“Original
Registration Rights Agreement” is defined in the Recitals.
“Piggy-Back
Registration” is defined in Section 2.2.1.
“Pro
Rata” is defined in Section 2.1.4.
“Register,”
“Registered” and “Registration” mean a registration effected by preparing and filing
a registration statement or similar document in compliance with the requirements of the Securities Act, and the applicable rules and regulations
promulgated thereunder, and such registration statement becoming effective.
“Registrable
Securities” means (a) any outstanding shares of Common Stock or any other equity security (including the Warrants and
shares of Common Stock issued or issuable upon the exercise of any other equity security) of the Company held by an Investor immediately
following the Closing or distributable to an Investor pursuant to the Merger Agreement, (b) any outstanding shares of Common Stock or
any other equity security (including the Warrants and shares of Common Stock issued or issuable upon the exercise of any other equity
security) of the Company acquired by an Investor following the date hereof to the extent that such securities are “restricted securities”
(as defined in Rule 144) or are otherwise held by an “affiliate” (as defined in Rule 144) of the Company, and (c) any other
equity security of the Company or any of its subsidiaries issued or issuable with respect to any securities referenced in clause (a) or
(b) above by way of a stock dividend or stock split or in connection with a recapitalization, merger, consolidation, spin-off, reorganization
or similar transaction. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when: (a) a
Registration Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities
shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement; (b) such securities shall
have been otherwise transferred, new certificates for them not bearing a legend restricting further transfer shall have been delivered
by the Company and subsequent public distribution of them shall not require registration under the Securities Act; (c) such securities
shall have ceased to be outstanding, or (d) the Registrable Securities are freely saleable under Rule 144 under the Securities Act
without volume limitations.
“Registration
Statement” means a registration statement filed by the Company with the Commission in compliance with the Securities Act
and the rules and regulations promulgated thereunder for a public offering and sale of equity securities, or securities or other obligations
exercisable or exchangeable for, or convertible into, equity securities (other than a registration statement on Form S-4 or
Form S-8, or their successors, or any registration statement covering only securities proposed to be issued in exchange for
securities or assets of another entity).
“Rule
144” is defined in Section 3.6.
“Seller
Lock-Up Agreement” means that agreement by and among the Company, Ambunlz, Inc., and certain holders of securities of Ambulnz,
Inc., dated March 8, 2021.
“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder,
all as the same shall be in effect at the time.
“Underwriter”
means a securities dealer who purchases any Registrable Securities as principal in an underwritten offering and not as part of such dealer’s
market-making activities.
“Warrants”
means the warrants of the Company with each whole warrant entitling the holder to purchase one share of Common Stock.
2. REGISTRATION
RIGHTS.
2.1 Demand
Registration.
2.1.1. Request
for Registration. At any time and from time to time on or after the Closing, an Investor may make a written demand for registration
under the Securities Act of all or part of the Investor’s Registrable Securities (a “Demand Registration”).
Any demand for a Demand Registration shall specify the number of shares of Registrable Securities proposed to be sold and the intended
method(s) of distribution thereof. The Company will within five (5) Business Days of the Company’s receipt of the Demand Registration
notify all holders of Registrable Securities of the demand, and each holder of Registrable Securities who wishes to include all or a portion
of such holder’s Registrable Securities in the Demand Registration (each such holder including shares of Registrable Securities
in such registration, a “Demanding Holder”) shall so notify the Company within five (5) Business Days after
the receipt by the holder of the notice from the Company. Upon any such request, the Demanding Holders shall be entitled to have their
Registrable Securities included in the Demand Registration, subject to Section 2.1.4 and the provisos set forth in Section 3.1.1.
The Company shall not be obligated to effect more than an aggregate of five (5) Demand Registrations under this Section 2.1.1
in respect of all Registrable Securities.
2.1.2 Effective
Registration. A registration will not count as a Demand Registration until the Registration Statement filed with the Commission with
respect to such Demand Registration has been declared effective and the Company has complied with all of its obligations under this Agreement
with respect thereto; provided, however, that if, after such Registration Statement has been declared effective, the offering of Registrable
Securities pursuant to a Demand Registration is interfered with by any stop order or injunction of the Commission or any other governmental
agency or court, the Registration Statement with respect to such Demand Registration will be deemed not to have been declared effective,
unless and until, (i) such stop order or injunction is removed, rescinded or otherwise terminated, and (ii) a majority-in-interest of
the Demanding Holders thereafter elect to continue the offering; provided, further, that the Company shall not be obligated to file a
second Registration Statement until a Registration Statement that has been filed is counted as a Demand Registration or is terminated.
2.1.3 Underwritten
Offering. If a majority-in-interest of the Demanding Holders so elect and such holders so advise the Company as part of
their written demand for a Demand Registration, the offering of such Registrable Securities pursuant to such Demand Registration shall
be in the form of an underwritten offering, including any bought deal or block sale to a financial institution conducted as an underwritten
offering. In such event, the right of any holder to include its Registrable Securities in such registration shall be conditioned upon
such holder’s participation in such underwriting and the inclusion of such holder’s Registrable Securities in the underwriting
to the extent provided herein. All Demanding Holders proposing to distribute their Registrable Securities through such underwriting shall
enter into an underwriting agreement in customary form with the Underwriter or Underwriters selected for such underwriting by a majority-in-interest of
the holders initiating the Demand Registration.
2.1.4 Reduction
of Offering. If the managing Underwriter or Underwriters for a Demand Registration that is to be an underwritten offering, in good
faith, advises the Company and the Demanding Holders in writing that the dollar amount or number of shares of Registrable Securities which
the Demanding Holders desire to sell, taken together with all other shares of Common Stock or other securities which the Company desires
to sell and the shares of Common Stock, if any, as to which registration has been requested pursuant to written contractual piggy-back
registration rights held by other stockholders of the Company who desire to sell, exceeds the maximum dollar amount or maximum number
of shares that can be sold in such offering without adversely affecting the proposed offering price, the timing, the distribution method,
or the probability of success of such offering (such maximum dollar amount or maximum number of shares, as applicable, the “Maximum
Number of Shares”), then the Company shall include in such registration: (i) first, the Registrable Securities as to
which Demand Registration has been requested by the Demanding Holders (pro rata in accordance with the number of shares that each such
Person has requested be included in such registration, regardless of the number of shares held by each such Person (such proportion is
referred to herein as “Pro Rata”)) that can be sold without exceeding the Maximum Number of Shares; (ii) second,
to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (i), the shares of Common Stock or other
securities that the Company desires to sell that can be sold without exceeding the Maximum Number of Shares; (iii) third, to the
extent that the Maximum Number of Shares has not been reached under the foregoing clauses (i) and (ii), the Registrable Securities
of holders exercising their rights to register their Registrable Securities pursuant to Section 2.2; and (iv) fourth, to the
extent that the Maximum Number of Shares has not been reached under the foregoing clauses (i), (ii) and (iii), the shares of Common Stock
or other securities for the account of other persons that the Company is obligated to register pursuant to written contractual arrangements
with such persons and that can be sold without exceeding the Maximum Number of Shares.
2.1.5 Withdrawal.
If a majority-in-interest of the Demanding Holders disapprove of the terms of any underwriting or are not entitled to include
all of their Registrable Securities in any offering, such majority-in-interest of the Demanding Holders may elect to withdraw
from such offering by giving written notice to the Company and the Underwriter or Underwriters of their request to withdraw prior to the
effectiveness of the Registration Statement filed with the Commission with respect to such Demand Registration. If the majority-in-interest of
the Demanding Holders withdraws from a proposed offering relating to a Demand Registration, then such registration shall not count as
a Demand Registration provided for in Section 2.1.
2.2 Piggy-Back
Registration.
2.2.1 Piggy-Back
Rights. If at any time on or after the Closing, the Company proposes to file a Registration Statement under the Securities Act with
respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into,
equity securities, by the Company for its own account or for shareholders of the Company for their account (or by the Company and by shareholders
of the Company including, without limitation, pursuant to Section 2.1), other than a Registration Statement (i) filed in connection
with any employee stock option or other benefit plan, (ii) for an exchange offer or offering of securities solely to the Company’s
existing shareholders, (iii) for an offering of debt that is convertible into equity securities of the Company or (iv) for a
dividend reinvestment plan, then the Company shall (x) give written notice of such proposed filing to the holders of Registrable
Securities as soon as practicable but in no event less than five (5) Business Days before the anticipated filing date, which notice
shall describe the amount and type of securities to be included in such offering, the intended method(s) of distribution, and the name
of the proposed managing Underwriter or Underwriters, if any, of the offering, and (y) offer to the holders of Registrable Securities
in such notice the opportunity to register the sale of such number of shares of Registrable Securities as such holders may request in
writing within three (3) Business Days following receipt of such notice (a “Piggy-Back Registration”).
The Company shall, in good faith, cause such Registrable Securities to be included in such registration and shall use its best efforts
to cause the managing Underwriter or Underwriters of a proposed underwritten offering to permit the Registrable Securities requested to
be included in a Piggy-Back Registration on the same terms and conditions as any similar securities of the Company and to permit the sale
or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. All holders of
Registrable Securities proposing to distribute their securities through a Piggy-Back Registration that involves an Underwriter or Underwriters
shall enter into an underwriting agreement in customary form with the Underwriter or Underwriters selected for such Piggy-Back Registration.
2.2.2 Reduction
of Offering. If the managing Underwriter or Underwriters for a Piggy-Back Registration that is to be an underwritten offering advises
the Company and the holders of Registrable Securities in writing that the dollar amount or number of shares of Common Stock which the
Company desires to sell, taken together with shares of Common Stock, if any, as to which registration has been demanded pursuant to separate
written contractual arrangements with persons or entities other than the holders of Registrable Securities hereunder, the Registrable
Securities as to which registration has been requested under this Section 2.2, and the shares of Common Stock, if any, as to which
registration has been requested pursuant to the written contractual piggy-back registration rights of other stockholders of the Company,
exceeds the Maximum Number of Shares, then the Company shall include in any such registration:
a) If the
registration is undertaken for the Company’s account: (A) the shares of Common Stock or other securities that the Company desires
to sell that can be sold without exceeding the Maximum Number of Shares; (B) to the extent that the Maximum Number of Shares has
not been reached under the foregoing clause (A), the shares of Common Stock or other securities, if any, comprised of Registrable Securities,
as to which registration has been requested pursuant to the applicable written contractual piggy-back registration rights of such security
holders, Pro Rata, that can be sold without exceeding the Maximum Number of Shares; and (C) to the extent that the Maximum Number
of Shares has not been reached under the foregoing clauses (A) and (B), the shares of Common Stock or other securities for the account
of other persons that the Company is obligated to register pursuant to written contractual piggy-back registration rights with such persons
and that can be sold without exceeding the Maximum Number of Shares; and
b) If the
registration is a “demand” registration undertaken at the demand of persons or entities other than either the holders of Registrable
Securities, (A) first, the shares of Common Stock or other securities for the account of the demanding persons that can be sold without
exceeding the Maximum Number of Shares; (B) second, to the extent that the Maximum Number of Shares has not been reached under the
foregoing clause (A), the Common Stock or other securities that the Company desires to sell that can be sold without exceeding the Maximum
Number of Shares; (C) third, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A) and
(B), collectively the Common Stock or other securities comprised of Registrable Securities, Pro Rata, as to which registration has been
requested pursuant to the terms hereof, as applicable, that can be sold without exceeding the Maximum Number of Shares; and (D) fourth,
to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A), (B) and (C), the shares of Common
Stock or other securities for the account of other persons that the Company is obligated to register pursuant to written contractual arrangements
with such persons, that can be sold without exceeding the Maximum Number of Shares.
2.2.3 Withdrawal.
Any holder of Registrable Securities may elect to withdraw such holder’s request for inclusion of Registrable Securities in any
Piggy-Back Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the Registration
Statement. The Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written
contractual obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement.
Notwithstanding any such withdrawal, the Company shall pay all expenses incurred by the holders of Registrable Securities in connection
with such Piggy-Back Registration as provided in Section 3.3.
2.2.4 Unlimited
Piggy-Back Registration Rights. For purposes of clarity, any registration effected pursuant to Section 2.2 hereof shall not be
counted as a registration pursuant to a Demand Registration effected under Section 2.1 hereof.
23 Registrations
on Form S-3. The holders of Registrable Securities may at any time and from time to time request in writing that the Company
register the resale of any or all of such Registrable Securities on Form S-3 or any similar short-form registration which may
be available at such time (“Form S-3”); provided, however, that the Company shall not be obligated to effect
such request through an underwritten offering. Upon receipt of such written request, the Company will promptly give written notice of
the proposed registration to all other holders of Registrable Securities, and each holder of Registrable Securities who thereafter wishes
to include all or a portion of such holder’s Registrable Securities in such registration shall so notify the Company, in writing,
within five (5) Business Days after the receipt by the holder of the notice from the Company, and, as soon as practicable thereafter
but not more than seven (7) Business Days after the Company’s initial receipt of such written request for a registration, effect
the registration of all or such portion of such holder’s or holders’ Registrable Securities as are specified in such request,
together with all or such portion of the Registrable Securities or other securities of the Company, if any, of any other holder or holders
joining in such request; provided, however, that the Company shall not be obligated to effect any such registration pursuant to this Section 2.3:
(i) if Form S-3 is not available for such offering; or (ii) if the holders of the Registrable Securities, together with
the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities
and such other securities (if any) at any aggregate price to the public of less than $500,000. Registrations effected pursuant to this
Section 2.3 shall not be counted as Demand Registrations effected pursuant to Section 2.1.
2.4
Block Trades. Notwithstanding anything contained in this Section 2, in the event of a sale of Registrable Securities in an underwritten
offering requiring the involvement of the Company but not involving (i) any “road show” or (ii) a lock-up agreement of more
than sixty (60) days to which the Company is a party, and which is commonly known as a “block trade” (a “Block
Trade”), (1) the Demanding Holder, as applicable, shall (i) give at least five (5) Business Days prior notice in writing
(the “Block Trade Notice”) of such transaction to the Company and (ii) identify the potential underwriter(s)
in such notice with contact information for such underwriter(s); and (2) the Company shall cooperate with such requesting Holder or Holders
to the extent it is reasonably able to effect such Block Trade. The Company shall give written notice (the “Block Trade Offer
Notice”) of the proposed Block Trade to all Holders holding Registrable Shares as soon as practicable (but in no event more
than two (2) Business Days following the Company’s receipt of the Block Trade Notice), and such notice shall offer such Holders
the opportunity to participate in such Block Trade by providing written notice of intent to so participate within two (2) Business Days
following receipt of the Block Trade Offer Notice. Any Block Trade shall be for at least $10 million in expected gross proceeds. The Company
shall not be required to effectuate more than two (2) Block Trades in any 90-day period. For the avoidance of doubt, a Block Trade shall
not constitute a Demand Registration. The Holders of at least a majority of the Registrable Securities being sold in any Block Trade shall
select the underwriter(s) to administer such Block Trade; provided that such underwriter(s) shall be reasonably acceptable to the Company.
3. REGISTRATION
PROCEDURES.
3.1 Filings;
Information. Whenever the Company is required to effect the registration of any Registrable Securities pursuant to Section 2,
the Company shall use its best efforts to effect the registration and sale of such Registrable Securities in accordance with the intended
method(s) of distribution thereof as expeditiously as practicable, and in connection with any such request:
3.1.1 Filing
Registration Statement. The Company shall, as expeditiously as possible and in any event within forty-five (45) days after receipt
of a request for a Demand Registration pursuant to Section 2.1, prepare and file with the Commission a Registration Statement on
any form for which the Company then qualifies or which counsel for the Company shall deem appropriate and which form shall be available
for the sale of all Registrable Securities to be registered thereunder in accordance with the intended method(s) of distribution thereof,
and shall use its best efforts to cause such Registration Statement to become effective and use its best efforts to keep it effective
for the period required by Section 3.1.3; provided, however, that the Company shall have the right to defer any Demand Registration
for up to thirty (30) consecutive days, and any Piggy-Back Registration for such period as may be applicable to deferment of any
demand registration to which such Piggy-Back Registration relates, in each case if the Company shall furnish to the holders a certificate
signed by the President or Chairman of the Company stating that, in the good faith judgment of the Board of Directors of the Company,
it would be materially detrimental to the Company and its shareholders for such Registration Statement to be effected at such time; provided
further, however, that the Company shall not have the right to exercise the right set forth in the immediately preceding proviso more
than once in any 365-day period in respect of a Demand Registration hereunder.
3.1.2 Copies.
The Company shall, prior to filing a Registration Statement or prospectus, or any amendment or supplement thereto, furnish without charge
to the holders of Registrable Securities included in such registration, and such holders’ legal counsel, copies of such Registration
Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits thereto
and documents incorporated by reference therein), the prospectus included in such Registration Statement (including each preliminary prospectus),
and such other documents as the holders of Registrable Securities included in such registration or legal counsel for any such holders
may request in order to facilitate the disposition of the Registrable Securities owned by such holders.
3.1.3 Amendments
and Supplements. The Company shall prepare and file with the Commission such amendments, including post-effective amendments, and
supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration
Statement effective and in compliance with the provisions of the Securities Act until all Registrable Securities and other securities
covered by such Registration Statement have been disposed of in accordance with the intended method(s) of distribution set forth in such
Registration Statement or such securities have been withdrawn.
3.1.4 Notification.
After the filing of a Registration Statement, the Company shall promptly, and in no event more than two (2) business days after such
filing, notify the holders of Registrable Securities included in such Registration Statement of such filing, and shall further notify
such holders promptly and confirm such advice in writing in all events within two (2) business days of the occurrence of any of the
following: (i) when such Registration Statement becomes effective; (ii) when any post-effective amendment to such Registration
Statement becomes effective; (iii) the issuance or threatened issuance by the Commission of any stop order (and the Company shall
take all actions required to prevent the entry of such stop order or to remove it if entered); and (iv) any request by the Commission
for any amendment or supplement to such Registration Statement or any prospectus relating thereto or for additional information or of
the occurrence of an event requiring the preparation of a supplement or amendment to such prospectus so that, as thereafter delivered
to the purchasers of the securities covered by such Registration Statement, such prospectus will not contain an untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading,
and promptly make available to the holders of Registrable Securities included in such Registration Statement any such supplement or amendment;
except that before filing with the Commission a Registration Statement or prospectus or any amendment or supplement thereto, including
documents incorporated by reference, the Company shall furnish to the holders of Registrable Securities included in such Registration
Statement and to the legal counsel for any such holders, copies of all such documents proposed to be filed sufficiently in advance of
filing to provide such holders and legal counsel with a reasonable opportunity to review such documents and comment thereon, and the Company
shall not file any Registration Statement or prospectus or amendment or supplement thereto, including documents incorporated by reference,
to which such holders or their legal counsel shall object.
3.1.5 State
Securities Laws Compliance. The Company shall use its best efforts to (i) register or qualify the Registrable Securities covered
by the Registration Statement under such securities or “blue sky” laws of such jurisdictions in the United States as the holders
of Registrable Securities included in such Registration Statement (in light of their intended plan of distribution) may request and (ii) take
such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by
such other governmental authorities as may be necessary by virtue of the business and operations of the Company and do any and all other
acts and things that may be necessary or advisable to enable the holders of Registrable Securities included in such Registration Statement
to consummate the disposition of such Registrable Securities in such jurisdictions; provided, however, that the Company shall not be required
to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this paragraph or
subject itself to taxation in any such jurisdiction.
3.1.6 Agreements
for Disposition. The Company shall enter into customary agreements (including, if applicable, an underwriting agreement in customary
form) and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such Registrable Securities.
The representations, warranties and covenants of the Company in any underwriting agreement which are made to or for the benefit of any
Underwriters, to the extent applicable, shall also be made to and for the benefit of the holders of Registrable Securities included in
such registration statement. No holder of Registrable Securities included in such registration statement shall be required to make any
representations or warranties in the underwriting agreement except, if applicable, with respect to such holder’s organization, good
standing, authority, title to Registrable Securities, lack of conflict of such sale with such holder’s material agreements and organizational
documents, and with respect to written information relating to such holder that such holder has furnished in writing expressly for inclusion
in such Registration Statement.
3.1.7 Cooperation.
The principal executive officer of the Company, the principal financial officer of the Company, the principal accounting officer of the
Company and all other officers and members of the management of the Company shall cooperate fully in any offering of Registrable Securities
hereunder, which cooperation shall include, without limitation, the preparation of the Registration Statement with respect to such offering
and all other offering materials and related documents, and participation in meetings with Underwriters, attorneys, accountants and potential
investors.
3.1.8 Records.
The Company shall make available for inspection by the holders of Registrable Securities included in such Registration Statement, any
Underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant or other professional
retained by any holder of Registrable Securities included in such Registration Statement or any Underwriter, all financial and other records,
pertinent corporate documents and properties of the Company, as shall be necessary to enable them to exercise their due diligence responsibility,
and cause the Company’s officers, directors and employees to supply all information requested by any of them in connection with
such Registration Statement.
3.1.9 Opinions
and Comfort Letters. The Company shall furnish to each holder of Registrable Securities included in any Registration Statement a signed
counterpart, addressed to such holder, of (i) any opinion of counsel to the Company delivered to any Underwriter and (ii) any
comfort letter from the Company’s independent public accountants delivered to any Underwriter. In the event no legal opinion is
delivered to any Underwriter, the Company shall furnish to each holder of Registrable Securities included in such Registration Statement,
at any time that such holder elects to use a prospectus, an opinion of counsel to the Company to the effect that the Registration Statement
containing such prospectus has been declared effective and that no stop order is in effect.
3.1.10 Earnings
Statement. The Company shall comply with all applicable rules and regulations of the Commission and the Securities Act, and make available
to its shareholders, as soon as practicable, an earnings statement covering a period of twelve (12) months, which earnings statement
shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder.
3.1.11 Listing.
The Company shall use its best efforts to cause all Registrable Securities included in any registration to be listed on such exchanges
or otherwise designated for trading in the same manner as similar securities issued by the Company are then listed or designated or, if
no such similar securities are then listed or designated, in a manner satisfactory to the holders of a majority of the Registrable Securities
included in such registration.
3.1.12. Transfer
Agent. The Company shall provide a transfer agent or warrant agent, as applicable, and registrar for all such Registrable Securities
no later than the effective date of the registration statement.
3.1.13. Misstatements.
The Company shall notify the holders at any time when a prospectus relating to such registration statement is required to be delivered
under the Securities Act, of the happening of any event as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or an omission to state a material fact required to be stated in a registration
statement or prospectus, or necessary to make the statements therein in the light of the circumstances under which they were made not
misleading (a “Misstatement”), and then to correct such Misstatement.
3.1.14 Road
Show. If the registration involves the registration of Registrable Securities involving gross proceeds in excess of $15,000,000, the
Company shall use its reasonable efforts to make available senior executives of the Company to participate in customary “road show”
presentations that may be reasonably requested by the Underwriter in any underwritten offering.
3.2 Obligation
to Suspend Distribution. Upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3.1.4(iv),
or, in the case of a resale registration on Form S-3 pursuant to Section 2.3 hereof, upon any suspension by the Company,
pursuant to a written insider trading compliance program adopted by the Company’s Board of Directors, of the ability of all “insiders”
covered by such program to transact in the Company’s securities because of the existence of material non-public information,
each of Registrable Securities included in any registration shall immediately discontinue disposition of such Registrable Securities pursuant
to the Registration Statement covering such Registrable Securities until such holder receives the supplemented or amended prospectus contemplated
by Section 3.1.4(iv) or the restriction on the ability of “insiders” to transact in the Company’s securities is
removed, as applicable, and, if so directed by the Company, each such holder will deliver to the Company all written copies, other than
permanent file copies then in such holder’s possession, of the most recent prospectus covering such Registrable Securities at the
time of receipt of such notice.
3.3 Registration
Expenses. The Company shall bear all costs and expenses incurred in connection with any Demand Registration pursuant to Section 2.1,
any Piggy-Back Registration pursuant to Section 2.2, and any registration on Form S-3 effected pursuant to Section 2.3,
any Block Trade pursuant to Section 2.4, and all expenses incurred in performing or complying with its other obligations under this Agreement,
whether or not the Registration Statement becomes effective, including, without limitation: (i) all registration and filing fees
and fees of any securities exchange on which the Common Stock is then listed; (ii) fees and expenses of compliance with securities
or “blue sky” laws (including fees and disbursements of counsel for the Underwriters in connection with blue sky qualifications
of the Registrable Securities); (iii) fees and expenses related to registration in any non-U.S. jurisdictions, as applicable; (iv) printing,
messenger, telephone and delivery expenses; (v) the Company’s internal expenses (including, without limitation, all salaries
and expenses of its officers and employees); (vi) the fees and expenses incurred in connection with the listing of the Registrable Securities
as required by Section 3.1.11; (vii) Financial Industry Regulatory Authority fees; (viii) fees and disbursements of counsel
for the Company and fees and expenses for independent certified public accountants retained by the Company (including the expenses or
costs associated with the delivery of any opinions or comfort letters requested pursuant to Section 3.1.9); (ix) the fees and expenses
of any special experts retained by the Company in connection with such registration; and (x) the fees and expenses of one legal counsel
selected by the holders of a majority-in-interest of the Registrable Securities included in such registration (including the
expenses or costs associated with the delivery of any opinions). The Company shall have no obligation to pay any underwriting discounts
or selling commissions attributable to the Registrable Securities being sold by the holders thereof, which underwriting discounts or selling
commissions shall be borne by such holders. Additionally, in an underwritten offering, all selling shareholders and the Company shall
bear the expenses of the Underwriter pro rata in proportion to the respective amount of shares each is selling in such offering.
3.4 Information.
The holders of Registrable Securities shall provide such information as may reasonably be requested by the Company, or the managing Underwriter,
if any, in connection with the preparation of any Registration Statement, including amendments and supplements thereto, in order to effect
the registration of any Registrable Securities under the Securities Act pursuant to Section 2 and in connection with the Company’s
obligation to comply with federal and applicable state securities laws.
3.5 Suspension
of Sales; Adverse Disclosure. Upon receipt of written notice from the Company that a registration statement or prospectus contains
a Misstatement, each of the Holders shall forthwith discontinue disposition of Registrable Securities until it has received copies of
a supplemented or amended prospectus correcting the Misstatement (it being understood that the Company hereby covenants to prepare and
file such supplement or amendment as soon as practicable after the time of such notice), or until it is advised in writing by the Company
that the use of the prospectus may be resumed. If the filing, initial effectiveness or continued use of a registration statement in respect
of any registration at any time would require the Company to make an Adverse Disclosure (as defined below) or would require the inclusion
in such registration statement of financial statements that are unavailable to the Company for reasons beyond the Company’s control,
the Company may, upon giving prompt written notice of such action to the holders, delay the filing or initial effectiveness of, or suspend
use of, such registration statement for the shortest period of time, but in no event for more than thirty (30) consecutive days and
on more than two occasions during any 365-day period, determined in good faith by the Company to be necessary for such purpose. In the
event the Company exercises its rights under the preceding sentence, the holders agree to suspend, immediately upon their receipt of the
notice referred to above, their use of the prospectus relating to any registration in connection with any sale or offer to sell Registrable
Securities. The Company shall immediately notify the Holders of the expiration of any period during which it exercised its rights under
this Section 3.5. “Adverse Disclosure” shall mean any public disclosure of material non-public information,
which disclosure, in the good faith judgment of the Chief Executive Officer or principal financial officer of the Company, after consultation
with counsel to the Company, (i) would be required to be made in any registration statement or prospectus in order for the applicable
registration statement or prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements contained therein (in the case of any prospectus and any preliminary prospectus, in the light of the circumstances
under which they were made) not misleading, (ii) would not be required to be made at such time if the registration statement were
not being filed, and (iii) the Company has a bona fide business purpose for not making such information public.
3.6 Reporting
Obligations. As long as any holder shall own Registrable Securities, the Company, at all times while it shall be reporting under the
Exchange Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange Act and to promptly furnish
the holders with true and complete copies of all such filings. The Company further covenants that it shall take such further action as
any holder may reasonably request, all to the extent required from time to time to enable such holder to sell Common Stock held by such
holder without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 (or any successor provision)
promulgated under the Securities Act (“Rule 144”), including providing any legal opinions. Upon the request
of any holder, the Company shall deliver to such holder a written certification of a duly authorized officer as to whether it has complied
with such requirements.
4. INDEMNIFICATION
AND CONTRIBUTION.
4.1 Indemnification
by the Company. The Company agrees to indemnify and hold harmless each Investor and each other holder of Registrable Securities, and
each of their respective officers, employees, affiliates, directors, partners, members, attorneys and agents, and each person, if any,
who controls an Investor and each other holder of Registrable Securities (within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act) (each, an “Investor Indemnified Party”), from and against any expenses,
losses, judgments, claims, damages or liabilities, whether joint or several, arising out of or based upon any untrue statement (or allegedly
untrue statement) of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was registered
under the Securities Act, any preliminary prospectus, final prospectus or summary prospectus contained in the Registration Statement,
or any amendment or supplement to such Registration Statement, or arising out of or based upon any omission (or alleged omission) to state
a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Company
of the Securities Act or any rule or regulation promulgated thereunder applicable to the Company and relating to action or inaction required
of the Company in connection with any such registration; and the Company shall promptly reimburse the Investor Indemnified Party for any
legal and any other expenses reasonably incurred by such Investor Indemnified Party in connection with investigating and defending any
such expense, loss, judgment, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case
to the extent that any such expense, loss, claim, damage or liability arises out of or is based upon any untrue statement or allegedly
untrue statement or omission or alleged omission made in such Registration Statement, preliminary prospectus, final prospectus, or summary
prospectus, or any such amendment or supplement, in reliance upon and in conformity with information furnished to the Company, in writing,
by such selling holder expressly for use therein. The Company also shall indemnify any Underwriter of the Registrable Securities, their
officers, affiliates, directors, partners, members and agents and each person who controls such Underwriter on substantially the same
basis as that of the indemnification provided above in this Section 4.1.
4.2 Indemnification
by Holders of Registrable Securities. Each selling holder of Registrable Securities will, in the event that any registration is being
effected under the Securities Act pursuant to this Agreement of any Registrable Securities held by such selling holder, indemnify and
hold harmless the Company, each of its directors and officers and each Underwriter (if any), and each other selling holder and each other
person, if any, who controls another selling holder or such Underwriter within the meaning of the Securities Act, against any losses,
claims, judgments, damages or liabilities, whether joint or several, insofar as such losses, claims, judgments, damages or liabilities
(or actions in respect thereof) arise out of or are based upon any untrue statement or allegedly untrue statement of a material fact contained
in any Registration Statement under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary
prospectus, final prospectus or summary prospectus contained in the Registration Statement, or any amendment or supplement to the Registration
Statement, or arise out of or are based upon any omission or the alleged omission to state a material fact required to be stated therein
or necessary to make the statement therein not misleading, if the statement or omission was made in reliance upon and in conformity with
information furnished in writing to the Company by such selling holder expressly for use therein, and shall reimburse the Company, its
directors and officers, and each other selling holder or controlling person for any legal or other expenses reasonably incurred by any
of them in connection with investigation or defending any such loss, claim, damage, liability or action. Each selling holder’s indemnification
obligations hereunder shall be several and not joint and shall be limited to the amount of any net proceeds actually received by such
selling holder.
4.3 Conduct
of Indemnification Proceedings. Promptly after receipt by any person of any notice of any loss, claim, damage or liability or any
action in respect of which indemnity may be sought pursuant to Section 4.1 or 4.2, such person (the “Indemnified Party”)
shall, if a claim in respect thereof is to be made against any other person for indemnification hereunder, notify such other person (the
“Indemnifying Party”) in writing of the loss, claim, judgment, damage, liability or action; provided, however,
that the failure by the Indemnified Party to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability
which the Indemnifying Party may have to such Indemnified Party hereunder, except and solely to the extent the Indemnifying Party is actually
prejudiced by such failure. If the Indemnified Party is seeking indemnification with respect to any claim or action brought against the
Indemnified Party, then the Indemnifying Party shall be entitled to participate in such claim or action, and, to the extent that it wishes,
jointly with all other Indemnifying Parties, to assume control of the defense thereof with counsel satisfactory to the Indemnified Party.
After notice from the Indemnifying Party to the Indemnified Party of its election to assume control of the defense of such claim or action,
the Indemnifying Party shall not be liable to the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified
Party in connection with the defense thereof other than reasonable costs of investigation; provided, however, that in any action in which
both the Indemnified Party and the Indemnifying Party are named as defendants, the Indemnified Party shall have the right to employ separate
counsel (but no more than one such separate counsel) to represent the Indemnified Party and its controlling persons who may be subject
to liability arising out of any claim in respect of which indemnity may be sought by the Indemnified Party against the Indemnifying Party,
with the fees and expenses of such counsel to be paid by such Indemnifying Party if, based upon the written advice of counsel of such
Indemnified Party, representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests
between them. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, consent to entry of judgment or
effect any settlement of any claim or pending or threatened proceeding in respect of which the Indemnified Party is or could have been
a party and indemnity could have been sought hereunder by such Indemnified Party, unless such judgment or settlement includes an unconditional
release of such Indemnified Party from all liability arising out of such claim or proceeding.
4.4 Contribution.
4.4.1
If the indemnification provided for in the foregoing Sections 4.1, 4.2 and 4.3 is unavailable to any Indemnified Party in respect of any
loss, claim, damage, liability or action referred to herein, then each such Indemnifying Party, in lieu of indemnifying such Indemnified
Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, claim, damage, liability or
action in such proportion as is appropriate to reflect the relative fault of the Indemnified Parties and the Indemnifying Parties in connection
with the actions or omissions which resulted in such loss, claim, damage, liability or action, as well as any other relevant equitable
considerations. The relative fault of any Indemnified Party and any Indemnifying Party shall be determined by reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by such Indemnified Party or such Indemnifying Party and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission.
4.4.2
The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 4.4 were determined by
pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the
immediately preceding Section 4.4.1.
4.4.3
The amount paid or payable by an Indemnified Party as a result of any loss, claim, damage, liability or action referred to in the immediately
preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such
Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 4.4,
no holder of Registrable Securities shall be required to contribute any amount in excess of the dollar amount of the net proceeds (after
payment of any underwriting fees, discounts, commissions or taxes) actually received by such holder from the sale of Registrable Securities
which gave rise to such contribution obligation. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Securities Act) with respect to any action shall be entitled to contribution in such action from any person who was not guilty
of such fraudulent misrepresentation.
4.5 Survival.
The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or
on behalf of the Indemnified Party or any officer, director or controlling person of such Indemnified Party and shall survive the transfer
of securities.
5. UNDERWRITING
AND DISTRIBUTION.
5.1 Rule
144. The Company covenants that it shall file any reports required to be filed by it under the Securities Act and the Exchange Act
and shall take such further action as the holders of Registrable Securities may reasonably request, all to the extent required from time
to time to enable such holders to sell Registrable Securities without registration under the Securities Act within the limitation of the
exemptions provided by Rule 144 under the Securities Act, as such Rules may be amended from time to time, or any similar rule or regulation
hereafter adopted by the Commission.
6. MISCELLANEOUS.
6.1 Other
Registration Rights. The Company represents and warrants that no person, other than the holders of the Registrable Securities, has
any right to require the Company to register any shares of the Company’s capital stock for sale or to include shares of the Company’s
capital stock in any registration filed by the Company for the sale of shares of capital stock for its own account or for the account
of any other person. Further, the Company represents and warrants that this Agreement supersedes any other registration rights agreement
or agreement with similar terms and conditions and in the event of a conflict between any such agreement or agreements and this Agreement,
the terms of this Agreement shall prevail.
6.2 Assignment;
No Third Party Beneficiaries.
6.2.1
General. This Agreement and the rights, duties and obligations of the Company hereunder may not be assigned or delegated by the
Company in whole or in part. This Agreement and the provisions hereof shall be binding upon and shall inure to the benefit of each of
the parties, to the permitted assigns of the Investors or holder of Registrable Securities or of any assignee of the Investors or holder
of Registrable Securities. This Agreement is not intended to confer any rights or benefits on any persons that are not party hereto other
than as expressly set forth in Article 4 and this Section 6.2.
6.2.2
Motion Transfer Restrictions. Prior to the expiration of the lockup restrictions provided in the Insider Letter Agreement with
respect to those (i) Private Warrants (as defined in the Insider Letter Agreement) and (ii) shares of Class B common stock, par value
$0.0001 per share, of the Company held by Motion Acquisition LLC (the “Motion Holder”) that were converted to Common
Stock pursuant to the terms of the Merger Agreement, Motion Holder may not assign or delegate any of its rights, duties or obligations
under this Agreement, in whole or in part, except in connection with a transfer of Registrable Securities in accordance with Section 6(a)
or 6(c) of the Insider Letter Agreement (a “Motion Permitted Transferee”), provided that such Motion Permitted Transferee
agrees in writing to become bound by the transfer restrictions set forth in this Agreement.
6.2.3
Ambulnz Transfer Restrictions. Prior to the expiration of the lockup restrictions provided in the Seller Lock-Up Agreement with
respect to those shares of Common Stock issued pursuant to the terms of the Merger Agreement to those Investors signatories hereto, other
than the Motion Holder, as of the date of this Agreement (the “Ambulnz Holders”), the Ambulnz Holders may not assign
or delegate any of its rights, duties or obligations under this Agreement, in whole or in part, except in connection with a transfer of
Registrable Securities in accordance with Section 1(a) of the Seller Lock-Up Agreement (an “Ambulnz Permitted Transferee”),
provided that such Ambulnz Permitted Transferee agrees in writing to become bound by the transfer restrictions set forth in this Agreement.
6.3 Notices.
All notices, demands, requests, consents, approvals or other communications (collectively, “Notices”) required
or permitted to be given hereunder or which are given with respect to this Agreement shall be in writing and shall be personally served,
delivered by reputable air courier service with charges prepaid, or transmitted by hand delivery or email , addressed as set forth below,
or to such other address as such party shall have specified most recently by written notice. Notice shall be deemed given on the date
of service or transmission if personally served or transmitted by email; provided, that if such service or transmission is not on a Business
Say or is after normal business hours, then such notice shall be deemed given on the next Business Day. Notice otherwise sent as provided
herein shall be deemed given on the next Business Day following timely delivery of such notice to a reputable air courier service with
an order for next-day delivery.
To the Company:
Ambulnz, Inc.
35
West 35th Street, 6th Floor
New
York, NY 10001
Attention:
Stan Vashovsky
Email:
stan@ambulnz.com
with a copy to:
Gibson,
Dunn & Crutcher LLP
200
Park Avenue
New
York, NY 10166
William
Sorabella
Evan
M. D’Amico
|
|
Email:
|
gstamas@gibsondunn.com
|
wsorabella@gibsondunn.com
edamico@gibsondunn.com
To an Investor,
to the address or email set forth below such Investor’s name on Exhibit A hereto.
6.4 Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to
such invalid or unenforceable provision as may be possible that is valid and enforceable.
6.5 Counterparts.
This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which taken together shall
constitute one and the same instrument. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall
constitute valid and sufficient delivery thereof.
6.6 Entire
Agreement. This Agreement (including all agreements entered into pursuant hereto and all certificates and instruments delivered pursuant
hereto and thereto) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede all prior and
contemporaneous agreements, representations, understandings, negotiations and discussions between the parties, whether oral or written.
6.7 Modifications
and Amendments. No amendment, modification or termination of this Agreement shall be binding upon any party unless executed in writing
by such party.
6.8 Titles
and Headings. Titles and headings of sections of this Agreement are for convenience only and shall not affect the construction of
any provision of this Agreement.
6.9 Waivers
and Extensions. Any party to this Agreement may waive any right, breach or default which such party has the right to waive, provided
that such waiver will not be effective against the waiving party unless it is in writing, is signed by such party, and specifically refers
to this Agreement. Waivers may be made in advance or after the right waived has arisen or the breach or default waived has occurred. Any
waiver may be conditional. No waiver of any breach of any agreement or provision herein contained shall be deemed a waiver of any preceding
or succeeding breach thereof nor of any other agreement or provision herein contained. No waiver or extension of time for performance
of any obligations or acts shall be deemed a waiver or extension of the time for performance of any other obligations or acts.
6.10 Remedies
Cumulative. In the event that the Company fails to observe or perform any covenant or agreement to be observed or performed under
this Agreement, the Investor or any other holder of Registrable Securities may proceed to protect and enforce its rights by suit in equity
or action at law, whether for specific performance of any term contained in this Agreement or for an injunction against the breach of
any such term or in aid of the exercise of any power granted in this Agreement or to enforce any other legal or equitable right, or to
take any one or more of such actions, without being required to post a bond. None of the rights, powers or remedies conferred under this
Agreement shall be mutually exclusive, and each such right, power or remedy shall be cumulative and in addition to any other right, power
or remedy, whether conferred by this Agreement or now or hereafter available at law, in equity, by statute or otherwise.
6.11 Governing
Law. This Agreement shall be governed by, interpreted under, and construed in accordance with the internal laws of the State of New
York applicable to agreements made and to be performed within the State of New York, without giving effect to any choice-of-law provisions
thereof that would compel the application of the substantive laws of any other jurisdiction. The Company irrevocably submits to the nonexclusive
jurisdiction of any New York State or United States Federal court sitting in The City of New York, Borough of Manhattan, over any suit,
action or proceeding arising out of or relating to this Agreement. The Company irrevocably waives, to the fullest extent permitted by
law, any objection that they may now or hereafter have to the laying of venue of any such suit, action or proceeding brought in such a
court and any claim that any such suit, action or proceeding brought in such a court has been brought in an inconvenient forum.
6.12 Waiver
of Trial by Jury. EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY ACTION, SUIT, COUNTERCLAIM
OR OTHER PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF, CONNECTED WITH OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS
CONTEMPLATED HEREBY, OR THE ACTIONS OF THE INVESTOR IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.
[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]
IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered by their duly authorized representatives as of the
date first written above.
|
|
COMPANY:
|
|
|
|
|
|
|
MOTION ACQUISITION CORP.
|
|
|
|
|
|
|
By:
|
/s/ Michael Burdiek
|
|
|
|
Name: Michael Burdiek
|
|
|
|
Title: Chief Executive Officer
|
|
|
|
|
|
|
INVESTORS:
|
|
|
|
|
|
|
MOTION ACQUISITION LLC
|
|
|
|
|
|
|
By:
|
/s/ Rick Vitelle
|
|
|
|
Name: Rick Vitelle
|
|
|
|
Title: Managing Member
|
|
|
|
|
|
|
Stan Vashovsky
|
|
|
|
|
|
|
By:
|
/s/ Stan Vashovsky
|
[Signature Page to Amended and Restated Registration
Rights Agreement]
EXHIBIT A
|
Investor Name
|
|
Address
|
|
Motion Acquisition LLC
|
|
Motion Acquisition LLC
|
|
|
|
c/o Graubard Miller
|
|
|
|
405 Lexington Avenue
|
|
|
|
New York, New York 10174
|
|
|
|
Email: rvitelle@motionacquisition.com
|
|
|
|
|
|
Stan Vashovsky
|
|
763 Raleigh Street
|
|
|
|
Woodmere NY 11598
|
|
|
|
Email: stan@ambulnz.com
|
16
Exhibit 10.6
EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment
Agreement (the “Agreement”) is entered into as of November 5, 2021, by and between Stan Vashovsky (“Executive”)
and Motion Acquisition Corp., a Delaware corporation (the “Company”).
WHEREAS, Executive
has been serving as the Chief Executive Officer of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (“Ambulnz”);
WHEREAS, Ambulnz has
entered into that certain Agreement and Plan of Merger, dated of March 8, 2021, by and among the Company, Motion Merger Sub Corp., a Delaware
corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and Ambulnz (such agreement, the “Merger
Agreement”);
WHEREAS, pursuant to
the terms of the Merger Agreement, Merger Sub will merge with and into Ambulnz with Ambulnz continuing as the surviving company and a
wholly-owned subsidiary of the Company (the “Merger”);
WHEREAS, the Company
wishes to employ, and Executive wishes to accept employment with the Company, as the Chief Executive Officer of the Company and Ambulnz,
Inc., pursuant to the terms and conditions set forth in this Agreement, effective as of the date of the consummation of the Merger (the
“Effective Date”).
NOW, THEREFORE, in
consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
ARTICLE I
DEFINITIONS
For purposes of the Agreement,
the following terms are defined as follows:
1.1. “Board”
means the Board of Directors of the Company.
1.2. “Cause”
means the termination of Executive’s employment for one of the following reasons: (i) willful failure to comply with, breach of
or continued refusal to comply with, in each case, in any material respect, the material terms of this Agreement, of any written agreement
or covenant with the Company or any affiliate (including, without limitation, any employment, consulting, confidentiality, non-competition,
non-solicitation, non-disparagement or similar agreement or covenant); (ii) violation of any lawful material policies, standards or regulations
of the Company which have been furnished to Executive, including policies related to discrimination, harassment, performance of illegal
or unethical activities, and ethical misconduct; (iii) indictment for, conviction of or plea of no contest to a felony under the laws
of the United States or any state; (iv) fraud, embezzlement, dishonesty or breach of fiduciary duty against the Company or its affiliates
or material misappropriation of property belonging to the Company or its affiliates; (v) Executive’s willful failure to perform
Executive’s duties as specifically directed in any reasonable and lawful written directive of the Board; or (vi) willful misconduct
or gross negligence in connection with the performance of Executive’s duties, in each case of (i), (v), (vi), after the receipt
of written notice from the Board and Executive’s failure to cure (if curable) within thirty (30) days of Executive’s receipt
of the written notice, providing that the Company must provide Executive with at least thirty (30) days to cure and if Executive cures,
Cause shall not exist under (i), (v), (vi), as applicable.
1.3. “Change
in Control” shall have the meaning ascribed to that term in the Ambulnz, Inc. 2021 Stock Incentive Plan (the “Plan”)
or any successor equity compensation plan of the Company.
1.4. “COBRA”
means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.
1.5. “Code”
means the Internal Revenue Code of 1986, as amended.
1.6. “Covered
Termination” means (i) an Involuntary Termination Without Cause or (ii) a voluntary termination for Good Reason. For
the avoidance of doubt, neither (x) the termination of Executive’s employment as a result of Executive’s death or Disability
nor (y) the expiration of this Agreement due to non-renewal pursuant to the terms of Section 2.2 of this Agreement will be deemed
to be a Covered Termination.
1.7. “Disability”
shall mean a termination of Executive’s employment due to Executive’s absence from Executive’s duties with the Company
on a full-time basis for at least 180 consecutive days as a result of Executive’s incapacity due to physical or mental illness which
is determined to be total and permanent by a physician selected by the Company or its insurers.
1.8. “Good
Reason” means any of the following taken without Executive’s written consent: (i) failure or refusal by the Company to
comply in any material respect with the material terms of this Agreement, (ii) a material diminution in Executive’s duties, title,
authority or responsibilities, (iii) a material reduction in Executive’s Base Salary (unless the annual base salary of all other
executive officers is similarly reduced), or (iv) the Company requiring Executive to be located at any office or location more than 35
miles from the Company’s current headquarters in New York, New York, provided that any request or directive from the Company to
not work in such office pursuant to any stay-at-home or work from home or similar law, order, directive, request or recommendation from
a governmental entity shall not give rise to Good Reason under this Agreement. Notwithstanding the foregoing, Executive’s resignation
shall not constitute a resignation for “Good Reason” as a result of any event described in the preceding sentence unless (x)
Executive provides written notice thereof to the Company within thirty (30) days after the first occurrence of such event, (y) to the
extent correctable, the Company fails to remedy such circumstance or event within thirty (30) days following the Company’s receipt
of such written notice and (z) the effective date of Executive’s resignation for “Good Reason” is not later than ninety
(90) days after the initial existence of the circumstances constituting Good Reason.
1.9. “Involuntary
Termination Without Cause” means Executive’s dismissal or discharge by the Company other than for Cause or by reason of
Executive’s death or Disability.
1.10. “Section
409A” means Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued
thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date.
1.11. “Separation
from Service” means Executive’s termination of employment constitutes a “separation from service” within the
meaning of Treasury Regulation Section 1.409A-1(h).
ARTICLE II
EMPLOYMENT BY THE COMPANY
2.1. Position
and Duties. Subject to terms set forth herein, Executive shall serve in an executive capacity and shall perform such duties as are
customarily associated with the position of Chief Executive Officer and such other duties as are assigned to Executive by the Board. During
the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all
of Executive’s business time and attention (except for vacation periods and absences due to reasonable periods of illness or other
incapacities permitted by the Company’s general employment policies or as otherwise set forth in this Agreement) to the business
of the Company.
2.2. Term.
The initial term of this Agreement shall commence on the Effective Date and shall terminate on the earlier of (i) the third (3rd)
anniversary of the Effective Date and (ii) the termination of Executive’s employment under this Agreement; provided,
that if the Merger is not consummated, this Agreement shall be null and void ab initio and neither the Company, Ambulnz nor any
other person shall have any liability to Executive under this Agreement. On the third (3rd) anniversary of the Effective Date
and each annual anniversary of such date thereafter (in either case, provided Executive’s employment has not been terminated under
this Agreement prior thereto), this Agreement shall automatically be extended for one additional year unless either Executive or the Company
gives written notice of non-renewal to the other at least sixty (60) days prior to the automatic extension date. The period from the Effective
Date until the earlier of (i) termination of Executive’s employment under this Agreement and (ii) the expiration of the
term of this Agreement due to non-renewal pursuant to this Section 2.2 is referred to as the “Term.”
2.3. Employment
at Will. The Company shall have the right to terminate Executive’s employment with the Company at any time, with or without
cause, and, in the case of a termination by the Company, with or without prior notice. In addition to Executive’s right to resign
for Good Reason, Executive shall have the right to resign at any time and for any reason or no reason at all, upon ninety (90) days’
advance written notice to the Company; provided, however, that if Executive has provided a resignation notice to the Company, the Company
may determine, in its sole discretion, that such termination shall be effective on any date prior to the effective date of termination
provided in such notice (and, if such earlier date is so required, then it shall not change the basis for Executive’s termination
of employment nor be construed or interpreted as a termination of Executive’s employment by the Company) and any requirement to
continue salary or benefits shall cease as of such earlier date. Upon certain terminations of Executive’s employment with the Company,
Executive may become eligible to receive the severance benefits provided in Article IV of this Agreement.
2.4. Deemed
Resignations. Except as otherwise determined by the Board or as otherwise agreed to in writing by Executive and the Company or any
of its affiliates prior to the termination of Executive’s employment with the Company or any of its affiliates, any termination
of Executive’s employment shall constitute, as applicable, an automatic resignation of Executive: (a) as an officer of the Company
and each of its affiliates; (b) from the Board; and (c) from the board of directors or board of managers (or similar governing body) of
any affiliate of the Company and from the board of directors or board of managers (or similar governing body) of any corporation, limited
liability entity, unlimited liability entity or other entity in which the Company or any of its affiliates holds an equity interest and
with respect to which board of directors or board of managers (or similar governing body) Executive serves as such designee or other representative
of the Company or any of its affiliates. Executive agrees to take any further actions that the Company or any of its affiliates reasonably
requests to effectuate or document the foregoing.
2.5. Employment
Policies. The employment relationship between the parties shall also be governed by the general employment policies and practices
of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the
terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement
shall control.
ARTICLE III
COMPENSATION
3.1. Base
Salary. As of the Effective Date, Executive shall receive for services to be rendered hereunder an annualized base salary of $571,000.00
(“Base Salary”), payable on the regular payroll dates of the Company (but no less often than monthly), subject to increase
in the sole discretion of the Board or a committee of the Board.
3.2. Annual
Bonus. For each calendar year ending during the Term, Executive shall be eligible to receive an annual performance bonus (the “Annual
Bonus”) targeted at one hundred percent (100%) of Base Salary or such other amount as determined in the sole discretion of the
Board or a committee of the Board (the “Target Bonus”), on such terms and conditions determined by the Board or a committee
of the Board. The actual amount of any Annual Bonus (if any) will be determined in the discretion of the Board or a committee of the Board
and will be (i) subject to achievement of any applicable bonus objectives and/or conditions determined by the Board or a committee
of the Board and (ii) subject to Executive’s continued employment with the Company through the date the Annual Bonus is paid (except
as otherwise provided in Section 4.1). The Annual Bonus for any calendar year will be paid at the same time as bonuses for other Company
executives are paid related annual bonuses generally.
3.3. Standard
Company Benefits. During the Term, Executive shall be entitled to all rights and benefits for which Executive is eligible under the
terms and conditions of the standard Company benefits and compensation practices that may be in effect from time to time and are provided
by the Company to its executive employees generally, as well as any additional benefits provided to Executive consistent with past practice.
Notwithstanding the foregoing, this Section 3.3 shall not create or be deemed to create any obligation on the part of the Company
to adopt or maintain any benefits or compensation practices at any time.
3.4. Paid
Time Off. During the Term, Executive shall be entitled to such periods of paid time off (“PTO”) each year as provided
from time to time under the Company’s PTO policies and as otherwise provided for executive officers, as it may be amended from time
to time.
3.5. Equity
Awards. Executive will be eligible to receive equity incentive grants as determined by the Board or a committee of the Board in its
sole discretion. All equity awards granted to Executive will be subject to the terms and conditions of the Company’s 2021 Equity
Incentive Plan (the “LTIP”) and the applicable award agreement approved by the Board or a committee thereof (the “Award
Agreements”), which shall be consistent with this Section 3.5. Nothing herein shall be construed to give any Executive any rights
to any amount or type of grant or award except as provided in an award agreement and authorized by the Board or a committee thereof.
(a) Closing
Grant. Promptly following the filing of the Form S-8 registration statement for the LTIP, Executive will receive a one-time grant
of restricted stock units (the “Closing Grant”).
(b) Annual
Grant. Executive will be eligible to receive an annual equity award under the LTIP for the Company’s fiscal years beginning
in 2022 and thereafter, subject to the terms and conditions established by the Board or a committee of the Board.
ARTICLE IV
SEVERANCE AND CHANGE IN CONTROL BENEFITS
4.1. Severance
Benefits. Upon Executive’s termination of employment, Executive shall receive any accrued but unpaid Base Salary and other accrued
and unpaid compensation, including any accrued but unpaid vacation. If the termination is due to a Covered Termination, provided that
Executive (A) delivers an effective general release of all claims against the Company and its affiliates in a form provided by the Company
(a “Release of Claims”) that becomes effective and irrevocable within sixty (60) days following the Covered Termination
and (B) continues to comply with Articles V through VII of this Agreement, Executive shall be entitled to receive the severance benefits
described in Section 4.1(a) or (b), as applicable.
(a) Covered
Termination Not Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination which occurs
at any time other than during the period beginning three (3) months prior to a Change in Control and ending twelve (12) months after a
Change in Control (the “CIC Protection Period”), Executive shall receive the following:
(i) An
amount equal to twelve (12) months of Executive’s Base Salary at the rate in effect (or required to be in effect before any
diminution that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment,
payable in equal installments over twelve (12) months pursuant to the Company’s standard payroll procedures, less applicable withholdings,
as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any event, no later
than the sixtieth (60th) day following the date of the Covered Termination; provided, however, if such sixty (60) day
period falls in two different calendar years, payment will be made in the later calendar year.
(ii) Notwithstanding
anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for
the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions
determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would
be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year
of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B)
the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable,
less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event
later than March 15 of the year following the year of Executive’s termination of employment.
(iii) Subject
to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for
the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of
COBRA through the earlier of (A) the twelve (12)-month anniversary of the date of Executive’s termination of employment and (B)
the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans
without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case,
an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.
(iv) Accelerated
vesting of the unvested portion of the Closing Grant that would have vested in the twelve (12) months following the date of Executive’s
termination of employment.
(b) Covered
Termination Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination that occurs during
the CIC Protection Period, Executive shall receive the following:
(i) An
amount equal to the sum of (i) Executive’s Base Salary at the rate in effect (or required to be in effect before any diminution
that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment and (ii) Executive’s
Target Bonus in effect for the year in which Executive’s termination of employment occurs, payable in a lump sum payment, less applicable
withholdings, as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any
event, no later than the sixtieth (60th) day following the date of the Covered Termination; provided, however, if such
sixty (60) day period falls in two different calendar years, payment will be made in the later calendar year.
(ii) Notwithstanding
anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for
the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions
determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would
be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year
of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B)
the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable,
less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event
later than March 15 of the year following the year of Executive’s termination of employment.
(iii) Subject
to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for
the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of
COBRA through the earlier of (A) the twelve (12)-month anniversary of the date of Executive’s termination of employment and (B)
the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans
without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case,
an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.
(iv) Full
vesting of any unvested portion of the Closing Grant.
4.2. 280G
Provisions. Notwithstanding anything in this Agreement to the contrary, if any payment or distribution Executive would receive pursuant
to this Agreement or otherwise (“Payment”) would (a) constitute a “parachute payment” within the meaning
of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the
Code (the “Excise Tax”), then such Payment shall either be (i) delivered in full, or (ii) delivered as to
such lesser extent which would result in no portion of such Payment being subject to the Excise Tax, whichever of the foregoing amounts,
taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Executive on an
after-tax basis, of the largest payment, notwithstanding that all or some portion of the Payment may be taxable under Section 4999
of the Code. The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change
in Control shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting
firm required to be made hereunder. The accounting firm shall provide its calculations to the Company and Executive within fifteen (15) calendar
days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive)
or such other time as requested by the Company or Executive. Any good faith determinations of the accounting firm made hereunder shall
be final, binding and conclusive upon the Company and Executive. Any reduction in payments and/or benefits pursuant to this Section 4.2
will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of equity awards
other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits payable
to Executive. Nothing in this Section 4.2 shall require the Company or any of its affiliates to be responsible for,
or have any liability or obligation with respect to, Executive’s excise tax liabilities under Section 4999 of the Code.
4.3. Section 409A.
Notwithstanding any provision to the contrary in this Agreement:
(a) All
provisions of this Agreement are intended to comply with Section 409A of the Code, and the applicable Treasury regulations and administrative
guidance issued thereunder (collectively, “Section 409A”) or an exemption therefrom and shall be construed and
administered in accordance with such intent. Any payments under this Agreement that may be excluded from Section 409A either as separation
pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent
possible. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement
are exempt from, or compliant with, Section 409A and in no event shall the Company or any of its affiliates be liable for all or any portion
of any taxes, penalties, interest or other expenses that may be incurred by Executive on account of non-compliance with Section 409A.
(b) If
Executive is deemed at the time of Executive’s Separation from Service to be a “specified employee” for purposes of
Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled
under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code which would
subject Executive to a tax obligation under Section 409A, such portion of Executive’s benefits shall not be provided to Executive
prior to the earlier of (i) the expiration of the six- month period measured from the date of Executive’s Separation from Service
or (ii) the date of Executive’s death. Upon the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all
payments deferred pursuant to this Section 4.3(b) shall be paid in a lump sum to Executive, and any remaining payments due under
the Agreement shall be paid as otherwise provided herein.
(c) Any
reimbursements payable to Executive pursuant to the Agreement shall be paid to Executive no later than 30 days after Executive provides
the Company with a written request for reimbursement, and to the extent that any such reimbursements are deemed to constitute “nonqualified
deferred compensation” within the meaning of Section 409A (i) such amounts shall be paid or reimbursed to Executive promptly,
but in no event later than December 31 of the year following the year in which the expense is incurred, (ii) the amount of any
such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement
in any other taxable year, and (iii) Executive’s right to such payments or reimbursement shall not be subject to liquidation
or exchange for any other benefit; provided, that the foregoing clause shall not be violated with regard to expenses reimbursed under
any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period in which
the arrangement is in effect..
(d) For
purposes of Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)),
Executive’s right to receive installment payments under the Agreement shall be treated as a right to receive a series of separate
payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.
4.4. Mitigation.
Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment
or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive
as a result of employment by another employer or by any retirement benefits received by Executive after the date of the Covered Termination,
or otherwise.
ARTICLE V
PROPRIETARY INFORMATION AND CONFIDENTIALITY OBLIGATIONS
5.1. Proprietary
Information. All Company Innovations shall be the sole and exclusive property of the Company without further compensation and are
“works made for hire” as that term is defined under the United States copyright laws. Executive shall promptly notify the
Company of any Company Innovations that Executive solely or jointly Creates. “Company Innovations” means all Innovations,
and any associated intellectual property rights, which Executive may solely or jointly Create, during Executive’s employment with
the Company, which (i) relate, at the time Created, to the Company’s business or actual or demonstrably anticipated research
or development, or (ii) were developed on any amount of the Company’s time or with the use of any of the Company’s equipment,
supplies, facilities or trade secret information, or (iii) resulted from any work Executive performed for the Company. “Create”
means to create, conceive, reduce to practice, derive, develop or make. “Innovations” means processes, machines, manufactures,
compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed
in any tangible medium of expression (whether or not protectable under copyright laws), mask works, trademarks, trade names, trade dress,
trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and other subject matter protectable under patent,
copyright, moral rights, mask work, trademark, trade secret or other laws regarding proprietary rights, including new or useful art, combinations,
discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software and designs. Executive hereby
assigns (and will assign) to the Company all Company Innovations. Executive shall perform (at the Company’s expense), during and
after Executive’s employment, all acts reasonably deemed necessary or desirable by the Company to assist the Company in obtaining
and enforcing the full benefits, enjoyment, rights and title throughout the world in the Company Innovations. Such acts may include execution
of documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization of assignment of patent,
copyright, mask work or other applications, (ii) in the enforcement of any applicable Proprietary Rights, and (iii) in other
legal proceedings related to the Company’s Innovations. “Proprietary Rights” means patents, copyrights, mask
work, moral rights, trade secrets and other proprietary rights. No provision in this Agreement is intended to require Executive to assign
or offer to assign any of Executive’s rights in any invention for which Executive can establish that no trade secret information
of the Company were used, and which was developed on Executive’s own time, unless the invention relates to the Company’s actual
or demonstrably anticipated research or development, or the invention results from any work performed by Executive for the Company.
5.2. Confidentiality.
In the course of Executive’s employment with the Company and the performance of Executive’s duties on behalf of the Company
and its affiliates hereunder, Executive will be provided with, and will have access to, Confidential Information (as defined below). In
consideration of Executive’s receipt and access to such Confidential Information, and as a condition of Executive’s employment,
Executive shall comply with this Section 5.2
(a) Both
during the Term and thereafter, except as expressly permitted by this Agreement, Executive shall not disclose any Confidential Information
to any person or entity and shall not use any Confidential Information except for the benefit of the Company or its affiliates. Executive
shall follow all Company policies and protocols regarding the security of all documents and other materials containing Confidential Information
(regardless of the medium on which Confidential Information is stored). Except to the extent required for the performance of Executive’s
duties on behalf of the Company or any of its affiliates, Executive shall not remove from facilities of the Company or any of its affiliates
any information, property, equipment, drawings, notes, reports, manuals, invention records, computer software, customer information, or
other data or materials that relate in any way to the Confidential Information, whether paper or electronic and whether produced by Executive
or obtained by the Company or any of its affiliates. The covenants of this Section 5.2(a) shall apply to all Confidential Information,
whether now known or later to become known to Executive during the period that Executive is employed by or affiliated with the Company
or any of its affiliates.
(b) Notwithstanding
any provision of Section 5.2(a) to the contrary, Executive may make the following disclosures and uses of Confidential Information:
(i) disclosures
to other employees, officers or directors of the Company or any of its affiliates who have a need to know the information in connection
with the businesses of the Company or any of its affiliates;
(ii) disclosures
to customers and suppliers when, in the reasonable and good faith belief of Executive, such disclosure is in connection with Executive’s
performance of Executive’s duties ;
(iii) disclosures
and uses that are approved in writing by the Board; or
(iv) disclosures
to a person or entity that has (x) been retained by the Company or any of its affiliates to provide services to the Company and/or its
affiliates and (y) agreed in writing to abide by the terms of a confidentiality agreement.
(c) Upon
the expiration of the Term, and at any other time upon request of the Company, Executive shall promptly and permanently surrender and
deliver to the Company all documents (including electronically stored information) and all copies thereof and all other materials of any
nature containing or pertaining to all Confidential Information and any other Company property (including any Company-issued computer,
mobile device or other equipment) in Executive’s possession, custody or control and Executive shall not retain any such documents
or other materials or property of the Company or any of its affiliates. Within ten (10) days of any such request, Executive shall certify
to the Company in writing that all such documents, materials and property have been returned to the Company or otherwise destroyed.
(d) “Confidential
Information” means all confidential, competitively valuable, non-public or proprietary information that is conceived, made,
developed or acquired by or disclosed to Executive (whether conveyed orally or in writing), individually or in conjunction with others,
during the period that Executive is employed or engaged by the Company or any of its affiliates (whether during business hours or otherwise
and whether on the Company’s premises or otherwise) including: (i) technical information of the Company, its affiliates, its investors,
customers, vendors, suppliers or other third parties, including computer programs, software, databases, data, ideas, know-how, formulae,
compositions, processes, discoveries, machines, inventions (whether patentable or not), designs, developmental or experimental work, techniques,
improvements, work in process, research or test results, original works of authorship, training programs and procedures, diagrams, charts,
business and product development plans, and similar items; (ii) information relating to the Company or any of its affiliates’ businesses
or properties, products or services (including all such information relating to corporate opportunities, operations, future plans, methods
of doing business, business plans, strategies for developing business and market share, research, financial and sales data, pricing terms,
evaluations, opinions, interpretations, acquisition prospects, the identity of customers or acquisition targets or their requirements,
the identity of key contacts within customers’ organizations or within the organization of acquisition prospects, or marketing and
merchandising techniques, prospective names and marks) or pursuant to which the Company or any of its affiliates owes a confidentiality
obligation; and (iii) other valuable, confidential information and trade secrets of the Company, its affiliates, its customers or other
third parties. Moreover, all documents, videotapes, written presentations, brochures, drawings, memoranda, notes, records, files, correspondence,
manuals, models, specifications, computer programs, e-mail, voice mail, electronic databases, maps, drawings, architectural renditions,
models and all other writings or materials of any type including or embodying any of such information, ideas, concepts, improvements,
discoveries, inventions and other similar forms of expression are and shall be the sole and exclusive property of the Company or its other
applicable affiliates and be subject to the same restrictions on disclosure applicable to all Confidential Information pursuant to this
Agreement. For purposes of this Agreement, Confidential Information shall not include any information that (A) is or becomes generally
available to the public other than as a result of a disclosure or wrongful act of Executive or any of Executive’s agents; (B) was
available to Executive on a non-confidential basis before its disclosure by the Company or any of its affiliates; (C) becomes available
to Executive on a non-confidential basis from a source other than the Company or any of its affiliates; provided, however, that such source
is not bound by a confidentiality agreement with, or other obligation with respect to confidentiality to, the Company or any of its affiliates;
or (D) is required to be disclosed by applicable law.
(e) Notwithstanding
the foregoing, nothing in this Agreement shall prohibit or restrict Executive from lawfully: (i) initiating communications directly with,
cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by, any
governmental authority regarding a possible violation of any law; (ii) responding to any inquiry or legal process directed to Executive
from any such governmental authority; (iii) testifying, participating or otherwise assisting in any action or proceeding by any such governmental
authority relating to a possible violation of law; or (iv) making any other disclosures that are protected under the whistleblower provisions
of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, an individual shall not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (1) in confidence
to a federal, state or local government official, either directly or indirectly, or to an attorney and (2) solely for the purpose of reporting
or investigating a suspected violation of law; (B) is made to the individual’s attorney in relation to a lawsuit for retaliation
against the individual for reporting a suspected violation of law; or (C) is made in a complaint or other document filed in a lawsuit
or proceeding, if such filing is made under seal. Nothing in this Agreement requires Executive to obtain prior authorization before engaging
in any conduct described in this paragraph, or to notify the Company that Executive has engaged in any such conduct.
5.3. Nondisparagement.
Subject to Section 5.2(e) above, Executive agrees that from and after the Effective Date, Executive will not, directly or indirectly,
make, publish, or communicate any disparaging or defamatory comments regarding the Company or any of its current or former directors,
officers, members, managers, partners, or executives. The foregoing shall not be violated by truthful statements in response to legal
process, required governmental testimony or filings or administrative or arbitral proceedings (including, without limitation, depositions
in connection with such proceedings).
5.4. Remedies.
Executive’s duties under this Article V shall survive termination of Executive’s employment with the Company and
the termination of this Agreement. Because of the difficulty of measuring economic losses to the Company and its affiliates as a result
of a breach or threatened breach of the covenants set forth in this Article V, Section 6.2 and Article VII, and because of the immediate
and irreparable damage that would be caused to the Company and its affiliates for which they would have no other adequate remedy, Executive
acknowledges that a remedy at law for any breach or threatened breach by Executive of Article V, as well as Executive’s obligations
pursuant to Section 6.2 and Article VII below, would be inadequate, and Executive therefore agrees that the Company shall be
entitled to seek injunctive relief in case of any such breach or threatened breach from any court of competent jurisdiction, without the
necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting
any bond or other security. The aforementioned equitable relief shall not be the Company’s or any of its affiliates’ exclusive
remedy for a breach but instead shall be in addition to all other rights and remedies available to the Company and each of its affiliates
at law and equity.
5.5. Modification.
The covenants in this Article V, Section 6.2 and Article VII, and each provision and portion hereof, are severable and separate, and the
unenforceability of any specific covenant (or portion thereof) shall not affect the provisions of any other covenant (or portion thereof).
If it is determined by an arbitrator or a court of competent jurisdiction in any state that any restriction in this Article V, Section
6.2 and Article VII is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention
of the parties that such restriction may be modified or amended by the arbitrator or the court to render it enforceable to the maximum
extent permitted by the law of that state.
ARTICLE VI
OUTSIDE ACTIVITIES
6.1. Other
Activities.
(a) Except
as otherwise provided in Section 6.1(b), Executive shall not, during the term of this Agreement undertake or engage in any other
employment, occupation or business enterprise, other than ones in which Executive is a passive investor, unless Executive obtains the
prior written consent of the Board.
(b) Executive
may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of Executive’s
duties hereunder. In addition, subject to advance approval by the Board, Executive shall be allowed to serve as a member of the board
of directors of one (1) for-profit entity at any time during the term of this Agreement, so long as such service does not materially
interfere with the performance of Executive’s duties hereunder; provided, however, that the Board, in its discretion, may require
that Executive resign from such director position if it determines that such resignation would be in the best interests of the Company.
6.2. Competition/Investments.
During the term of Executive’s employment by the Company and for twelve (12) months thereafter, Executive shall not (except
on behalf of the Company) directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative,
consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection
with any other person, corporation, firm, partnership or other entity whatsoever which compete directly with the Company or any of its
affiliates, throughout the world, in any line of business engaged in (or planned to be engaged in as of the date of termination) by the
Company; provided, however, that anything above to the contrary notwithstanding, Executive may own, as a passive investor, securities
of any publicly-traded competitor corporation, so long as Executive’s direct holdings in any one such corporation do not, in the
aggregate, constitute more than 1% of the voting stock of such corporation.
6.3. Defense
of Claims; Cooperation. During the Term and thereafter, upon reasonable request from the Company, Executive shall use commercially
reasonable efforts to cooperate with the Company and its affiliates in the defense of any claims or actions that may be made by or against
the Company or any of its affiliates that relate to Executive’s actual or prior areas of responsibility or knowledge. Executive
shall further use commercially reasonable efforts to provide reasonable and timely cooperation in connection with any actual or threatened
claim, action, inquiry, review, investigation, process, or other matter (whether conducted by or before any court, arbitrator, regulatory,
or governmental entity, or by or on behalf of the Company or any of its affiliates), that relates to Executive’s actual or prior
areas of responsibility or knowledge. The Company shall reimburse Executive’s reasonable out of pocket expenses incurred in connection
with such cooperation.
ARTICLE VII
NONINTERFERENCE
Executive shall not, during
the term of Executive’s employment by the Company and for a period of twelve (12) months thereafter, except in the furtherance of
Executive’s duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other
entity, (i) solicit, aid or induce any customer of the Company or its subsidiaries to purchase goods or services then sold by the Company
or its subsidiaries from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying
or soliciting any such customer, (ii) solicit, aid or induce any employee, representative or agent of the Company or its subsidiaries
to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or
other entity unaffiliated with the Company, or hire or retain any such employee, representative or agent, or take any action to materially
assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative
or agent, or (iii) interfere, or aid or induce any other person or entity in interfering, with the relationship between the Company and
its subsidiaries and any of their respective vendors, joint venturers or licensors in a material way. An employee, representative or agent
shall be deemed covered by this Article VII while so employed or retained and for a period of six (6) months thereafter. If it is determined
by a court of competent jurisdiction in any state that any restriction in Article VII or this Article VII is excessive in duration
or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified
or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.
ARTICLE VIII
GENERAL PROVISIONS
8.1. Notices.
Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal
delivery by facsimile or electronic mail) or the third day after mailing by first class mail, to the Company at its primary office location
and to Executive at Executive’s address as listed on the Company’s books and records.
8.2. Tax
Withholding. Executive acknowledges that all amounts and benefits payable under this Agreement are subject to deduction and withholding
to the extent required by applicable law.
8.3. Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or
rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction,
but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions
had never been contained herein.
8.4. Indemnification/D&O
Insurance. The Company hereby agrees to indemnify the Executive and hold the Executive harmless to the extent provided under the organizational
documents of the Company against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses
(including reasonable attorney’s fees), losses, and damages resulting from the Employee’s good faith performance of the Employee’s
duties and obligations with the Company, whether such claim relates to events occurring before or after the date of this Agreement. In
all events, the Executive shall be provided with indemnification protection no less favorable than the indemnification protection provided
to the Company’s directors and other officers. The Company shall cover the Executive under directors’ and officers’
liability insurance both during and, while potential liability exists, after the term of this Agreement in the same amount and to the
same extent as the Company covers its directors and other officers. The Company hereby reaffirms that this Agreement does not in any way
limit the Company’s indemnification obligations to the Executive for matters arising prior to the date of this Agreement that were
subject to indemnification. The foregoing obligations shall survive the termination of the Executive’s employment with the Company.
8.5. Waiver.
Any waiver of this Agreement must be executed by the party to be bound by such waiver. If either party should waive any breach of
any provisions of this Agreement, they shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any
other provision of this Agreement or any similar or dissimilar provision or condition at the same or any subsequent time. The failure
of either party hereto to take any action by reason of any breach will not deprive such party of the right to take action at any time.
8.6. Complete
Agreement. This Agreement constitutes the entire agreement between Executive and the Company and is the complete, final, and exclusive
embodiment of their agreement with regard to this subject matter, and will supersede all prior agreements, understandings, discussions,
negotiations and undertakings, whether written or oral, between the parties with respect to the subject matter hereof [(including, for
the avoidance of doubt, the Prior Agreement)]. This Agreement is entered into without reliance on any promise or representation other
than those expressly contained herein or therein, and cannot be modified or amended except in a writing signed by a duly-authorized officer
of the Company and Executive.
8.7. Counterparts.
This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but
all of which taken together will constitute one and the same Agreement.
8.8. Headings.
The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect
the meaning thereof.
8.9. Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their
respective successors, assigns, heirs, executors and administrators, except that Executive may not assign Executive’s rights or
delegate Executive’s duties or obligations hereunder without the prior written consent of the Company.
8.10. Effect
of Termination. The provisions of Section 2.4 and Articles IV, V, VII and VIII and those provisions necessary to interpret and enforce
them, shall survive any termination of this Agreement and any termination of the employment relationship between Executive and the Company.
8.11. Third-Party
Beneficiaries. Each affiliate of the Company that is not a signatory to this Agreement shall be a third-party beneficiary of Executive’s
obligations under Sections 2.4 and 8.14 and Articles V, VI and VII and shall be entitled to enforce such obligations as if a party hereto.
8.12. Executive
Acknowledgement. Executive acknowledges and agrees that (a) Executive was represented by counsel in connection with the negotiation
of this Agreement, and (b) that Executive has read and understands the Agreement, is fully aware of its legal effect, and has entered
into it freely based on Executive’s own judgment.
8.13. Choice
of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the
State of Delaware without regard to the conflicts of law provisions thereof. With respect to any claim or dispute related to or arising
under this Agreement, the parties hereby consent to the arbitration provisions of Section 8.14 and recognize and agree that should any
resort to a court be necessary and permitted under this Agreement, then they consent to the exclusive jurisdiction, forum and venue of
the state and federal courts (as applicable) located in Delaware.
8.14. Arbitration.
Subject to Section 5.4 (which, for the avoidance of doubt, shall control with respect to the matters specified therein) any dispute between
the Executive and the Company shall be resolved pursuant to the Mutual Dispute Resolution Agreement between the Executive and the Company.
[Signature page follows]
In Witness Whereof, the
parties have executed this Agreement as of the date first written above.
|
|
MOTION ACQUISITION CORP.
|
|
|
|
|
|
By:
|
/s/ Michael Burdiek
|
|
|
|
Name: Michael Burdiek
|
|
|
|
Title: Chief Executive Officer
|
|
Accepted and Agreed:
|
|
|
|
|
|
/s/ Stan Vashovsky
|
|
|
Stan Vashovsky
|
|
Signature Page to Executive Employment Agreement
Exhibit 10.7
EXECUTIVE EMPLOYMENT AGREEMENT
This Executive Employment
Agreement (the “Agreement”) is entered into as of November 5, 2021, by and between Andre Oberholzer (“Executive”)
and Motion Acquisition Corp., a Delaware corporation (the “Company”).
WHEREAS,
Executive has been serving as the Chief Financial Officer
of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (“Ambulnz”)
pursuant to that certain employment offer letter agreement, dated August 9, 2015, by and between Ambulnz and Executive (the “Prior
Agreement”);
WHEREAS, Ambulnz has
entered into that certain Agreement and Plan of Merger, dated of March 8, 2021, by and among the Company, Motion Merger Sub Corp., a Delaware
corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and Ambulnz (such agreement, the “Merger
Agreement”);
WHEREAS, pursuant to
the terms of the Merger Agreement, Merger Sub will merge with and into Ambulnz with Ambulnz continuing as the surviving company and a
wholly-owned subsidiary of the Company (the “Merger”);
WHEREAS,
the Company wishes to employ, and Executive wishes to accept employment with the Company, as the Chief Financial Officer
of the Company and Ambulnz, Inc., pursuant to the terms and conditions set forth in this Agreement, effective as of the date of the consummation
of the Merger (the “Effective Date”).
NOW, THEREFORE, in
consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
ARTICLE I
DEFINITIONS
For purposes of the Agreement,
the following terms are defined as follows:
1.1. “Board”
means the Board of Directors of the Company.
1.2. “Cause”
means the termination of Executive’s employment for one of the following reasons: (i) willful failure to comply with, breach
of or continued refusal to comply with, in each case, in any material respect, the material terms of this Agreement, of any written
agreement or covenant with the Company or any affiliate (including, without limitation, any employment, consulting, confidentiality,
non-competition, non-solicitation, non-disparagement or similar agreement or covenant); (ii) violation of any lawful material
policies, standards or regulations of the Company which have been furnished to Executive, including policies related to
discrimination, harassment, performance of illegal or unethical activities, and ethical misconduct; (iii) indictment for, conviction
of or plea of no contest to a felony under the laws of the United States or any state; (iv) fraud, embezzlement, dishonesty or
breach of fiduciary duty against the Company or its affiliates or material misappropriation of property belonging to the Company or
its affiliates; (v) Executive’s willful failure to perform Executive’s duties as specifically directed in any reasonable
and lawful written directive of the Board or the person to whom Executive reports; or (vi) willful misconduct or gross negligence in
connection with the performance of Executive’s duties, in each case of (i), (v), (vi), after the receipt of written notice
from the Board and Executive’s failure to cure (if curable) within thirty (30) days of Executive’s receipt of the
written notice, providing that the Company must provide Executive with at least thirty (30) days to cure and if Executive cures,
Cause shall not exist under (i), (v), (vi), as applicable.
1.3. “Change
in Control” shall have the meaning ascribed to that term in the Ambulnz, Inc. 2021 Stock Incentive Plan (the “Plan”)
or any successor equity compensation plan of the Company.
1.4. “COBRA”
means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.
1.5. “Code”
means the Internal Revenue Code of 1986, as amended.
1.6. “Covered
Termination” means (i) an Involuntary Termination Without Cause or (ii) a voluntary termination for Good Reason. For
the avoidance of doubt, neither (x) the termination of Executive’s employment as a result of Executive’s death or Disability
nor (y) the expiration of this Agreement due to non-renewal pursuant to the terms of Section 2.2 of this Agreement will be deemed
to be a Covered Termination.
1.7. “Disability”
shall mean a termination of Executive’s employment due to Executive’s absence from Executive’s duties with the Company
on a full-time basis for at least 180 consecutive days as a result of Executive’s incapacity due to physical or mental illness which
is determined to be total and permanent by a physician selected by the Company or its insurers.
1.8. “Good
Reason” means any of the following taken without Executive’s written
consent: (i) failure or refusal by the Company to comply in any material respect with the material terms of this Agreement,
(ii) a material diminution in Executive’s duties, title, authority or responsibilities, (iii) a material reduction in
Executive’s Base Salary (unless the annual base salary of all other executive officers is similarly reduced), or (iv) the
Company requiring Executive to be located at any office or location more than 35 miles from the Executive’s agreed
location of employment, currently Orlando, Florida, provided that any request or directive from the
Company to not work in such office pursuant to any stay-at-home or work from home or similar law, order, directive, request or
recommendation from a governmental entity shall not give rise to Good Reason under this Agreement. Notwithstanding the foregoing,
Executive’s resignation shall not constitute a resignation for “Good Reason” as a result of any event described in
the preceding sentence unless (x) Executive provides written notice thereof to the Company within thirty (30) days after the first
occurrence of such event, (y) to the extent correctable, the Company fails to remedy such circumstance or event within thirty (30)
days following the Company’s receipt of such written notice and (z) the effective date of Executive’s resignation for
“Good Reason” is not later than ninety (90) days after the initial existence of the circumstances constituting Good
Reason.
1.9. “Involuntary
Termination Without Cause” means Executive’s dismissal or discharge by the Company other than for Cause or by reason of
Executive’s death or Disability.
1.10. “Section
409A” means Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued
thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date.
1.11. “Separation
from Service” means Executive’s termination of employment constitutes a “separation from service” within the
meaning of Treasury Regulation Section 1.409A-1(h).
ARTICLE II
EMPLOYMENT BY THE COMPANY
2.1. Position
and Duties. Subject to terms set forth herein, Executive
shall serve in an executive capacity and shall perform such duties as are customarily associated with the position of Chief Financial Officer
of DocGo and such other duties as are assigned to Executive by the Board and/or the
Company’s Chief Executive Officer. During the term of Executive’s employment with the
Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention
(except for vacation periods and absences due to reasonable periods of illness or other incapacities permitted by the
Company’s general employment policies or as otherwise set forth in this Agreement) to the business of the Company.
2.2. Term.
The initial term of this Agreement shall commence on the Effective Date and shall terminate on the earlier of (i) the third (3rd)
anniversary of the Effective Date and (ii) the termination of Executive’s employment under this Agreement; provided,
that if the Merger is not consummated, this Agreement shall be null and void ab initio and neither the Company, Ambulnz nor any
other person shall have any liability to Executive under this Agreement. On the third (3rd) anniversary of the Effective Date
and each annual anniversary of such date thereafter (in either case, provided Executive’s employment has not been terminated under
this Agreement prior thereto), this Agreement shall automatically be extended for one additional year unless either Executive or the Company
gives written notice of non-renewal to the other at least sixty (60) days prior to the automatic extension date. The period from the Effective
Date until the earlier of (i) termination of Executive’s employment under this Agreement and (ii) the expiration of the
term of this Agreement due to non-renewal pursuant to this Section 2.2 is referred to as the “Term.”
2.3. Employment
at Will. The Company shall have the right to terminate Executive’s employment with the Company at any time, with or without
cause, and, in the case of a termination by the Company, with or without prior notice. In addition to Executive’s right to resign
for Good Reason, Executive shall have the right to resign at any time and for any reason or no reason at all, upon ninety (90) days’
advance written notice to the Company; provided, however, that if Executive has provided a resignation notice to the Company, the Company
may determine, in its sole discretion, that such termination shall be effective on any date prior to the effective date of termination
provided in such notice (and, if such earlier date is so required, then it shall not change the basis for Executive’s termination
of employment nor be construed or interpreted as a termination of Executive’s employment by the Company) and any requirement to
continue salary or benefits shall cease as of such earlier date. Upon certain terminations of Executive’s employment with the Company,
Executive may become eligible to receive the severance benefits provided in Article IV of this Agreement.
2.4. Deemed
Resignations. Except as otherwise determined by the Board or as otherwise agreed to in writing by Executive and the Company or any
of its affiliates prior to the termination of Executive’s employment with the Company or any of its affiliates, any termination
of Executive’s employment shall constitute, as applicable, an automatic resignation of Executive: (a) as an officer of the Company
and each of its affiliates; (b) from the Board; and (c) from the board of directors or board of managers (or similar governing body) of
any affiliate of the Company and from the board of directors or board of managers (or similar governing body) of any corporation, limited
liability entity, unlimited liability entity or other entity in which the Company or any of its affiliates holds an equity interest and
with respect to which board of directors or board of managers (or similar governing body) Executive serves as such designee or other representative
of the Company or any of its affiliates. Executive agrees to take any further actions that the Company or any of its affiliates reasonably
requests to effectuate or document the foregoing.
2.5. Employment
Policies. The employment relationship between the parties shall also be governed by the general employment policies and practices
of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the
terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement
shall control.
ARTICLE III
COMPENSATION
3.1. Base
Salary. As of the Effective Date, Executive shall receive
for services to be rendered hereunder an annualized base salary of $412,000.00
(“Base Salary”), payable on the regular payroll dates of the Company (but no
less often than monthly), subject to increase in the sole discretion of the Board or a committee of the Board.
3.2. Annual
Bonus. For each calendar year ending during the Term,
Executive shall be eligible to receive an annual performance bonus (the “Annual Bonus”)
targeted at sixty percent (60%) of Base Salary or
such other amount as determined in the sole discretion of the Board or a committee of the Board (the “Target Bonus”),
on such terms and conditions determined by the Board or a committee of the Board. The actual amount of any Annual Bonus (if any)
will be determined in the discretion of the Board or a committee of the Board and will be (i) subject to achievement of any
applicable bonus objectives and/or conditions determined by the Board or a committee of the Board and (ii) subject to
Executive’s continued employment with the Company through the date the Annual Bonus is paid (except as otherwise provided in
Section 4.1). The Annual Bonus for any calendar year will be paid at the same time as bonuses for other Company executives are paid
related annual bonuses generally.
3.3. Standard
Company Benefits. During the Term, Executive shall be entitled to all rights and benefits for which Executive is eligible under the
terms and conditions of the standard Company benefits and compensation practices that may be in effect from time to time and are provided
by the Company to its executive employees generally, as well as any additional benefits provided to Executive consistent with past practice.
Notwithstanding the foregoing, this Section 3.3 shall not create or be deemed to create any obligation on the part of the Company
to adopt or maintain any benefits or compensation practices at any time.
3.4. Paid
Time Off. During the Term, Executive shall be entitled to such periods of paid time off (“PTO”) each year as provided
from time to time under the Company’s PTO policies and as otherwise provided for executive officers, as it may be amended from time
to time.
3.5. Equity
Awards. Executive will be eligible to receive equity incentive grants as determined by the Board or a committee of the Board in its
sole discretion. All equity awards granted to Executive will be subject to the terms and conditions of the Company’s 2021 Equity
Incentive Plan (the “LTIP”) and the applicable award agreement approved by the Board or a committee thereof (the “Award
Agreements”), which shall be consistent with this Section 3.5. Nothing herein shall be construed to give any Executive any rights
to any amount or type of grant or award except as provided in an award agreement and authorized by the Board or a committee thereof.
(a) Closing
Grant. Promptly following the filing of the Form S-8 registration statement for the LTIP, Executive will receive a one-time grant
of restricted stock units (the “Closing Grant”).
(b) Annual
Grant. Executive will be eligible to receive an annual equity award under the LTIP for the Company’s fiscal years beginning
in 2022 and thereafter, subject to the terms and conditions established by the Board or a committee of the Board.
ARTICLE IV
SEVERANCE AND CHANGE IN CONTROL BENEFITS
4.1. Severance
Benefits. Upon Executive’s termination of employment, Executive shall receive any accrued but unpaid Base Salary and other accrued
and unpaid compensation, including any accrued but unpaid vacation. If the termination is due to a Covered Termination, provided that
Executive (A) delivers an effective general release of all claims against the Company and its affiliates in a form provided by the Company
(a “Release of Claims”) that becomes effective and irrevocable within sixty (60) days following the Covered Termination
and (B) continues to comply with Articles V through VII of this Agreement, Executive shall be entitled to receive the severance benefits
described in Section 4.1(a) or (b), as applicable.
(a) Covered
Termination Not Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination which occurs
at any time other than during the period beginning three (3) months prior to a Change in Control and ending twelve (12) months after a
Change in Control (the “CIC Protection Period”), Executive shall receive the following:
(i) An
amount equal to twelve (12) months of Executive’s Base Salary at the rate in effect (or required to be in effect before any
diminution that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment,
payable in equal installments over twelve (12) months pursuant to the Company’s standard payroll procedures, less applicable withholdings,
as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any event, no later
than the sixtieth (60th) day following the date of the Covered Termination; provided, however, if such sixty (60) day
period falls in two different calendar years, payment will be made in the later calendar year.
(ii) Notwithstanding
anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for
the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions
determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would
be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year
of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B)
the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable,
less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event
later than March 15 of the year following the year of Executive’s termination of employment.
(iii) Subject
to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for
the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of
COBRA through the earlier of (A) the twelve (12)-month anniversary of the date of Executive’s termination of employment and (B)
the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans
without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case,
an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.
(iv) Accelerated
vesting of the unvested portion of the Closing Grant that would have vested in the twelve (12) months following the date of Executive’s
termination of employment.
(b) Covered
Termination Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination that occurs during
the CIC Protection Period, Executive shall receive the following:
(i) An
amount equal to the sum of (i) Executive’s Base Salary at the rate in effect (or required to be in effect before any diminution
that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment and (ii) Executive’s
Target Bonus in effect for the year in which Executive’s termination of employment occurs, payable in a lump sum payment, less applicable
withholdings, as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any
event, no later than the sixtieth (60th) day following the date of the Covered Termination; provided, however, if such
sixty (60) day period falls in two different calendar years, payment will be made in the later calendar year.
(ii) Notwithstanding
anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for
the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions
determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would
be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year
of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B)
the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable,
less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event
later than March 15 of the year following the year of Executive’s termination of employment.
(iii) Subject
to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for
the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of
COBRA through the earlier of (A) the twelve (12)-month anniversary of the date of Executive’s termination of employment and (B)
the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans
without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case,
an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.
(iv) Full
vesting of any unvested portion of the Closing Grant.
4.2. 280G
Provisions. Notwithstanding anything in this Agreement to the contrary, if any payment or distribution Executive would receive pursuant
to this Agreement or otherwise (“Payment”) would (a) constitute a “parachute payment” within the meaning
of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the
Code (the “Excise Tax”), then such Payment shall either be (i) delivered in full, or (ii) delivered as to
such lesser extent which would result in no portion of such Payment being subject to the Excise Tax, whichever of the foregoing amounts,
taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Executive on an
after-tax basis, of the largest payment, notwithstanding that all or some portion of the Payment may be taxable under Section 4999
of the Code. The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change
in Control shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting
firm required to be made hereunder. The accounting firm shall provide its calculations to the Company and Executive within fifteen (15) calendar
days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive)
or such other time as requested by the Company or Executive. Any good faith determinations of the accounting firm made hereunder shall
be final, binding and conclusive upon the Company and Executive. Any reduction in payments and/or benefits pursuant to this Section 4.2
will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of equity awards
other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits payable
to Executive. Nothing in this Section 4.2 shall require the Company or any of its affiliates to be responsible for,
or have any liability or obligation with respect to, Executive’s excise tax liabilities under Section 4999 of the Code.
4.3. Section 409A.
Notwithstanding any provision to the contrary in this Agreement:
(a) All
provisions of this Agreement are intended to comply with Section 409A of the Code, and the applicable Treasury regulations and administrative
guidance issued thereunder (collectively, “Section 409A”) or an exemption therefrom and shall be construed and
administered in accordance with such intent. Any payments under this Agreement that may be excluded from Section 409A either as separation
pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent
possible. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement
are exempt from, or compliant with, Section 409A and in no event shall the Company or any of its affiliates be liable for all or any portion
of any taxes, penalties, interest or other expenses that may be incurred by Executive on account of non-compliance with Section 409A.
(b) If
Executive is deemed at the time of Executive’s Separation from Service to be a “specified employee” for purposes of
Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled
under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code which would
subject Executive to a tax obligation under Section 409A, such portion of Executive’s benefits shall not be provided to Executive
prior to the earlier of (i) the expiration of the six- month period measured from the date of Executive’s Separation from Service
or (ii) the date of Executive’s death. Upon the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all
payments deferred pursuant to this Section 4.3(b) shall be paid in a lump sum to Executive, and any remaining payments due under
the Agreement shall be paid as otherwise provided herein.
(c) Any
reimbursements payable to Executive pursuant to the Agreement shall be paid to Executive no later than 30 days after Executive provides
the Company with a written request for reimbursement, and to the extent that any such reimbursements are deemed to constitute “nonqualified
deferred compensation” within the meaning of Section 409A (i) such amounts shall be paid or reimbursed to Executive promptly,
but in no event later than December 31 of the year following the year in which the expense is incurred, (ii) the amount of any
such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement
in any other taxable year, and (iii) Executive’s right to such payments or reimbursement shall not be subject to liquidation
or exchange for any other benefit; provided, that the foregoing clause shall not be violated with regard to expenses reimbursed under
any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period in which
the arrangement is in effect.
(d) For
purposes of Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)),
Executive’s right to receive installment payments under the Agreement shall be treated as a right to receive a series of separate
payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.
4.4. Mitigation.
Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment
or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive
as a result of employment by another employer or by any retirement benefits received by Executive after the date of the Covered Termination,
or otherwise.
ARTICLE V
PROPRIETARY INFORMATION AND CONFIDENTIALITY OBLIGATIONS
5.1. Proprietary
Information. All Company Innovations shall be the sole and exclusive property of the Company without further compensation and are
“works made for hire” as that term is defined under the United States copyright laws. Executive shall promptly notify the
Company of any Company Innovations that Executive solely or jointly Creates. “Company Innovations” means all Innovations,
and any associated intellectual property rights, which Executive may solely or jointly Create, during Executive’s employment with
the Company, which (i) relate, at the time Created, to the Company’s business or actual or demonstrably anticipated research
or development, or (ii) were developed on any amount of the Company’s time or with the use of any of the Company’s equipment,
supplies, facilities or trade secret information, or (iii) resulted from any work Executive performed for the Company. “Create”
means to create, conceive, reduce to practice, derive, develop or make. “Innovations” means processes, machines, manufactures,
compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed
in any tangible medium of expression (whether or not protectable under copyright laws), mask works, trademarks, trade names, trade dress,
trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and other subject matter protectable under patent,
copyright, moral rights, mask work, trademark, trade secret or other laws regarding proprietary rights, including new or useful art, combinations,
discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software and designs. Executive hereby
assigns (and will assign) to the Company all Company Innovations. Executive shall perform (at the Company’s expense), during and
after Executive’s employment, all acts reasonably deemed necessary or desirable by the Company to assist the Company in obtaining
and enforcing the full benefits, enjoyment, rights and title throughout the world in the Company Innovations. Such acts may include execution
of documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization of assignment of patent,
copyright, mask work or other applications, (ii) in the enforcement of any applicable Proprietary Rights, and (iii) in other
legal proceedings related to the Company’s Innovations. “Proprietary Rights” means patents, copyrights, mask
work, moral rights, trade secrets and other proprietary rights. No provision in this Agreement is intended to require Executive to assign
or offer to assign any of Executive’s rights in any invention for which Executive can establish that no trade secret information
of the Company were used, and which was developed on Executive’s own time, unless the invention relates to the Company’s actual
or demonstrably anticipated research or development, or the invention results from any work performed by Executive for the Company.
5.2. Confidentiality.
In the course of Executive’s employment with the Company and the performance of Executive’s duties on behalf of the Company
and its affiliates hereunder, Executive will be provided with, and will have access to, Confidential Information (as defined below). In
consideration of Executive’s receipt and access to such Confidential Information, and as a condition of Executive’s employment,
Executive shall comply with this Section 5.2
(a) Both
during the Term and thereafter, except as expressly permitted by this Agreement, Executive shall not disclose any Confidential Information
to any person or entity and shall not use any Confidential Information except for the benefit of the Company or its affiliates. Executive
shall follow all Company policies and protocols regarding the security of all documents and other materials containing Confidential Information
(regardless of the medium on which Confidential Information is stored). Except to the extent required for the performance of Executive’s
duties on behalf of the Company or any of its affiliates, Executive shall not remove from facilities of the Company or any of its affiliates
any information, property, equipment, drawings, notes, reports, manuals, invention records, computer software, customer information, or
other data or materials that relate in any way to the Confidential Information, whether paper or electronic and whether produced by Executive
or obtained by the Company or any of its affiliates. The covenants of this Section 5.2(a) shall apply to all Confidential Information,
whether now known or later to become known to Executive during the period that Executive is employed by or affiliated with the Company
or any of its affiliates.
(b) Notwithstanding
any provision of Section 5.2(a) to the contrary, Executive may make the following disclosures and uses of Confidential Information:
(i) disclosures
to other employees, officers or directors of the Company or any of its affiliates who have a need to know the information in connection
with the businesses of the Company or any of its affiliates;
(ii) disclosures
to customers and suppliers when, in the reasonable and good faith belief of Executive, such disclosure is in connection with Executive’s
performance of Executive’s duties;
(iii) disclosures
and uses that are approved in writing by the Board; or
(iv) disclosures
to a person or entity that has (x) been retained by the Company or any of its affiliates to provide services to the Company and/or its
affiliates and (y) agreed in writing to abide by the terms of a confidentiality agreement.
(c) Upon
the expiration of the Term, and at any other time upon request of the Company, Executive shall promptly and permanently surrender and
deliver to the Company all documents (including electronically stored information) and all copies thereof and all other materials of any
nature containing or pertaining to all Confidential Information and any other Company property (including any Company-issued computer,
mobile device or other equipment) in Executive’s possession, custody or control and Executive shall not retain any such documents
or other materials or property of the Company or any of its affiliates. Within ten (10) days of any such request, Executive shall certify
to the Company in writing that all such documents, materials and property have been returned to the Company or otherwise destroyed.
(d) “Confidential
Information” means all confidential, competitively valuable, non-public or proprietary information that is conceived, made,
developed or acquired by or disclosed to Executive (whether conveyed orally or in writing), individually or in conjunction with others,
during the period that Executive is employed or engaged by the Company or any of its affiliates (whether during business hours or otherwise
and whether on the Company’s premises or otherwise) including: (i) technical information of the Company, its affiliates, its investors,
customers, vendors, suppliers or other third parties, including computer programs, software, databases, data, ideas, know-how, formulae,
compositions, processes, discoveries, machines, inventions (whether patentable or not), designs, developmental or experimental work, techniques,
improvements, work in process, research or test results, original works of authorship, training programs and procedures, diagrams, charts,
business and product development plans, and similar items; (ii) information relating to the Company or any of its affiliates’ businesses
or properties, products or services (including all such information relating to corporate opportunities, operations, future plans, methods
of doing business, business plans, strategies for developing business and market share, research, financial and sales data, pricing terms,
evaluations, opinions, interpretations, acquisition prospects, the identity of customers or acquisition targets or their requirements,
the identity of key contacts within customers’ organizations or within the organization of acquisition prospects, or marketing and
merchandising techniques, prospective names and marks) or pursuant to which the Company or any of its affiliates owes a confidentiality
obligation; and (iii) other valuable, confidential information and trade secrets of the Company, its affiliates, its customers or other
third parties. Moreover, all documents, videotapes, written presentations, brochures, drawings, memoranda, notes, records, files, correspondence,
manuals, models, specifications, computer programs, e-mail, voice mail, electronic databases, maps, drawings, architectural renditions,
models and all other writings or materials of any type including or embodying any of such information, ideas, concepts, improvements,
discoveries, inventions and other similar forms of expression are and shall be the sole and exclusive property of the Company or its other
applicable affiliates and be subject to the same restrictions on disclosure applicable to all Confidential Information pursuant to this
Agreement. For purposes of this Agreement, Confidential Information shall not include any information that (A) is or becomes generally
available to the public other than as a result of a disclosure or wrongful act of Executive or any of Executive’s agents; (B) was
available to Executive on a non-confidential basis before its disclosure by the Company or any of its affiliates; (C) becomes available
to Executive on a non-confidential basis from a source other than the Company or any of its affiliates; provided, however, that such source
is not bound by a confidentiality agreement with, or other obligation with respect to confidentiality to, the Company or any of its affiliates;
or (D) is required to be disclosed by applicable law.
(e) Notwithstanding
the foregoing, nothing in this Agreement shall prohibit or restrict Executive from lawfully: (i) initiating communications directly with,
cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by, any
governmental authority regarding a possible violation of any law; (ii) responding to any inquiry or legal process directed to Executive
from any such governmental authority; (iii) testifying, participating or otherwise assisting in any action or proceeding by any such governmental
authority relating to a possible violation of law; or (iv) making any other disclosures that are protected under the whistleblower provisions
of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, an individual shall not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (1) in confidence
to a federal, state or local government official, either directly or indirectly, or to an attorney and (2) solely for the purpose of reporting
or investigating a suspected violation of law; (B) is made to the individual’s attorney in relation to a lawsuit for retaliation
against the individual for reporting a suspected violation of law; or (C) is made in a complaint or other document filed in a lawsuit
or proceeding, if such filing is made under seal. Nothing in this Agreement requires Executive to obtain prior authorization before engaging
in any conduct described in this paragraph, or to notify the Company that Executive has engaged in any such conduct.
5.3. Nondisparagement.
Subject to Section 5.2(e) above, Executive agrees that from and after the Effective Date, Executive will not, directly or indirectly,
make, publish, or communicate any disparaging or defamatory comments regarding the Company or any of its current or former directors,
officers, members, managers, partners, or executives. The foregoing shall not be violated by truthful statements in response to legal
process, required governmental testimony or filings or administrative or arbitral proceedings (including, without limitation, depositions
in connection with such proceedings).
5.4. Remedies.
Executive’s duties under this Article V shall survive termination of Executive’s employment with the Company and
the termination of this Agreement. Because of the difficulty of measuring economic losses to the Company and its affiliates as a result
of a breach or threatened breach of the covenants set forth in this Article V, Section 6.2 and Article VII, and because of the immediate
and irreparable damage that would be caused to the Company and its affiliates for which they would have no other adequate remedy, Executive
acknowledges that a remedy at law for any breach or threatened breach by Executive of Article V, as well as Executive’s obligations
pursuant to Section 6.2 and Article VII below, would be inadequate, and Executive therefore agrees that the Company shall be
entitled to seek injunctive relief in case of any such breach or threatened breach from any court of competent jurisdiction, without the
necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting
any bond or other security. The aforementioned equitable relief shall not be the Company’s or any of its affiliates’ exclusive
remedy for a breach but instead shall be in addition to all other rights and remedies available to the Company and each of its affiliates
at law and equity.
5.5. Modification.
The covenants in this Article V, Section 6.2 and Article VII, and each provision and portion hereof, are severable and separate, and the
unenforceability of any specific covenant (or portion thereof) shall not affect the provisions of any other covenant (or portion thereof).
If it is determined by an arbitrator or a court of competent jurisdiction in any state that any restriction in this Article V, Section
6.2 and Article VII is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention
of the parties that such restriction may be modified or amended by the arbitrator or the court to render it enforceable to the maximum
extent permitted by the law of that state.
ARTICLE VI
OUTSIDE ACTIVITIES
6.1. Other
Activities.
(a) Except
as otherwise provided in Section 6.1(b), Executive shall not, during the term of this Agreement undertake or engage in any other
employment, occupation or business enterprise, other than ones in which Executive is a passive investor, unless Executive obtains the
prior written consent of the Board.
(b) Executive
may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of Executive’s
duties hereunder. In addition, subject to advance approval by the Board, Executive shall be allowed to serve as a member of the board
of directors of one (1) for-profit entity at any time during the term of this Agreement, so long as such service does not materially
interfere with the performance of Executive’s duties hereunder; provided, however, that the Board, in its discretion, may require
that Executive resign from such director position if it determines that such resignation would be in the best interests of the Company.
6.2. Competition/Investments.
During the term of Executive’s employment by the Company and for twelve (12) months thereafter, Executive shall not (except
on behalf of the Company) directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative,
consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection
with any other person, corporation, firm, partnership or other entity whatsoever which compete directly with the Company or any of its
affiliates, throughout the world, in any line of business engaged in (or planned to be engaged in as of the date of termination) by the
Company; provided, however, that anything above to the contrary notwithstanding, Executive may own, as a passive investor, securities
of any publicly-traded competitor corporation, so long as Executive’s direct holdings in any one such corporation do not, in the
aggregate, constitute more than 1% of the voting stock of such corporation.
6.3. Defense
of Claims; Cooperation. During the Term and thereafter, upon reasonable request from the Company, Executive shall use commercially
reasonable efforts to cooperate with the Company and its affiliates in the defense of any claims or actions that may be made by or against
the Company or any of its affiliates that relate to Executive’s actual or prior areas of responsibility or knowledge. Executive
shall further use commercially reasonable efforts to provide reasonable and timely cooperation in connection with any actual or threatened
claim, action, inquiry, review, investigation, process, or other matter (whether conducted by or before any court, arbitrator, regulatory,
or governmental entity, or by or on behalf of the Company or any of its affiliates), that relates to Executive’s actual or prior
areas of responsibility or knowledge. The Company shall reimburse Executive’s reasonable out of pocket expenses incurred in connection
with such cooperation.
ARTICLE VII
NONINTERFERENCE
Executive shall not, during
the term of Executive’s employment by the Company and for a period of twelve (12) months thereafter, except in the furtherance of
Executive’s duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other
entity, (i) solicit, aid or induce any customer of the Company or its subsidiaries to purchase goods or services then sold by the Company
or its subsidiaries from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying
or soliciting any such customer, (ii) solicit, aid or induce any employee, representative or agent of the Company or its subsidiaries
to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or
other entity unaffiliated with the Company, or hire or retain any such employee, representative or agent, or take any action to materially
assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative
or agent, or (iii) interfere, or aid or induce any other person or entity in interfering, with the relationship between the Company and
its subsidiaries and any of their respective vendors, joint venturers or licensors in a material way. An employee, representative or agent
shall be deemed covered by this Article VII while so employed or retained and for a period of six (6) months thereafter. If it is determined
by a court of competent jurisdiction in any state that any restriction in Article VII or this Article VII is excessive in duration
or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified
or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.
ARTICLE VIII
GENERAL PROVISIONS
8.1. Notices.
Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal
delivery by facsimile or electronic mail) or the third day after mailing by first class mail, to the Company at its primary office location
and to Executive at Executive’s address as listed on the Company’s books and records.
8.2. Tax
Withholding. Executive acknowledges that all amounts and benefits payable under this Agreement are subject to deduction and withholding
to the extent required by applicable law.
8.3. Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or
rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction,
but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions
had never been contained herein.
8.4. Indemnification/D&O
Insurance. The Company hereby agrees to indemnify the Executive and hold the Executive harmless to the extent provided under the organizational
documents of the Company against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses
(including reasonable attorney’s fees), losses, and damages resulting from the Employee’s good faith performance of the Employee’s
duties and obligations with the Company, whether such claim relates to events occurring before or after the date of this Agreement. In
all events, the Executive shall be provided with indemnification protection no less favorable than the indemnification protection provided
to the Company’s directors and other officers. The Company shall cover the Executive under directors’ and officers’
liability insurance both during and, while potential liability exists, after the term of this Agreement in the same amount and to the
same extent as the Company covers its directors and other officers. The Company hereby reaffirms that this Agreement does not in any way
limit the Company’s indemnification obligations to the Executive for matters arising prior to the date of this Agreement that were
subject to indemnification. The foregoing obligations shall survive the termination of the Executive’s employment with the Company.
8.5. Waiver.
Any waiver of this Agreement must be executed by the party to be bound by such waiver. If either party should waive any breach of
any provisions of this Agreement, they shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any
other provision of this Agreement or any similar or dissimilar provision or condition at the same or any subsequent time. The failure
of either party hereto to take any action by reason of any breach will not deprive such party of the right to take action at any time.
8.6. Complete
Agreement. This Agreement constitutes the entire agreement between Executive and the Company and is the complete, final, and exclusive
embodiment of their agreement with regard to this subject matter, and will supersede all prior agreements, understandings, discussions,
negotiations and undertakings, whether written or oral, between the parties with respect to the subject matter hereof [(including, for
the avoidance of doubt, the Prior Agreement)]. This Agreement is entered into without reliance on any promise or representation other
than those expressly contained herein or therein, and cannot be modified or amended except in a writing signed by a duly-authorized officer
of the Company and Executive.
8.7. Counterparts.
This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but
all of which taken together will constitute one and the same Agreement.
8.8. Headings.
The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect
the meaning thereof.
8.9. Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their
respective successors, assigns, heirs, executors and administrators, except that Executive may not assign Executive’s rights or
delegate Executive’s duties or obligations hereunder without the prior written consent of the Company.
8.10. Effect
of Termination. The provisions of Section 2.4 and Articles IV, V, VII and VIII and those provisions necessary to interpret and enforce
them, shall survive any termination of this Agreement and any termination of the employment relationship between Executive and the Company.
8.11. Third-Party
Beneficiaries. Each affiliate of the Company that is not a signatory to this Agreement shall be a third-party beneficiary of Executive’s
obligations under Sections 2.4 and 8.14 and Articles V, VI and VII and shall be entitled to enforce such obligations as if a party hereto.
8.12. Executive
Acknowledgement. Executive acknowledges and agrees that (a) Executive was represented by counsel in connection with the negotiation
of this Agreement, and (b) that Executive has read and understands the Agreement, is fully aware of its legal effect, and has entered
into it freely based on Executive’s own judgment.
8.13. Choice
of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the
State of Delaware without regard to the conflicts of law provisions thereof. With respect to any claim or dispute related to or arising
under this Agreement, the parties hereby consent to the arbitration provisions of Section 8.14 and recognize and agree that should any
resort to a court be necessary and permitted under this Agreement, then they consent to the exclusive jurisdiction, forum and venue of
the state and federal courts (as applicable) located in Delaware.
8.14. Arbitration.
Subject to Section 5.4 (which, for the avoidance of doubt, shall control with respect to the matters specified therein) any dispute between
the Executive and the Company shall be resolved pursuant to the Mutual Dispute Resolution Agreement between the Executive and the Company.
[Signature page follows]
In Witness Whereof, the
parties have executed this Agreement as of the date first written above.
|
|
MOTION ACQUISITION CORP.
|
|
|
|
|
|
By:
|
/s/ Michael Burdiek
|
|
|
|
Name: Michael Burdiek
|
|
|
|
Title: Chief Executive Officer
|
|
Accepted and Agreed:
|
|
|
|
|
|
/s/ Andre Oberholzer
|
|
|
Andre Oberholzer
|
|
Signature Page to Executive Employment Agreement
Exhibit 10.8
EXECUTIVE EMPLOYMENT AGREEMENT
This
Executive Employment Agreement (the “Agreement”) is entered into as of November
5, 2021, by and between Anthony Capone (“Executive”)
and Motion Acquisition Corp., a Delaware corporation (the “Company”).
WHEREAS,
Executive has been serving as the Chief Technology Officer
of Ambulnz, Inc. and/or of its subsidiary Ambulnz Holdings LLC (“Ambulnz”)
pursuant to that certain employment offer letter agreement, dated January 18, 2017, by and between
Ambulnz and Executive (the “Prior Agreement”);
WHEREAS, Ambulnz has
entered into that certain Agreement and Plan of Merger, dated of March 8, 2021, by and among the Company, Motion Merger Sub Corp., a Delaware
corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and Ambulnz (such agreement, the “Merger
Agreement”);
WHEREAS, pursuant to
the terms of the Merger Agreement, Merger Sub will merge with and into Ambulnz with Ambulnz continuing as the surviving company and a
wholly-owned subsidiary of the Company (the “Merger”);
WHEREAS,
the Company wishes to employ, and Executive wishes to accept employment with the Company, as the President of
the Company and Ambulnz, Inc., pursuant to the terms and conditions set forth in this Agreement, effective as of the date of the consummation
of the Merger (the “Effective Date”).
NOW, THEREFORE, in
consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
ARTICLE I
DEFINITIONS
For purposes of the Agreement,
the following terms are defined as follows:
1.1. “Board”
means the Board of Directors of the Company.
1.2. “Cause”
means the termination of Executive’s employment for one of the following reasons: (i) willful failure to comply with, breach
of or continued refusal to comply with, in each case, in any material respect, the material terms of this Agreement, of any written
agreement or covenant with the Company or any affiliate (including, without limitation, any employment, consulting, confidentiality,
non-competition, non-solicitation, non-disparagement or similar agreement or covenant); (ii) violation of any lawful material
policies, standards or regulations of the Company which have been furnished to Executive, including policies related to
discrimination, harassment, performance of illegal or unethical activities, and ethical misconduct; (iii) indictment for, conviction
of or plea of no contest to a felony under the laws of the United States or any state; (iv) fraud, embezzlement, dishonesty or
breach of fiduciary duty against the Company or its affiliates or material misappropriation of property belonging to the Company or
its affiliates; (v) Executive’s willful failure to perform Executive’s duties as specifically directed in any reasonable
and lawful written directive of the Board or the person to whom Executive reports; or (vi) willful misconduct or gross negligence in
connection with the performance of Executive’s duties, in each case of (i), (v), (vi), after the receipt of written notice
from the Board and Executive’s failure to cure (if curable) within thirty (30) days of Executive’s receipt of the
written notice, providing that the Company must provide Executive with at least thirty (30) days to cure and if Executive cures,
Cause shall not exist under (i), (v), (vi), as applicable.
1.3. “Change
in Control” shall have the meaning ascribed to that term in the Ambulnz, Inc. 2021 Stock Incentive Plan (the “Plan”)
or any successor equity compensation plan of the Company.
1.4. “COBRA”
means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.
1.5. “Code”
means the Internal Revenue Code of 1986, as amended.
1.6. “Covered
Termination” means (i) an Involuntary Termination Without Cause or (ii) a voluntary termination for Good Reason. For
the avoidance of doubt, neither (x) the termination of Executive’s employment as a result of Executive’s death or Disability
nor (y) the expiration of this Agreement due to non-renewal pursuant to the terms of Section 2.2 of this Agreement will be deemed
to be a Covered Termination.
1.7. “Disability”
shall mean a termination of Executive’s employment due to Executive’s absence from Executive’s duties with the Company
on a full-time basis for at least 180 consecutive days as a result of Executive’s incapacity due to physical or mental illness which
is determined to be total and permanent by a physician selected by the Company or its insurers.
1.8. “Good
Reason” means any of the following taken without Executive’s written
consent: (i) failure or refusal by the Company to comply in any material respect with the material terms of this Agreement,
(ii) a material diminution in Executive’s duties, title, authority or responsibilities, (iii) a material reduction in
Executive’s Base Salary (unless the annual base salary of all other executive officers is similarly reduced), or (iv) the
Company requiring Executive to be located at any office or location more than 35 miles from the Company’s current
headquarters in New York, New York, provided that any request or directive from the Company to not
work in such office pursuant to any stay-at-home or work from home or similar law, order, directive, request or recommendation from
a governmental entity shall not give rise to Good Reason under this Agreement. Notwithstanding the foregoing, Executive’s
resignation shall not constitute a resignation for “Good Reason” as a result of any event described in the preceding
sentence unless (x) Executive provides written notice thereof to the Company within thirty (30) days after the first occurrence of
such event, (y) to the extent correctable, the Company fails to remedy such circumstance or event within thirty (30) days following
the Company’s receipt of such written notice and (z) the effective date of Executive’s resignation for “Good
Reason” is not later than ninety (90) days after the initial existence of the circumstances constituting Good
Reason.
1.9. “Involuntary
Termination Without Cause” means Executive’s dismissal or discharge by the Company other than for Cause or by reason of
Executive’s death or Disability.
1.10. “Section
409A” means Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued
thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date.
1.11. “Separation
from Service” means Executive’s termination of employment constitutes a “separation from service” within the
meaning of Treasury Regulation Section 1.409A-1(h).
ARTICLE II
EMPLOYMENT BY THE COMPANY
2.1. Position
and Duties. Subject to terms set forth herein, Executive
shall serve in an executive capacity and shall perform such duties as are customarily associated with the position of President and
such other duties as are assigned to Executive by the Board and/or the Company’s Chief Executive Officer. During the term of
Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of
Executive’s business time and attention (except for vacation periods and absences due to reasonable periods of illness or
other incapacities permitted by the Company’s general employment policies or as otherwise set forth in this Agreement) to the
business of the Company.
2.2. Term.
The initial term of this Agreement shall commence on the Effective Date and shall terminate on the earlier of (i) the third (3rd)
anniversary of the Effective Date and (ii) the termination of Executive’s employment under this Agreement; provided,
that if the Merger is not consummated, this Agreement shall be null and void ab initio and neither the Company, Ambulnz nor any
other person shall have any liability to Executive under this Agreement. On the third (3rd) anniversary of the Effective Date
and each annual anniversary of such date thereafter (in either case, provided Executive’s employment has not been terminated under
this Agreement prior thereto), this Agreement shall automatically be extended for one additional year unless either Executive or the Company
gives written notice of non-renewal to the other at least sixty (60) days prior to the automatic extension date. The period from the Effective
Date until the earlier of (i) termination of Executive’s employment under this Agreement and (ii) the expiration of the
term of this Agreement due to non-renewal pursuant to this Section 2.2 is referred to as the “Term.”
2.3. Employment
at Will. The Company shall have the right to terminate Executive’s employment with the Company at any time, with or without
cause, and, in the case of a termination by the Company, with or without prior notice. In addition to Executive’s right to resign
for Good Reason, Executive shall have the right to resign at any time and for any reason or no reason at all, upon ninety (90) days’
advance written notice to the Company; provided, however, that if Executive has provided a resignation notice to the Company, the Company
may determine, in its sole discretion, that such termination shall be effective on any date prior to the effective date of termination
provided in such notice (and, if such earlier date is so required, then it shall not change the basis for Executive’s termination
of employment nor be construed or interpreted as a termination of Executive’s employment by the Company) and any requirement to
continue salary or benefits shall cease as of such earlier date. Upon certain terminations of Executive’s employment with the Company,
Executive may become eligible to receive the severance benefits provided in Article IV of this Agreement.
2.4. Deemed
Resignations. Except as otherwise determined by the Board or as otherwise agreed to in writing by Executive and the Company or any
of its affiliates prior to the termination of Executive’s employment with the Company or any of its affiliates, any termination
of Executive’s employment shall constitute, as applicable, an automatic resignation of Executive: (a) as an officer of the Company
and each of its affiliates; (b) from the Board; and (c) from the board of directors or board of managers (or similar governing body) of
any affiliate of the Company and from the board of directors or board of managers (or similar governing body) of any corporation, limited
liability entity, unlimited liability entity or other entity in which the Company or any of its affiliates holds an equity interest and
with respect to which board of directors or board of managers (or similar governing body) Executive serves as such designee or other representative
of the Company or any of its affiliates. Executive agrees to take any further actions that the Company or any of its affiliates reasonably
requests to effectuate or document the foregoing.
2.5. Employment
Policies. The employment relationship between the parties shall also be governed by the general employment policies and practices
of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the
terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement
shall control.
ARTICLE III
COMPENSATION
3.1. Base
Salary. As of the Effective Date, Executive shall receive
for services to be rendered hereunder an annualized base salary of $425,000
(“Base Salary”), payable on the regular payroll dates of the Company (but no
less often than monthly), subject to increase in the sole discretion of the Board or a committee of the Board.
3.2. Annual
Bonus. For each calendar year ending during the Term,
Executive shall be eligible to receive an annual performance bonus (the “Annual Bonus”)
targeted at seventy three percent (73%) of Base
Salary or such other amount as determined in the sole discretion of the Board or a committee of the Board (the “Target
Bonus”), on such terms and conditions determined by the Board or a committee of the
Board. The actual amount of any Annual Bonus (if any) will be determined in the discretion of the Board or a committee of the Board
and will be (i) subject to achievement of any applicable bonus objectives and/or conditions determined by the Board or a
committee of the Board and (ii) subject to Executive’s continued employment with the Company through the date the Annual Bonus
is paid (except as otherwise provided in Section 4.1). The Annual Bonus for any calendar year will be paid at the same time as
bonuses for other Company executives are paid related annual bonuses generally.
3.3. Standard
Company Benefits. During the Term, Executive shall be entitled to all rights and benefits for which Executive is eligible under the
terms and conditions of the standard Company benefits and compensation practices that may be in effect from time to time and are provided
by the Company to its executive employees generally, as well as any additional benefits provided to Executive consistent with past practice.
Notwithstanding the foregoing, this Section 3.3 shall not create or be deemed to create any obligation on the part of the Company
to adopt or maintain any benefits or compensation practices at any time.
3.4. Paid
Time Off. During the Term, Executive shall be entitled to such periods of paid time off (“PTO”) each year as provided
from time to time under the Company’s PTO policies and as otherwise provided for executive officers, as it may be amended from time
to time.
3.5. Equity
Awards. Executive will be eligible to receive equity incentive grants as determined by the Board or a committee of the Board in its
sole discretion. All equity awards granted to Executive will be subject to the terms and conditions of the Company’s 2021 Equity
Incentive Plan (the “LTIP”) and the applicable award agreement approved by the Board or a committee thereof (the “Award
Agreements”), which shall be consistent with this Section 3.5. Nothing herein shall be construed to give any Executive any rights
to any amount or type of grant or award except as provided in an award agreement and authorized by the Board or a committee thereof.
(a) Closing
Grant. Promptly following the filing of the Form S-8 registration statement for the LTIP, Executive will receive a one-time grant
of restricted stock units (the “Closing Grant”).
(b) Annual
Grant. Executive will be eligible to receive an annual equity award under the LTIP for the Company’s fiscal years beginning
in 2022 and thereafter, subject to the terms and conditions established by the Board or a committee of the Board.
ARTICLE IV
SEVERANCE AND CHANGE IN CONTROL BENEFITS
4.1. Severance
Benefits. Upon Executive’s termination of employment, Executive shall receive any accrued but unpaid Base Salary and other accrued
and unpaid compensation, including any accrued but unpaid vacation. If the termination is due to a Covered Termination, provided that
Executive (A) delivers an effective general release of all claims against the Company and its affiliates in a form provided by the Company
(a “Release of Claims”) that becomes effective and irrevocable within sixty (60) days following the Covered Termination
and (B) continues to comply with Articles V through VII of this Agreement, Executive shall be entitled to receive the severance benefits
described in Section 4.1(a) or (b), as applicable.
(a) Covered
Termination Not Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination which occurs
at any time other than during the period beginning three (3) months prior to a Change in Control and ending twelve (12) months after a
Change in Control (the “CIC Protection Period”), Executive shall receive the following:
(i) An
amount equal to twelve (12) months of Executive’s Base Salary at the rate in effect (or required to be in effect before any
diminution that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment,
payable in equal installments over twelve (12) months pursuant to the Company’s standard payroll procedures, less applicable withholdings,
as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any event, no later
than the sixtieth (60th) day following the date of the Covered Termination; provided, however, if such sixty (60) day
period falls in two different calendar years, payment will be made in the later calendar year.
(ii) Notwithstanding
anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for
the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions
determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would
be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year
of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B)
the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable,
less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event
later than March 15 of the year following the year of Executive’s termination of employment.
(iii) Subject
to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for
the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of
COBRA through the earlier of (A) the twelve (12)-month anniversary of the date of Executive’s termination of employment and (B)
the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans
without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case,
an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.
(iv) Accelerated
vesting of the unvested portion of the Closing Grant that would have vested in the twelve (12) months following the date of Executive’s
termination of employment.
(b) Covered
Termination Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination that occurs during
the CIC Protection Period, Executive shall receive the following:
(i) An
amount equal to the sum of (i) Executive’s Base Salary at the rate in effect (or required to be in effect before any diminution
that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment and (ii) Executive’s
Target Bonus in effect for the year in which Executive’s termination of employment occurs, payable in a lump sum payment, less applicable
withholdings, as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any
event, no later than the sixtieth (60th) day following the date of the Covered Termination; provided, however, if such
sixty (60) day period falls in two different calendar years, payment will be made in the later calendar year.
(ii) Notwithstanding
anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for
the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions
determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would
be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year
of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B)
the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable,
less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event
later than March 15 of the year following the year of Executive’s termination of employment.
(iii) Subject
to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for
the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of
COBRA through the earlier of (A) the twelve (12)-month anniversary of the date of Executive’s termination of employment and (B)
the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans
without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case,
an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.
(iv) Full
vesting of any unvested portion of the Closing Grant.
4.2. 280G
Provisions. Notwithstanding anything in this Agreement to the contrary, if any payment or distribution Executive would receive pursuant
to this Agreement or otherwise (“Payment”) would (a) constitute a “parachute payment” within the meaning
of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the
Code (the “Excise Tax”), then such Payment shall either be (i) delivered in full, or (ii) delivered as to
such lesser extent which would result in no portion of such Payment being subject to the Excise Tax, whichever of the foregoing amounts,
taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Executive on an
after-tax basis, of the largest payment, notwithstanding that all or some portion of the Payment may be taxable under Section 4999
of the Code. The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change
in Control shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting
firm required to be made hereunder. The accounting firm shall provide its calculations to the Company and Executive within fifteen (15) calendar
days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive)
or such other time as requested by the Company or Executive. Any good faith determinations of the accounting firm made hereunder shall
be final, binding and conclusive upon the Company and Executive. Any reduction in payments and/or benefits pursuant to this Section 4.2
will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of equity awards
other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits payable
to Executive. Nothing in this Section 4.2 shall require the Company or any of its affiliates to be responsible for,
or have any liability or obligation with respect to, Executive’s excise tax liabilities under Section 4999 of the Code.
4.3. Section 409A.
Notwithstanding any provision to the contrary in this Agreement:
(a) All
provisions of this Agreement are intended to comply with Section 409A of the Code, and the applicable Treasury regulations and administrative
guidance issued thereunder (collectively, “Section 409A”) or an exemption therefrom and shall be construed and
administered in accordance with such intent. Any payments under this Agreement that may be excluded from Section 409A either as separation
pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent
possible. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement
are exempt from, or compliant with, Section 409A and in no event shall the Company or any of its affiliates be liable for all or any portion
of any taxes, penalties, interest or other expenses that may be incurred by Executive on account of non-compliance with Section 409A.
(b) If
Executive is deemed at the time of Executive’s Separation from Service to be a “specified employee” for purposes of
Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled
under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code which would
subject Executive to a tax obligation under Section 409A, such portion of Executive’s benefits shall not be provided to Executive
prior to the earlier of (i) the expiration of the six- month period measured from the date of Executive’s Separation from Service
or (ii) the date of Executive’s death. Upon the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all
payments deferred pursuant to this Section 4.3(b) shall be paid in a lump sum to Executive, and any remaining payments due under
the Agreement shall be paid as otherwise provided herein.
(c) Any
reimbursements payable to Executive pursuant to the Agreement shall be paid to Executive no later than 30 days after Executive provides
the Company with a written request for reimbursement, and to the extent that any such reimbursements are deemed to constitute “nonqualified
deferred compensation” within the meaning of Section 409A (i) such amounts shall be paid or reimbursed to Executive promptly,
but in no event later than December 31 of the year following the year in which the expense is incurred, (ii) the amount of any
such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement
in any other taxable year, and (iii) Executive’s right to such payments or reimbursement shall not be subject to liquidation
or exchange for any other benefit; provided, that the foregoing clause shall not be violated with regard to expenses reimbursed under
any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period in which
the arrangement is in effect..
(d) For
purposes of Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)),
Executive’s right to receive installment payments under the Agreement shall be treated as a right to receive a series of separate
payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.
4.4. Mitigation.
Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment
or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive
as a result of employment by another employer or by any retirement benefits received by Executive after the date of the Covered Termination,
or otherwise.
ARTICLE V
PROPRIETARY INFORMATION AND CONFIDENTIALITY OBLIGATIONS
5.1. Proprietary
Information. All Company Innovations shall be the sole and exclusive property of the Company without further compensation and are
“works made for hire” as that term is defined under the United States copyright laws. Executive shall promptly notify the
Company of any Company Innovations that Executive solely or jointly Creates. “Company Innovations” means all Innovations,
and any associated intellectual property rights, which Executive may solely or jointly Create, during Executive’s employment with
the Company, which (i) relate, at the time Created, to the Company’s business or actual or demonstrably anticipated research
or development, or (ii) were developed on any amount of the Company’s time or with the use of any of the Company’s equipment,
supplies, facilities or trade secret information, or (iii) resulted from any work Executive performed for the Company. “Create”
means to create, conceive, reduce to practice, derive, develop or make. “Innovations” means processes, machines, manufactures,
compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed
in any tangible medium of expression (whether or not protectable under copyright laws), mask works, trademarks, trade names, trade dress,
trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and other subject matter protectable under patent,
copyright, moral rights, mask work, trademark, trade secret or other laws regarding proprietary rights, including new or useful art, combinations,
discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software and designs. Executive hereby
assigns (and will assign) to the Company all Company Innovations. Executive shall perform (at the Company’s expense), during and
after Executive’s employment, all acts reasonably deemed necessary or desirable by the Company to assist the Company in obtaining
and enforcing the full benefits, enjoyment, rights and title throughout the world in the Company Innovations. Such acts may include execution
of documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization of assignment of patent,
copyright, mask work or other applications, (ii) in the enforcement of any applicable Proprietary Rights, and (iii) in other
legal proceedings related to the Company’s Innovations. “Proprietary Rights” means patents, copyrights, mask
work, moral rights, trade secrets and other proprietary rights. No provision in this Agreement is intended to require Executive to assign
or offer to assign any of Executive’s rights in any invention for which Executive can establish that no trade secret information
of the Company were used, and which was developed on Executive’s own time, unless the invention relates to the Company’s actual
or demonstrably anticipated research or development, or the invention results from any work performed by Executive for the Company.
5.2. Confidentiality.
In the course of Executive’s employment with the Company and the performance of Executive’s duties on behalf of the Company
and its affiliates hereunder, Executive will be provided with, and will have access to, Confidential Information (as defined below). In
consideration of Executive’s receipt and access to such Confidential Information, and as a condition of Executive’s employment,
Executive shall comply with this Section 5.2
(a) Both
during the Term and thereafter, except as expressly permitted by this Agreement, Executive shall not disclose any Confidential Information
to any person or entity and shall not use any Confidential Information except for the benefit of the Company or its affiliates. Executive
shall follow all Company policies and protocols regarding the security of all documents and other materials containing Confidential Information
(regardless of the medium on which Confidential Information is stored). Except to the extent required for the performance of Executive’s
duties on behalf of the Company or any of its affiliates, Executive shall not remove from facilities of the Company or any of its affiliates
any information, property, equipment, drawings, notes, reports, manuals, invention records, computer software, customer information, or
other data or materials that relate in any way to the Confidential Information, whether paper or electronic and whether produced by Executive
or obtained by the Company or any of its affiliates. The covenants of this Section 5.2(a) shall apply to all Confidential Information,
whether now known or later to become known to Executive during the period that Executive is employed by or affiliated with the Company
or any of its affiliates.
(b) Notwithstanding
any provision of Section 5.2(a) to the contrary, Executive may make the following disclosures and uses of Confidential Information:
(i) disclosures
to other employees, officers or directors of the Company or any of its affiliates who have a need to know the information in connection
with the businesses of the Company or any of its affiliates;
(ii) disclosures
to customers and suppliers when, in the reasonable and good faith belief of Executive, such disclosure is in connection with Executive’s
performance of Executive’s duties ;
(iii) disclosures
and uses that are approved in writing by the Board; or
(iv) disclosures
to a person or entity that has (x) been retained by the Company or any of its affiliates to provide services to the Company and/or its
affiliates and (y) agreed in writing to abide by the terms of a confidentiality agreement.
(c) Upon
the expiration of the Term, and at any other time upon request of the Company, Executive shall promptly and permanently surrender and
deliver to the Company all documents (including electronically stored information) and all copies thereof and all other materials of any
nature containing or pertaining to all Confidential Information and any other Company property (including any Company-issued computer,
mobile device or other equipment) in Executive’s possession, custody or control and Executive shall not retain any such documents
or other materials or property of the Company or any of its affiliates. Within ten (10) days of any such request, Executive shall certify
to the Company in writing that all such documents, materials and property have been returned to the Company or otherwise destroyed.
(d) “Confidential
Information” means all confidential, competitively valuable, non-public or proprietary information that is conceived, made,
developed or acquired by or disclosed to Executive (whether conveyed orally or in writing), individually or in conjunction with others,
during the period that Executive is employed or engaged by the Company or any of its affiliates (whether during business hours or otherwise
and whether on the Company’s premises or otherwise) including: (i) technical information of the Company, its affiliates, its investors,
customers, vendors, suppliers or other third parties, including computer programs, software, databases, data, ideas, know-how, formulae,
compositions, processes, discoveries, machines, inventions (whether patentable or not), designs, developmental or experimental work, techniques,
improvements, work in process, research or test results, original works of authorship, training programs and procedures, diagrams, charts,
business and product development plans, and similar items; (ii) information relating to the Company or any of its affiliates’ businesses
or properties, products or services (including all such information relating to corporate opportunities, operations, future plans, methods
of doing business, business plans, strategies for developing business and market share, research, financial and sales data, pricing terms,
evaluations, opinions, interpretations, acquisition prospects, the identity of customers or acquisition targets or their requirements,
the identity of key contacts within customers’ organizations or within the organization of acquisition prospects, or marketing and
merchandising techniques, prospective names and marks) or pursuant to which the Company or any of its affiliates owes a confidentiality
obligation; and (iii) other valuable, confidential information and trade secrets of the Company, its affiliates, its customers or other
third parties. Moreover, all documents, videotapes, written presentations, brochures, drawings, memoranda, notes, records, files, correspondence,
manuals, models, specifications, computer programs, e-mail, voice mail, electronic databases, maps, drawings, architectural renditions,
models and all other writings or materials of any type including or embodying any of such information, ideas, concepts, improvements,
discoveries, inventions and other similar forms of expression are and shall be the sole and exclusive property of the Company or its other
applicable affiliates and be subject to the same restrictions on disclosure applicable to all Confidential Information pursuant to this
Agreement. For purposes of this Agreement, Confidential Information shall not include any information that (A) is or becomes generally
available to the public other than as a result of a disclosure or wrongful act of Executive or any of Executive’s agents; (B) was
available to Executive on a non-confidential basis before its disclosure by the Company or any of its affiliates; (C) becomes available
to Executive on a non-confidential basis from a source other than the Company or any of its affiliates; provided, however, that such source
is not bound by a confidentiality agreement with, or other obligation with respect to confidentiality to, the Company or any of its affiliates;
or (D) is required to be disclosed by applicable law.
(e) Notwithstanding
the foregoing, nothing in this Agreement shall prohibit or restrict Executive from lawfully: (i) initiating communications directly with,
cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by, any
governmental authority regarding a possible violation of any law; (ii) responding to any inquiry or legal process directed to Executive
from any such governmental authority; (iii) testifying, participating or otherwise assisting in any action or proceeding by any such governmental
authority relating to a possible violation of law; or (iv) making any other disclosures that are protected under the whistleblower provisions
of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, an individual shall not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (1) in confidence
to a federal, state or local government official, either directly or indirectly, or to an attorney and (2) solely for the purpose of reporting
or investigating a suspected violation of law; (B) is made to the individual’s attorney in relation to a lawsuit for retaliation
against the individual for reporting a suspected violation of law; or (C) is made in a complaint or other document filed in a lawsuit
or proceeding, if such filing is made under seal. Nothing in this Agreement requires Executive to obtain prior authorization before engaging
in any conduct described in this paragraph, or to notify the Company that Executive has engaged in any such conduct.
5.3. Nondisparagement.
Subject to Section 5.2(e) above, Executive agrees that from and after the Effective Date, Executive will not, directly or indirectly,
make, publish, or communicate any disparaging or defamatory comments regarding the Company or any of its current or former directors,
officers, members, managers, partners, or executives. The foregoing shall not be violated by truthful statements in response to legal
process, required governmental testimony or filings or administrative or arbitral proceedings (including, without limitation, depositions
in connection with such proceedings).
5.4. Remedies.
Executive’s duties under this Article V shall survive termination of Executive’s employment with the Company and
the termination of this Agreement. Because of the difficulty of measuring economic losses to the Company and its affiliates as a result
of a breach or threatened breach of the covenants set forth in this Article V, Section 6.2 and Article VII, and because of the immediate
and irreparable damage that would be caused to the Company and its affiliates for which they would have no other adequate remedy, Executive
acknowledges that a remedy at law for any breach or threatened breach by Executive of Article V, as well as Executive’s obligations
pursuant to Section 6.2 and Article VII below, would be inadequate, and Executive therefore agrees that the Company shall be
entitled to seek injunctive relief in case of any such breach or threatened breach from any court of competent jurisdiction, without the
necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting
any bond or other security. The aforementioned equitable relief shall not be the Company’s or any of its affiliates’ exclusive
remedy for a breach but instead shall be in addition to all other rights and remedies available to the Company and each of its affiliates
at law and equity.
5.5. Modification.
The covenants in this Article V, Section 6.2 and Article VII, and each provision and portion hereof, are severable and separate, and the
unenforceability of any specific covenant (or portion thereof) shall not affect the provisions of any other covenant (or portion thereof).
If it is determined by an arbitrator or a court of competent jurisdiction in any state that any restriction in this Article V, Section
6.2 and Article VII is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention
of the parties that such restriction may be modified or amended by the arbitrator or the court to render it enforceable to the maximum
extent permitted by the law of that state.
ARTICLE VI
OUTSIDE ACTIVITIES
6.1. Other
Activities.
(a) Except
as otherwise provided in Section 6.1(b), Executive shall not, during the term of this Agreement undertake or engage in any other
employment, occupation or business enterprise, other than ones in which Executive is a passive investor, unless Executive obtains the
prior written consent of the Board.
(b) Executive
may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of Executive’s
duties hereunder. In addition, subject to advance approval by the Board, Executive shall be allowed to serve as a member of the board
of directors of one (1) for-profit entity at any time during the term of this Agreement, so long as such service does not materially
interfere with the performance of Executive’s duties hereunder; provided, however, that the Board, in its discretion, may require
that Executive resign from such director position if it determines that such resignation would be in the best interests of the Company.
6.2. Competition/Investments.
During the term of Executive’s employment by the Company and for twelve (12) months thereafter, Executive shall not (except
on behalf of the Company) directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative,
consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection
with any other person, corporation, firm, partnership or other entity whatsoever which compete directly with the Company or any of its
affiliates, throughout the world, in any line of business engaged in (or planned to be engaged in as of the date of termination) by the
Company; provided, however, that anything above to the contrary notwithstanding, Executive may own, as a passive investor, securities
of any publicly-traded competitor corporation, so long as Executive’s direct holdings in any one such corporation do not, in the
aggregate, constitute more than 1% of the voting stock of such corporation.
6.3. Defense
of Claims; Cooperation. During the Term and thereafter, upon reasonable request from the Company, Executive shall use commercially
reasonable efforts to cooperate with the Company and its affiliates in the defense of any claims or actions that may be made by or against
the Company or any of its affiliates that relate to Executive’s actual or prior areas of responsibility or knowledge. Executive
shall further use commercially reasonable efforts to provide reasonable and timely cooperation in connection with any actual or threatened
claim, action, inquiry, review, investigation, process, or other matter (whether conducted by or before any court, arbitrator, regulatory,
or governmental entity, or by or on behalf of the Company or any of its affiliates), that relates to Executive’s actual or prior
areas of responsibility or knowledge. The Company shall reimburse Executive’s reasonable out of pocket expenses incurred in connection
with such cooperation.
ARTICLE VII
NONINTERFERENCE
Executive shall not, during
the term of Executive’s employment by the Company and for a period of twelve (12) months thereafter, except in the furtherance of
Executive’s duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other
entity, (i) solicit, aid or induce any customer of the Company or its subsidiaries to purchase goods or services then sold by the Company
or its subsidiaries from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying
or soliciting any such customer, (ii) solicit, aid or induce any employee, representative or agent of the Company or its subsidiaries
to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or
other entity unaffiliated with the Company, or hire or retain any such employee, representative or agent, or take any action to materially
assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative
or agent, or (iii) interfere, or aid or induce any other person or entity in interfering, with the relationship between the Company and
its subsidiaries and any of their respective vendors, joint venturers or licensors in a material way. An employee, representative or agent
shall be deemed covered by this Article VII while so employed or retained and for a period of six (6) months thereafter. If it is determined
by a court of competent jurisdiction in any state that any restriction in Article VII or this Article VII is excessive in duration
or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified
or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.
ARTICLE VIII
GENERAL PROVISIONS
8.1. Notices.
Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal
delivery by facsimile or electronic mail) or the third day after mailing by first class mail, to the Company at its primary office location
and to Executive at Executive’s address as listed on the Company’s books and records.
8.2. Tax
Withholding. Executive acknowledges that all amounts and benefits payable under this Agreement are subject to deduction and withholding
to the extent required by applicable law.
8.3. Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or
rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction,
but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions
had never been contained herein.
8.4. Indemnification/D&O
Insurance. The Company hereby agrees to indemnify the Executive and hold the Executive harmless to the extent provided under the organizational
documents of the Company against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses
(including reasonable attorney’s fees), losses, and damages resulting from the Employee’s good faith performance of the Employee’s
duties and obligations with the Company, whether such claim relates to events occurring before or after the date of this Agreement. In
all events, the Executive shall be provided with indemnification protection no less favorable than the indemnification protection provided
to the Company’s directors and other officers. The Company shall cover the Executive under directors’ and officers’
liability insurance both during and, while potential liability exists, after the term of this Agreement in the same amount and to the
same extent as the Company covers its directors and other officers. The Company hereby reaffirms that this Agreement does not in any way
limit the Company’s indemnification obligations to the Executive for matters arising prior to the date of this Agreement that were
subject to indemnification. The foregoing obligations shall survive the termination of the Executive’s employment with the Company.
8.5. Waiver.
Any waiver of this Agreement must be executed by the party to be bound by such waiver. If either party should waive any breach of
any provisions of this Agreement, they shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any
other provision of this Agreement or any similar or dissimilar provision or condition at the same or any subsequent time. The failure
of either party hereto to take any action by reason of any breach will not deprive such party of the right to take action at any time.
8.6. Complete
Agreement. This Agreement constitutes the entire agreement between Executive and the Company and is the complete, final, and exclusive
embodiment of their agreement with regard to this subject matter, and will supersede all prior agreements, understandings, discussions,
negotiations and undertakings, whether written or oral, between the parties with respect to the subject matter hereof [(including, for
the avoidance of doubt, the Prior Agreement)]. This Agreement is entered into without reliance on any promise or representation other
than those expressly contained herein or therein, and cannot be modified or amended except in a writing signed by a duly-authorized officer
of the Company and Executive.
8.7. Counterparts.
This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but
all of which taken together will constitute one and the same Agreement.
8.8. Headings.
The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect
the meaning thereof.
8.9. Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their
respective successors, assigns, heirs, executors and administrators, except that Executive may not assign Executive’s rights or
delegate Executive’s duties or obligations hereunder without the prior written consent of the Company.
8.10. Effect
of Termination. The provisions of Section 2.4 and Articles IV, V, VII and VIII and those provisions necessary to interpret and enforce
them, shall survive any termination of this Agreement and any termination of the employment relationship between Executive and the Company.
8.11. Third-Party
Beneficiaries. Each affiliate of the Company that is not a signatory to this Agreement shall be a third-party beneficiary of Executive’s
obligations under Sections 2.4 and 8.14 and Articles V, VI and VII and shall be entitled to enforce such obligations as if a party hereto.
8.12. Executive
Acknowledgement. Executive acknowledges and agrees that (a) Executive was represented by counsel in connection with the negotiation
of this Agreement, and (b) that Executive has read and understands the Agreement, is fully aware of its legal effect, and has entered
into it freely based on Executive’s own judgment.
8.13. Choice
of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the
State of Delaware without regard to the conflicts of law provisions thereof. With respect to any claim or dispute related to or arising
under this Agreement, the parties hereby consent to the arbitration provisions of Section 8.14 and recognize and agree that should any
resort to a court be necessary and permitted under this Agreement, then they consent to the exclusive jurisdiction, forum and venue of
the state and federal courts (as applicable) located in Delaware.
8.14. Arbitration.
Subject to Section 5.4 (which, for the avoidance of doubt, shall control with respect to the matters specified therein) any dispute between
the Executive and the Company shall be resolved pursuant to the Mutual Dispute Resolution Agreement between the Executive and the Company.
[Signature page follows]
In Witness Whereof, the
parties have executed this Agreement as of the date first written above.
|
|
MOTION ACQUISITION CORP.
|
|
|
|
|
|
By:
|
/s/ Michael Burdiek
|
|
|
|
Name: Michael Burdiek
|
|
|
|
Title: Chief Executive Officer
|
|
Accepted and Agreed:
|
|
|
|
|
|
/s/ Anthony Capone
|
|
|
Anthony Capone
|
|
Signature Page to Executive Employment Agreement
Exhibit 10.9
EXECUTIVE EMPLOYMENT AGREEMENT
This
Executive Employment Agreement (the “Agreement”) is entered into as of November
5, 2021, by and between Norman Rosenburg (“Executive”)
and Motion Acquisition Corp., a Delaware corporation (the “Company”).
WHEREAS,
Executive has been serving as the Chief Financial Officer of Ambulnz Holdings LLC (“Ambulnz
Holdings”) pursuant to that certain
employment offer letter agreement, dated December 26, 2019, by and between Ambulnz Holdings
and Executive (the “Prior Agreement”);
WHEREAS,
Ambulnz has entered into that certain Agreement and Plan of Merger, dated of March 8, 2021, by and among the Company, Motion Merger
Sub Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”),
and Ambulnz Inc. (“Ambulnz”) (such
agreement, the “Merger Agreement”);
WHEREAS, pursuant to
the terms of the Merger Agreement, Merger Sub will merge with and into Ambulnz with Ambulnz continuing as the surviving company and a
wholly-owned subsidiary of the Company (the “Merger”);
WHEREAS,
the Company wishes to employ, and Executive wishes to accept employment with the Company, as the Chief Financial Officer of Ambulnz
Holdings, pursuant to the terms and conditions set forth in this Agreement, effective as of the date of
the consummation of the Merger (the “Effective Date”).
NOW, THEREFORE, in
consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:
ARTICLE I
DEFINITIONS
For purposes of the Agreement,
the following terms are defined as follows:
1.1. “Board”
means the Board of Directors of the Company.
1.2. “Cause”
means the termination of Executive’s employment for one of the following reasons: (i) willful failure to comply with, breach
of or continued refusal to comply with, in each case, in any material respect, the material terms of this Agreement, of any written
agreement or covenant with the Company or any affiliate (including, without limitation, any employment, consulting, confidentiality,
non-competition, non-solicitation, non-disparagement or similar agreement or covenant); (ii) violation of any lawful material
policies, standards or regulations of the Company which have been furnished to Executive, including policies related to
discrimination, harassment, performance of illegal or unethical activities, and ethical misconduct; (iii) indictment for, conviction
of or plea of no contest to a felony under the laws of the United States or any state; (iv) fraud, embezzlement, dishonesty or
breach of fiduciary duty against the Company or its affiliates or material misappropriation of property belonging to the Company or
its affiliates; (v) Executive’s willful failure to perform Executive’s duties as specifically directed in any reasonable
and lawful written directive of the Board or the person to whom Executive reports; or (vi) willful misconduct or gross negligence in
connection with the performance of Executive’s duties, in each case of (i), (v), (vi), after the receipt of written notice
from the Board and Executive’s failure to cure (if curable) within thirty (30) days of Executive’s receipt of the
written notice, providing that the Company must provide Executive with at least thirty (30) days to cure and if Executive cures,
Cause shall not exist under (i), (v), (vi), as applicable.
1.3. “Change
in Control” shall have the meaning ascribed to that term in the Ambulnz, Inc. 2021 Stock Incentive Plan (the “Plan”)
or any successor equity compensation plan of the Company.
1.4. “COBRA”
means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.
1.5. “Code”
means the Internal Revenue Code of 1986, as amended.
1.6. “Covered
Termination” means (i) an Involuntary Termination Without Cause or (ii) a voluntary termination for Good Reason. For
the avoidance of doubt, neither (x) the termination of Executive’s employment as a result of Executive’s death or Disability
nor (y) the expiration of this Agreement due to non-renewal pursuant to the terms of Section 2.2 of this Agreement will be deemed
to be a Covered Termination.
1.7. “Disability”
shall mean a termination of Executive’s employment due to Executive’s absence from Executive’s duties with the Company
on a full-time basis for at least 180 consecutive days as a result of Executive’s incapacity due to physical or mental illness which
is determined to be total and permanent by a physician selected by the Company or its insurers.
1.8. “Good
Reason” means any of the following taken without Executive’s written
consent: (i) failure or refusal by the Company to comply in any material respect with the material terms of this Agreement,
(ii) a material diminution in Executive’s duties, title, authority or responsibilities, (iii) a material reduction in
Executive’s Base Salary (unless the annual base salary of all other executive officers is similarly reduced), or (iv) the
Company requiring Executive to be located at any office or location more than 35 miles from the Company’s current
headquarters in New York, New York, provided that any request or directive from the Company to not
work in such office pursuant to any stay-at-home or work from home or similar law, order, directive, request or recommendation from
a governmental entity shall not give rise to Good Reason under this Agreement. Notwithstanding the foregoing, Executive’s
resignation shall not constitute a resignation for “Good Reason” as a result of any event described in the preceding
sentence unless (x) Executive provides written notice thereof to the Company within thirty (30) days after the first occurrence of
such event, (y) to the extent correctable, the Company fails to remedy such circumstance or event within thirty (30) days following
the Company’s receipt of such written notice and (z) the effective date of Executive’s resignation for “Good
Reason” is not later than ninety (90) days after the initial existence of the circumstances constituting Good
Reason.
1.9. “Involuntary
Termination Without Cause” means Executive’s dismissal or discharge by the Company other than for Cause or by reason of
Executive’s death or Disability.
1.10. “Section
409A” means Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued
thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date.
1.11. “Separation
from Service” means Executive’s termination of employment constitutes a “separation from service” within the
meaning of Treasury Regulation Section 1.409A-1(h).
ARTICLE II
EMPLOYMENT BY THE COMPANY
2.1. Position
and Duties. Subject to terms set forth herein, Executive
shall serve in an executive capacity and shall perform such duties as are customarily associated with the position of Chief
Financial Officer of Ambulnz Holdings and such other duties as are assigned to Executive by the
Board and/or the Company’s Chief Executive Officer. During the term of Executive’s employment with the Company,
Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention (except
for vacation periods and absences due to reasonable periods of illness or other incapacities permitted by the Company’s
general employment policies or as otherwise set forth in this Agreement) to the business of the Company.
2.2. Term. The
initial term of this Agreement shall commence on the Effective Date and shall terminate on the earlier of (i) the third
(3rd) anniversary of the Effective Date and (ii) the
termination of Executive’s employment under this Agreement; provided, that if the Merger is not consummated, this
Agreement shall be null and void ab initio and neither the Company, Ambulnz, Ambulnz Holdings nor
any other person shall have any liability to Executive under this Agreement. On the third (3rd)
anniversary of the Effective Date and each annual anniversary of such date thereafter (in either case, provided Executive’s
employment has not been terminated under this Agreement prior thereto), this Agreement shall automatically be extended for one
additional year unless either Executive or the Company gives written notice of non-renewal to the other at least sixty (60) days
prior to the automatic extension date. The period from the Effective Date until the earlier of (i) termination of
Executive’s employment under this Agreement and (ii) the expiration of the term of this Agreement due to non-renewal
pursuant to this Section 2.2 is referred to as the “Term.”
2.3. Employment
at Will. The Company shall have the right to terminate Executive’s employment with the Company at any time, with or without
cause, and, in the case of a termination by the Company, with or without prior notice. In addition to Executive’s right to resign
for Good Reason, Executive shall have the right to resign at any time and for any reason or no reason at all, upon ninety (90) days’
advance written notice to the Company; provided, however, that if Executive has provided a resignation notice to the Company, the Company
may determine, in its sole discretion, that such termination shall be effective on any date prior to the effective date of termination
provided in such notice (and, if such earlier date is so required, then it shall not change the basis for Executive’s termination
of employment nor be construed or interpreted as a termination of Executive’s employment by the Company) and any requirement to
continue salary or benefits shall cease as of such earlier date. Upon certain terminations of Executive’s employment with the Company,
Executive may become eligible to receive the severance benefits provided in Article IV of this Agreement.
2.4. Deemed
Resignations. Except as otherwise determined by the Board or as otherwise agreed to in writing by Executive and the Company or any
of its affiliates prior to the termination of Executive’s employment with the Company or any of its affiliates, any termination
of Executive’s employment shall constitute, as applicable, an automatic resignation of Executive: (a) as an officer of the Company
and each of its affiliates; (b) from the Board; and (c) from the board of directors or board of managers (or similar governing body) of
any affiliate of the Company and from the board of directors or board of managers (or similar governing body) of any corporation, limited
liability entity, unlimited liability entity or other entity in which the Company or any of its affiliates holds an equity interest and
with respect to which board of directors or board of managers (or similar governing body) Executive serves as such designee or other representative
of the Company or any of its affiliates. Executive agrees to take any further actions that the Company or any of its affiliates reasonably
requests to effectuate or document the foregoing.
2.5. Employment
Policies. The employment relationship between the parties shall also be governed by the general employment policies and practices
of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the
terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement
shall control.
ARTICLE III
COMPENSATION
3.1. Base
Salary. As of the Effective Date, Executive shall receive
for services to be rendered hereunder an annualized base salary of $321,000
(“Base Salary”), payable on the regular payroll dates of the Company (but no
less often than monthly), subject to increase in the sole discretion of the Board or a committee of the Board.
3.2. Annual
Bonus. For each calendar year ending during the Term,
Executive shall be eligible to receive an annual performance bonus (the “Annual Bonus”)
targeted at thirty eight percent (38%) of Base
Salary or such other amount as determined in the sole discretion of the Board or a committee of the Board (the “Target
Bonus”), on such terms and conditions determined by the Board or a committee of the
Board. The actual amount of any Annual Bonus (if any) will be determined in the discretion of the Board or a committee of the Board
and will be (i) subject to achievement of any applicable bonus objectives and/or conditions determined by the Board or a
committee of the Board and (ii) subject to Executive’s continued employment with the Company through the date the Annual Bonus
is paid (except as otherwise provided in Section 4.1). The Annual Bonus for any calendar year will be paid at the same time as
bonuses for other Company executives are paid related annual bonuses generally.
3.3. Standard
Company Benefits. During the Term, Executive shall be entitled to all rights and benefits for which Executive is eligible under the
terms and conditions of the standard Company benefits and compensation practices that may be in effect from time to time and are provided
by the Company to its executive employees generally, as well as any additional benefits provided to Executive consistent with past practice.
Notwithstanding the foregoing, this Section 3.3 shall not create or be deemed to create any obligation on the part of the Company
to adopt or maintain any benefits or compensation practices at any time.
3.4. Paid
Time Off. During the Term, Executive shall be entitled to such periods of paid time off (“PTO”) each year as provided
from time to time under the Company’s PTO policies and as otherwise provided for executive officers, as it may be amended from time
to time.
3.5. Equity
Awards. Executive will be eligible to receive equity incentive grants as determined by the Board or a committee of the Board in its
sole discretion. All equity awards granted to Executive will be subject to the terms and conditions of the Company’s 2021 Equity
Incentive Plan (the “LTIP”) and the applicable award agreement approved by the Board or a committee thereof (the “Award
Agreements”), which shall be consistent with this Section 3.5. Nothing herein shall be construed to give any Executive any rights
to any amount or type of grant or award except as provided in an award agreement and authorized by the Board or a committee thereof.
(a) Closing
Grant. Promptly following the filing of the Form S-8 registration statement for the LTIP, Executive will receive a one-time grant
of restricted stock units (the “Closing Grant”).
(b) Annual
Grant. Executive will be eligible to receive an annual equity award under the LTIP for the Company’s fiscal years beginning
in 2022 and thereafter, subject to the terms and conditions established by the Board or a committee of the Board.
ARTICLE IV
SEVERANCE AND CHANGE IN CONTROL BENEFITS
4.1. Severance
Benefits. Upon Executive’s termination of employment, Executive shall receive any accrued but unpaid Base Salary and other accrued
and unpaid compensation, including any accrued but unpaid vacation. If the termination is due to a Covered Termination, provided that
Executive (A) delivers an effective general release of all claims against the Company and its affiliates in a form provided by the Company
(a “Release of Claims”) that becomes effective and irrevocable within sixty (60) days following the Covered Termination
and (B) continues to comply with Articles V through VII of this Agreement, Executive shall be entitled to receive the severance benefits
described in Section 4.1(a) or (b), as applicable.
(a) Covered
Termination Not Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination which occurs
at any time other than during the period beginning three (3) months prior to a Change in Control and ending twelve (12) months after a
Change in Control (the “CIC Protection Period”), Executive shall receive the following:
(i) An
amount equal to twelve (12) months of Executive’s Base Salary at the rate in effect (or required to be in effect before any
diminution that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment,
payable in equal installments over twelve (12) months pursuant to the Company’s standard payroll procedures, less applicable withholdings,
as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any event, no later
than the sixtieth (60th) day following the date of the Covered Termination; provided, however, if such sixty (60) day
period falls in two different calendar years, payment will be made in the later calendar year.
(ii) Notwithstanding
anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for
the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions
determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would
be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year
of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B)
the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable,
less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event
later than March 15 of the year following the year of Executive’s termination of employment.
(iii) Subject
to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for
the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of
COBRA through the earlier of (A) the twelve (12)-month anniversary of the date of Executive’s termination of employment and (B)
the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans
without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case,
an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.
(iv) Accelerated
vesting of the unvested portion of the Closing Grant that would have vested in the twelve (12) months following the date of Executive’s
termination of employment.
(b) Covered
Termination Related to a Change in Control. If Executive’s employment terminates due to a Covered Termination that occurs during
the CIC Protection Period, Executive shall receive the following:
(i) An
amount equal to the sum of (i) Executive’s Base Salary at the rate in effect (or required to be in effect before any diminution
that is the basis of Executive’s termination for Good Reason) at the time of Executive’s termination of employment and (ii) Executive’s
Target Bonus in effect for the year in which Executive’s termination of employment occurs, payable in a lump sum payment, less applicable
withholdings, as soon as administratively practicable following the date on which the Release of Claims becomes effective and, in any
event, no later than the sixtieth (60th) day following the date of the Covered Termination; provided, however, if such
sixty (60) day period falls in two different calendar years, payment will be made in the later calendar year.
(ii) Notwithstanding
anything set forth in an award agreement or incentive plan to the contrary, (A) a pro-rata portion of Executive’s Annual Bonus for
the fiscal year in which Executive’s termination occurs based on actual achievement of the applicable bonus objectives and/or conditions
determined by the Board or a committee of the Board for such year (determined by multiplying the amount of the Annual Bonus that would
be payable for the full fiscal year by a fraction, the numerator of which shall be equal to the number of days during the fiscal year
of termination that Executive is employed by, and performing services for, the Company and the denominator of which is 365 days) and (B)
the amount of any Annual Bonus earned, but not yet paid, for the fiscal year prior to Executive’s termination, in each case, payable,
less applicable withholdings, at the same time bonuses for such year are paid to other senior executives of the Company, but in no event
later than March 15 of the year following the year of Executive’s termination of employment.
(iii) Subject
to Executive’s timely election of continuation coverage under COBRA, the Company shall directly pay, or reimburse Executive for
the premium for Executive and Executive’s covered dependents to maintain continued health coverage pursuant to the provisions of
COBRA through the earlier of (A) the twelve (12)-month anniversary of the date of Executive’s termination of employment and (B)
the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s
plan(s). Notwithstanding the foregoing, if the Company is otherwise unable to continue to cover Executive under its group health plans
without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case,
an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.
(iv) Full
vesting of any unvested portion of the Closing Grant.
4.2. 280G
Provisions. Notwithstanding anything in this Agreement to the contrary, if any payment or distribution Executive would receive pursuant
to this Agreement or otherwise (“Payment”) would (a) constitute a “parachute payment” within the meaning
of Section 280G of the Code, and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the
Code (the “Excise Tax”), then such Payment shall either be (i) delivered in full, or (ii) delivered as to
such lesser extent which would result in no portion of such Payment being subject to the Excise Tax, whichever of the foregoing amounts,
taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Executive on an
after-tax basis, of the largest payment, notwithstanding that all or some portion of the Payment may be taxable under Section 4999
of the Code. The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change
in Control shall perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting
firm required to be made hereunder. The accounting firm shall provide its calculations to the Company and Executive within fifteen (15) calendar
days after the date on which Executive’s right to a Payment is triggered (if requested at that time by the Company or Executive)
or such other time as requested by the Company or Executive. Any good faith determinations of the accounting firm made hereunder shall
be final, binding and conclusive upon the Company and Executive. Any reduction in payments and/or benefits pursuant to this Section 4.2
will occur in the following order: (1) reduction of cash payments; (2) cancellation of accelerated vesting of equity awards
other than stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits payable
to Executive. Nothing in this Section 4.2 shall require the Company or any of its affiliates to be responsible for,
or have any liability or obligation with respect to, Executive’s excise tax liabilities under Section 4999 of the Code.
4.3. Section 409A.
Notwithstanding any provision to the contrary in this Agreement:
(a) All
provisions of this Agreement are intended to comply with Section 409A of the Code, and the applicable Treasury regulations and administrative
guidance issued thereunder (collectively, “Section 409A”) or an exemption therefrom and shall be construed and
administered in accordance with such intent. Any payments under this Agreement that may be excluded from Section 409A either as separation
pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent
possible. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement
are exempt from, or compliant with, Section 409A and in no event shall the Company or any of its affiliates be liable for all or any portion
of any taxes, penalties, interest or other expenses that may be incurred by Executive on account of non-compliance with Section 409A.
(b) If
Executive is deemed at the time of Executive’s Separation from Service to be a “specified employee” for purposes of
Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled
under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code which would
subject Executive to a tax obligation under Section 409A, such portion of Executive’s benefits shall not be provided to Executive
prior to the earlier of (i) the expiration of the six- month period measured from the date of Executive’s Separation from Service
or (ii) the date of Executive’s death. Upon the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all
payments deferred pursuant to this Section 4.3(b) shall be paid in a lump sum to Executive, and any remaining payments due under
the Agreement shall be paid as otherwise provided herein.
(c) Any
reimbursements payable to Executive pursuant to the Agreement shall be paid to Executive no later than 30 days after Executive provides
the Company with a written request for reimbursement, and to the extent that any such reimbursements are deemed to constitute “nonqualified
deferred compensation” within the meaning of Section 409A (i) such amounts shall be paid or reimbursed to Executive promptly,
but in no event later than December 31 of the year following the year in which the expense is incurred, (ii) the amount of any
such payments eligible for reimbursement in one year shall not affect the payments or expenses that are eligible for payment or reimbursement
in any other taxable year, and (iii) Executive’s right to such payments or reimbursement shall not be subject to liquidation
or exchange for any other benefit; provided, that the foregoing clause shall not be violated with regard to expenses reimbursed under
any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period in which
the arrangement is in effect..
(d) For
purposes of Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)),
Executive’s right to receive installment payments under the Agreement shall be treated as a right to receive a series of separate
payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.
4.4. Mitigation.
Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment
or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive
as a result of employment by another employer or by any retirement benefits received by Executive after the date of the Covered Termination,
or otherwise.
ARTICLE V
PROPRIETARY INFORMATION AND CONFIDENTIALITY OBLIGATIONS
5.1. Proprietary
Information. All Company Innovations shall be the sole and exclusive property of the Company without further compensation and are
“works made for hire” as that term is defined under the United States copyright laws. Executive shall promptly notify the
Company of any Company Innovations that Executive solely or jointly Creates. “Company Innovations” means all Innovations,
and any associated intellectual property rights, which Executive may solely or jointly Create, during Executive’s employment with
the Company, which (i) relate, at the time Created, to the Company’s business or actual or demonstrably anticipated research
or development, or (ii) were developed on any amount of the Company’s time or with the use of any of the Company’s equipment,
supplies, facilities or trade secret information, or (iii) resulted from any work Executive performed for the Company. “Create”
means to create, conceive, reduce to practice, derive, develop or make. “Innovations” means processes, machines, manufactures,
compositions of matter, improvements, inventions (whether or not protectable under patent laws), works of authorship, information fixed
in any tangible medium of expression (whether or not protectable under copyright laws), mask works, trademarks, trade names, trade dress,
trade secrets, know-how, ideas (whether or not protectable under trade secret laws), and other subject matter protectable under patent,
copyright, moral rights, mask work, trademark, trade secret or other laws regarding proprietary rights, including new or useful art, combinations,
discoveries, formulae, manufacturing techniques, technical developments, discoveries, artwork, software and designs. Executive hereby
assigns (and will assign) to the Company all Company Innovations. Executive shall perform (at the Company’s expense), during and
after Executive’s employment, all acts reasonably deemed necessary or desirable by the Company to assist the Company in obtaining
and enforcing the full benefits, enjoyment, rights and title throughout the world in the Company Innovations. Such acts may include execution
of documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization of assignment of patent,
copyright, mask work or other applications, (ii) in the enforcement of any applicable Proprietary Rights, and (iii) in other
legal proceedings related to the Company’s Innovations. “Proprietary Rights” means patents, copyrights, mask
work, moral rights, trade secrets and other proprietary rights. No provision in this Agreement is intended to require Executive to assign
or offer to assign any of Executive’s rights in any invention for which Executive can establish that no trade secret information
of the Company were used, and which was developed on Executive’s own time, unless the invention relates to the Company’s actual
or demonstrably anticipated research or development, or the invention results from any work performed by Executive for the Company.
5.2. Confidentiality.
In the course of Executive’s employment with the Company and the performance of Executive’s duties on behalf of the Company
and its affiliates hereunder, Executive will be provided with, and will have access to, Confidential Information (as defined below). In
consideration of Executive’s receipt and access to such Confidential Information, and as a condition of Executive’s employment,
Executive shall comply with this Section 5.2
(a) Both
during the Term and thereafter, except as expressly permitted by this Agreement, Executive shall not disclose any Confidential Information
to any person or entity and shall not use any Confidential Information except for the benefit of the Company or its affiliates. Executive
shall follow all Company policies and protocols regarding the security of all documents and other materials containing Confidential Information
(regardless of the medium on which Confidential Information is stored). Except to the extent required for the performance of Executive’s
duties on behalf of the Company or any of its affiliates, Executive shall not remove from facilities of the Company or any of its affiliates
any information, property, equipment, drawings, notes, reports, manuals, invention records, computer software, customer information, or
other data or materials that relate in any way to the Confidential Information, whether paper or electronic and whether produced by Executive
or obtained by the Company or any of its affiliates. The covenants of this Section 5.2(a) shall apply to all Confidential Information,
whether now known or later to become known to Executive during the period that Executive is employed by or affiliated with the Company
or any of its affiliates.
(b) Notwithstanding
any provision of Section 5.2(a) to the contrary, Executive may make the following disclosures and uses of Confidential Information:
(i) disclosures
to other employees, officers or directors of the Company or any of its affiliates who have a need to know the information in connection
with the businesses of the Company or any of its affiliates;
(ii) disclosures
to customers and suppliers when, in the reasonable and good faith belief of Executive, such disclosure is in connection with Executive’s
performance of Executive’s duties ;
(iii) disclosures
and uses that are approved in writing by the Board; or
(iv) disclosures
to a person or entity that has (x) been retained by the Company or any of its affiliates to provide services to the Company and/or its
affiliates and (y) agreed in writing to abide by the terms of a confidentiality agreement.
(c) Upon
the expiration of the Term, and at any other time upon request of the Company, Executive shall promptly and permanently surrender and
deliver to the Company all documents (including electronically stored information) and all copies thereof and all other materials of any
nature containing or pertaining to all Confidential Information and any other Company property (including any Company-issued computer,
mobile device or other equipment) in Executive’s possession, custody or control and Executive shall not retain any such documents
or other materials or property of the Company or any of its affiliates. Within ten (10) days of any such request, Executive shall certify
to the Company in writing that all such documents, materials and property have been returned to the Company or otherwise destroyed.
(d) “Confidential
Information” means all confidential, competitively valuable, non-public or proprietary information that is conceived, made,
developed or acquired by or disclosed to Executive (whether conveyed orally or in writing), individually or in conjunction with others,
during the period that Executive is employed or engaged by the Company or any of its affiliates (whether during business hours or otherwise
and whether on the Company’s premises or otherwise) including: (i) technical information of the Company, its affiliates, its investors,
customers, vendors, suppliers or other third parties, including computer programs, software, databases, data, ideas, know-how, formulae,
compositions, processes, discoveries, machines, inventions (whether patentable or not), designs, developmental or experimental work, techniques,
improvements, work in process, research or test results, original works of authorship, training programs and procedures, diagrams, charts,
business and product development plans, and similar items; (ii) information relating to the Company or any of its affiliates’ businesses
or properties, products or services (including all such information relating to corporate opportunities, operations, future plans, methods
of doing business, business plans, strategies for developing business and market share, research, financial and sales data, pricing terms,
evaluations, opinions, interpretations, acquisition prospects, the identity of customers or acquisition targets or their requirements,
the identity of key contacts within customers’ organizations or within the organization of acquisition prospects, or marketing and
merchandising techniques, prospective names and marks) or pursuant to which the Company or any of its affiliates owes a confidentiality
obligation; and (iii) other valuable, confidential information and trade secrets of the Company, its affiliates, its customers or other
third parties. Moreover, all documents, videotapes, written presentations, brochures, drawings, memoranda, notes, records, files, correspondence,
manuals, models, specifications, computer programs, e-mail, voice mail, electronic databases, maps, drawings, architectural renditions,
models and all other writings or materials of any type including or embodying any of such information, ideas, concepts, improvements,
discoveries, inventions and other similar forms of expression are and shall be the sole and exclusive property of the Company or its other
applicable affiliates and be subject to the same restrictions on disclosure applicable to all Confidential Information pursuant to this
Agreement. For purposes of this Agreement, Confidential Information shall not include any information that (A) is or becomes generally
available to the public other than as a result of a disclosure or wrongful act of Executive or any of Executive’s agents; (B) was
available to Executive on a non-confidential basis before its disclosure by the Company or any of its affiliates; (C) becomes available
to Executive on a non-confidential basis from a source other than the Company or any of its affiliates; provided, however, that such source
is not bound by a confidentiality agreement with, or other obligation with respect to confidentiality to, the Company or any of its affiliates;
or (D) is required to be disclosed by applicable law.
(e) Notwithstanding
the foregoing, nothing in this Agreement shall prohibit or restrict Executive from lawfully: (i) initiating communications directly with,
cooperating with, providing information to, causing information to be provided to, or otherwise assisting in an investigation by, any
governmental authority regarding a possible violation of any law; (ii) responding to any inquiry or legal process directed to Executive
from any such governmental authority; (iii) testifying, participating or otherwise assisting in any action or proceeding by any such governmental
authority relating to a possible violation of law; or (iv) making any other disclosures that are protected under the whistleblower provisions
of any applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, an individual shall not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (1) in confidence
to a federal, state or local government official, either directly or indirectly, or to an attorney and (2) solely for the purpose of reporting
or investigating a suspected violation of law; (B) is made to the individual’s attorney in relation to a lawsuit for retaliation
against the individual for reporting a suspected violation of law; or (C) is made in a complaint or other document filed in a lawsuit
or proceeding, if such filing is made under seal. Nothing in this Agreement requires Executive to obtain prior authorization before engaging
in any conduct described in this paragraph, or to notify the Company that Executive has engaged in any such conduct.
5.3. Nondisparagement.
Subject to Section 5.2(e) above, Executive agrees that from and after the Effective Date, Executive will not, directly or indirectly,
make, publish, or communicate any disparaging or defamatory comments regarding the Company or any of its current or former directors,
officers, members, managers, partners, or executives. The foregoing shall not be violated by truthful statements in response to legal
process, required governmental testimony or filings or administrative or arbitral proceedings (including, without limitation, depositions
in connection with such proceedings).
5.4. Remedies.
Executive’s duties under this Article V shall survive termination of Executive’s employment with the Company and
the termination of this Agreement. Because of the difficulty of measuring economic losses to the Company and its affiliates as a result
of a breach or threatened breach of the covenants set forth in this Article V, Section 6.2 and Article VII, and because of the immediate
and irreparable damage that would be caused to the Company and its affiliates for which they would have no other adequate remedy, Executive
acknowledges that a remedy at law for any breach or threatened breach by Executive of Article V, as well as Executive’s obligations
pursuant to Section 6.2 and Article VII below, would be inadequate, and Executive therefore agrees that the Company shall be
entitled to seek injunctive relief in case of any such breach or threatened breach from any court of competent jurisdiction, without the
necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting
any bond or other security. The aforementioned equitable relief shall not be the Company’s or any of its affiliates’ exclusive
remedy for a breach but instead shall be in addition to all other rights and remedies available to the Company and each of its affiliates
at law and equity.
5.5. Modification.
The covenants in this Article V, Section 6.2 and Article VII, and each provision and portion hereof, are severable and separate, and the
unenforceability of any specific covenant (or portion thereof) shall not affect the provisions of any other covenant (or portion thereof).
If it is determined by an arbitrator or a court of competent jurisdiction in any state that any restriction in this Article V, Section
6.2 and Article VII is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention
of the parties that such restriction may be modified or amended by the arbitrator or the court to render it enforceable to the maximum
extent permitted by the law of that state.
ARTICLE VI
OUTSIDE ACTIVITIES
6.1. Other
Activities.
(a) Except
as otherwise provided in Section 6.1(b), Executive shall not, during the term of this Agreement undertake or engage in any other
employment, occupation or business enterprise, other than ones in which Executive is a passive investor, unless Executive obtains the
prior written consent of the Board.
(b) Executive
may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of Executive’s
duties hereunder. In addition, subject to advance approval by the Board, Executive shall be allowed to serve as a member of the board
of directors of one (1) for-profit entity at any time during the term of this Agreement, so long as such service does not materially
interfere with the performance of Executive’s duties hereunder; provided, however, that the Board, in its discretion, may require
that Executive resign from such director position if it determines that such resignation would be in the best interests of the Company.
6.2. Competition/Investments.
During the term of Executive’s employment by the Company and for twelve (12) months thereafter, Executive shall not (except
on behalf of the Company) directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative,
consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection
with any other person, corporation, firm, partnership or other entity whatsoever which compete directly with the Company or any of its
affiliates, throughout the world, in any line of business engaged in (or planned to be engaged in as of the date of termination) by the
Company; provided, however, that anything above to the contrary notwithstanding, Executive may own, as a passive investor, securities
of any publicly-traded competitor corporation, so long as Executive’s direct holdings in any one such corporation do not, in the
aggregate, constitute more than 1% of the voting stock of such corporation.
6.3. Defense
of Claims; Cooperation. During the Term and thereafter, upon reasonable request from the Company, Executive shall use commercially
reasonable efforts to cooperate with the Company and its affiliates in the defense of any claims or actions that may be made by or against
the Company or any of its affiliates that relate to Executive’s actual or prior areas of responsibility or knowledge. Executive
shall further use commercially reasonable efforts to provide reasonable and timely cooperation in connection with any actual or threatened
claim, action, inquiry, review, investigation, process, or other matter (whether conducted by or before any court, arbitrator, regulatory,
or governmental entity, or by or on behalf of the Company or any of its affiliates), that relates to Executive’s actual or prior
areas of responsibility or knowledge. The Company shall reimburse Executive’s reasonable out of pocket expenses incurred in connection
with such cooperation.
ARTICLE VII
NONINTERFERENCE
Executive shall not, during
the term of Executive’s employment by the Company and for a period of twelve (12) months thereafter, except in the furtherance of
Executive’s duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other
entity, (i) solicit, aid or induce any customer of the Company or its subsidiaries to purchase goods or services then sold by the Company
or its subsidiaries from another person, firm, corporation or other entity or assist or aid any other person or entity in identifying
or soliciting any such customer, (ii) solicit, aid or induce any employee, representative or agent of the Company or its subsidiaries
to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation or
other entity unaffiliated with the Company, or hire or retain any such employee, representative or agent, or take any action to materially
assist or aid any other person, firm, corporation or other entity in identifying, hiring or soliciting any such employee, representative
or agent, or (iii) interfere, or aid or induce any other person or entity in interfering, with the relationship between the Company and
its subsidiaries and any of their respective vendors, joint venturers or licensors in a material way. An employee, representative or agent
shall be deemed covered by this Article VII while so employed or retained and for a period of six (6) months thereafter. If it is determined
by a court of competent jurisdiction in any state that any restriction in Article VII or this Article VII is excessive in duration
or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified
or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.
ARTICLE VIII
GENERAL PROVISIONS
8.1. Notices.
Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal
delivery by facsimile or electronic mail) or the third day after mailing by first class mail, to the Company at its primary office location
and to Executive at Executive’s address as listed on the Company’s books and records.
8.2. Tax
Withholding. Executive acknowledges that all amounts and benefits payable under this Agreement are subject to deduction and withholding
to the extent required by applicable law.
8.3. Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or
rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction,
but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions
had never been contained herein.
8.4. Indemnification/D&O
Insurance. The Company hereby agrees to indemnify the Executive and hold the Executive harmless to the extent provided under the organizational
documents of the Company against and in respect of any and all actions, suits, proceedings, claims, demands, judgments, costs, expenses
(including reasonable attorney’s fees), losses, and damages resulting from the Employee’s good faith performance of the Employee’s
duties and obligations with the Company, whether such claim relates to events occurring before or after the date of this Agreement. In
all events, the Executive shall be provided with indemnification protection no less favorable than the indemnification protection provided
to the Company’s directors and other officers. The Company shall cover the Executive under directors’ and officers’
liability insurance both during and, while potential liability exists, after the term of this Agreement in the same amount and to the
same extent as the Company covers its directors and other officers. The Company hereby reaffirms that this Agreement does not in any way
limit the Company’s indemnification obligations to the Executive for matters arising prior to the date of this Agreement that were
subject to indemnification. The foregoing obligations shall survive the termination of the Executive’s employment with the Company.
8.5. Waiver.
Any waiver of this Agreement must be executed by the party to be bound by such waiver. If either party should waive any breach of
any provisions of this Agreement, they shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any
other provision of this Agreement or any similar or dissimilar provision or condition at the same or any subsequent time. The failure
of either party hereto to take any action by reason of any breach will not deprive such party of the right to take action at any time.
8.6. Complete
Agreement. This Agreement constitutes the entire agreement between Executive and the Company and is the complete, final, and exclusive
embodiment of their agreement with regard to this subject matter, and will supersede all prior agreements, understandings, discussions,
negotiations and undertakings, whether written or oral, between the parties with respect to the subject matter hereof [(including, for
the avoidance of doubt, the Prior Agreement)]. This Agreement is entered into without reliance on any promise or representation other
than those expressly contained herein or therein, and cannot be modified or amended except in a writing signed by a duly-authorized officer
of the Company and Executive.
8.7. Counterparts.
This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but
all of which taken together will constitute one and the same Agreement.
8.8. Headings.
The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect
the meaning thereof.
8.9. Successors
and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their
respective successors, assigns, heirs, executors and administrators, except that Executive may not assign Executive’s rights or
delegate Executive’s duties or obligations hereunder without the prior written consent of the Company.
8.10. Effect
of Termination. The provisions of Section 2.4 and Articles IV, V, VII and VIII and those provisions necessary to interpret and enforce
them, shall survive any termination of this Agreement and any termination of the employment relationship between Executive and the Company.
8.11. Third-Party
Beneficiaries. Each affiliate of the Company that is not a signatory to this Agreement shall be a third-party beneficiary of Executive’s
obligations under Sections 2.4 and 8.14 and Articles V, VI and VII and shall be entitled to enforce such obligations as if a party hereto.
8.12. Executive
Acknowledgement. Executive acknowledges and agrees that (a) Executive was represented by counsel in connection with the negotiation
of this Agreement, and (b) that Executive has read and understands the Agreement, is fully aware of its legal effect, and has entered
into it freely based on Executive’s own judgment.
8.13. Choice
of Law. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the
State of Delaware without regard to the conflicts of law provisions thereof. With respect to any claim or dispute related to or arising
under this Agreement, the parties hereby consent to the arbitration provisions of Section 8.14 and recognize and agree that should any
resort to a court be necessary and permitted under this Agreement, then they consent to the exclusive jurisdiction, forum and venue of
the state and federal courts (as applicable) located in Delaware.
8.14. Arbitration.
Subject to Section 5.4 (which, for the avoidance of doubt, shall control with respect to the matters specified therein) any dispute between
the Executive and the Company shall be resolved pursuant to the Mutual Dispute Resolution Agreement between the Executive and the Company.
[Signature page follows]
In Witness Whereof, the
parties have executed this Agreement as of the date first written above.
|
|
MOTION ACQUISITION CORP.
|
|
|
|
|
|
By:
|
/s/ Michael Burdiek
|
|
|
|
Name: Michael Burdiek
|
|
|
|
Title: Chief Executive Officer
|
|
Accepted and Agreed:
|
|
|
|
|
|
/s/ Norm Rosenberg
|
|
|
Norm Rosenberg
|
|
Signature Page to Executive Employment Agreement
Exhibit 10.10
FORM OF INDEMNIFICATION AGREEMENT
This Indemnification Agreement (this “Agreement”)
is entered into as of November ___, 2021 (the “Effective Date”) by and between DocGo Inc., a Delaware corporation (the
“Company”), and the undersigned (the “Indemnitee”).
RECITALS
WHEREAS, the Board of Directors has determined
that the inability to attract and retain qualified persons as directors and officers is detrimental to the best interests of the Company’s
stockholders and that the Company should act to assure such persons that there shall be adequate certainty of protection through insurance
and indemnification against risks of claims and actions against them arising out of their service to and activities on behalf of the Company;
WHEREAS, the Company has adopted provisions in
its Amended and Restated Bylaws (the “Bylaws”) providing for indemnification and advancement of expenses of its directors
and officers to the fullest extent authorized by the General Corporation Law of the State of Delaware (the “DGCL”),
and the Company wishes to clarify and enhance the rights and obligations of the Company and the Indemnitee with respect to indemnification
and advancement of expenses;
WHEREAS, in order to induce and encourage highly
experienced and capable persons such as the Indemnitee to serve and continue to serve as directors and officers of the Company and in
any other capacity with respect to the Company as the Company may request, and to otherwise promote the desirable end that such persons
shall resist what they consider unjustified lawsuits and claims made against them in connection with the good faith performance of their
duties to the Company, with the knowledge that certain costs, judgments, penalties, fines, liabilities, and expenses incurred by them
in their defense of such litigation are to be borne by the Company and they shall receive appropriate protection against such risks and
liabilities, the Board of Directors of the Company has determined that the following Agreement is reasonable and prudent to promote and
ensure the best interests of the Company and its stockholders; and
WHEREAS, the Company desires to have the Indemnitee
continue to serve as a director or officer of the Company and in any other capacity with respect to the Company as the Company may request,
as the case may be, free from undue concern for unpredictable, inappropriate, or unreasonable legal risks and personal liabilities by
reason of the Indemnitee acting in good faith in the performance of the Indemnitee’s duty to the Company; and the Indemnitee desires
to continue so to serve the Company, provided, and on the express condition, that he or she is furnished with the protections set
forth hereinafter.
AGREEMENT
NOW, THEREFORE, in consideration of the Indemnitee’s
continued service as a director or officer of the Company, the parties hereto agree as follows:
1. Definitions.
For purposes of this Agreement:
(a) A
“Change in Control” will be deemed to have occurred if, with respect to any particular 24-month period, the individuals
who, at the beginning of such 24-month period, constituted the Board of Directors of the Company (the “Incumbent Board”)
cease for any reason to constitute at least a majority of the Board of Directors; provided, however, that any individual
becoming a director subsequent to the beginning of such 24-month period whose election, or nomination for election by the stockholders
of the Company, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered
as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption
of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other
actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board of Directors.
(b) “Disinterested
Director” means a director of the Company who is not or was not a party to the Proceeding in respect of which indemnification
is being sought by the Indemnitee.
(c) “Expenses”
includes, without limitation, expenses incurred in connection with the defense or settlement of any action, suit, arbitration, alternative
dispute resolution mechanism, investigation, inquiry, judicial, administrative, or legislative hearing, or any other threatened, pending,
or completed proceeding, whether brought by or in the right of the Company or otherwise, including any and all appeals, whether of a civil,
criminal, administrative, legislative, investigative, or other nature, attorneys’ fees, witness fees and expenses, fees and expenses
of accountants and other advisors, retainers and disbursements and advances thereon, the premium, security for, and other costs relating
to any bond (including cost bonds, appraisal bonds, or their equivalents), and any expenses of establishing a right to indemnification
or advancement under Sections 9, 11, 13, and 16 hereof, but shall not include the amount of judgments, fines, ERISA excise taxes,
or penalties actually levied against the Indemnitee, or any amounts paid in settlement by or on behalf of the Indemnitee.
(d) “Independent
Counsel” means a law firm or a member of a law firm that neither is presently nor in the past five years has been retained to
represent (i) the Company or the Indemnitee in any matter material to either such party or (ii) any other party to the Proceeding
giving rise to a request for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall
not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest
in representing either the Company or the Indemnitee in an action to determine the Indemnitee’s right to indemnification under this
Agreement.
(e) “Proceeding”
means any action, suit, arbitration, alternative dispute resolution mechanism, investigation, inquiry, judicial, administrative, or legislative
hearing, or any other threatened, pending, or completed proceeding, whether brought by or in the right of the Company or otherwise, including
any and all appeals, whether of a civil, criminal, administrative, legislative, investigative, or other nature, to which the Indemnitee
was or is a party or is threatened to be made a party or is otherwise involved in by reason of the fact that the Indemnitee is or was
a director, officer, employee, agent, or trustee of the Company or while a director, officer, employee, agent, or trustee of the Company
is or was serving at the request of the Company as a director, officer, employee, agent, or trustee of another corporation or of a partnership,
joint venture, trust, or other enterprise, including service with respect to an employee benefit plan, or by reason of anything done or
not done by the Indemnitee in any such capacity, whether or not the Indemnitee is serving in such capacity at the time any expense, liability,
or loss is incurred for which indemnification or advancement can be provided under this Agreement.
2. Service
by the Indemnitee. The Indemnitee shall serve and/or continue to serve as a director or officer of the Company faithfully and to the
best of the Indemnitee’s ability so long as the Indemnitee is duly elected or appointed and until such time as the Indemnitee’s
successor is elected and qualified or the Indemnitee is removed as permitted by applicable law or tenders a resignation in writing.
3. Indemnification
and Advancement of Expenses. The Company shall indemnify and hold harmless the Indemnitee, and shall pay to the Indemnitee in advance
of the final disposition of any Proceeding all Expenses incurred by the Indemnitee in defending any such Proceeding, to the fullest extent
authorized by the DGCL, as the same exists or may hereafter be amended, all on the terms and conditions set forth in this Agreement. Without
diminishing the scope of the rights provided by this Section, the rights of the Indemnitee to indemnification and advancement of Expenses
provided hereunder shall include but shall not be limited to those rights hereinafter set forth, except that no indemnification or advancement
of Expenses shall be paid to the Indemnitee:
(a) to
the extent expressly prohibited by applicable law;
(b) for
and to the extent that payment is actually made to the Indemnitee under a valid and collectible insurance policy or under a valid and
enforceable indemnity clause, provision of the amended and restated certificate of incorporation (the “Certificate of Incorporation”)
or Bylaws, or agreement of the Company or any other company or other enterprise (and the Indemnitee shall reimburse the Company for any
amounts paid by the Company and subsequently so recovered by the Indemnitee); or
(c) in
connection with an action, suit, or proceeding, or part thereof voluntarily initiated by the Indemnitee (including claims and counterclaims,
whether such counterclaims are asserted by (i) the Indemnitee, or (ii) the Company in an action, suit, or proceeding initiated by the
Indemnitee), except a judicial proceeding or arbitration pursuant to Section 11 to enforce rights under this Agreement, unless the
action, suit, or proceeding, or part thereof, was authorized or ratified by the Board of Directors of the Company or the Board of Directors
otherwise determines that indemnification or advancement of Expenses is appropriate.
4. Action
or Proceedings Other than an Action by or in the Right of the Company. Except as limited by Section 3 above, the Indemnitee shall
be entitled to the indemnification rights provided in this Section if the Indemnitee was or is a party or is threatened to be made a party
to, or was or is otherwise involved in, any Proceeding (other than an action by or in the right of the Company) by reason of the fact
that the Indemnitee is or was a director, officer, employee, agent, or trustee of the Company or while a director, officer, employee,
agent, or trustee of the Company is or was serving at the request of the Company as a director, officer, employee, agent, or trustee of
another corporation or of a partnership, joint venture, trust, or other enterprise, including service with respect to an employee benefit
plan, including as a deemed fiduciary thereto, or by reason of anything done or not done by the Indemnitee in any such capacity. Pursuant
to this Section, the Indemnitee shall be indemnified against all expense, liability, and loss (including judgments, fines, ERISA excise
taxes, penalties, amounts paid in settlement by or on behalf of the Indemnitee, and Expenses) actually and reasonably incurred by the
Indemnitee in connection with such Proceeding, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed
to be in or not opposed to the interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe
his or her conduct was unlawful.
5. Indemnity
in Proceedings by or in the Right of the Company. Except as limited by Section 3 above, the Indemnitee shall be entitled to the
indemnification rights provided in this Section if the Indemnitee was or is a party or is threatened to be made a party to, or was or
is otherwise involved in, any Proceeding brought by or in the right of the Company to procure a judgment in its favor by reason of the
fact that the Indemnitee is or was a director, officer, employee, agent, or trustee of the Company or while a director, officer, employee,
agent, or trustee of the Company is or was serving at the request of the Company as a director, officer, employee, agent, or trustee of
another corporation or of a partnership, joint venture, trust, or other enterprise, including service with respect to an employee benefit
plan, including as a deemed fiduciary thereto, or by reason of anything done or not done by the Indemnitee in any such capacity. Pursuant
to this Section, the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee in connection
with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed
to the interests of the Company; provided, however, that no such indemnification shall be made in respect of any claim,
issue, or matter as to which the DGCL expressly prohibits such indemnification by reason of any adjudication of liability of the Indemnitee
to the Company, unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such Proceeding
was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case,
the Indemnitee is entitled to indemnification for such expense, liability, and loss as such court shall deem proper.
6. Indemnification
for Costs, Charges, and Expenses of Successful Party. Notwithstanding any limitations of Sections 3(c), 4 and 5 above, to the
extent that the Indemnitee has been successful, on the merits or otherwise, in whole or in part, in defense of any Proceeding, or in defense
of any claim, issue, or matter therein, including, without limitation, the dismissal of any action without prejudice, or if it is ultimately
determined, by final judicial decision of a court of competent jurisdiction from which there is no further right to appeal, that the Indemnitee
is otherwise entitled to be indemnified against Expenses, the Indemnitee shall be indemnified against all Expenses actually and reasonably
incurred by the Indemnitee in connection therewith.
7. Partial
Indemnification. If the Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or
a portion of the expense, liability, and loss (including judgments, fines, ERISA excise taxes, penalties, amounts paid in settlement by
or on behalf of the Indemnitee, and Expenses) actually and reasonably incurred in connection with any Proceeding, or in connection with
any judicial proceeding or arbitration pursuant to Section 11 to enforce rights under this Agreement, but not, however, for all of
the total amount thereof, the Company shall nevertheless indemnify the Indemnitee for the portion of such expense, liability, and loss
actually and reasonably incurred to which the Indemnitee is entitled.
8. Indemnification
for Expenses as a Witness. Notwithstanding any other provision of this Agreement, to the maximum extent permitted by the DGCL, the
Indemnitee shall be entitled to indemnification against all Expenses actually and reasonably incurred by the Indemnitee or on the Indemnitee’s
behalf if the Indemnitee appears as a witness or otherwise incurs legal expenses as a result of or related to the Indemnitee’s service
as a director or officer of the Company, in any threatened, pending, or completed action, suit, arbitration, alternative dispute resolution
mechanism, investigation, inquiry, judicial, administrative, or legislative hearing, or any other threatened, pending, or completed proceeding,
whether of a civil, criminal, administrative, legislative, investigative, or other nature, to which the Indemnitee neither is, nor is
threatened to be made, a party.
9. Determination
of Entitlement to Indemnification. To receive indemnification under this Agreement, the Indemnitee shall submit a written request
to the Secretary of the Company. Such request shall include documentation or information that is reasonably necessary for such determination
and is reasonably available to the Indemnitee, but in no case shall Indemnitee be required to convey any information that would cause
Indemnitee to waive any privilege accorded by applicable law. Upon receipt by the Secretary of the Company of a written request by the
Indemnitee for indemnification, the entitlement of the Indemnitee to indemnification, to the extent not required pursuant to the terms
of Section 6 or Section 8 of this Agreement, shall be determined by the following person or persons who shall be empowered to
make such determination (as selected by the Board of Directors, except with respect to Section 9(e) below): (a) the Board of
Directors of the Company by a majority vote of Disinterested Directors, whether or not such majority constitutes a quorum; (b) a
committee of Disinterested Directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum;
(c) if there are no Disinterested Directors, or if the Disinterested Directors so direct, by Independent Counsel in a written opinion
to the Board of Directors, a copy of which shall be delivered to the Indemnitee; (d) the stockholders of the Company; or (e) in
the event that a Change in Control has occurred, by Independent Counsel in a written opinion to the Board of Directors, a copy of which
shall be delivered to the Indemnitee. Such Independent Counsel shall be selected by the Board of Directors and approved by the Indemnitee,
except that in the event that a Change in Control has occurred, Independent Counsel shall be selected by the Indemnitee. Upon failure
of the Board of Directors so to select such Independent Counsel or upon failure of the Indemnitee so to approve (or so to select, in the
event a Change in Control has occurred), such Independent Counsel shall be selected upon application to a court of competent jurisdiction.
The determination of entitlement to indemnification shall be made and, unless a contrary determination is made, such indemnification shall
be paid in full by the Company not later than 60 calendar days after receipt by the Secretary of the Company of a written request for
indemnification. If the person making such determination shall determine that the Indemnitee is entitled to indemnification as to part
(but not all) of the application for indemnification, such person shall reasonably prorate such partial indemnification among the claims,
issues, or matters at issue at the time of the determination.
10. Presumptions
and Effect of Certain Proceedings. The Secretary of the Company shall, promptly upon receipt of the Indemnitee’s written request
for indemnification, advise in writing the Board of Directors or such other person or persons empowered to make the determination as provided
in Section 9 that the Indemnitee has made such request for indemnification. Upon making such request for indemnification, the Indemnitee
shall be presumed to be entitled to indemnification hereunder and the Company shall have the burden of proof in making any determination
contrary to such presumption by clear and convincing evidence. If the person or persons so empowered to make such determination shall
have failed to make the requested determination with respect to indemnification within 60 calendar days after receipt by the Secretary
of the Company of such request, a requisite determination of entitlement to indemnification shall be deemed to have been made and the
Indemnitee shall be absolutely entitled to such indemnification, absent actual fraud in the request for indemnification. The termination
of any Proceeding described in Sections 4 or 5 by judgment, order, settlement, or conviction, or upon a plea of nolo contendere
or its equivalent, shall not, of itself (a) create a presumption that the Indemnitee did not act in good faith and in a manner the
Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding,
had reasonable cause to believe his or her conduct was unlawful or (b) otherwise adversely affect the rights of the Indemnitee to
indemnification except as may be provided herein.
11. Remedies
of the Indemnitee in Cases of Determination Not to Indemnify or to Advance Expenses; Right to Bring Suit. In the event that a determination
is made that the Indemnitee is not entitled to indemnification or advancement of Expenses hereunder or if payment is not timely made following
a determination of entitlement to indemnification pursuant to Sections 9 and 10, or if an advancement of Expenses is not timely made
pursuant to Section 16, the Indemnitee may at any time thereafter bring suit against the Company seeking an adjudication of entitlement
to such indemnification or advancement of Expenses, and any such suit shall be brought in the Court of Chancery of the State of Delaware
unless otherwise required by the law of the state in which the Indemnitee primarily resides and works. Alternatively, the Indemnitee at
the Indemnitee’s option may seek an award in an arbitration to be conducted by a single arbitrator in the State of Delaware pursuant
to the rules of the American Arbitration Association, such award to be made within 60 calendar days following the filing of the demand
for arbitration. The Company shall not oppose the Indemnitee’s right to seek any such adjudication or award in arbitration. In any
suit or arbitration brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit or arbitration brought
by the Indemnitee to enforce a right to an advancement of Expenses), it shall be a defense that the Indemnitee has not met any applicable
standard of conduct for indemnification set forth in the DGCL, including the standard described in Section 4 or 5, as applicable
(the “Standard of Conduct”). In any suit or arbitration brought by the Indemnitee to enforce a right to an advancement
of Expenses, it shall be a defense that the advancement of Expenses was properly denied pursuant to the terms of Section 16. Further,
in any suit brought by the Company to recover an advancement of Expenses pursuant to the terms of an undertaking, the Company shall be
entitled to recover such Expenses upon a final judicial decision of a court of competent jurisdiction from which there is no further right
to appeal that the Indemnitee has not met the Standard of Conduct . Neither the failure of the Company (including the Disinterested Directors,
a committee of Disinterested Directors, Independent Counsel, or its stockholders) to have made a determination prior to the commencement
of such suit or arbitration that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the Standard
of Conduct, nor an actual determination by the Company (including the Disinterested Directors, a committee of Disinterested Directors,
Independent Counsel, or its stockholders) that the Indemnitee has not met the standard of conduct described above shall create a presumption
that the Indemnitee has not met the standard of conduct described above, or, in the case of such a suit brought by the Indemnitee, be
a defense to such suit. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of Expenses hereunder,
or brought by the Company to recover an advancement of Expenses pursuant to the terms of an undertaking, the burden of proving that the
Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Section 11 or otherwise shall be on
the Company by clear and convincing evidence. If a determination is made or deemed to have been made pursuant to the terms of Section 9
or 10 that the Indemnitee is entitled to indemnification, the Company shall be bound by such determination and is precluded from
asserting that such determination has not been made or that the procedure by which such determination was made is not valid, binding,
and enforceable. The Company further agrees to stipulate in any court or before any arbitrator pursuant to this Section 11 that the
Company is bound by all the provisions of this Agreement and is precluded from making any assertions to the contrary. If the court or
arbitrator shall determine that the Indemnitee is entitled to any indemnification or advancement of Expenses hereunder, the Company shall
pay all Expenses actually and reasonably incurred by the Indemnitee in connection with such adjudication or award in arbitration (including,
but not limited to, any appellate proceedings) to the fullest extent permitted by law, and in any suit brought by the Company to recover
an advancement of Expenses pursuant to the terms of an undertaking, the Company shall pay all Expenses actually and reasonably incurred
by the Indemnitee in connection with such suit to the extent the Indemnitee has been successful, on the merits or otherwise, in whole
or in part, in defense of such suit, to the fullest extent permitted by law. Indemnitee shall be entitled to the advancement of legal
fees to enforce Indemnitee’s rights pursuant to this Section 11. To the extent required by Delaware law, Indemnitee hereby undertakes
to repay any and all of the amount of legal fees advanced to Indemnitee pursuant to this Section 11 if it is finally determined by a court
of competent jurisdiction that Indemnitee is not entitled under this Agreement to indemnification with respect to such Expenses. No other
form of undertaking shall be required other than the execution of this Agreement.
12. Non-Exclusivity
of Rights. The rights to indemnification and to the advancement of Expenses provided by this Agreement shall not be deemed exclusive
of any other right that the Indemnitee may now or hereafter acquire under any applicable law, agreement, vote of stockholders or Disinterested
Directors, provisions of a charter or bylaws (including the Certificate of Incorporation or Bylaws of the Company), or otherwise.
13. Expenses
to Enforce Agreement. In the event that the Indemnitee is subject to or intervenes in any action, suit, or proceeding in which the
validity or enforceability of this Agreement is at issue or seeks an adjudication or award in arbitration to enforce the Indemnitee’s
rights under, or to recover damages for breach of, this Agreement, the Indemnitee, if the Indemnitee prevails in whole or in part in such
action, suit, or proceeding, shall be entitled to recover from the Company and shall be indemnified by the Company against any Expenses
actually and reasonably incurred by the Indemnitee in connection therewith.
14. Continuation
of Indemnity. All agreements and obligations of the Company contained herein shall continue during the period the Indemnitee is a
director, officer, employee, agent, or trustee of the Company or while a director, officer, employee, agent, or trustee is serving at
the request of the Company as a director, officer, employee, agent, or trustee of another corporation or of a partnership, joint venture,
trust, or other enterprise, including service with respect to an employee benefit plan, and shall continue thereafter with respect to
any possible claims based on the fact that the Indemnitee was a director, officer, employee, agent, or trustee of the Company or was serving
at the request of the Company as a director, officer, employee, agent, or trustee of another corporation or of a partnership, joint venture,
trust, or other enterprise, including service with respect to an employee benefit plan. This Agreement shall be binding upon all successors
and assigns of the Company (including any transferee of all or substantially all of its assets and any successor by merger or operation
of law) and shall inure to the benefit of the Indemnitee’s heirs, executors, and administrators. The Company shall require and cause
any successor (whether direct or indirect by purchase, merger, consolidation, or otherwise) to all, substantially all, or a substantial
part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to
assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if
no such succession had taken place.
15. Notification
and Defense of Proceeding. Promptly after receipt by the Indemnitee of notice of any Proceeding, the Indemnitee shall, if a request
for indemnification or an advancement of Expenses in respect thereof is to be made against the Company under this Agreement, notify the
Company in writing of the commencement thereof; but the omission so to notify the Company shall not relieve it from any liability that
it may have to the Indemnitee. Notwithstanding any other provision of this Agreement, with respect to any such Proceeding of which the
Indemnitee notifies the Company:
(a) The
Company shall be entitled to participate therein at its own expense;
(b) Except
as otherwise provided in this Section 15(b), to the extent that it may wish, the Company, jointly with any other indemnifying party
similarly notified, shall be entitled to assume the defense thereof, with counsel satisfactory to the Indemnitee. After notice from the
Company to the Indemnitee of its election so to assume the defense thereof, the Company shall not be liable to the Indemnitee under this
Agreement for any expenses of counsel subsequently incurred by the Indemnitee in connection with the defense thereof except as otherwise
provided below. The Indemnitee shall have the right to employ the Indemnitee’s own counsel in such Proceeding, but the fees and
expenses of such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the expense of the
Indemnitee unless (i) the employment of counsel by the Indemnitee has been authorized by the Company, (ii) the Indemnitee shall
have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the conduct of the defense
of such Proceeding, or (iii) the Company shall not within 60 calendar days of receipt of notice from the Indemnitee in fact have
employed counsel to assume the defense of the Proceeding, in each of which cases the fees and expenses of the Indemnitee’s counsel
shall be at the expense of the Company. The Company shall not be entitled to assume the defense of any Proceeding brought by or on behalf
of the Company or as to which the Indemnitee shall have made the conclusion provided for in (ii) above; and
(c) Notwithstanding
any other provision of this Agreement, the Company shall not be liable to indemnify the Indemnitee under this Agreement for any amounts
paid in settlement of any Proceeding effected without the Company’s written consent, or for any judicial or other award, if the
Company was not given an opportunity, in accordance with this Section 15, to participate in the defense of such Proceeding. The Company
shall not settle any Proceeding in any manner that would impose any penalty or limitation on or disclosure obligation with respect to
the Indemnitee, or that would directly or indirectly constitute or impose any admission or acknowledgment of fault or culpability with
respect to the Indemnitee, without the Indemnitee’s written consent. Neither the Company nor the Indemnitee shall unreasonably withhold
its consent to any proposed settlement.
16. Advancement
of Expenses. All Expenses incurred by the Indemnitee in defending any Proceeding described in Section 4 or 5 shall be paid by
the Company in advance of the final disposition of such Proceeding at the request of the Indemnitee. Notwithstanding the foregoing, the
Company shall not advance or continue to advance Expenses to the Indemnitee if a determination is reasonably made that the facts known
at the time such determination is made demonstrate clearly and convincingly that the Indemnitee acted in bad faith or in a manner that
the Indemnitee did not reasonably believe to be in or not opposed to the best interests of the Company, or, with respect to any criminal
Proceeding, that the Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such determination shall be made: (i)
by the Board by a majority vote of directors who are not parties to such proceeding, whether or not such majority constitutes a quorum;
(ii) by a committee of such directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum;
or (iii) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion to the Board
, a copy of which shall be delivered to the Indemnitee. To receive an advancement of Expenses under this Agreement, the Indemnitee shall
submit a written request to the Secretary of the Company. Such request shall reasonably evidence the Expenses incurred by the Indemnitee
and shall include or be accompanied by an undertaking, by or on behalf of the Indemnitee, to repay all amounts so advanced if it shall
ultimately be determined, by final judicial decision of a court of competent jurisdiction from which there is no further right to appeal,
that the Indemnitee is not entitled to be indemnified for such Expenses by the Company as provided by this Agreement or otherwise. The
Indemnitee’s undertaking to repay any such amounts is not required to be secured. Each such advancement of Expenses shall be made
within 20 calendar days after the receipt by the Secretary of the Company of such written request. The Indemnitee’s entitlement
to Expenses under this Agreement shall include those incurred in connection with any action, suit, or proceeding by the Indemnitee seeking
an adjudication or award in arbitration pursuant to Section 11 of this Agreement (including the enforcement of this provision) to
the extent the court or arbitrator shall determine that the Indemnitee is entitled to an advancement of Expenses hereunder...
17. D&O
Insurance. In the event of a Change of Control or the Company’s becoming insolvent, the Company shall maintain in force any
and all insurance policies then maintained by the Company in providing insurance--directors’ and officers’ liability, fiduciary,
employment practices or otherwise--in respect of the individual directors and officers of the Company, for a fixed period of six years
thereafter (a “Tail Policy”). Such coverage shall be non-cancellable and shall be placed and serviced for the duration of
its term by the Company’s incumbent insurance broker. Such broker shall place the Tail policy with the incumbent insurance carriers
using the policies that were in place at the time of the change of control event (unless the incumbent carriers will not offer such policies,
in which case the Tail Policy placed by the Company’s insurance broker shall be substantially comparable in scope and amount as
the expiring policies, and the insurance carriers for the Tail Policy shall have an AM Best rating that is the same or better than the
AM Best ratings of the expiring policies).
18. Monetary
Damages Insufficient/Specific Performance. The Company and Indemnitee agree that a monetary remedy for breach of this Agreement may
be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly,
the parties hereto agree that Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without
any necessity of showing actual damage or irreparable harm (having agreed that actual and irreparable harm will result in not forcing
the Company to specifically perform its obligations pursuant to this Agreement) and that by seeking injunctive relief and/or specific
performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled. The Company and
Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining
orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith.
The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by the Court, and the Company
hereby waives any such requirement of a bond or undertaking. If Indemnitee seeks mandatory injunctive relief, it shall not be a defense
to enforcement of the Company’s obligations set forth in this Agreement that Indemnitee has an adequate remedy at law for damages.
19. Notice
by Company. If the Indemnitee is the subject of, or is, to the knowledge of the Company, implicated in any way during an investigation,
whether formal or informal, that is related to Indemnitee’s Corporate Status and that reasonably could lead to a Proceeding for
which indemnification can be provided under this Agreement, the Company shall notify the Indemnitee of such investigation and shall share
with Indemnitee any information it has provided to any third parties concerning the investigation (“Shared Information”).
By executing this Agreement, Indemnitee agrees that such Shared Information is material non-public information that Indemnitee is obligated
to hold in confidence and may not disclose publicly; provided, however, that Indemnitee may use the Shared Information and disclose such
Shared Information to Indemnitee’s legal counsel and third parties, in each case solely in connection with defending Indemnitee
from legal liability.
20. Severability;
Prior Indemnification Agreements. If any provision or provisions of this Agreement shall be held to be invalid, illegal, or unenforceable
as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law (a) the
validity, legality, and enforceability of such provision in any other circumstance and of the remaining provisions of this Agreement (including,
without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal, or unenforceable,
that are not by themselves invalid, illegal, or unenforceable) and the application of such provision to other persons or entities or circumstances
shall not in any way be affected or impaired thereby, and (b) to the fullest extent possible, the provisions of this Agreement (including,
without limitation, all portions of any paragraph of this Agreement containing any such provision held to be invalid, illegal, or unenforceable,
that are not themselves invalid, illegal, or unenforceable) shall be construed so as to give effect to the intent of the parties that
the Company provide protection to the Indemnitee to the fullest extent set forth in this Agreement. This Agreement shall supersede and
replace any prior indemnification agreements entered into by and between the Company and the Indemnitee and any such prior agreements
shall be terminated upon execution of this Agreement.
21. Headings;
References; Pronouns. The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to
constitute part of this Agreement or to affect the construction thereof. References herein to section numbers are to sections of this
Agreement. All pronouns and any variations thereof shall be deemed to refer to the singular or plural as appropriate.
22. Other
Provisions.
(a) This
Agreement and all disputes or controversies arising out of or related to this Agreement shall be governed by, and construed in accordance
with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of
conflicts of laws principles of the State of Delaware, unless otherwise required by the law of the state in which the Indemnitee primarily
resides and works.
(b) This
Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become effective
when one or more counterparts have been signed by each of the parties and delivered to the other party.
(c) This
Agreement shall not be deemed an employment contract between the Company and any Indemnitee who is an officer of the Company, and, if
the Indemnitee is an officer of the Company, the Indemnitee specifically acknowledges that the Indemnitee may be discharged at any time
for any reason, with or without cause, and with or without severance compensation, except as may be otherwise provided in a separate written
contract between the Indemnitee and the Company.
(d) In
the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery
of the Indemnitee (excluding insurance obtained on the Indemnitee’s own behalf), and the Indemnitee shall execute all papers required
and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable the
Company effectively to bring suit to enforce such rights.
(e) This
Agreement may not be amended, modified, or supplemented in any manner, whether by course of conduct or otherwise, except by an instrument
in writing specifically designated as an amendment hereto, signed on behalf of each party. No failure or delay of either party in exercising
any right or remedy hereunder shall operate as a waiver thereof, and no single or partial exercise of any such right or power, or any
abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, shall preclude any other or further exercise
thereof or the exercise of any other right or power.
[The remainder of this page is intentionally left
blank.]
IN WITNESS WHEREOF, the Company and the Indemnitee
have caused this Agreement to be executed as of the date first written above.
|
|
DocGo Inc.
|
|
|
|
|
|
By:
|
|
|
|
|
Name:
|
|
|
|
|
Title:
|
|
|
|
|
|
|
|
|
|
|
|
Indemnitee
|
Signature Page to Indemnification
Agreement
Exhibit 10.11
STOCK ESCROW AGREEMENT
STOCK ESCROW AGREEMENT, dated
as of November 5, 2021 (“Agreement”), by and among Motion Acquisition Corp. (to be renamed DocGo Inc.), a Delaware
corporation (“Parent”), Motion Acquisition LLC, a Delaware limited liability company (“Sponsor”),
and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (“Escrow Agent”).
WHEREAS, prior to Parent’s
initial public offering, Sponsor purchased 2,875,000 shares of Parent’s Class B common stock, par value $0.001 per share (“Parent
Class B Common Stock”);
WHEREAS, Parent entered into
that certain Merger Agreement (the “Merger Agreement”), dated as of March 8, 2021, by and among Parent, Motion Merger
Sub Corp., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and Ambulnz, Inc., a Delaware
corporation (the “Company”) pursuant to which, on or about the date hereof, Merger Sub will merge (the “Merger”)
with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the “Surviving Corporation”);
WHEREAS, on August 24, 2021,
the Sponsor elected to convert all 2,875,000 shares of Parent Class B Common Stock owned by the Sponsor into an aggregate of 2,875,000
shares of Class A Common Stock, par value $0.0001, of Parent (the “Parent Common Stock”) on a one-to-one basis;
WHEREAS, pursuant to Section
1.9 of the Merger Agreement, and as a material inducement to the Company to enter into the Merger Agreement, Sponsor is required to place
up to 575,000 shares of Parent Common Stock, less any adjustments pursuant to the A&R Sponsor Agreement (the “Sponsor Earnout
Shares”) into escrow upon the terms and conditions hereof;
WHEREAS, pursuant to that
certain Amended and Restated Sponsor Agreement, dated November 4, 2021, by and among Motion, Sponsor and the Company (the “A&R
Sponsor Agreement”), Sponsor agreed to, among other things, place up to an additional 675,000 shares of Parent Common Stock
(such shares, the “Additional Earnout Shares”) into escrow upon the terms and conditions hereof and thereof; and
WHEREAS, Parent and Sponsor
desire that the Escrow Agent accept the Sponsor Earnout Shares and Additional Earnout Shares in escrow, to be held and disbursed as hereinafter
provided.
IT IS AGREED:
1. Appointment of
Escrow Agent. Parent and Sponsor hereby appoint the Escrow Agent to act in accordance with and subject to the terms of this Agreement
and the Escrow Agent hereby accepts such appointment and agrees to act in accordance with and subject to such terms.
2. Deposit of Shares.
Immediately prior to the effective time of the Merger, the Sponsor Earnout Shares and Additional Earnout Shares shall be deposited in
escrow, to be held and disbursed subject to the terms and conditions of this Agreement.
3. Disbursement of
the Sponsor Earnout Shares and Additional Earnout shares.
3.1 Unless released pursuant
to Section 3.2, the Sponsor Earnout Shares and Additional Earnout Shares shall be held in escrow: (a) with respect to 287,500 of
the Sponsor Earnout Shares, less any adjustments pursuant to the A&R Sponsor Agreement (the “First Sponsor Earnout Shares”),
from the date hereof until the third anniversary of the Closing Date (such period, the “First Earnout Period”), (b)
with respect to the remaining 287,500 of the Sponsor Earnout Shares, less any adjustments pursuant to the A&R Sponsor Agreement (the
“Second Sponsor Earnout Shares”), from the date hereof until the fifth anniversary of the Closing Date (such period,
the “Second Earnout Period”), and (c) with respect to the Additional Earnout Shares, from the date hereof until such
period as specified in Section 3.2(c) (such periods, the “Additional Earnout Periods” and, together with the
First Earnout Period and Second Earnout Period, the “Escrow Period”). In the event that any First Sponsor Earnout Shares
are still held in escrow at the end of the First Earnout Period, or any Second Sponsor Earnout Shares are still held in escrow at the
end of the Second Earnout Period, or any Additional Earnout Shares are still held in escrow at the end of the applicable Additional Earnout
Period, those Sponsor Earnout Shares or Additional Earnout Shares, as applicable, will automatically and without further action by Sponsor
be forfeited and delivered by the Escrow Agent to Parent for cancellation by Parent.
3.2 The Escrow Agent shall release
the Sponsor Earnout Shares and Additional Earnout Shares from escrow as follows:
(a) the
First Sponsor Earnout Shares shall be released from escrow if the closing price of the Parent Common Stock equals or exceeds $12.50 per
share (as adjusted for share splits, share dividends, reorganizations, and recapitalizations) on any twenty (20) trading days in a thirty
(30)-trading-day period during the First Earnout Period;
(b) the
Second Sponsor Earnout Shares shall be released from escrow if the closing price of the Parent Common Stock equals or exceeds $15.00 per
share (as adjusted for share splits, share dividends, reorganizations, and recapitalizations) on any twenty (20) trading days in a thirty
(30)-trading-day period during the Second Earnout Period.
(c) Additional
Earnout Shares shall be released from escrow upon satisfaction of any of the following conditions (each, an “Additional Earnout
Condition”):
(i) twenty-five
percent (25%) of the Additional Earnout Shares shall be released from escrow if the closing price of the Parent Common Stock equals or
exceeds $12.50 per share (as adjusted for share splits, share dividends, reorganizations, and recapitalizations) on any twenty (20) trading
days in a thirty (30)-trading-day period at any time after the Closing Date and by the first anniversary of the Closing Date.
(ii) an
additional twenty-five percent (25%) of the Additional Earnout Shares shall be released from escrow if the closing price of the Parent
Common Stock equals or exceeds $15.00 per share (as adjusted for share splits, share dividends, reorganizations, and recapitalizations)
on any twenty (20) trading days in a thirty (30)-trading-day period at any time after the Closing Date and by the third anniversary of
the Closing Date.
(iii) an
additional twenty-five percent (25%) of the Additional Earnout Shares shall be released from escrow if the closing price of the Parent
Common Stock equals or exceeds $18.00 per share (as adjusted for share splits, share dividends, reorganizations, and recapitalizations)
on any twenty (20) trading days in a thirty (30)-trading-day period at any time after the Closing Date and by the third anniversary of
the Closing Date.
(iv) the
remaining twenty-five percent (25%) of the Additional Earnout Shares shall be released from escrow if the closing price of the Parent
Common Stock equals or exceeds $21.00 per share (as adjusted for share splits, share dividends, reorganizations, and recapitalizations)
on any twenty (20) trading days in a thirty (30)-trading-day period at any time after the Closing Date and by the fifth anniversary of
the Closing Date.
(v) For
the avoidance of doubt, each Additional Earnout Condition will be evaluated on a stand-alone basis, without reference to any other Additional
Earnout Condition.
3.3 Upon the achievement of
any of the conditions set forth in Section 3.2 above, Parent shall promptly provide notice to the Escrow Agent, in form reasonably
acceptable to the Escrow Agent, and the Escrow Agent shall promptly disburse the applicable Sponsor Earnout Shares and/or Additional Earnout
Shares to the Sponsor.
3.4. The Escrow Agent shall
have no further duties hereunder after the disbursement of the Sponsor Earnout Shares in accordance with this Section 3.
4. Rights of Sponsor
in Sponsor Earnout Shares and Additional Earnout Shares.
4.1 Voting Rights as
a Stockholder. Sponsor shall retain all of its rights as a stockholder of Parent with respect to the Sponsor Earnout Shares and Additional
Earnout Shares as long as any such Sponsor Earnout Shares or Additional Earnout Shares are held in escrow pursuant to this Agreement,
including, without limitation, the right to vote such Sponsor Earnout Shares and Additional Earnout Shares.
4.2 Dividends and Other
Distributions in Respect of the Sponsor Earnout Shares and Additional Earnout Shares. For as long as any Sponsor Earnout Shares or
Additional Earnout Shares are held in escrow pursuant to this Agreement, all dividends payable in cash with respect to the Sponsor Earnout
Shares and Additional Earnout Shares shall be paid to Sponsor, but all dividends payable in stock or other non-cash property (“Non-Cash
Dividends”) shall be delivered to the Escrow Agent to hold in accordance with the terms hereof. As used herein, the term “Sponsor
Earnout Shares” shall be deemed to include the Non-Cash Dividends distributed thereon, if any.
4.3 Restrictions on
Transfer. During the Escrow Period, the only permitted transfers of the Sponsor Earnout Shares and Additional Earnout Shares will
be to: (i) Parent or an Affiliate of Parent, (ii) Sponsor’s members upon Sponsor’s liquidation or (iii) an entity, if such
entity’s equity securities are 100% owned by Sponsor or its members; provided, however, that except with Parent’s prior written
consent, such permitted transfers may be implemented only upon the respective transferee’s written agreement to be bound by the
terms and conditions of this Agreement; provided that, for the avoidance of doubt and notwithstanding any such permitted transfer, such
Sponsor Earnout Shares and Additional Earnout Shares shall be held in escrow during the Escrow Period until released or forfeited in accordance
with Section 3 hereof.
5. Concerning the
Escrow Agent.
5.1 Good Faith Reliance.
The Escrow Agent shall not be liable for any action taken or omitted by it in good faith and in the exercise of its own best judgment,
and may rely conclusively and shall be protected in acting upon any order, notice, demand, certificate, opinion or advice of counsel (including
counsel chosen by the Escrow Agent), statement, instrument, report or other paper or document (not only as to its due execution and the
validity and effectiveness of its provisions, but also as to the truth and acceptability of any information therein contained) which is
believed by the Escrow Agent in good faith to be genuine and to be signed or presented by the proper person or persons. The Escrow Agent
shall not be bound by any notice or demand, or any waiver, modification, termination or rescission of this Agreement unless evidenced
by a writing delivered to the Escrow Agent signed by the proper party or parties and, if the duties or rights of the Escrow Agent are
affected, unless it shall have given its prior written consent thereto.
5.2 Indemnification.
Subject to Section 5.7 below, the Escrow Agent shall be indemnified and held harmless by Parent from and against any expenses,
including reasonable counsel fees and disbursements, or loss suffered by the Escrow Agent in connection with any action, suit or other
proceeding involving any claim which in any way, directly or indirectly, arises out of or relates to this Agreement, the services of the
Escrow Agent hereunder, or the Sponsor Earnout Shares and Additional Earnout Shares held by it hereunder, other than expenses or losses
arising from the gross negligence, fraud or willful misconduct of the Escrow Agent. Promptly after the receipt by the Escrow Agent of
notice of any demand or claim or the commencement of any action, suit or proceeding, the Escrow Agent shall notify the other parties hereto
in writing. In the event of the receipt of such notice, the Escrow Agent, in its sole discretion, may commence an action in the nature
of interpleader in an appropriate court to determine ownership or disposition of the Sponsor Earnout Shares and Additional Earnout Shares
or it may deposit the Sponsor Earnout Shares and Additional Earnout Shares with the clerk of any appropriate court or it may retain the
Sponsor Earnout Shares and Additional Earnout Shares pending receipt of a final, non-appealable order of a court having jurisdiction over
all of the parties hereto directing to whom and under what circumstances the Sponsor Earnout Shares and Additional Earnout Shares are
to be disbursed and delivered. The provisions of this Section 5.2 shall survive in the event the Escrow Agent resigns or is discharged
pursuant to Sections 5.5 or 5.6 below.
5.3 Compensation.
The Escrow Agent shall be entitled to reasonable compensation from Parent for all services rendered by it hereunder. The Escrow Agent
shall also be entitled to reimbursement from Parent for all reasonable and documented expenses paid or incurred by it in the administration
of its duties hereunder including, but not limited to, all counsel, advisors’ and agents’ fees and disbursements and all taxes
or other governmental charges.
5.4 Further Assurances.
From time to time on and after the date hereof, Parent and Sponsor shall deliver or cause to be delivered to the Escrow Agent such further
documents and instruments and shall do or cause to be done such further acts as the Escrow Agent shall reasonably request to carry out
more effectively the provisions and purposes of this Agreement, to evidence compliance herewith or to assure itself that it is protected
in acting hereunder.
5.5 Resignation.
The Escrow Agent may resign at any time and be discharged from its duties as escrow agent hereunder by its giving the other parties hereto
written notice and such resignation shall become effective as hereinafter provided. Such resignation shall become effective at such time
that the Escrow Agent shall turn the Sponsor Earnout Shares and Additional Earnout Shares over to a successor escrow agent appointed by
Parent and approved by each of Sponsor and the Company, which approval will not be unreasonably withheld, conditioned or delayed. If no
new escrow agent is so appointed within the 60-day period following the giving of such notice of resignation, the Escrow Agent may deposit
the Sponsor Earnout Shares and Additional Earnout Shares with any court it reasonably deems appropriate in the State of New York.
5.6 Discharge of Escrow
Agent. The Escrow Agent shall resign and be discharged from its duties as escrow agent hereunder if so requested in writing at any
time by all of the other parties hereto; provided, however, that such resignation shall become effective only upon the appointment of
a successor escrow agent selected by Parent and approved by each of Sponsor and the Company, which approval will not be unreasonably withheld,
conditioned or delayed.
5.7 Liability. Notwithstanding
anything herein to the contrary, the Escrow Agent shall not be relieved from liability hereunder for its own gross negligence, fraud or
willful misconduct.
6. Miscellaneous.
6.1 Governing Law.
This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect
to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereto
consent to the jurisdiction and venue of any state or federal court located in the City of New York, Borough of Manhattan, for purposes
of resolving any disputes hereunder. As to any claim, cross-claim, or counterclaim in any way relating to this Agreement, each party waives
the right to trial by jury.
6.2 Entire Agreement.
This Agreement contains the entire agreement of the parties hereto with respect to the subject matter hereof and, except as expressly
provided herein, may only be changed, amended, or modified by a writing signed by each of the parties hereto.
6.3 Headings. The
headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation thereof.
6.4 Binding Effect.
This Agreement shall be binding upon and inure to the benefit of the respective parties hereto and their legal representatives, successors
and assigns.
6.5 Third Party Beneficiaries.
Each of the parties to this Agreement acknowledges that the Company is an intended third party beneficiary of this Agreement.
6.6 Notices. Any
notice, consent or request to be given in connection with any of the terms or provisions of this Agreement shall be in writing and shall
be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery, by email or
by facsimile transmission:
If to Parent, to:
DocGo, Inc.
35 West 35th Street, 6th Floor
New York, NY 10001
Attention: Stan Vashovsky
Email: stan@ambulnz.com
If to Sponsor, to:
Motion Acquisition Sponsor, LLC
c/o Graubard Miller
The Chrysler Building
405 Lexington Ave, 11th Floor
New York, NY 10174
Attention: Michael Burdiek
Email: mburdiek@motionacquisition.com
and if to the Escrow Agent,
to:
Continental Stock Transfer & Trust
Parent
1 State Street, 30th Floor
New York, New York 10004
Attn: Client Administration Dept.
Email: accountadmin@continentalstock.com
A copy of any notice sent hereunder
shall be sent to:
Gibson Dunn & Crutcher LLP
200 Park Avenue
New York, NY 10166
|
|
Attention:
|
George Stamas
|
|
|
|
William Sorabella
|
|
|
|
Evan M. D’Amico
|
|
|
Email:
|
gstamas@gibsondunn.com
|
|
|
|
wsorabella@gibsondunn.com
|
|
|
|
edamico@gibsondunn.com
|
and:
Graubard Miller
The Chrysler Building
405 Lexington Avenue
New York, New York 10174
Attn: David Alan Miller, Esq. / Jeffrey
M. Gallant, Esq.
Email: dmiller@graubard.com / jgallant@graubard.com
The parties may change the persons
and addresses to which the notices or other communications are to be sent by giving written notice to any such change in the manner provided
herein for giving notice.
6.7 Counterparts.
This Agreement may be executed in several counterparts, each one of which shall constitute an original and may be delivered by facsimile
transmission and together shall constitute one instrument.
[Signature Page Follows]
WITNESS the execution of this
Agreement as of the date first above written.
|
|
MOTION ACQUISITION CORP.
|
|
|
|
|
|
|
By:
|
/s/ Michael Burdiek
|
|
|
Name:
|
Michael Burdiek
|
|
|
Title:
|
CEO
|
|
|
|
|
|
|
CONTINENTAL STOCK TRANSFER & TRUST COMPANY
|
|
|
|
|
|
|
By:
|
/s/ Erika Young
|
|
|
Name:
|
Erika Young
|
|
|
Title:
|
Vice President
|
|
|
|
|
|
|
MOTION ACQUISITION, LLC
|
|
|
|
|
|
|
By:
|
/s/ Rick Vitelle
|
|
|
Name:
|
Rick Vitelle
|
|
|
Title:
|
Managing Member
|
[Signature Page to Stock Escrow Agreement]
Exhibit
14.1
CODE
OF BUSINESS CONDUCT AND ETHICS
(dated
November 5, 2021)
I.
INTRODUCTION
This
Code of Business Conduct and Ethics (this “Code”) provides a general statement of the expectations of DocGo Inc. (the “Company”
or “DocGo”) regarding the ethical standards to which each director, officer and employee should adhere while acting on behalf
of the Company. You are expected to read and become familiar with the ethical standards described in this Code and will be required,
from time to time, to affirm your agreement to adhere to such standards by signing the Compliance Certificate that appears at the end
of this Code.
We
are proud of what the Company has accomplished to date, and your commitment to continued excellence is crucial as our Company changes
and grows. We expect all individuals associated with the Company to conduct themselves with the highest degree of honesty and integrity
at all times.
This
Code should be read in conjunction with our other policies and procedures, including the Employee Handbook, copies of which are available
from Human Resources. This Code is not a substitute for those other documents. Instead, this Code should be viewed as a general statement
of the guiding principles that should help you keep our core values in mind as you conduct business on behalf of the Company.
We
consider any violation of this Code to be a serious breach of our trust, and any violation will result in disciplinary action, up to
and including termination, as well as potential civil or criminal penalties, depending on the nature of the violation and applicable
law. Similarly, if you are aware of someone’s violation of this Code, you have a duty to report the violation in accordance with
the procedure detailed below. We depend on your commitment to protect our culture and values and will view your reporting of violations
in that context.
While
this Code covers multiple scenarios and activities, it cannot possibly address every challenging situation. Therefore, if you are faced
with an issue that you feel may not be covered specifically or adequately by this Code, and are making a decision to act, please keep
the following in mind:
|
|
●
|
consider
whether your actions would conform to the intent of the Code;
|
|
|
●
|
consider
whether your actions could create even a perception of impropriety;
|
|
|
●
|
make
sure you have all of the relevant facts;
|
|
|
●
|
consider
discussing the matter with your supervisor, as applicable, or reporting the matter anonymously as described below; and
|
|
|
●
|
seek
help; it is always better to seek assistance before you act, rather than making a preventable mistake.
|
If
you encounter a situation where you have a question about the law, the Code or any DocGo policy or are unsure of the best course of action,
you should always seek guidance. Except as otherwise specifically noted in the Code, when you have a specific question, please contact
your supervisor, Human Resources , Chief Compliance Officer (“CCO”) or the General Counsel (the “GC”).1
II.
REPORTING VIOLATIONS
If
you know or reasonably believe that there has been a violation of this Code or any other illegal behavior, you must report such violation
or illegal behavior to your supervisor, Human Resources or the GC. Additionally, employees, consultants and others may report any violations
of this Code or any other illegal behavior anonymously through the Company’s whistleblower hotline. There are two methods of logging
complaints anonymously:
Website:
ambulnz.ethicspoint.com.
Phone:
1-844-996-0286
Such
complaints will be directed to the Company’s GC and CCO.. However, if the complaint involves the GC or CCO, or otherwise gives
rise to a conflict of interest, such complaints will be directed to the Company’s Audit and Compliance Committee and/or outside
counsel.
Failure
to report a known or suspected violation of this Code is itself a violation, and may result in disciplinary action up to, and including,
termination.
Any
director, officer or employee who obtains information about a Code violation or illegal act has the responsibility to report the matter
immediately to one of the above individuals. The Company will not discharge, demote, suspend, threaten, harass or in any manner discriminate
or tolerate discrimination or retaliation against any director, officer or employee for reporting, in good faith, a potential violation,
and any supervisor intimidating or imposing sanctions on any such person for reporting a matter in good faith will be disciplined.
III.
PERSONAL RESPONSIBILITY AND INTEGRITY
A.
Fair Dealing
You
are expected to be honest, ethical and fair and should endeavor to deal fairly with customers, vendors, suppliers, business partners,
service providers, competitors and employees. You should not take unfair advantage of anyone through manipulation, concealment, abuse
of privileged information, misrepresentation of material facts or any other unfair-dealing practice.
|
|
1
|
At any time
when the Company does not have a GC or CCO, the duties and responsibilities of the GC and CCO under this Code of Business Conduct and
Ethics shall be fulfilled by the Chief Financial Officer of the Company.
|
B.
Confidential Information and Privacy
The
Company holds many types of confidential information that must be carefully safeguarded. Protecting this information is essential to
maintaining our relationships with our suppliers, customers and other business partners. In addition, Company information, which includes
confidential information and third-party information the Company has a duty to keep confidential, should not be used other than for its
intended use, and documents including such information should be disposed of properly and should not be copied or removed from the work
area, except as required for job performance. Company information should never be disclosed to outsiders without specific approval by
the Company.
Confidential
information includes:
|
|
●
|
information
marked “Confidential,” “Private,” “For Internal Use Only” or with a similar legend;
|
|
|
●
|
technical
or scientific information relating to current and future product candidates, services or research;
|
|
|
●
|
business
or marketing plans, strategies, forecasts or projections;
|
|
|
●
|
budgets,
earnings and other internal financial data;
|
|
|
●
|
personnel
information (such as HIPAA protected medical information);
|
|
|
●
|
business
contracts and other customer and vendor information;
|
|
|
●
|
training
materials and methods;
|
|
|
●
|
other
nonpublic information that, if disclosed, might be of use to the Company’s competitors or harmful to the Company or its business
partners; and
|
|
|
●
|
other
nonpublic information that, if disclosed, would violate federal or state securities laws.
|
Regardless
of whether information is specifically marked as confidential, it is each employee’s responsibility to keep confidential information
in confidence (except as otherwise allowed, if at all, by applicable law). You must not use, reveal or divulge any such information unless
it is necessary for you to do so in the performance of your duties (or except as otherwise allowed, if at all, by applicable law). Generally,
access to confidential information should be granted, provided or given on a “need-to-know” basis and must be authorized
by your manager. For further discussion of our policies with respect to the treatment of material non-public information please review
our Insider Trading Policy.
C.
Use of Company Systems
The
data and other information you use, send, receive and store on the Company’s telecommunications equipment (including email, voicemail
and the internet) are business records owned by the Company. Therefore, subject to applicable laws and regulations, the Company
has the right to access, read, monitor, inspect, review and disclose the contents of, postings to and downloads from all of the Company’s
information systems. In addition, your use of the Company’s systems and equipment reflects on the Company as a whole, and
at no time may you use Company systems or equipment to view, access, store, share or send illegal, derogatory, harassing or inappropriate
information, including obscene, racist or sexually explicit information, or engage in any activity that violates the intellectual property
rights of others. We strongly encourage all directors, officers and employees to avoid references to the Company on social networking
sites or other Internet-based communications sites. For further discussion on our policies with respect to communications with the investment
community please review our Guidelines for Public Disclosures and Communications with the Investment Community.
D.
Conflicts of Interest
Directors,
officers and employees should avoid activities that create or give the appearance of a conflict of interest between their personal interests
and the Company’s interests. A conflict of interest exists when a personal interest or activity of a director, officer or employee
could influence or interfere with that person’s performance of duties, responsibilities or commitments to the Company. A conflict
of interest also exists when a director, officer or employee (or member of his or her family) receives an improper personal benefit as
a result of his or her position at the Company. Below are some examples that could result in a conflict of interest:
|
|
●
|
be
a consultant to, or a director, officer or employee of, or otherwise operate an outside business that is a significant competitor, supplier
or customer of the Company;
|
|
|
●
|
be
a consultant to, or a director, officer or employee of, or otherwise operate an outside business if the demands of the outside business
would materially interfere with the director’s, officer’s or employee’s responsibilities to the Company;
|
|
|
●
|
take
personal advantage or obtain personal gain from an opportunity learned of or discovered during the course and scope of your employment
when that opportunity or discovery could be of benefit or interest to the Company;
|
|
|
●
|
have
significant financial interest, including direct stock ownership, in any outside business that does or seeks to do a material amount
of business with the Company;
|
|
|
●
|
seek
or accept any personal loan or services from any such outside business, except from financial institutions or service providers offering
similar loans or services to third parties under similar terms in the ordinary course of their respective businesses;
|
|
|
●
|
accept
any personal loan or guarantee of obligations from the Company, except to the extent such arrangements are legally permissible; or
|
|
|
●
|
conduct
business on behalf of the Company with immediate family members, which include spouses, children, parents, siblings and persons sharing
the same home, whether or not legal relatives.
|
Whether
or not a conflict of interest exists or will exist can be unclear. Persons other than directors and executive officers who have questions
about a potential conflict of interest or who become aware of an actual or potential conflict should discuss the matter with their supervisor,
as applicable, or the GC. Directors and executive officers must consult and seek prior approval of potential conflicts of interest exclusively
from the Audit and Compliance Committee.
For
avoidance of doubt, a director affiliated with an investment firm shall not be presumed to have a conflict of interest due to such investment
firm or the director acting on its behalf conducting normal activities.
E.
Proper Use of Corporate Assets
The
Company’s assets shall be used for their intended business purposes. Personal use of the Company’s funds or property, including
charging personal expenses as business expenses, inappropriate reporting or overstatement of business or travel expenses, and inappropriate
usage of Company equipment or the personal use of supplies or facilities without advance approval from an appropriate officer of the
Company shall be considered a breach of the Code.
F.
Corporate Opportunities
You
owe a duty to the Company to advance its interests when the opportunity to do so arises and are prohibited from taking for yourself opportunities
that are discovered through the use of Company property, information or position. You may not use Company property, information or position
for personal gain. In addition, you may not compete with the Company. If you become aware of any actual or potential business opportunity
that relates to the Company, you may not take advantage of the opportunity or share the opportunity with anyone outside the Company without
first receiving the approval of the GC’s office or the Board of Directors, as applicable. Notwithstanding the foregoing, the duties
of directors and officers with respect to corporate opportunities are subject to the terms of the Company’s certificate of incorporation,
as it may be amended and/or restated from time to time.
IV.
LEGAL REQUIREMENTS
A.
Legal Compliance
The
Company conducts its affairs consistent with the applicable laws and regulations of the United States and the states and foreign jurisdictions
in which it does business, and adherence to all legal and regulatory requirements is among our highest priorities. As a Company director
or employee, you are expected to comply with all such applicable laws and regulations.
B. Gifts
A
gift is any item that is intended just for you or your family to use and enjoy. It can be anything of value, including such items as
tickets to a sporting event, wine, a coffee mug, a service, etc. Directors and employees may not accept or give non-cash gifts to anyone
with whom the Company does business without prior approval from the CCO, unless that gift is promotional in nature and nominal in value.
There
are similar concerns involving potential conflicts of interest in other external business relationships. Generally, giving or receiving
gifts, meals or entertainment involving our external business relationships should meet all of the following criteria:
|
|
●
|
they
do not violate applicable law or fail to comply with Company policy;
|
|
|
●
|
they
do not constitute a bribe, kickback or other improper payment;
|
|
|
●
|
they
have a valid business purpose;
|
|
|
●
|
they
are appropriate as to time, place and value (modest, not lavish or extravagant);
|
|
|
●
|
they
are infrequent; and
|
|
|
●
|
they
do not influence or appear to influence the behavior of the recipient.
|
Gifts
of cash or cash-equivalents or marketable securities may not be given or accepted regardless of amount.
C. Dealing
with Government Officials
All
dealings with government officials, including, but not limited to lobbying, political contributions to candidates and meeting with government
agencies, shall be in accordance with all applicable national, state and local laws and regulations in each country in which the Company
conducts business (and shall comply with the Foreign Corrupt Practices Act (the “FCPA”), as set forth below) and the Company’s
International Trade Policy.
No
director, officer or employee shall offer or promise a payment or reward of any kind, directly or indirectly, to any federal, state,
local or foreign government official (i) for or because of an official act performed or to be performed by that official; or (ii) in
order to secure preferential treatment for the Company or its employees. No director, officer or employee shall offer or promise any
federal, state, local or foreign government official gifts, entertainment, gratuities, meals, lodging, travel or similar items that are
designed to influence such officials. Further, because of the potential for misunderstanding, no director, officer or employee of the
Company may confer gifts, special favors, gratuities or benefits to such an official even if there is no matter pending before that official.
The Company also strictly prohibits any director, officer or employee from making any payment or providing a thing of value if the person
knows, or reasonably believes or suspects that any portion of the payment or thing of value will be offered, given or promised, directly
or indirectly, to any government official.
It
is our policy to cooperate fully with all legal and reasonable government investigations. Accordingly, the Company directors, officers
and employees shall comply with any and all lawful requests from government investigators and, consistent with preserving the Company’s
legal rights, shall cooperate in lawful government inquiries. No director, officer or employee shall make a false or misleading written
or oral statement to a government official with regard to any matter involving a government inquiry into the Company matters.
Employees
shall contact the GC when presented with any such government request or inquiry prior to responding to such inquiry. Employees with questions
about contacts with government officials should seek guidance from senior management. Officers and directors should contact the GC prior
to responding to any such inquiries.
D. Foreign
Corrupt Practices Act
All
employees must comply with the FCPA, which sets forth requirements for the Company’s relationships with non-U.S. government representatives,
which in many countries include individuals who would not be deemed government representatives in the U.S. (e.g., medical professionals
and employees of educational institutions). It is important to note that these limitations apply with respect to a government representative
at any level and not only with respect to senior or policy-making roles. As a U.S.-based company, the Company is required to adhere to
all standards set forth in the FCPA regardless of the nationality or overseas location of the individual acting on behalf of the Company,
whether an employee, officer or third party.
The
FCPA requires that relations between U.S. businesses and foreign government representatives conform to the standards that exist in the
United States, even if a different business ethic is prevalent in the other country. Accordingly, no employee or third-party person or
enterprise acting on behalf of the Company, directly or indirectly, may offer a gift, payment or bribe, or anything else of value, whether
directly or indirectly, to any foreign official, foreign political party or party official, or candidate for foreign political office
for the purpose of influencing an official act or decision or seeking influence with a foreign government in order to obtain, retain
or direct business to the Company or to any person or to otherwise secure an improper advantage. In short, such activity cannot be used
to improve the business environment for the Company in any way. Thus, even if such payment is customary and generally thought to be legal
in the host country, it is forbidden by the FCPA and violates U.S. law, unless it is a reasonable and bona fide expenditure, such as
entertainment or travel and lodging expenses, that is directly related to (a) the promotion, demonstration or explanation of products
or services or (b) the execution or performance of a contract with a foreign government or government agency, and the payment was not
made for an improper purpose.
As
in the case under U.S. law, even inexpensive gifts to government or political party officials, such as tickets to sporting events, may
constitute a violation of the FCPA. If questions arise with respect to expenses to be incurred on behalf of foreign officials, consult
with the CFO before the Company pays or agrees to pay such expenses.
Some
“expediting” payments are authorized under the FCPA. Such payments must be directly related to non-discretionary conduct
by lower-level bureaucrats and unrelated to efforts by a company to obtain significant concessions, permits or approvals. Examples include
processing of visas and work orders, mail delivery or loading and unloading of cargo. Such payments do not include payments of any kind
relating to terms of continuing or new business agreements. Consult with the CFO prior to making or authorizing any proposed expediting
payment.
A
violation of the FCPA can result in criminal and civil charges against the Company, its officers, its managers and the individuals involved
in the violation, regardless of the person’s nationality or location.
E. Inside
Information
While
at the Company, you may also come into contact with another form of information that requires special handling and discretion. Inside
information is material, nonpublic information about the Company or another company that, if made public, would be reasonably expected
to affect the price of a company’s securities or investment decisions regarding the purchase or sale of such securities. Employees
must never use inside information to obtain any type of personal advantage and should not disclose inside information to any third parties
without the prior approval of senior management. For further discussion on our policy with respect to inside information, please review
our Insider Trading Policy and Guidelines for Public Disclosures and Communications with the Investment Community, which are incorporated
herein by reference.
F. Company
Disclosure Obligations
The
Company’s business affairs are also subject to certain internal and external disclosure obligations and recordkeeping procedures.
As a public company, we are committed to abiding by our disclosure obligations in a full, fair, accurate, timely and understandable manner.
Only with reliable records and clear disclosure procedures can we make informed and responsible business decisions. When disclosing information
to the public, it is our policy to provide consistent and accurate information. To maintain consistency and accuracy, specific Company
spokespersons are designated to respond to questions from the public. Only these individuals are authorized to release information to
the public at appropriate times. All inquiries from the media or investors should be forwarded immediately to the GC or CFO. The GC or
the CFO must approve all press releases, speeches, publications or other official Company disclosures in advance. For further discussion
on our policies with respect to communications with the investment community please review our Guidelines for Public Disclosures and
Communications with the Investment Community
Our
internal control procedures are further regulated by the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). The Sarbanes-Oxley
Act was a U.S. legislative response to events at public companies involving pervasive breakdowns in corporate ethics and internal controls
over financial reporting. It was designed to rebuild confidence in the capital markets by ensuring that public companies are operated
in a transparent and honest manner. Ensuring proper and effective internal controls is among the Company’s highest priorities.
We
take seriously the reliance our investors place on us to provide accurate and timely information about our business. In support of our
disclosure obligations, it is our policy to always:
|
|
●
|
comply
with generally accepted accounting principles;
|
|
|
●
|
maintain
a system of internal accounting and disclosure controls and procedures that provides management with reasonable assurances that transactions
are properly recorded and that material information is made known to management;
|
|
|
●
|
maintain
books and records that accurately and fairly reflect transactions; and
|
|
|
●
|
prohibit
establishment of material undisclosed or unrecorded funds or assets.
|
G.
Environmental Matters
The
Company is committed to operating its business in a manner that protects the environment as much as possible, and is further committed
to compliance with all applicable environmental laws, regulations and industry best practices, such as those that affect hazardous waste
disposal, emissions and water purity. You are expected to be aware of environmental issues and maintain compliance with all internal
environmental policies.
H.
Prohibition Against Discrimination, Equal Opportunity Employment
The
Company is committed to maintaining the highest integrity in our work environment. Our employees must comply with all applicable employment
laws and our policies addressing workplace conduct. We base hiring, promotions and performance management decisions on qualifications
and job performance. The Company’s policy is to treat each employee and job applicant without regard to race, color, age, sex,
religion, national origin, sexual orientation, ancestry, veteran status or any other category protected by law. Employees must refrain
from acts that are intended to cause, or that do cause, unlawful employment discrimination. The Company also accommodates qualified disabled
employees and applicants consistent with applicable laws.
The
Company prohibits harassment in the workplace, including but not limited to sexual harassment. Consistent with this policy, we will not
tolerate harassment by any of our employees, customers or other third parties. Harassment includes verbal or physical conduct which threatens,
offends or belittles any individual because of his or her gender identity, race, color, age, religion, national origin, sexual orientation,
ancestry, veteran status or any other category protected by law. Retaliation against an employee for alleging a complaint of harassment
or discrimination or for participating in an investigation relating to such a complaint will also not be tolerated.
I. Health
and Safety
The
Company is committed to providing a safe and healthy work environment for its employees, and all other individuals working on behalf
of the Company. The Company also recognizes that the responsibilities for a safe and healthy work environment are shared with you. The
Company will continue to establish and implement appropriate health and safety policies that managers and their employees are expected
to uphold at all times. You are expected to conduct your work in a safe manner in compliance with all Company policies and report all
safety or health concerns to your manager or Human Resources.
Part
of providing a safe and healthy environment is the prohibition of illegal drugs or alcohol (except when alcohol is pre-approved for special
Company-sponsored events) on the premises. Individuals who consume alcohol at such events do so at their own risk. In addition, you are
expected to avoid excessive consumption of alcohol at any Company-sponsored event, and will be asked to leave an event at which you are
violating this requirement. You also may be subject to other disciplinary measures.
V.
AMENDMENTS AND WAIVERS OF THIS CODE
This
Code applies to all Company directors, officers and employees. Please contact the GC if you believe that a waiver under a provision of
this Code is warranted. There shall be no substantive amendment or waiver of any provision of this Code except by a vote of the Board
of Directors or the Audit and Compliance Committee of the Board of Directors, which will ascertain whether an amendment or waiver is
appropriate and ensure that any amendment or waiver is accompanied by appropriate controls designed to protect the Company. In the case
of non-officer employees or consultants of the Company, waivers may also be approved by the CFO. Any such waiver of a provision of this
Code shall be evaluated to determine whether timely public disclosure of such waiver is required under the rules and regulations of the
Securities and Exchange Commission or applicable exchange listing standards.
The
Company reserves the right to amend any provision of this Code at any time, subject to the requirements for approval set forth above.
This
Code is not an employment contract. By issuing this Code, the Company has not created any contractual rights.
RECEIPT
AND ACKNOWLEDGMENT
I,
__________________________________, hereby acknowledge that I have received and read a copy of the DocGo Inc. Code of Business Conduct
and Ethics. I agree to comply with this Code. I understand that violation of this Code may subject me to discipline DocGo Inc., up to
and including termination for cause.
[RECEIPT AND ACKNOWLEDGEMENT
OF CODE OF BUSINESS CONDUCT AND ETHICS]
Exhibit 16.1
November 10, 2021
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read Docgo Inc. (formerly known as Motion Acquisition Corp.)
statements included under Item 4.01 of its Form 8-K dated November 12, 2021. We agree with the statements concerning our Firm under Item
4.01, in which we were informed of our dismissal on November 10, 2021. We are not in a position to agree or disagree with other statements
contained therein.
Very truly yours,
/s/ WithumSmith+Brown, PC
New York, New York
Exhibit 99.1
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
STATEMENTS
Defined terms included below have the same meaning
as terms defined and included elsewhere in the Current Report on Form 8-K to which this Unaudited Pro Forma Condensed Combined Financial
Information is attached (the “Form 8-K”) and, if not defined in the Form 8-K, the proxy statement/consent solicitation prospectus
filed with the Securities and Exchange Commission (the “SEC”) on October 14, 2021.
On March 8, 2021, Motion entered into the Merger
Agreement with Ambulnz and Motion Merger Sub Corp. (“Merger Sub”), pursuant to which, among other things, Merger Sub, a direct
wholly owned subsidiary of Motion, merged with and into Ambulnz (the “Merger”), with Ambulnz surviving the Merger as a wholly
owned subsidiary of DocGo. In connection with the Merger, Motion was renamed DocGo, Inc. (“DocGo”).
The following unaudited pro forma condensed combined
balance sheet as of June 30, 2021 combines the unaudited historical condensed consolidated balance sheet of Motion as of June 30,
2021 with the unaudited historical condensed consolidated balance sheet of Ambulnz as of June 30, 2021, giving further effect to
the Business Combination and the PIPE Transaction, as if they had been consummated as of June 30, 2021.
The following unaudited pro forma condensed combined
statement of operations for the six months ended June 30, 2021 combines the unaudited condensed consolidated statement of operations
of Motion for the six months ended June 30, 2021 with the unaudited condensed consolidated statement of operations of Ambulnz for
the six months ended June 30, 2021, giving effect to the Business Combination and the PIPE Transaction as if they had occurred
on January 1, 2020, which is the beginning of the earliest period presented.
The following unaudited pro forma condensed combined
statement of operations for the year ended December 31, 2020 combines the audited restated statement of operations of Motion for
the period from August 11, 2020 (inception) through December 31, 2020 with the audited consolidated statement of operations
of Ambulnz for the year ended December 31, 2020, giving effect to the Business Combination and the PIPE Transaction as if they had
occurred on January 1, 2020. The restatement of Motion’s statement of operations for the period from August 11, 2020 to
December 31, 2020 is more fully described in Note 2 of the notes to Motion’s fiscal 2020 financial statements included
in the proxy statement/consent solicitation/prospectus filed with the SEC on October 14, 2021.
The unaudited pro forma condensed combined financial
statements have been derived from and should be read in conjunction with the following, which are included or otherwise incorporated by
reference into the Form 8-K to which this Unaudited Pro Forma Condensed Combined Financial Information is attached:
|
|
●
|
the accompanying notes to these unaudited pro forma condensed combined financial statements;
|
|
|
●
|
Motion’s historical unaudited condensed consolidated financial statements as of June 30, 2021 and for the six months then
ended and the related notes thereto;
|
|
|
●
|
Motion’s historical audited restated condensed financial statements for the period from August 11, 2020 (inception) through
December 31, 2020 and the related notes thereto;
|
|
|
●
|
Ambulnz’s historical unaudited condensed consolidated financial statements as of June 30, 2021 and for the six months ended
June 30, 2021 and 2020 and the related notes thereto;
|
|
|
●
|
Ambulnz’s historical audited consolidated financial statements as of December 31, 2020 and 2019 and for the years then
ended and related notes thereto; and
|
|
|
●
|
the sections entitled “Motion’s Management’s Discussion and Analysis of Financial Condition
and Results of Operations,” “Ambulnz’s Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” and other financial information relating to Motion and Ambulnz included and/or incorporated
by reference into the Form 8-K to which this Unaudited Pro Forma Condensed Combined Financial Information is attached.
|
The unaudited pro forma condensed combined financial
information is for illustrative purposes only and is not necessarily indicative of what the actual results of operations and financial
position would have been had the Business Combination and the PIPE Transaction taken place on the dates indicated, nor are they indicative
of the future consolidated results of operations or financial position of the combined company.
UNAUDITED PRO FORMA CONDENSED COMBINED
BALANCE SHEET
AS OF JUNE 30, 2021
(in thousands)
|
|
|
Historical
Motion
5(A)
|
|
|
Historical
Ambulnz
5(B)
|
|
|
Transaction
Accounting
Adjustments
|
|
|
|
|
PIPE
Financing
Adjustments
|
|
|
|
|
Pro Forma
Balance
Sheet
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
234
|
|
|
$
|
33,146
|
|
|
$
|
37,291
|
|
|
5(f)
|
|
$
|
120,850
|
|
|
5(k)
|
|
$
|
191,521
|
|
|
Account receivable—net
|
|
|
—
|
|
|
|
41,062
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
41,062
|
|
|
Prepaid expenses and other current assets
|
|
|
223
|
|
|
|
3,504
|
|
|
|
(223
|
)
|
|
5(g)
|
|
|
—
|
|
|
|
|
|
3,504
|
|
|
Total current assets
|
|
|
457
|
|
|
|
77,712
|
|
|
|
37,068
|
|
|
|
|
|
120,850
|
|
|
|
|
|
236,087
|
|
|
Property and equipment, net
|
|
|
—
|
|
|
|
10,417
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
10,417
|
|
|
Intangible assets, net
|
|
|
—
|
|
|
|
10,818
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
10,818
|
|
|
Goodwill
|
|
|
—
|
|
|
|
6,610
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
6,610
|
|
|
Restricted cash
|
|
|
—
|
|
|
|
3,718
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
3,718
|
|
|
Operating lease right-of-use assets
|
|
|
—
|
|
|
|
4,629
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
4,629
|
|
|
Finance lease right-of-use assets
|
|
|
—
|
|
|
|
7,820
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
7,820
|
|
|
Cash and marketable securities held in Trust Account
|
|
|
115,007
|
|
|
|
—
|
|
|
|
(62,029
|
)
|
|
5(a)
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,025
|
)
|
|
5(b)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,855
|
)
|
|
5(c)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,801
|
)
|
|
5(d)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6
|
)
|
|
5(e)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(37,291
|
)
|
|
5(f)
|
|
|
|
|
|
|
|
|
|
|
|
Other non-current assets
|
|
|
—
|
|
|
|
1,411
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
1,411
|
|
|
Total assets
|
|
$
|
115,464
|
|
|
$
|
123,135
|
|
|
$
|
(77,939
|
)
|
|
|
|
$
|
120,850
|
|
|
|
|
$
|
281,510
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
25
|
|
|
$
|
6,745
|
|
|
$
|
(25
|
)
|
|
5(g)
|
|
$
|
—
|
|
|
|
|
$
|
6,745
|
|
|
Accrued and other current liabilities
|
|
|
69
|
|
|
|
26,476
|
|
|
|
(69
|
)
|
|
5(g)
|
|
|
—
|
|
|
|
|
|
26,476
|
|
|
Line of credit
|
|
|
—
|
|
|
|
8,000
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
8,000
|
|
|
Current portion of long-term debt
|
|
|
—
|
|
|
|
5,460
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
5,460
|
|
|
Accrued offering costs
|
|
|
70
|
|
|
|
—
|
|
|
|
(70
|
)
|
|
5(g)
|
|
|
—
|
|
|
|
|
|
—
|
|
|
Total current liabilities
|
|
|
164
|
|
|
|
46,681
|
|
|
|
(164
|
)
|
|
|
|
|
—
|
|
|
|
|
|
46,681
|
|
|
Deferred underwriting fee payable
|
|
|
4,025
|
|
|
|
—
|
|
|
|
(4,025
|
)
|
|
5(b)
|
|
|
—
|
|
|
|
|
|
—
|
|
|
Warrant liabilities
|
|
|
9,486
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
9,486
|
|
|
Long-term debt
|
|
|
—
|
|
|
|
10,206
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
10,206
|
|
|
Total liabilities
|
|
|
13,675
|
|
|
|
56,887
|
|
|
|
(4,189
|
)
|
|
|
|
|
—
|
|
|
|
|
|
66,373
|
|
|
Motion Class A common stock, subject to possible redemption
|
|
|
96,789
|
|
|
|
—
|
|
|
|
(62,029
|
)
|
|
5(a)
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(34,760
|
)
|
|
5(h)
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Motion Class B common stock
|
|
|
1
|
|
|
|
—
|
|
|
|
(1
|
)
|
|
5(i)
|
|
|
—
|
|
|
|
|
|
—
|
|
|
Ambulnz Series A preferred stock, no par value
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
Ambulnz common stock, no par value
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
DocGo common stock, par value $0.0001 per share (post merger)
|
|
|
—
|
|
|
|
—
|
|
|
|
1
|
|
|
5(i)
|
|
|
1
|
|
|
5(k)
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8
|
|
|
5(j)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional paid-in capital
|
|
|
10,275
|
|
|
|
143,109
|
|
|
|
(5,284
|
)
|
|
5(j)
|
|
|
120,849
|
|
|
5(k)
|
|
|
292,053
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34,760
|
|
|
5(h)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,855
|
)
|
|
5(c)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,801
|
)
|
|
5(d)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated deficit
|
|
|
(5,276
|
)
|
|
|
(90,625
|
)
|
|
|
(59
|
)
|
|
5(g)
|
|
|
—
|
|
|
|
|
|
(90,690
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
5,276
|
|
|
5(j)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6
|
)
|
|
5(e)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated other comprehensive loss
|
|
|
—
|
|
|
|
54
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
54
|
|
|
Total stockholders’ equity attributable to controlling interests
|
|
|
5,000
|
|
|
|
52,538
|
|
|
|
23,039
|
|
|
|
|
|
120,850
|
|
|
|
|
|
201,427
|
|
|
Noncontrolling interest
|
|
|
—
|
|
|
|
13,710
|
|
|
|
—
|
|
|
|
|
|
—
|
|
|
|
|
|
13,710
|
|
|
Total stockholders’ equity
|
|
|
5,000
|
|
|
|
66,248
|
|
|
|
23,039
|
|
|
|
|
|
120,850
|
|
|
|
|
|
215,137
|
|
|
Total liabilities and stockholders’ equity
|
|
$
|
115,464
|
|
|
$
|
123,135
|
|
|
$
|
(77,939
|
)
|
|
|
|
$
|
120,850
|
|
|
|
|
$
|
281,510
|
|
See accompanying notes to the unaudited pro forma
condensed combined financial information.
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
OF OPERATIONS
FOR THE SIX MONTHS ENDED JUNE 30, 2021
(in thousands, except share and per share amounts)
|
|
|
Historical
Motion
6(A)
|
|
|
Historical
Ambulnz
6(A)
|
|
|
Transaction
Accounting
Adjustments
|
|
|
|
|
Pro Forma
Statement of
Operations
|
|
|
Revenue
|
|
$
|
—
|
|
|
$
|
111,555
|
|
|
$
|
—
|
|
|
|
|
$
|
111,555
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue
|
|
|
—
|
|
|
|
76,884
|
|
|
|
—
|
|
|
|
|
|
76,884
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
—
|
|
|
|
27,797
|
|
|
|
—
|
|
|
|
|
|
27,797
|
|
|
Depreciation and amortization
|
|
|
—
|
|
|
|
3,495
|
|
|
|
—
|
|
|
|
|
|
3,495
|
|
|
Legal and regulatory
|
|
|
—
|
|
|
|
1,833
|
|
|
|
—
|
|
|
|
|
|
1,833
|
|
|
Technology and development
|
|
|
—
|
|
|
|
1,126
|
|
|
|
—
|
|
|
|
|
|
1,126
|
|
|
Sales, advertising and marketing
|
|
|
—
|
|
|
|
2,035
|
|
|
|
—
|
|
|
|
|
|
2,035
|
|
|
Formation costs and other operating expenses
|
|
|
628
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
628
|
|
|
Total costs and operating expenses
|
|
|
628
|
|
|
|
113,170
|
|
|
|
—
|
|
|
|
|
|
113,798
|
|
|
Loss from operations
|
|
|
(628
|
)
|
|
|
(1,615
|
)
|
|
|
—
|
|
|
|
|
|
(2,243
|
)
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income (expense), net
|
|
|
21
|
|
|
|
(245
|
)
|
|
|
(21
|
)
|
|
6(a)
|
|
|
(245
|
)
|
|
Change in fair value of warrant liabilities
|
|
|
(446
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
(446
|
)
|
|
Other
|
|
|
—
|
|
|
|
(28
|
)
|
|
|
—
|
|
|
|
|
|
(28
|
)
|
|
Total other expense, net
|
|
|
(425
|
)
|
|
|
(273
|
)
|
|
|
(21
|
)
|
|
|
|
|
(719
|
)
|
|
Loss before income taxes
|
|
|
(1,053
|
)
|
|
|
(1,888
|
)
|
|
|
(21
|
)
|
|
|
|
|
(2,962
|
)
|
|
Provision for income taxes
|
|
|
—
|
|
|
|
(9
|
)
|
|
|
—
|
|
|
|
|
|
(9
|
)
|
|
Net loss
|
|
|
(1,053
|
)
|
|
|
(1,897
|
)
|
|
|
(21
|
)
|
|
|
|
|
(2,971
|
)
|
|
Net income attributable to noncontrolling interest
|
|
|
—
|
|
|
|
1,428
|
|
|
|
—
|
|
|
|
|
|
1,428
|
|
|
Net loss excluding noncontrolling interest
|
|
$
|
(1,053
|
)
|
|
$
|
(3,325
|
)
|
|
$
|
(21
|
)
|
|
|
|
$
|
(4,399
|
)
|
|
Net loss per share attributable to Class A common stockholders—basic and diluted
|
|
$
|
—
|
|
|
$
|
(36.73
|
)
|
|
|
|
|
|
|
|
$
|
(0.04
|
)
|
|
Weighted average common shares used to compute net income (loss) per share attributable to Class A common stockholders—basic and diluted
|
|
|
11,500,000
|
|
|
|
90,505
|
|
|
|
91,641,837
|
|
|
6(b)
|
|
|
103,232,342
|
|
|
Net loss per share attributable to Class B common stockholders—basic and diluted
|
|
$
|
(0.37
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares used to compute net loss per share attributable to Class B common stockholders—basic and diluted
|
|
|
2,875,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to the unaudited pro forma
condensed combined financial information.
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 2020
(in thousands, except share and per share amounts)
|
|
|
Historical
Motion
6(B)
|
|
|
Historical
Ambulnz
6(C)
|
|
|
Transaction
Accounting
Adjustments
|
|
|
|
|
Pro Forma
Statement of
Operations
|
|
|
Revenue
|
|
$
|
—
|
|
|
$
|
94,091
|
|
|
$
|
—
|
|
|
|
|
$
|
94,091
|
|
|
Cost of revenue
|
|
|
—
|
|
|
|
62,744
|
|
|
|
—
|
|
|
|
|
|
62,744
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative
|
|
|
—
|
|
|
|
34,913
|
|
|
|
|
|
|
|
|
|
34,913
|
|
|
Depreciation and amortization
|
|
|
—
|
|
|
|
5,508
|
|
|
|
—
|
|
|
|
|
|
5,508
|
|
|
Legal and regulatory
|
|
|
—
|
|
|
|
3,748
|
|
|
|
—
|
|
|
|
|
|
3,748
|
|
|
Technology and development
|
|
|
—
|
|
|
|
1,190
|
|
|
|
—
|
|
|
|
|
|
1,190
|
|
|
Sales, advertising and marketing
|
|
|
—
|
|
|
|
746
|
|
|
|
—
|
|
|
|
|
|
746
|
|
|
Formation costs and other operating expenses
|
|
|
169
|
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
169
|
|
|
Total costs and operating expenses
|
|
|
169
|
|
|
|
108,849
|
|
|
|
|
|
|
|
|
|
109,018
|
|
|
Loss from operations
|
|
|
(169
|
)
|
|
|
(14,758
|
)
|
|
|
|
|
|
|
|
|
(14,927
|
)
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income (expense), net
|
|
|
20
|
|
|
|
(205
|
)
|
|
|
(20
|
)
|
|
6(a)
|
|
|
(205
|
)
|
|
Gain on disposal of fixed assets
|
|
|
—
|
|
|
|
31
|
|
|
|
—
|
|
|
|
|
|
31
|
|
|
Change in fair value of warrant liabilities
|
|
|
(3,884
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
(3,884
|
)
|
|
Other income (expense)
|
|
|
(191
|
)
|
|
|
300
|
|
|
|
—
|
|
|
|
|
|
109
|
|
|
Total other income (expense), net
|
|
|
(4,055
|
)
|
|
|
126
|
|
|
|
(20
|
)
|
|
|
|
|
(3,949
|
)
|
|
Loss before income taxes
|
|
|
(4,224
|
)
|
|
|
(14,632
|
)
|
|
|
(20
|
)
|
|
|
|
|
(18,876
|
)
|
|
Provision for income taxes
|
|
|
—
|
|
|
|
(167
|
)
|
|
|
—
|
|
|
|
|
|
(167
|
)
|
|
Net loss
|
|
|
(4,224
|
)
|
|
|
(14,799
|
)
|
|
|
(20
|
)
|
|
|
|
|
(19,043
|
)
|
|
Net loss attributable to noncontrolling interest
|
|
|
—
|
|
|
|
(439
|
)
|
|
|
—
|
|
|
|
|
|
(439
|
)
|
|
Net loss excluding noncontrolling interest
|
|
$
|
(4,224
|
)
|
|
$
|
(14,360
|
)
|
|
$
|
(20
|
)
|
|
|
|
$
|
(18,604
|
)
|
|
Net loss per share attributable to Class A common stockholders—basic and diluted
|
|
$
|
—
|
|
|
$
|
(158.72
|
)
|
|
|
|
|
|
|
|
$
|
(0.18
|
)
|
|
Weighted average common shares used to compute net loss per share attributable to Class A common stockholders—basic and diluted
|
|
|
11,500,000
|
|
|
|
90,476
|
|
|
|
91,641,866
|
|
|
6(b)
|
|
|
103,232,342
|
|
|
Net loss per share attributable to Class B common stockholders—basic and diluted
|
|
$
|
(1.48
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares used to compute net loss per share attributable to Class B common stockholders—basic and diluted
|
|
|
2,875,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to the unaudited pro forma
condensed combined financial information.
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED
FINANCIAL INFORMATION
|
|
1.
|
Description of the Merger
|
The board of directors of Motion Acquisition Corp.,
a Delaware corporation (“Motion”), unanimously approved the Merger Agreement dated as of March 8, 2021 (the “Merger
Agreement”), by and among Motion, Motion Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Motion (“Merger
Sub”), and Ambulnz, Inc., a Delaware corporation (“Ambulnz”), pursuant to which Merger Sub merged with and into Ambulnz,
with Ambulnz surviving as a wholly owned subsidiary of Motion and the securityholders of Ambulnz becoming securityholders of Motion (the
“Merger”). We refer to the Merger and the other transactions contemplated by the Merger Agreement as the “Business Combination.”
At the consummation of the Business Combination (the “Closing”), Motion changed its name to “DocGo, Inc.” and
now has only one class of common stock, par value $0.0001 (“DocGo Common Stock”) issued and outstanding.
As a result of the Closing, each share of Ambulnz’s
Class A common stock, Class B common stock, and preferred stock issued and outstanding immediately prior to the effective time of the
Merger, on a fully diluted basis including outstanding unexercised Ambulnz employee stock options, were automatically converted into the
right to receive a number of shares of Motion common stock equal to the Exchange Ratio. The “Exchange Ratio” is the quotient
obtained by dividing 83,600,000 by the fully-diluted number of shares of Ambulnz’s common stock outstanding immediately prior
to the effective time of the Merger. The Exchange Ratio was approximately 645.1452 at the effective time of the Merger.
Each of the options to purchase shares of Ambulnz’s
common stock (“Ambulnz Options”), whether or not exercisable and whether or not vested, that were outstanding immediately
prior to the effective time of the Merger, were assumed by DocGo and converted into an option to purchase a number of shares of DocGo
common stock equal to the number of shares of Ambulnz’s common stock subject to such option immediately prior to the effective time
multiplied by the Exchange Ratio, at an exercise price equal to the exercise price immediately prior to the effective time divided by
the Exchange Ratio.
At the Closing, Ambulnz stockholders received 79,699,128 shares
of DocGo Common Stock as consideration, and DocGo reserved an additional 3,900,872 shares of DocGo Common Stock for issuance to the holders
of Ambulnz Options upon exercise thereof. Additionally, Ambulnz stockholders immediately prior to the Closing have a contingent right
to up to 5,000,000 additional shares of DocGo Common Stock as earn-out consideration issuable in the future upon attainment of certain
specified stock price conditions.
Pursuant to those certain subscription agreements
by and between Motion and certain investors (the “PIPE Investors”), at the Closing, Motion issued 12,500,000 shares of
DocGo Common Stock in a private placement at a price of $10.00 per share for an aggregate payment of $125.0 million (the “PIPE
Transaction”).
|
|
2.
|
Basis of Pro Forma Presentation
|
The unaudited pro forma condensed combined financial
statements were prepared in accordance with Article 11 of SEC Regulation S-X, which includes requirements to depict the accounting for
the transaction.
The unaudited pro forma condensed combined balance
sheet as of June 30, 2021 was derived from the respective unaudited historical condensed consolidated balance sheets of Motion and
Ambulnz as of June 30, 2021, and gives effect to the Business Combination and the PIPE Transaction as if they occurred on June 30,
2021. The unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2021 combines the respective
historical condensed consolidated statements of operations of Motion and Ambulnz for the six months ended June 30, 2021, the unaudited
pro forma condensed combined statement of operations for the year ended December 31, 2020 includes the historical restated condensed
consolidated statement of operations of Motion for the period from August 11, 2020 (inception) through December 31, 2020, and
the historical consolidated statement of operations of Ambulnz for the year ended December 31, 2020, in each case giving effect to
the Business Combination and the PIPE Transaction as if they had been consummated on January 1, 2020, the beginning of the earliest
period presented.
The unaudited pro forma condensed combined financial
information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated
with the Business Combination. Motion and Ambulnz have not had any historical relationship prior to the Business Combination. Accordingly,
no pro forma adjustments were required to eliminate activities between the companies.
Shares outstanding as presented in the unaudited
pro forma condensed combined financial statements include the 79,699,128 shares of DocGo Common Stock issued to Ambulnz’s stockholders
at Closing, the 5,297,097 public shares of DocGo Common Stock issued in the IPO (after accounting for the Motion stockholders who exercise
their redemption rights for 6,202,903 shares), 1,835,248 shares of Motion common stock issued to its Sponsor (net of 301,787 shares
forfeited by the Sponsor and 737,965 shares to be held in escrow and that are subject to forfeiture if certain specified future stock
price conditions are not attained), and the 12,500,000 shares of DocGo Common Stock issued in connection with the PIPE Transaction.
As a result of the Business Combination and the
PIPE Transaction, (i) Ambulnz’s stockholders (but not including the holders of Ambulnz Options) own approximately 80.2% of the total
outstanding shares of DocGo Common Stock, (ii) public stockholders of Motion prior to the Business Combination own approximately 5.3%
of the total outstanding shares of DocGo Common Stock, (iii) the Sponsor owns approximately 1.9% of the total outstanding shares of DocGo
Common Stock, and (iv) investors from the PIPE Transaction own approximately 12.6% of the total outstanding shares of DocGo Common Stock,
in each case, not giving effect to any shares issuable upon exercise of DocGo’s Public Warrants and Private Placement Warrants,
the 5,000,000 shares of DocGo Common Stock contingently issuable to Ambulnz stockholders, the shares of Common Stock issuable upon
exercise of the Ambulnz Options, and the 737,965 shares of DocGo Common Stock owned by Sponsor that will be held in escrow and are
subject to forfeiture.
|
|
3.
|
Accounting for the Merger
|
The Business Combination represents a reverse merger
and will be accounted for as a reverse recapitalization in accordance with GAAP. Under this method of accounting, Motion will be treated
as the “acquired” company for financial reporting purposes. This determination is primarily based on the fact that subsequent
to the Business Combination, Ambulnz stockholders will have a majority of the voting power of the combined company, Ambulnz will comprise
all of the ongoing operations of the combined entity, Ambulnz will control a majority of the governing body of the combined company, and
Ambulnz’s senior management will comprise all of the senior management of the combined company. Accordingly, for accounting purposes,
the Business Combination will be treated as the equivalent of Ambulnz issuing shares for the net assets of Motion, accompanied by a recapitalization.
The net assets of Ambulnz will be stated at historical cost. No new goodwill or other intangible assets will be recorded as a result of
the Business Combination. Operations after the Business Combination will be those of Ambulnz.
|
|
4.
|
Shares of DocGo Common Stock Issued to Ambulnz Stockholders
upon Closing of the Business Combination and the PIPE Transaction
|
Based on the aggregate of 129,583.2 shares
of Ambulnz common stock and preferred stock that were outstanding immediately prior to the closing of the Business Combination and the
PIPE Transaction on a fully diluted basis (i.e., giving effect to the exercise of outstanding Ambulnz Options), assuming the closing occurred
on June 30, 2021, and based on the Exchange Ratio determined in accordance with the terms of the Merger Agreement of March 8, 2021,
DocGo issued and reserved for issuance upon the exercise of outstanding Ambulnz Options an aggregate of 83,599,997 shares of DocGo
Common Stock, determined as follows:
|
Ambulnz Class A Common Stock, Class B Common Stock,
and Preferred Stock (as converted to Class A Common Stock) shares outstanding prior to the closing of the Business Combination and
the PIPE Transaction
|
|
|
123,536.7
|
|
|
Plus Ambulnz Class A Common
Stock, Class B Common Stock, and Preferred Stock (as converted to Class A Common Stock) shares issuable upon exercise of the Ambulnz
Options
|
|
|
6,046.5
|
|
|
Total Ambulnz shares of common stock outstanding on a fully
diluted basis prior to the closing of the Business Combination and the PIPE Transaction
|
|
|
129,583.2
|
|
|
Multiplied by
the Exchange Ratio
|
|
|
645.1452
|
|
|
DocGo Common Stock issued to Ambulnz Stockholders
or reserved for issuance upon the exercise of outstanding Ambulnz Options
|
|
|
83,599,997
|
|
In addition to the DocGo Common Stock issued to
Ambulnz stockholders or reserved for issuance upon the exercise of Ambulnz Options outstanding at the time of consummating the Business
Combination, up to 5,000,000 shares of Class A common stock are issuable to Ambulnz’s stockholders as earn-out consideration
in the future upon attainment of the following stock price conditions: (i) 1,250,000 shares if the closing stock price equals or
exceeds $12.50 per share on any 20 trading days in a 30-trading-day period at any time until the first anniversary of the closing
date; (ii) 1,250,000 shares if the closing stock price equals or exceeds $15.00 per share on any 20 trading days in a 30-trading-day period
at any time until the third anniversary of the closing date; (iii) 1,250,000 shares if the closing stock price equals or exceeds
$15.00 per share on any 20 trading days in a 30-trading-day period at any time until the third anniversary of the closing date; and
(iv) 1,250,000 shares if the closing stock price stock equals or exceeds $15.00 per share on any 20 trading days in a 30-trading-day period
at any time until the fifth anniversary of the closing date.
Approximately 6,047 Ambulnz Options are currently
outstanding, representing the right to acquire an aggregate of approximately 3.9 million shares of DocGo Common Stock.
|
|
5.
|
Adjustments to Unaudited Pro Forma Condensed Combined Balance
Sheet as of June 30, 2021
|
The unaudited pro forma condensed combined balance
sheet as of June 30, 2021 has been prepared to illustrate the effect of the Business Combination and the PIPE Transaction and has
been prepared for informational purposes only, and includes pro forma adjustments that are (1) directly attributable to the Business
Combination, and (2) directly attributable to the PIPE Transaction. Motion and Ambulnz did not have any historical relationship prior
to the Business Combination, and accordingly no pro forma adjustments were required to eliminate activities between the companies.
The pro forma notes and adjustments are as follows:
Pro forma notes
|
|
(A)
|
Derived from the unaudited condensed consolidated balance
sheet of Motion as of June 30, 2021.
|
|
|
(B)
|
Derived from the unaudited condensed consolidated balance
sheet of Ambulnz as of June 30, 2021.
|
Pro forma transaction accounting:
|
|
(a)
|
To reflect the redemption of 6,202,903 shares of Motion’s
publicly traded Class A common stock at approximately $10.00 per share pursuant to stockholder elections made prior to the consummation
of the Business Combination.
|
|
|
(b)
|
To reflect the settlement of the $4.0 million of deferred
underwriting fee incurred during Motion’s IPO that was payable upon completion of the Business Combination.
|
|
|
(c)
|
To reflect the payment of Motion’s total advisory,
legal, accounting and auditing fees and other expenses in the aggregate amount of $3.8 million (not including the $4.0 million
deferred underwriting fee or the $4.1 million PIPE Transaction placement fees) that are deemed to be direct and incremental costs
of the Business Combination, which have been recorded as a reduction to additional paid-in capital.
|
|
|
(d)
|
To reflect the payment of Ambulnz’s
total advisory, legal, accounting and auditing fees, and other expenses in the aggregate amount of $7.8 million that are deemed to
be direct and incremental costs of the Business Combination. The payment of $7.8 million of costs directly attributable to the Business
Combination has been recorded as a reduction to additional paid-in capital.
|
|
|
(e)
|
To reflect a permitted withdrawal from the Trust Account
by Motion to pay Delaware franchise taxes.
|
|
|
(f)
|
To reflect the release of cash from the Trust Account to
DocGo’s unrestricted cash and cash equivalents upon consummation of the Business Combination.
|
|
|
(g)
|
To reflect the payment of the outstanding accounts payable,
accrued expenses and accrued offering costs of Motion, net of its prepaid expenses, as of June 30, 2021.
|
|
|
(h)
|
To reflect the reclassification to stockholders’ equity
of 3,476,035 potentially redeemable shares of Motion’s publicly traded Class A common stock that were not redeemed upon consummation
of the Business Combination at $10.00 per share.
|
|
|
(i)
|
To reflect the conversion of all outstanding shares of Motion’s
Class B common stock into Class A common stock on a one-for-one basis.
|
|
|
(j)
|
To reflect the recapitalization of Ambulnz through the contribution
of all outstanding common and preferred stock of Ambulnz to DocGo, and the assumption of outstanding Ambulnz Options by post-merger DocGo,
in the aggregate amount of 83,599,997 shares of DocGo Common Stock and the elimination of the accumulated deficit of Motion, the
accounting acquiree. As a result of the recapitalization, Motion’s accumulated deficit of $5.3 million was derecognized, the
par value of the DocGo shares issued in exchange for Ambulnz’s capital were recorded to common stock in the amount of $8,000, and
a reduction of additional paid in capital in the amount of $5.3 million was recorded.
|
Pro forma adjustments directly attributable to the PIPE
Transaction:
|
|
(k)
|
To reflect the issuance of an aggregate of 12,500,000 shares
of DocGo Common Stock in the PIPE Transaction at a price of $10.00 per share, for an aggregate purchase price of $125.0 million,
and to record the fees associated with the PIPE Transaction in the amount of $4.1 million.
|
|
|
6.
|
Adjustments to Unaudited Pro Forma Condensed Combined Statements
of Operations for the Six Months Ended June 30, 2021 and the Year Ended December 31, 2020
|
Motion and Ambulnz did not have any historical relationship
prior to the Business Combination, and accordingly no pro forma adjustments were required to eliminate activities between the companies.
The pro forma basic and diluted earnings per share
amounts presented in the unaudited pro forma condensed combined statements of operations are based upon the number of Motion’s shares
outstanding at the closing of the Business Combination and the PIPE Transaction, assuming the Business Combination and the PIPE Transaction
occurred on January 1, 2020, which is the beginning of the earliest period presented.
The pro forma notes and adjustments are as follows:
Pro forma notes:
|
|
(A)
|
Derived from the unaudited condensed consolidated statements
of operations of Motion and Ambulnz for the six month period ended June 30, 2021.
|
|
|
(B)
|
Derived from the audited restated consolidated statement
of operations of Motion for the period from August 11, 2020 (inception) through December 31, 2020.
|
|
|
(C)
|
Derived from the audited consolidated statement of operations
of Ambulnz for the year ended December 31, 2020.
|
Pro forma adjustments:
|
|
(a)
|
Reflects the elimination of interest income earned on investments
held in Motion’s Trust Account.
|
|
|
(b)
|
Because the Business Combination is being reflected as if
it had occurred at the beginning of the earliest period presented, the calculation of weighted average shares outstanding for pro forma
basic and diluted net loss per share assumes that the shares issuable in connection with the Business Combination and the PIPE Transaction
have been outstanding for the entirety of the periods presented, and further assumes that Motion’s publicly traded Class A common
shares that were redeemed at the time of the Business Combination were not outstanding for any portion of the periods presented.
|
Pro forma weighted average common shares outstanding
— basic and diluted for the six months ended June 30, 2021 and the year ended December 31, 2020 are calculated as follows:
|
Weighted average shares calculation – basic and diluted
|
|
|
|
|
Total Class A common shares prior to the Business Combination
|
|
|
14,375,000
|
|
|
Less: Class A common shares redeemed
|
|
|
(6,202,903
|
)
|
|
Less: Class A common shares placed in escrow by Sponsor and subject to forfeiture
|
|
|
(737,965
|
)
|
|
Less: Class A common shares forfeited by Sponsor at Closing
|
|
|
(301,787
|
)
|
|
Issuance of Class A common stock in connection with closing of the PIPE Transaction
|
|
|
12,500,000
|
|
|
Issuance of Motion common stock to Ambulnz shareholders and reservation of shares underlying Ambulnz Options in connection with Business Combination
|
|
|
83,599,997.0
|
|
|
Pro forma weighted average shares outstanding – basic and diluted
|
|
|
103,232,342
|
|
8